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Researchers and sponsors are required to help HIV vaccine trial participants remain HIV-
uninfected by ensuring access to HIV risk-reduction interventions, termed the standard of 
prevention. Ethics guidelines for biomedical HIV prevention trials make a range of 
recommendations on the standard of prevention, including that participants should be 
provided with ‘state-of-the-art’ prevention interventions; what should be declared in 
protocols and informed consent documents; and about how decisions should be made. 
Recommendations in these guidelines have been intensely debated, and argued to be 
infeasible and impractical. 
 
This qualitative study aimed to identify standard of prevention decision-making and 
implementation practices at five South African trial sites, explore whether practices meet 
guideline recommendations, and discuss implications for practices and ethics guidelines. 
Stakeholders’ perspectives on key recommendations in ethics guidelines were also explored. 
Practices were examined through a review of site documents and interviews with key 
research stakeholders.  
 
Despite concerns in the literature that guidelines establish ideals that cannot be achieved in 
practice, this study found high concordance between practices and guideline 
recommendations. In some instances, site practices exceeded recommendations in guidelines. 
Practices deviated most from guidelines with regard to ‘negotiating’ standards of prevention 
packages, the description of prevention plans in protocols and informed consent forms, and 
the ethical review of monitoring plans.  
 
The ‘state-of-the-art’ recommendation was argued as being ‘in the eye of the beholder’ and 
considered too vague, too absolute and as requiring localisation. The requirement for 
stakeholder consultation on the evolving standard of prevention was also questioned in terms 
of who would constitute relevant stakeholders, the difficulties with achieving consensus, and 
the nature of the consultation process. Stakeholders endorsed ethics requirements that new 
tools be added to the prevention package when they are scientifically validated and approved 
by regulatory authorities. In addition, they argued that public health sector availability of the 




Funding restrictions, power inequalities, provider promotion of interventions and cultural 
dynamics, among other complexities were identified as influencing standards of prevention 
decision-making and/or implementation. Recommendations are made for strengthened 
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CHAPTER 1  
INTRODUCTION 
 
1. HIV and AIDS: A global snapshot 
It is estimated that there are 35.3 million people living with HIV in the world (UNAIDS, 
2013), and the global prevalence of HIV among adults is 0.8% (WHO, 2013). The number of 
new infections in 2012 was 2.3 million worldwide, a significant decrease from the 3.4 million 
recorded in 2001 (UNAIDS, 2013). Given increasing access to antiretroviral treatment 
(ART), the number of AIDS deaths have declined to 1.6 million from 2.3 million in 2005 
(UNAIDS, 2013). Figure 1 provides a global view of adult HIV prevalence in 2012. Over 
95% of all people living with HIV reside in low- and middle-income countries, and Africa 
remains the continent most affected by HIV.   
 
Figure 1: Global adult HIV prevalence by WHO region (WHO, 2013) 
 
2. HIV and AIDS in sub-Saharan Africa  
Sub-Saharan Africa bears a disproportionate burden of the HIV/AIDS epidemic. In 2012, 25 
million people in sub-Saharan Africa were living with HIV, also home to 70% (1.6 million) 
of all new HIV infections (UNAIDS, 2013). In 2011, 92% of all pregnant women living with 
HIV resided in sub-Saharan Africa, as did the more than 90% of children who acquired HIV 
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in the same year (UNAIDS, 2012). Many countries in the region have shown commendable 
decreases in HIV infections among young people. However, young girls remain at increased 
risk for HIV infection (UNAIDS, 2013) with women comprising 58% of those living with 
HIV in 2011 (UNAIDS, 2012).   
 
In South Africa, an estimated 6.4 million people were living with HIV in 2012 (Shisana et al., 
2014) and 240,000 succumbed because of AIDS-related causes (UNAIDS, 2013). With an 
adult HIV prevalence of 17.9% and 469,000 new infections in 2012 (Shisana et al., 2014), 
South Africa bears the most severe burden of HIV in the world. Given high prevalence and 
incidence rates, the epidemic has been characterised as “mature, generalized and hyper-
endemic” (Delva & Abdool Karim, 2014, p. 100). The prevalence however, differs according 
to province (see Figure 2), with KwaZulu-Natal having the highest HIV prevalence in the 
country – 16.9% compared to 12.2% in the general population (Shisana et al., 2014).  
 
Figure 2: Overall HIV prevalence by province in South Africa (Shisana et al., 2014) 
 
Although the epidemic in South Africa is generalised, certain groups have been identified as 
at increased risk for HIV infection including people living in informal settlements, young 
women, recreational drug users, disabled persons (Shisana et al., 2014), men who have sex 
with men (MSM) (Lane et al., 2011), and sex workers and their clients (Ramjee & Gouws, 





South Africa has the largest ART rollout programme in the world and has made impressive 
progress in terms of ART coverage. In 2012, adult HIV treatment coverage was 81% 
(UNAIDS, 2013), with 1.9 million people on triple ART (Motsoaledi, 2012). Expanding 
access to ART has resulted in decreases in HIV-related adult mortality (Evans, 2013) and life 
expectancy has increased from 54 years in 2005 to 60 years in 2011 (Bradshaw, Dorrington 
& Laubscher, 2012). In addition, the country has made significant progress in terms of 
reducing mother-to-child transmission of HIV (Pillay & Barron, 2014). Despite these 
remarkable achievements, the number of new infections globally supersedes the number of 
persons on ART (UNAIDS/WHO, 2012). Further, South Africa has faced numerous crises in 
the rollout of ART (Bateman, 2013). A survey conducted between September and October 
2013 found that one in five South African health facilities reported stock outs of ART in the 
preceding three months (Stop Stock Outs Project, 2013). Moreover, the alarming rate of new 
infections in the country, and trends of increased HIV risk behaviour, underscore the urgent 
need to intensify prevention efforts (Shisana et al., 2014) and develop increased options for 
HIV prevention (Merson, O'Malley, Serwadda, & Apisuk, 2008). 
 
3. HIV prevention research 
Given the devastating impact of the HIV epidemic over the last three decades, it is evident 
that the optimal approach to controlling new HIV infections is via multiple prevention 
strategies. To this end, several strategies for HIV prevention are currently being developed 
and tested, including microbicides, vaccines, index partner treatment, antiretroviral pre-
exposure prophylaxis (PrEP) and drug substitution therapy for people who inject drugs 
(UNAIDS/WHO, 2012). Most of these HIV prevention strategies address sexual transmission 
of HIV, which accounts for the vast majority of new infections (Lagakos & Gable, 2008), 
particularly in Africa. Given the profound impact and burden of HIV, South Africa has 
become a hub for HIV prevention research, including trials of HIV vaccines, microbicides, 
PrEP and male circumcision. Further, South Africa has identified the prevention of new HIV 
infections as a key priority in its National Strategic Plan on HIV, STIs and TB (NSP) 2012-
2016 (SANAC, 2011).  
 
4. The research problem 
All HIV prevention trials enrol HIV-uninfected participants, and in late-phase efficacy trials, 
participants are at high risk for HIV infection. The ethical obligation to protect the welfare of 
trial participants entails that they should be provided with access to an HIV prevention 
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package to help them remain HIV-uninfected. At a minimum, this package generally includes 
risk-reduction counselling, condoms, and testing and treatment for sexually transmitted 
infections (STIs), with some trials providing other additional interventions (McGrory, 
Philpott, Hankins, Paxton & Heise, 2010). The HIV risk-reduction interventions offered to 
participants in HIV prevention trials have traditionally been subsumed under the broad 
umbrella term of ‘standard of care’ (Heise, Shapiro & West Slevin, 2008), but have more 
recently been termed ‘the standard of prevention’ (cf. UNAIDS/WHO, 2012). Standards of 
prevention refer to the prevention package provided to all participants in a trial to lower their 
risk of HIV infection (Haire et al., 2013; Rennie & Sugarman, 2010). Within the context of 
biomedical prevention trials, this new ethical concept is already controversial (Macklin, 
2008).  
 
Efficacy trials of biomedical HIV prevention products are often conducted among high 
incidence populations, who are also most likely to benefit from effective prevention 
interventions (UNAIDS/WHO, 2012). Such trials are funded by high-income countries but 
typically conducted in resource-constrained contexts which are often characterised by poor 
access to healthcare services (UNAIDS/WHO, 2012). Such disparities in resources have 
fuelled much debate about sponsor/investigator obligations to protect the welfare of trial 
participants by keeping them HIV-uninfected (Moorhouse, Slack, Quayle, Essack & 
Lindegger, 2014). The standard of prevention is a prominent ethical concern in HIV 
prevention trials (Macklin, 2009) and has become a recent topic of intense debate and 
consultation (cf. GCM, 2007; Haire, 2013; Macklin, 2008; McGrory et al., 2010; Philpott et 
al., 2011).  
 
Given the unique ethical complexities in HIV prevention trials, specific guidelines have been 
developed to guide HIV prevention research in South Africa (MRC, 2003) and internationally 
(HPTN, 2009; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). However, standard of 
prevention norms in these guidelines are contentious (Essack, Slack, Koen & Gray, 2010; 
Philpott et al., 2011), with different guidelines proposing different normative standards 
(Haire, 2013).  
 
There is debate about the practical feasibility of standard of prevention norms in ethics 
guidelines. Current ethics guidelines assert that participants should be provided with access to 
‘optimal’ (MRC, 2003) or ‘state-of-the-art’ (UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) 
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HIV risk-reduction interventions. However, some contend that the ‘state-of-the-art’ standard 
may be too aspirational and not practically feasible (HPTN, 2009; Macklin, 2009) especially 
in resource-constrained contexts with limited access to high quality prevention modalities 
(Macklin, 2010).  
 
The ethical rationale underpinning the provision of HIV prevention services to participants is 
not settled. Some have argued that, given the experimental nature of HIV vaccine trials 
(HVTs), the fact that some participants receive placebo, and that HIV is incurable, 
researchers are ethically required to help participants remain HIV-negative by providing them 
with proven HIV preventive methods (Essack, Slack, et al., 2010; IAVI, 2007). Current ethics 
guidelines for biomedical HIV prevention trials (UNAIDS/WHO, 2012) assert that 
beneficence and non-maleficence support the obligation to provide prevention interventions 
to participants. Still, others have described reciprocal justice (Heise & Wood, 2005; McGrory 
et al., 2010), the therapeutic misconception and clinical equipoise, behavioural disinhibition, 
standards of care, and the duty of rescue as justifying the provision of a standard of 
prevention (McGrory et al., 2010). 
 
There is little clarity about how decisions should be made about the standard of prevention in 
trials (cf. GCM, 2007; Macklin, 2008; McGrory et al., 2010), including when to add new 
effective prevention interventions to the standard package of prevention (e.g., Cowan & 
Macklin, 2014; GCM, 2007; Philpott et al., 2011). These decisions are complicated by many 
factors including that there are no set standards for making decisions, with variable standards 
apparently being used across trials and stakeholder groups (cf. Essack, Slack, et al., 2010; 
McGrory et al., 2010; Philpott et al., 2011). Therefore, there have been calls for the 
documentation of decision-making practices in HVTs (Essack, Slack, et al., 2010).  
 
There has been debate about which prevention methods should be included in the prevention 
package (Macklin, 2008). While there is broad agreement that participants should receive 
access to certain HIV risk-reduction interventions (such as condoms, counselling and STI 
treatment), there has been some disagreement about obligations to ensure access to other 
interventions such as voluntary medical male circumcision (VMMC) (cf. Lie, Emanuel & 
Grady, 2006), post-exposure prophylaxis (PEP) (UNAIDS, 2000) and PrEP (McEnery, 
2012). There are also concerns that offering enhanced standard of prevention packages to all 
participants in HIV prevention trials may severely constrain the ability to obtain meaningful 
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results in trials (Macklin, 2008). Particularly, a high standard of prevention may lower HIV 
incidence and result in trial futility. Therefore, efforts to explore the threshold at which 
enhancing the standard of prevention would invalidate trials is both ethically and 
scientifically imperative (Essack, Slack, et al., 2010). Other objections to a state-of-the-art 
standard of prevention include that it may introduce significant inequities between trial 
participants and communities, and may result in undue inducement and increased behavioural 
disinhibition (HPTN, 2009).  
 
Another complexity relates to who should pay for the provision of these HIV prevention 
interventions. Commentators have argued that the burden should not fall on sponsors and 
researchers alone; nor is it affordable for poorly resourced governments on their own 
(Macklin, 2008). One suggestion is that these costs be incorporated into budgets supported 
via public-private partnerships and that skilled negotiators be utilised in brokering such 
arrangements (Macklin, 2008). Ethics guidelines too, suggest that researchers and sponsors 
should collaborate with host country governments to ensure access to the highest standards of 
prevention and care (UNAIDS/WHO, 2012).  
 
5. The research questions 
There is increasing acknowledgement of the value of empirical research in bioethics. 
Empirical research can help describe facts to inform normative arguments, enable critical 
reflection on ethical norms (Kon, 2009a), identify the ethical challenges experienced in 
practice, ascertain whether ethical concerns have cultural nuances (Essack, Koen, et al., 
2010) and/or provide information that may facilitate the improvement of ethical 
recommendations (Carter, 2009; Essack, Koen, et al., 2010). 
 
There is little existing data on whether ethics recommendations are being implemented in 
HVTs, nor on the complexities faced by trial implementers. Recent research found that 
stakeholders perceived prevention norms in ethics guidelines as more controversial than care 
norms, especially regarding the extent to which they can be implemented (Moorhouse et al., 
2014). Further, commentators have called for an exploration of “the prevention services 
offered to HVT participants” (Essack, Slack, et al., 2010, p. 46) and an assessment of the 
extent to which actual practices (what is happening) correspond with ethics guidance (what 
ought to be happening according to norms) (Macklin, 2010). Such empirical data could 
respond to the criticism that ethics guidelines represent ideals that cannot realistically be 
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achieved in practice (c.f. Macklin, 2010), document actual practices in HVTs, including 
regarding decision-making (Essack, Slack, et al., 2010), provide an in-depth understanding of 
stakeholder reservations about selected ethics guideline recommendations (Moorhouse et al., 
2014), and gauge the extent to which enhanced standards of prevention are worrying to 
researchers (cf. Macklin, 2008). Further, ethics principles should be informed by “on the 
ground” realities and empirical data can contribute to understanding how successfully ethics 
aspirations are operationalised in practice (Heise et al., 2008).  
 
To this end, the present study, funded by the Wellcome Trust (Developing Country Projects 
Grant in Biomedical Ethics), aimed to explore 1) the extent to which standard of prevention 
decision-making and implementation practices at South African HVT sites resonate with 
related recommendations in ethics guidelines; 2) whether ethics guidelines address the 
concerns of key stakeholders about standards of prevention; and 3) the perspectives of HVT 
stakeholders on evolving standards of prevention and selected standard of prevention norms 
in ethics guidelines.  
 
6. Scope of the thesis 
This thesis uses empirical data to inform the debate on standards of prevention. It explores 
standard of prevention practices at five South African HVT sites (cf. Essack, Slack, et al., 
2010); examines whether norms are implementable in practice (cf. Macklin, 2010) and 
whether guidelines anticipate ‘on the ground’ complexities. It also explores stakeholders’ 
perspectives on evolving standards of prevention (cf. Macklin, 2008) and selected standard of 
prevention norms in ethics guidelines (cf. Moorhouse et al., 2014).  
 
These focused aims and objectives limit the ability of this thesis to comprehensively address 
all the complexities with standards of prevention in HVTs. This study focuses on HVTs 
conducted in South Africa only, and exclusively explores HIV prevention practices rather 
than reproductive healthcare services more broadly. 
 
This study is framed within the social sciences. While it is hoped that data from this study 
will usefully inform the debate on standards of prevention, this study does not provide a 
normative philosophical analysis of standards of prevention. Empirical data are less relevant 
to questions about whether trial participants should receive prevention interventions, on what 
ethical grounds, and what standard of prevention is owed to trial participants and by whom. 
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Such questions are better suited to normative analyses. Further, given its qualitative approach 
this study does not define the threshold at which adding new tools to the prevention package 
will invalidate trials (cf. Essack, Slack, et al., 2010).  
 
7. Overview of the thesis 
Part one (Chapters 1-2) aims to provide an overview of the research problem and situate the 
study by describing the context within which HVTs are conducted. Chapter 2 offers an 
overview of HIV prevention research, with a focus on biomedical prevention interventions. A 
brief situational analysis of the South African HIV prevention trial landscape and the public 
healthcare system is undertaken. The chapter concludes by briefly documenting the major 
ethical issues that may arise when conducting prevention trials in South Africa.   
 
Part two of this thesis (Chapters 3-5) focuses on normative/theoretical issues. In chapter 
three, ethics guidelines relevant to HVTs are reviewed to identify standard of prevention 
norms. These guidelines are also critically evaluated and compared in terms of standard of 
prevention recommendations. The relevant norms identified in this chapter are compared with 
actual standard of prevention practices documented through the empirical research 
undertaken in this study. In this conceptual review, several complexities with ethics 
recommendations on standards of prevention are identified. In chapter four, frameworks and 
criteria for making standard of prevention decisions are presented and critically reviewed. A 
three-step framework (Jay, Mayer, Burris, Gray & McGowan, n.d., unpublished manuscript) 
provides operational guidance for the enhancement of the prevention package as do criteria 
for decision-making developed at a consultation on standards of prevention (McGrory et al., 
2010; Philpott et al., 2011). The good research governance model (Tarantola et al., 2007) 
spells out a process for operationalising stakeholder consultations that are recommended in 
guidelines for standard of prevention deliberations. Chapter 5 provides a detailed overview of 
the literature expanding on the current debates regarding standards of prevention outlined in 
the present chapter. Objections to providing a state-of-the-art standard of prevention to trial 
participants are also considered and previous empirical studies on standards of prevention are 
reviewed.  
 
Part three (Chapters 6-11) of this study relates to the empirical component. In chapter six, 
details of the research methodology are provided, and the specific research questions and 
aims of the study are outlined. Empirical approaches to bioethics are justified and briefly 
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described, followed by a description of the research design, methodology and the 
philosophical underpinnings of this study. The sampling, data collection and data analysis 
procedures are presented and the rationale for adopting particular approaches explained. 
Considerations pertaining ethics are also discussed. 
 
In chapter seven, empirical findings on standard of prevention decision-making are presented. 
Stakeholder perspectives on the ethical rationale for providing prevention services to trial 
participants are described. Standard of prevention decision-making practices and perspectives 
are presented according to the various stages at which decisions are made, namely protocol 
development, protocol review and protocol implementation. Chapter 8 presents stakeholder 
practices and perspectives regarding the evolving standard of prevention, and focuses on the 
criteria respondents considered relevant when making decisions on the enhancement of the 
prevention package. Chapter 9 presents the HIV prevention interventions provided in two 
HVTs at five South African HVT sites. It describes ‘what’ prevention interventions were 
provided, to ‘whom’ (participants, volunteers at screening, participants’ partners or the wider 
community) and ‘how’ (implementation practices). Stakeholder perspectives on challenges 
and complexities are also presented. Chapter 10 focuses on respondents’ perspectives on 
selected (and controversial) standard of prevention norms in ethics guidelines and details 
some of the challenges experienced with operationalising ethics recommendation in HVTs. In 
Chapters 8-10, actual practices and reported complexities are compared with related 
recommendations in ethics guidelines (MRC, 2003; UNAIDS/AVAC, 2011, UNAIDS/WHO, 
2012) and relevant literature. 
 
Chapter 11 attempts to identify and relate the underlying ideas or assumptions (latent themes) 
in respondents’ reports of their practices and perspectives on standards of prevention to the 
literature and normative framework. This chapter aims to move beyond a descriptive analysis 
of the results by offering an explanation and interpretation of the study’s key findings. It 
considers the limitations of the study and the role of the researcher in the research process 
(reflexivity).  
 
Chapter 12 concludes this thesis by reiterating the main study findings and drawing 
conclusions. It provides recommendations for future research, strengthened practices, more 




CONTEXTUALISING HIV VACCINE TRIALS IN SOUTH AFRICA  
 
This chapter aims to provide an overview of the HIV prevention research process, with a 
focus on biomedical HIV prevention interventions. It provides a historical overview of the 
South African HVT landscape and public healthcare system. The chapter concludes by 
briefly documenting some of the research undertaken in South Africa on the ethical issues 
that may arise when conducting HVTs in developing country contexts. 
 
1. The HIV prevention response  
HIV was first reported in the United States (US) in June 1981 among homosexual men. In 
South Africa, the first case of HIV was reported in 1982 (Abdool Karim & Abdool Karim, 
2002) and in its early years, HIV was limited to the white homosexual population. During the 
country’s transition to a democratic state, it emerged as the epicentre of the global HIV/AIDS 
epidemic, primarily because of sexual transmission among the black African heterosexual 
population (Rohleder, Swartz, Kalichman & Simbayi, 2009). Given the rapid pace at which 
the HIV prevalence increased, the spread of HIV was considered ‘explosive’ (Abdool Karim 
& Abdool Karim, 2002).  
 
In response, by the mid-1980s, community groups were established in many countries to 
provide care and support to those infected and to develop and promote HIV prevention 
strategies (Merson et al., 2008). History has demonstrated that vaccines are the most effective 
method to eradicate global viral epidemics (Bekker, Beyrer & Quinn, 2012; Morris, 
Williamson, Mlisana & Gray, 2009). However, the initial hope that the discovery of an 
effective HIV vaccine would be imminent proved unfounded (Esparza, 2013). Experience 
now indicates that the path to an effective prophylactic HIV vaccine is lengthy and 
complicated (Barouch, 2008; Morris et al., 2009). 
 
Much research has been conducted on the determinants of HIV and it is increasingly accepted 
that to be effective, HIV prevention should incorporate behavioural, biomedical, and 
structural interventions or a combination prevention approach (Bekker et al., 2012; Hankins 
& de Zalduondo, 2010; Rotheram-Borus, Swendeman & Chovnick, 2008). As promising HIV 
prevention interventions become available, “each new HIV prevention technology will 
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become an important additional tool for those at risk of HIV infection”, 
hopefullyapproximating the way in which an expanded array of contraceptive options has 
increased their overall use (Merson et al., 2008, p. 486).  
 
2. Testing HIV prevention interventions  
As outlined above, HIV prevention interventions target behavioural, biomedical and 
structural HIV risk factors (Vermund, Allen & Abdool Karim, 2009). While some 
interventions were evaluated in randomised controlled trials (RCTs) with HIV as the 
endpoint, for some interventions where RCTS were not feasible, effectiveness was estimated 
through observational studies and quasi-experimental research (Vermund et al., 2009).  
 
All biomedical HIV prevention interventions are evaluated in a stepwise manner over various 
stages. After initial laboratory testing and animal studies to establish safety, products are 
tested in clinical trials with human participants (Interagency Coalition on AIDS and 
Development (ICAD), 2010; SAAVI, n.d.). Prior to human trials, national regulatory 
authorities like the South African Medicines Control Council (the MCC), and 
international/national/local research ethics committees (RECs) must approve clinical trial 
protocols to ensure that trials are conducted both scientifically and ethically (ICAD, 2010; 
NHA, 2003). Products with approved protocols proceed to phase I trials, which enrol a small 
number of low-risk participants to evaluate safety. Phase II trials enrol larger numbers of 
low- and high-risk participants to gather extended safety data and in the case of vaccines, data 
on the human immune response. Phase IIB or “proof of concept” trials are designed to bridge 
the gap between phase II and phase III trials (Geise & Duerr, 2009) by providing information 
on the potential efficacy of the intervention and testing whether the candidate intervention 
warrants moving into larger efficacy studies. Such trials are less costly in terms of time, 
money and sample size but do not provide sufficient information for regulatory approval. 
Phase III trials are required to develop a useable and licensable HIV prevention strategy 
(UNAIDS/WHO, 2012) and enrol thousands of high-risk participants to establish whether the 
experimental product prevents HIV infection, and delays the onset of AIDS disease in the 
case of vaccines.  
 
Prophylactic HVTs involve healthy, HIV-uninfected participants. In these randomised, 
double-blinded, placebo-controlled trials, participants are randomly assigned to receive the 
experimental vaccine or placebo. HIV vaccine efficacy studies are conducted to determine 
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whether the experimental vaccine can decrease the risk of HIV infection more than the 
standard prevention package provided to participants in both arms of the study (cf. de Zoysa, 
Elias & Bentley, 1998). Clinical trials are overseen by data and safety monitoring boards 
(DSMBs) who monitor unblinded trial results at regular intervals to determine whether the 
experimental product is safe, effective, or whether the trial can no longer answer the 
questions it was designed to answer (Armstrong & Furberg, 1995). 
 
To measure the efficacy or effectiveness of an HIV prevention intervention, efficacy trials 
usually use proxy or surrogate markers that are predictive of the clinical endpoint. For 
example, in HIV treatment trials, viral suppression is used as a surrogate marker for clinical 
progression (Lagakos & Gable, 2008). However, in HIV prevention trials validated surrogate 
markers for HIV infection or product activity have yet to be identified (Lagakos & Gable, 
2008; McCormack, Gafos, Desai & Cohen, 2014; Richert et al., 2014). Therefore, the 
primary endpoint in HIV prevention trials is HIV infection. This ‘prevention paradox’ 
(Sugarman & Grace, 2010), which requires that participants contract HIV in order to 
determine the effectiveness of an HIV prevention intervention is one of the enduring ethical 
complexities in HIV prevention research. The size and statistical power of the trial is 
determined by the number of HIV infections that occur in the trial population (Richert et al., 
2014). In order to have sufficient power to evaluate efficacy, trials need to be conducted in 
contexts with a relatively high HIV incidence rate (Rida & Lawrence, 1994). However, in 
comparison to other disease outcomes, HIV infection is relatively rare even among high-risk 
groups. Therefore, in order to be feasible, HIV prevention efficacy trials enrol large numbers 
of participants (typically between 1000-4000) at one site or across multiple sites, in 
communities with an annual HIV incidence rate of at least 3-4%, and follow them up for 
several years (Lagakos & Gable, 2008).  
 
A comprehensive overview of all available and potential HIV prevention interventions is 
beyond the scope of this thesis. The following section focuses primarily on biomedical HIV 
prevention interventions, with some consideration of behavioural (counselling) approaches. 
 
2.1 Risk-reduction counselling  
Providing trial volunteers with education and counselling on how they can reduce their risk 
and protect themselves from HIV infection is a key component of HVTs (IAVI, 2005). 
However, in many of the countries where clinical trials of prevention interventions are being 
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conducted, the efficacy of behavioural risk-reduction strategies is yet to be proven (IAVI, 
2005; Lagakos & Gable, 2008). While some studies suggest that behavioural risk-reduction 
interventions are effective in reducing risk behaviours (IAVI, 2005) there are no studies 
demonstrating significant reduction in HIV infection rates (Lagakos & Gable, 2008). In a 
review of nine RCTs that tested five behavioural interventions, Ross (2010) reported that 
while some of these interventions had an impact on STIs, none of these trials demonstrated a 
significant reduction in HIV incidence. The only behavioural intervention study with an HIV 
infection endpoint (Project EXPLORE), found no effect of counselling on HIV acquisition 
(Bekker et al., 2012). However, risk-reduction counselling is argued to be invaluable for 
enhancing knowledge of HIV/STIs, enhancing skills for condom use, increasing the 
effectiveness of biomedical interventions (Lagakos & Gable, 2008) and minimising risk-
compensation when introducing partially effective technologies (Hankins & de Zalduondo, 
2010).  
 
2.2 Male and female condoms 
Evidence of the effectiveness of male condoms in preventing HIV infection has been 
increasing since the recommendation of their use in the early 1980s (Padian, Buvé, Balkus, 
Serwadda & Cates Jr, 2008). Male condoms are considered one of the cornerstones of HIV 
prevention programming (Rotheram-Borus et al., 2009). Condom use is recommended 
particularly for individuals with multiple partners, whose primary partner is HIV-infected or 
whose partner’s sero-status is unknown (Surgeon General, 1993, in Weller & Davis, 2002). 
The degree of protection conferred by condoms is unknown due to complexities which make 
the RCT an unethical design to test their effectiveness (Weller & Davis, 2002). However, the 
effectiveness of male condoms has been estimated at approximately 80%, based on data from 
longitudinal cohort studies with serodiscordant couples (Weller & Davis, 2002) and can be as 
high as 95% when used consistently (Pinkerton & Abramson, 1997).  
 
Female condoms have been evaluated in STI prevention efficacy trials but no trials have 
directly examined their effectiveness in preventing HIV (Padian et al. 2008). Female 
condoms have been estimated to be highly effective in reducing risk of HIV infection (Padian 
et al., 2008) and research has shown that when used correctly and consistently, they are as 
effective as male condoms (Vijayakumar, Mabude, Smit, Beksinska & Lurie, 2006). 
However, uptake of the female condom is low, partly due to its “conspicuous presence”, lack 
of availability and high cost (Padian et al., 2008).  
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2.3 STI Treatment 
STIs increase the risk of sexual transmission of HIV as indicated by evidence from multiple 
longitudinal studies (e.g., Røttingen, Cameron & Garnett, 2001). For this reason, the prompt 
diagnosis and treatment of STIs has been incorporated in HIV prevention programming 
(Bekker et al., 2012).  
 
Of four community-based RCTs of the effectiveness of syndromic STI treatment in reducing 
HIV risk, only one was found effective (Gray & Wawer, 2007). However, these findings may 
suggest that treating bacterial STIs may be more effective in reducing HIV incidence in 
contexts with a high prevalence of STIs and a high incidence of HIV (Bekker et al., 2012; 
Vermund et al., 2009).  
 
Research also suggests that infection with herpes simplex virus type 2 (HSV-2), increases the 
risk of HIV transmission three-fold (Freeman et al., 2006). However, three RCTs found that 
suppressing HSV-2 with chronic antivirals was ineffective in reducing the risk of HIV 
transmission (Hayes, Watson-Jones, Celum, van de Wijgert & Wasserheit, 2010). While 
biological evidence for STI treatment suggests it is potentially efficacious, trials have been 
challenged by several methodological complexities (Lagakos & Gable 2008).  
 
2.4 HIV prevention for injection drug users (IDUs)  
IDUs account for a fair proportion of global HIV infections (UNAIDS/WHO, 2012) and have 
been identified as at increased risk of infection in South Africa (Shisana et al., 2014). While 
RCTs of needle exchange programmes may not be feasible, access to sterile injecting 
equipment, drug treatment (substitution therapy) and behavioural risk-reduction counselling 
have been proven effective in preventing HIV acquisition among this sub-group (Valdiserri, 
Ogden, & McCray, 2003). However, “the provision of equipment for people who inject has 
proven politically challenging in many contexts, because this has been seen (based on no 
empirical evidence) as “encouraging” injecting” (Bekker et al., 2012, p. 16). 
 
2.5 Voluntary medical male circumcision (VMMC) 
Three trials conducted in South Africa, Kenya and Uganda, indicated that a man’s risk of 
contracting HIV through heterosexual sex is at least halved if he is circumcised (Auvert et al., 
2005; Bailey et al., 2007; Gray et al., 2007). The first RCT of male circumcision conducted in 
Orange Farm, South Africa was prematurely halted after an interim review of data revealed 
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that circumcision decreased chances of acquiring HIV by 60% (Auvert et al., 2005). Two 
additional studies which were conducted in Kenya and Uganda to assess the applicability of 
the South African findings across contexts, were stopped after interim data suggested that 
medically performed circumcision decreased a man’s risk of being infected with HIV from 
women by 53% and 48% respectively (Bailey et al. 2007; Gray et al. 2007). In reviewing this 
evidence, WHO/UNAIDS (2007, p. 3) recommended that VMMC “be recognized as an 
additional, important strategy for the prevention of heterosexually acquired HIV infection in 
men”.  
 
2.6 Topical microbicides 
Microbicides are substances (gels, creams, suppositories and vaginal rings) designed to be 
applied to the vagina to prevent HIV infection and other STIs. Several large-scale trials of 
first generation microbicides were conducted, all producing disappointing results (Padian et 
al., 2008; Vermund et al., 2009). In response, second-generation microbicides have included 
topical applications of antiretroviral agents (Klasse, Shattock & Moore, 2008; Padian et al., 
2008), and have started to produce some promising results (see CAPRISA 004 trial results 
described in 2.8 below).  
 
2.7 Post-exposure prophylaxis (PEP) 
Given that ART is effective in reducing HIV viral loads by suppressing viral replication, it 
may be effectively used as a preventive method prior to, or after exposure to HIV, and ART 
is now routinely used after occupational exposures in healthcare settings (cf. Young, Arens, 
Kennedy, Laurie & Rutherford, 2007). There is no conclusive evidence of the effectiveness 
of ART in preventing HIV acquisition after sexual exposure but “data from animal studies 
have suggested that a "window of opportunity" may exist in which ART could suppress viral 
replication and prevent HIV infection following the initial exposure” (Kim, Martin & Denny, 
2003, p. 102). Guidelines in many countries, including South Africa, also recommend PEP 
following potential sexual exposure to HIV (Venter, 2008). 
 
2.8 Pre-exposure prophylaxis (PrEP) 
PrEP for HIV is the use of antiretroviral drugs to prevent HIV acquisition. The concept of 
using treatment as prevention has been proven successful in the prevention of mother-to-child 
transmission (PMTCT) of HIV (Hammer, 2011). Several RCTs of PrEP have been completed 
or are ongoing to evaluate its effectiveness in reducing HIV acquisition among HIV-
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uninfected high-risk populations (Jiang et al., 2014), including IDUs, HIV serodiscordant 
couples, heterosexual men and women, and men and transgender women who have sex with 
men.  
 
Daily oral PrEP has been found effective in four RCTs (iPrEx, Partners’ PrEP, Botswana 
TDF2 and the Bangkok Tenofovir Study) but not in the Fem-PrEP or VOICE trials 
(Tenofovir arm) (Cowan & Macklin, 2014; Hankins & Dybul, 2013; Jiang et al., 2014). 
Tenofovir gel was proven effective in CAPRISA 004 (Abdool Karim et al., 2010) when used 
pericoitally but not in VOICE with daily use (Hankins & Dybul, 2013). The FACTS 001 trial, 
designed as a confirmatory trial for CAPRISA 004 and to provide evidence for the regulatory 
approval of Tenofovir gel, is currently underway (Abdool Karim, Baxter & Abdool Karim, 
2013). A recent meta-analysis found that “PrEP is associated with a reduced risk of HIV 
infection in high risk populations” (Jiang et al., 2014, p. 4).  
 
2.9 Treatment as prevention 
A study conducted with serodiscordant couples tested the impact of earlier access to ART for 
the HIV-infected partner on HIV transmission. The study was conducted with couples across 
multiple sites and countries, including South Africa. Findings indicated a very high protective 
effect of 96% (Cohen et al., 2011). 
 
2.10 Vaccines 
The development of a safe and effective HIV vaccine remains one of the greatest hopes for 
abating the HIV epidemic (Fauci, 2008). HIV vaccines can be either preventative or 
therapeutic. Preventative (or prophylactic) HIV vaccines are tested on HIV-negative 
participants and aim to prevent HIV infection or delay progression to AIDS disease in those 
participants who become HIV-infected (SAAVI, n.d.). Therapeutic vaccines are tested only 
in HIV-positive participants with the aim of determining whether the vaccine strengthens the 
immune response to HIV (SAAVI, n.d.). Most vaccines currently tested in clinical trials are 
preventative vaccines (the focus of this study).  
 
The first phase I trial of an HIV vaccine was conducted in 1987, and since then more than 
200 early-phase clinical trials have been conducted (Esparza, 2013). However, while over 50 
candidates have been tested in phase I trials, only about 20 have moved into phase II studies 
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and by 2011 only five had progressed to phase IIB/III clinical efficacy trials (Geise & Duerr, 
2009).  
 
Initiated in the mid-1990s, the first vaccine candidate to undergo phase III testing was 
AIDSVAX, which comprised two separate studies sponsored by VaxGen. One trial enrolled 
approximately 5,400 participants, mainly MSM in North America and the Netherlands, and 
the second involved around 2,500 IDUs in Thailand (Geise & Duerr, 2009). The vaccine was 
made from a single HIV protein and was meant to stimulate a protective antibody response. 
However, no protective effect was found in either trial (Esparza, 2013). Although the trials 
had disappointing results, they demonstrated that large-scale HIV trials could be conducted 
safely and successfully in a variety of settings (Geise & Duerr, 2009). 
 
The second trials were two phase IIB trials of the Merck Adenovirus-5 (Ad5) based vaccine 
candidate. The STEP Study (or HVTN 502) enrolled 3000 high-risk individuals from the 
Americas, Caribbean and Australia and included homosexual men who had multiple partners 
or who practiced unprotected anal intercourse, and high-risk heterosexual men and women 
(Gray, Buchbinder & Duerr, 2010). A second trial of the same vaccine, HVTN 503 or 
Phambili, was conducted in South Africa and began enrolment in January 2007. An interim 
analysis of STEP trial data in September 2007 found that the vaccine would not meet its 
efficacy endpoints and further vaccinations were halted. The DSMB for the South African 
trial decided to discontinue immunisations and enrolments based on data from the STEP 
study, which showed that in addition to not meeting study endpoints, there was a trend 
towards increased risk of HIV infection among a subgroup of vaccinees (Gray et al., 2010).  
 
In 2009, results of the largest trial to date, the Thai prime-boost phase IIB vaccine trial 
(RV144) sponsored by the National Institutes of Health (NIH), the US military, and the Thai 
Ministry of Health, and which enrolled over 16000 Thai men and women, were announced. 
Results showed that the vaccine reduced HIV by 31.2% among vaccinated participants 
compared with those who received the placebo (Rerks-Ngarm et al., 2009). While the effect 
was modest, these results have demonstrated that a vaccine can protect against HIV (Rerks-
Ngarm et al., 2009) and there are plans to conduct confirmatory trials in other populations, 




The HVTN 505 phase IIB prime boost trial was prematurely closed in April 2013, after an 
interim analysis by the DSMB revealed that the vaccine was not effective in reducing HIV 
acquisition or viral load (Esparza, 2013; Nageswara Rao, 2014).  
 
The Pox-Protein Public-Private Partnership (P5)1 was established in 2010 to build on the 
results of the RV144 trial. To this end, a phase I trial (HVTN 097) testing the RV144 regimen 
commenced in South Africa in June 2013, with further phase II and III trials planned for 2015 
that are hoped to result in licensure of an ALVAC protein prime boost vaccine (similar to 
RV144). The efficacy trial (HVTN 702) is expected to enrol over 5000 participants in late 
2016 (HIV Vaccines and Microbicides Resource Tracking Working Group (RTWG), 2014). 
The HVTN is also planning to test different pox-protein combinations in phase I and II trials 
in Southern Africa, anticipated to commence in 2015.  
 
3. The South African HIV vaccine trial landscape 
HIV prevention research is a global undertaking. For scientific and statistical reasons, 
efficacy trials of HIV prevention interventions are conducted amongst populations with a 
high incidence of HIV infection, often in developing country contexts (de Zoysa et al., 1998; 
Esparza & Bhamarapravati, 2000). South Africa is ideally positioned to conduct large-scale 
HIV prevention trials given its scientific capacity, good infrastructure, high HIV incidence 
rates (Morris et al., 2009; Ramjee et al., 2010) and commitment to a human rights culture 
(Delany-Moretlwe, Stadler, Mayaud & Rees, 2011). Actually, most phase II and phase III 
trials are conducted in Southern Africa and Southeast Asia because of high HIV incidence 
and because it is socially valuable to conduct research in those countries where prevention 
tools are needed the most. This also ensures product acceptability among those populations 
most likely to benefit from effective interventions (ICAD, 2010). Of 669, 224 trial 
participants enrolled in HIV prevention trials globally in 2013, 510,689 were enrolled in 
Africa, with Southeast Asia a distant second at 76,192 (RTWG, 2014). South Africa has 
become a hub for HIV prevention research and to date, several biomedical trials of HIV 
prevention technologies have been undertaken in South Africa, including VMMC (Auvert et 
al., 2005), vaccines (e.g., Gray et al., 2010), microbicides (e.g., Abdool Karim et al., 2010; 
Ramjee, Govinden, Morar & Mbewu, 2007), PrEP (e.g., Grant et al., 2010), PMTCT (Petra 
                                                             
1 http://www.vaccineenterprise.org/content/P5Partnership  
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Study Team, 2002), treatment as prevention (Cohen et al., 2011), and the vaginal diaphragm 
(Padian et al., 2007).  
 
The South African AIDS Vaccine Initiative (SAAVI)2, a lead programme of the Medical 
Research Council (MRC), was established in 1999 with the mandate to coordinate the 
research, development and testing of safe and effective HIV vaccines in South Africa (MRC, 
2003). SAAVI received funding from the South African government through the Department 
of Health (DoH), the Department of Science and Technology, Eskom, the International AIDS 
Vaccine Initiative3 (IAVI), the NIH4 (MRC, 2003), and more recently the Italian government. 
There are six HVT units with various sites across South Africa, namely 1) Perinatal HIV 
Research Unit (PHRU: Soweto); 2) Desmond Tutu HIV Centre (DTHC: Cape Town); 3) 
Centre for the AIDS Programme of Research in South Africa (CAPRISA: Durban); 4) Aurum 
Institute (Klerksdorp, Orkney, Stilfontein, and Hartebeesfontein (KOSH)); 5) Medunsa 
Clinical Research Unit (MeCRU: Medunsa); and 6) Walter Sisulu University AIDS Vaccine 
Research Unit (Mthatha). To date, PHRU, DTHC, CAPRISA, KOSH and Medunsa have 
conducted clinical trials of HIV vaccines while the Walter Sisulu site is being developed to 
conduct trials in future. These sites have conducted various HVTs with funding from IAVI, 
SAAVI and/or the HIV Vaccine Trials Network5 (HVTN). IAVI is a global not-for-profit, 
public-private partnership working to accelerate the development of preventative HIV 
vaccines. Four of these sites, beside Walter Sisulu and Medunsa, are part of HVTN HIV 
vaccine trials units (or HVTUs) consisting of a global network of medical research 
institutions where experimental HIV vaccines are tested (HVTN, n.d.). HVTN is “the world’s 
largest publicly-funded international collaboration focused on the development of vaccines to 
prevent HIV/AIDS” (HVTN, n.d.). HVTN is supported through a cooperative agreement with 
the National Institute of Allergy and Infectious Diseases (NIAID), which is a component of 
the NIH (HVTN, n.d.). There are plans to expand site capacity in South Africa as it prepares 
to conduct two large-scale licensure trials. 
 
South African trial centres have sites over various locales, both rural and urban, some of 
which are nationally and internationally recognised as leaders in HIV prevention research. 
                                                             
2 http://www.saavi.org.za/  
3 https://www.iavi.org/  
4 http://www.nih.gov/  
5 http://www.hvtn.org/en.html  
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Sites have the benefit of being in close proximity to hospitals, primary healthcare clinics and 
government treatment centres. In South Africa, HIV infection risk is correlated with other 
structural risk factors, including poverty, social marginalisation, unemployment, and 
inadequate access to formal housing, education and healthcare services (Shisana et al., 2014). 
Most of the trial sites are located in communities that are particularly vulnerable to many of 
these structural risks.  
 
The first HVT conducted in South Africa in 2003 was a phase I trial of the of the AlphaVax 
replicon Vector clade C vaccine candidate. The trial, conducted by the HVTN, enrolled 48 
participants at two clinical trial sites in South Africa, namely, the PHRU and the SAAVI 
Vaccine Research Unit at the MRC in Durban. Subsequently several additional preventative 
vaccine trials of various phases have been conducted. The funding for these trials was largely 
from networks like HVTN and IAVI, with the candidate vaccine often supplied by 
pharmaceutical companies (Essack, Koen et al., 2010). 
 
The South African context however, presents some unique challenges for HIV prevention 
research. Firstly, host communities might be very distrusting of research given historical 
abuses during apartheid under the guise of research (Baldwin-Ragaven, London & de 
Gruchy, 2000; Barsdorf & Wassenaar, 2005). In post-apartheid South Africa, such suspicion 
and mistrust is evident in the notion that the AIDS epidemic was conjured up by the apartheid 
government to eliminate the black population (Niehaus & Jonsson, 2005). This mistrust has 
been amplified by the premature closures of some trials because of increased risk of HIV 
infection in the product arm, namely, the Cellulose Sulphate microbicide trial and the 
Phambili HVT (Essack, Koen, Slack, Lindegger & Newman, 2012). The closure of the 
Cellulose Sulphate trial in particular, received negative and sensationalised media coverage, 
which created anxiety and mistrust among trial participants and the community (Ramjee et 
al., 2007). Therefore, “in establishing and implementing HIV prevention trials in South 
Africa, researchers are required to build trust and address the historical stereotype of 
researchers as villains” (Delany-Moretlwe et al., 2011, p. S8). 
 
South Africa has a highly developed ethical-legal framework to regulate clinical trials. Apart 
from the Constitution, other relevant statutes are the National Health Act No. 61 of 2003 
(NHA) and the Medicines and Related Substances Act No. 101 of 1965 (Andanda, 2010). All 
clinical trials with sites in South Africa must be registered with the DoH and reviewed by the 
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MCC, a statutory body that reviews all clinical trials and is tasked with the registration of 
new medicines or a change in product indication (Andanda, 2010).  
 
South African law (NHA, 2003) requires that all health research in South Africa should be 
relevant to national health priorities, comply with obligations specified by the National 
Health Research Ethics Council (NHREC) and be submitted for ethics review (Strode, 2013) 
to a South African REC. The NHREC, established in terms of the National Health Act 
(2003), is responsible for the oversight and accreditation of South African RECs that review 
health research protocols (Moodley & Myer, 2007). All health research with human 
participants should obtain mandatory written informed consent, comply with prescribed 
norms, ensure that therapeutic research with minors is in their best interests and obtain 
consent from the minor’s parents/legal guardians, from the minors if they have 
understanding, and, controversially (Strode, Slack, Wassenaar & Singh, 2007), the Minister 
of Health if the study is classified as ‘non-therapeutic’. This legal framework has received 
some criticism including that it is overprotective of participants, stifles REC flexibility, and 
contradicts well-established ethical norms (Strode, 2013). However, compared to many 
developed and developing countries, South Africa has established a system of mandatory 
review to ensure that potentially harmful health research is less likely to be conducted. In 
comparison to the US for example, South Africa’s framework for ethics review “is in many 
cases equivalent to the US institutional review board (IRB) and Office for Human Research 
Protections (OHRP) oversight system, is wider reaching, and has no exclusions" (Cleaton-
Jones & Wassenaar, 2010, p. 710). Further, the regulatory and oversight system of non-
federally funded research in the US for example, is less well regulated than South Africa 
(Cleaton-Jones & Wassenaar, 2010).  
 
4. The healthcare system in South Africa 
The right to health is enshrined in the South African constitution (Republic of South Africa, 
1996). However, the healthcare system in South Africa has a challenging history. Historically 
healthcare, like all other facets of South African society, was racially disparate. The transition 
from apartheid to a democratic state came with significant health reforms, including the 





Post-apartheid South Africa has prioritised free healthcare for all citizens and services are 
available at no cost at the primary healthcare level (Coovadia, Jewkes, Barron, Sanders & 
McIntyre, 2009). However, one of the major obstacles to the creation of an effective and 
efficient healthcare system has been the HIV/AIDS epidemic, which has reversed many of 
the initial gains made in public healthcare (Harrison, 2009). Chief among reasons for the 
explosive HIV epidemic in South Africa has been poor HIV/AIDS policies (Nattrass, 2008). 
During the transition to democracy “AIDS denialism found its way into politics and policies 
in South Africa” (Nattrass & Kalichman, 2009, p. 132). Despite immense public criticism 
(see Figure 3), the government under the leadership of former President Thabo Mbeki and 
Health Minister Dr Manto Tshabalala-Msimang, rejected AIDS science in favour of 
pseudoscience and resisted the rollout of ART (Nattrass & Kalichman, 2009). It has been 
estimated that this restriction of access to ART resulted in the premature death of over 
330,000 people and 35,000 children being born HIV-positive (Chigwedere, Seage III, 
Gruskin, Lee & Essex 2008).  
 
 
Figure 3: Popular South African cartoonist Zapiro on AIDS denialism in South Africa 
 
Despite expansive health reform, apartheid continues to impact on health inequities to the 
extent that the current health system has been described as “unequal and racially skewed” 
(Mayosi et al., 2012, p. 12). Research has indicated that in terms of access to healthcare, 
inequalities between better-resourced and poorer provinces remain (Stuckler, Basu & McKee, 
2011). While primary healthcare services have become increasingly accessible, long 
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distances, time constraints and the cost of transportation impede access to secondary and 
tertiary facilities (Harris et al., 2011). Furthermore, “racial, socio-economic, and rural-urban 
differentials in health outcomes, and between the public and private health sectors” (Harris et 
al., 2011, p. S103) are pervasive. It is hoped that the introduction of National Health 
Insurance (NHI) may help reduce these inequities (Mayosi et al., 2012).  
 
While the debilitating effects of AIDS denialism remain (Rohelder et al., 2009), the politics 
of HIV/AIDS have shifted radically in South Africa. Under the stewardship of Barbara 
Hogan and later Dr Aaron Motsoaledi in the Ministry of Health, government funding 
increased from R4.5 billion in 2009/10 to R8.4 billion in 2010/11 to accommodate expanded 
access to ART, HIV prevention, and PMTCT scale-up (Mayosi et al., 2012). This 
commitment is reflected in South Africa’s current NSP, which specifies four primary 
strategic objectives, namely: 
1) Addressing social and structural barriers that increase vulnerability to HIV, STI 
and TB infection;  
2) Preventing new HIV, TB and STI infections;  
3) Sustaining health and wellness; and  
4) Increasing the protection of human rights and improving access to justice 
(SANAC, 2011, p. 9). 
 
The NSP aims to reduce new HIV infections by at least 50%, using approaches that combine 
biomedical, behavioural and structural interventions (SANAC, 2011). There are plans to 
increase access to male and female condoms by 2016, for the scale-up of VMMC services 
(1.6 million circumcisions by 2016) and to ensure access to high-quality STI treatment. In 
addition, the NSP specifies the need to determine the feasibility of implementing new 
innovative biomedical strategies such as PEP, PrEP, microbicides and treatment as 
prevention (SANAC, 2011). While these objectives and strategies are commendable, the high 
rate of new infections reported in Chapter 1 (469, 000 in 2012) casts doubt about whether 
targets to reduce incidence by 50% are achievable.  
 
4.1 HIV prevention services available in the public healthcare system 
Preventing new HIV infections remains a priority for the South African government. The 
increase in government spending on HIV and AIDS programmes has also had positive 
impacts on South Africa’s ability to implement and improve access to effective HIV 
prevention interventions. The South African public health sector implements a combination 
of HIV prevention interventions, including HIV counselling and testing, male and female 
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condom distribution, VMMC, and STI management, among others (DoH, 2013). Further, 
ARV prophylaxis (PEP) is offered in cases of sexual assault (DoH, 2013).  
 
4.1.1 Access to HIV counselling and testing (HCT) 
In March 2010, updated HCT guidelines were introduced. These guidelines revised 
counselling protocols and advocated a shift to voluntary provider-initiated HCT (DoH, 2010). 
In April 2010, an HCT campaign was launched and it is estimated that by June 2011, 13.4 
million people had tested for HIV (Mbengashe, Nevhutalu, Chipimo, Chidarikire & Diseko, 
2012), with 4500 public health facilities offering provider-initiated counselling and testing, 
and voluntary counselling and testing (VCT) (Peltzer & Matseke, 2013).  
 
4.1.2 Access to condoms 
The government-funded condom distribution programme has shown substantial growth over 
the years and in 2012/13 approximately 501,451,958 male condoms and 11,199,885 female 
condoms were distributed (DoH, 2013). However, this was below the targeted distribution 
rate, and the number of condoms distributed are insufficient to ensure consistently safer 
sexual acts (DoH, 2014). Further, the distribution of female condoms is substantially lower 
than male condoms. Stock outs and poor accessibility of female condoms have also been 
reported (DoH, 2014).  
 
4.1.3 VMMC 
Despite evidence from RCTs that VMMC is an effective HIV prevention strategy and its 
endorsement by normative bodies (UNAIDS and WHO) in 2007, South Africa only launched 
its ongoing campaign to promote and rollout VMMC in April 2010. VMMC is provided as 
part of integrated HIV prevention services at public health facilities, at standalone sites, at 
circumcision camps and using roving teams (DoH, 2014). It is estimated that 1,234,600 
circumcisions were conducted from the launch of the campaign until August 2013, including 
approximately 329,000 circumcisions carried out by non-governmental organisations (NGOs) 
(Shisana et al., 2014). However, in provinces practicing traditional circumcisions (e.g., 
Eastern Cape, Mpumalanga and Limpopo), rates of uptake of VMMC have been low 




4.1.4 Access to STI treatment  
The prevention and timely treatment of STIs is a key public health imperative in South 
Africa. To this end, the STI syndromic management approach is an integrated component in 
primary healthcare clinics and available at no cost (Lewis & Maruma, 2009).  
 
4.1.5 PEP 
Public healthcare facilities only provide access to PEP for occupational exposures and in 
cases of penetrative sexual abuse or sexual assault (DoH, 2008). However, the Minister of 
Health, Dr Aaron Motsoaledi has recently discussed plans to develop a PEP programme 
(Maurice, 2014), which may provide PEP for all risky sexual exposures (cf. SANAC, 2011). 
 
4.1.6 PrEP 
The current NSP (SANAC, 2011) calls for the consideration of new modalities for HIV 
prevention, including PrEP. Some commentators have argued that populations at high-risk for 
HIV in South Africa should be offered PrEP, noting that “PrEP is being offered in the private 
sector, but [that] no services exist in the state sector” (Rebe & McIntyre, 2014, p. 11). 
Truvada is not currently licensed for use as PrEP in South Africa (Abdool Karim & Baxter, 
2014). However, Southern African guidelines on PrEP have been developed in order to assist 
practitioners prescribing PrEP to MSM clients at risk for HIV (Bekker et al., 2012).  
 
5. Ethical issues in South African HVTs  
HVTs are often funded by sponsors from well-resourced contexts while the communities 
from which participants are recruited are often poor or marginalised, and may have limited 
access to education and healthcare services (Delany-Moretlwe et al., 2011; Miller et al., 
2010; UNAIDS/WHO, 2012). Such disparities have framed tensions about sponsor-
researcher obligations to participants in HVTs (Moorhouse et al., 2014). The ethics of 
research in developing countries is complex and has been extensively deliberated (Benatar, 
2002; Emanuel, Wendler, Killen & Grady, 2004; Nama & Swartz, 2002; Shapiro & Meslin, 
2001). In South Africa, there has been much consideration of the ethical issues that arise 
when conducting HVTs and other prevention trials (e.g., Moodley, 2002; 2007; Slack et al., 
2000), including an exploration of stakeholder perspectives on ethical challenges in South 
African HVTs (Essack, Koen, et al., 2010). While a detailed review of all the literature is 
beyond the scope of this study, some of the research on ethical issues in South African HIV 
prevention trials, and especially in HVTs, is briefly documented below. This review is 
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clustered according to principles for conducting research in developing country contexts 
(Emanuel et al., 2004), where relevant.  
 
There has been increasing emphasis on the value of community participation in research 
(MRC, 2003; Newman, 2006; Tindana, Singh, Tracy, Upshur & Daar, 2007) to the extent that 
specific guidelines on good participatory practice and stakeholder engagement 
(UNAIDS/AVAC, 2011) have been developed. Ensuring collaborative partnerships between 
stakeholders is also identified as an ethical principle for conducting research in developing 
countries (Emanuel et al., 2004). Studies have explored the potential contradictions between 
scientific imperatives for community participation (i.e., recruitment of participants) and 
community empowerment and participation (Swartz & Kagee, 2006). In South Africa and 
elsewhere, community advisory boards (CABs) are frequently used in HIV prevention 
research as a formal stakeholder advisory mechanism (UNAIDS/AVAC, 2011). To this end, 
their perspectives on ethical issues in HVTs have been sought (Essack, Koen, et al., 2010), 
the functions and operations of CABs in South African HVTs explored empirically (Reddy, 
Buchanan, Sifunda, James & Naidoo, 2010), and the extent to which they play meaningful 
roles in South African HVTs examined (Upton, 2011). As a pivotal stakeholder in HVTs, 
civil society organisations’ (CSOs) perspectives on stakeholder engagement in HIV 
prevention research have also been canvassed (Koen, Essack, Slack, Lindegger & Newman, 
2013). 
 
The fair selection of participants and communities (Emanuel et al., 2004) is pertinent in the 
South African context given historical research abuses during apartheid. Empirical research 
(Essack, Koen, et al., 2010) found concerns among South African stakeholders that certain 
groups were targeted for research, including that some participants may be selected because 
they are vulnerable. Given increasing concerns about the ‘over-research’ of particular 
communities, an in-depth empirical and ethical analysis of ‘over-research’ in communities 
was undertaken (Koen, 2010). There has also been intense focus on the ethics of research 
with vulnerable populations, for example, the enrolment of adolescents in HIV prevention 
trials (Bekker, Slack, Lee, Shah & Kapogiannis, 2014; Jaspan et al., 2010; McClure, Gray, 
Rybczyk, & Wright, 2004; Singh, Abdool Karim, Abdool Karim, Mlisana & Williamson, 
2006; Strode, Slack, Grant & Mushariwa, 2005), the ethics of research with IDUs (Mamotte, 




Ensuring that benefits of research are favourable in relation to risks (Emanuel et al., 2004) is 
an important ethical requirement of research. Several physiological risks of participation in 
HVTs have been described (Slack et al., 2000), including adverse reactions to the vaccine 
(Moodley, 2002) and vaccine-induced seropositivity. In addition, participation in HVTs may 
result in psychological risks (Slack et al., 2000) and social harm. Milford, Barsdorf and 
Kafaar (2007) described the potential social harms that may be experienced in South African 
HVTs. More recently, Stadler, Delany-Moretlwe, Palanee and Rees (2014) explored women’s 
experiences of participating in a South African microbicide trial and their experiences of 
intimate partner violence and conflict.  
 
The HIV prevention responsibilities of South African HVT researchers have been explored 
(Essack, Slack, et al., 2010), including regarding perspectives on standard of prevention 
norms in selected ethics guidelines (Moorhouse et al., 2014). The standard of prevention 
raises several complex ethical and scientific challenges. Standard of prevention norms in 
ethics guidelines have been debated (cf. Essack, Slack, et al., 2010; Haire et al., 2013; 
Philpott et al., 2011), decisions on adding new tools to the prevention package have not been 
easy (Essack, Slack, et al., 2010; Lie et al., 2006) and the prevention packages offered in 
trials have been variable (e.g., Ngongo, Priddy, et al., 2012). Complexities with standards of 
prevention in HVTs are the focus of Chapter 5 of this thesis.  
 
Access to care and treatment for participants who seroconvert in trials has been complex and 
divisive. In South Africa, challenges with access to ART during former President Thabo 
Mbeki’s tenure, further complicated access to treatment. This ethical concern has been 
vigorously debated (Slack et al., 2005; Stobie & Slack, 2010; Tucker & Slack, 2003) and 
empirically explored (Barsdorf, Maman, Kass & Slack, 2010), including regarding referral 
uptake of care services (Clouse et al., 2010) and community perspectives on appropriate 
benefits (Zvonareva et al., 2013). Given the debate about the responsibilities of 
sponsors/investigators to address the medical health needs of trial participants, an empirical 
study on ancillary care practices and perspectives in South African HVTs was undertaken 
(Slack, 2014).  
 
Concerns that payment of trial participants may compromise voluntariness have been raised 
by South African HVT stakeholders (Essack, Koen, et al., 2010). While payment to 
participants should not be considered to offset risk (Wassenaar & Mamotte, 2012), 
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commentators have argued that it is ethical to compensate research participants for their time 
and inconvenience (Koen, Slack, Barsdorf & Essack, 2008).  
 
Independent ethics review is both ethically (Emanuel et al., 2004) and legally (NHA, 2003) 
required. Empirical research has been conducted to identify the resource and capacity 
building requirements of African RECs for the review of HVT protocols (Milford, Wassenaar 
& Slack, 2006), and to compare US IRB and South African REC perspectives on the process 
and content of the ethics review of HVT protocols (Klitzman, 2008). US federal regulations 
and South African research ethics guidelines have been compared (Cleaton-Jones & 
Wassenaar, 2010) and the composition, operation and training needs of South African health 
RECs surveyed in relation to national and international guidelines (Moodley & Myer, 2007).  
 
Informed consent, derived from the ethical principle of respect for autonomy (NCPHSBBR, 
1979), is considered a cornerstone of ethical research. The quality of informed consent has 
been the root of much contention (Emanuel et al., 2004). Issues of informed consent have 
been considered in the South African context, including the need for cultural sensitivity in the 
informed consent process, challenges with understanding and comprehension (Lindegger & 
Richter, 2000), determining the most appropriate methods to assess understanding (Lindegger 
et al., 2006), exploring perceptions of voluntariness (Wassenaar & Barsdorf, 2005), and 
investigating communication in the informed consent process (Watermeyer & Penn, 2008). 
Ethics guideline recommendations on informed consent in trials were rated favourably 
amongst a sample of South African HVT stakeholders (Moorhouse et al., 2014). South 
African HVT stakeholders also identified informed consent as a critical ethical concern, 
particularly given limited access to education and South Africa’s socio-political history 
(Essack, Koen, et al., 2010). 
 
The principle of ongoing respect for participants and communities requires that 
confidentiality should be protected, participants should be allowed to withdraw from the 
study without penalty, issues such as research-related injury should be considered, and study 
results should be communicated to participants (Emanuel et al., 2004). Given negative trial 
outcomes of some HIV prevention trials, e.g., Cellulose Sulphate and STEP/Phambili, studies 
have explored perspectives on trial closures (Delany-Moretlwe et al., 2011; Essack et al., 
2012) and compensation for research-related injury in cases of harm (Mamotte, Wassenaar & 




This chapter aimed to describe the context of HVTs in South Africa. It outlined the clinical 
trial process and reviewed selected HIV prevention interventions. The South African HVT 
landscape was described and the history of the healthcare system, including South Africa’s 
current HIV prevention response, briefly reviewed. The chapter concluded by documenting 
the literature on ethical issues in South African HIV prevention research, especially HVTs.  
  
Part two of this thesis (Chapters 3-5) reviews the normative and theoretical issues regarding 
standards of prevention. The following Chapter documents standard of prevention norms in 




REVIEW OF STANDARD OF PREVENTION NORMS IN ETHICS 
GUIDELINES 
 
This chapter reviews ethics guidelines applicable to HVTs (MRC, 2003; UNAIDS/AVAC, 
2011; UNAIDS/WHO, 2012) to identify standard of prevention norms and to critically 
evaluate and compare ethics guidance on the standard of prevention. The norms documented 
in this chapter will serve as a basis for comparison with actual practices reported in the 
empirical component of this study (see Chapters 7-11).  
 
1. Ethics guidelines specific to HVTs  
General ethics guidelines on biomedical research and practice (e.g. CIOMS, 2002; Helsinki, 
2013; Nuffield Council on Bioethics, 2002) provide little specific guidance relevant to HIV 
prevention trials because they were largely developed to address issues relevant to new 
medical treatments for those who are already ill (McGrory et al., 2010).  
 
As a result, two international ethics guidance documents were developed to deal specifically 
with biomedical HIV prevention trials, namely, UNAIDS/WHO (2012) Ethical 
considerations in biomedical HIV prevention trials and the companion document 
UNAIDS/AVAC (2011) Good participatory practice (GPP) guidelines for biomedical HIV 
prevention trials. UNAIDS/WHO (2012) is a revision of UNAIDS (2000) ethics guidance. It 
was originally published in 2007, but an additional guidance point on IDUs was added in 
2012. UNAIDS (2000) was the culmination of several international consultations with 
various research stakeholders on the ethical issues in HIV prevention research (UNAIDS, 
2000). The resulting ethics guidance document on HVTs consisted of 18 guidance points, 
including one on risk-reduction interventions. These guidelines were revised due to evolution 
of the HIV prevention field. The revised guidelines (UNAIDS/WHO, 2012) consist of 20 
guidance points, including a guidance point on the standard of prevention. Recommendations 
in these guidelines have been extensively considered in relation to the standard of prevention 
(e.g., Essack, Slack, et al., 2010; Macklin, 2008; 2009; 2010; 2012; Haire et al., 2012; Haire 
et al., 2013; Philpott et al., 2011; Rennie & Sugarman, 2010) and have also been assessed by 




The GPP guidelines (UNAIDS/AVAC, 2011) for biomedical HIV prevention trials are a 
revision of the GPP guidelines (UNAIDS/AVAC, 2007) which emanated from consultations 
with various research stakeholders that aimed to elucidate the elements of effective 
partnerships for HIV prevention trials. These guidelines seek to offer mechanisms for 
systematising community engagement with the aim of providing “trial funders, sponsors, and 
implementers with systematic guidance on how to effectively engage with stakeholders in the 
design and conduct of biomedical HIV prevention trials” (UNAIDS/AVAC, 2011, p. 5). 
Since their initial publication these guidelines have been “widely discussed, promoted and 
endorsed” (Allman, Ditmore & Kaplan, 2014, p. 2), applied to ethical issues in HIV 
prevention trials (e.g., Koen et al., 2013), implemented in biomedical HIV prevention trials 
(e.g., Mack et al., 2013), advocated for making decisions on standards of prevention (e.g., 
Haire et al., 2013), and noted in the U.S. Presidential Commission for the Study of Bioethical 
Issues (2011), amongst others (see Allman et al., 2014). 
 
There is also South African national ethics guidance applicable to HVTs, namely, MRC 
(2003) Guidelines on ethics for medical research: HIV preventive vaccine research. These 
guidelines were adapted from the first edition of the UNAIDS guidelines (UNAIDS, 2000) to 
suit the local South African context given that the UNAIDS document lacked local specificity 
(MacQueen, Abdool Karim & Sugarman, 2003). These guidelines comprise 18 guidance 
points, including one on risk-reduction interventions. The South African guidelines (MRC, 
2003) are endorsed in South Africa’s good clinical practice (GCP) guidelines (DoH, 2006). 
The National Health Act (2003) legally enforces trial implementers to comply with GCP 
guidelines (2006) and by inference compliance with MRC (2003) ethics guidelines may be 
legally mandated. Standard of prevention practices at South African HVT sites are likely to 
be influenced by South African and international ethics guidelines that are directly applicable 
to HVTs. Therefore, the sample of ethics guidance documents for review here was limited to 
the South African ethics guidelines (MRC, 2003) and the two UNAIDS ethics guidance 
documents (UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). 
 
There are also other HVT-specific ethics guidance documents, e.g., the Kenya National 
Guidelines for Research and Development of HIV/AIDS Vaccines (Kenyan Ministry of 
Health, 2005) and the Uganda Guidelines for AIDS Vaccine Research (Uganda AIDS 
Commission, 2006). The HIV Prevention Trials Network (HPTN) Ethics Guidance for 
Research was revised by the HPTN in 2009 specifically for an HPTN audience with the aim 
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“to facilitate HPTN's mission by raising awareness of the associated ethical considerations, 
engaging network members at all levels in discussion about those considerations, and 
facilitating the integration of ethical considerations into the design and implementation of 
HPTN research” (HPTN, 2009, p. 6). HPTN is a clinical trial network that develops and tests 
the safety and efficacy of non-vaccine HIV preventative interventions.  
 
2. Desk review of ethics guidelines applicable to HVTs 
A desk review was conducted of the three HVT-specific ethics guidelines (MRC, 2003; 
UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) to identify ethical provisions on standards of 
prevention, and to critically evaluate and compare guidance with regard to standards of 
prevention.  
 
These HVT-specific guidelines were reviewed for any text dealing with HIV prevention. This 
text was then extracted verbatim into an MS Word document and clustered according to key 
dimensions using an inductive-deductive approach (Fereday & Muir-Cochrane, 2006). Text 
was initially clustered according to five pre-determined dimensions, namely, “who” should 
receive prevention methods, “what” prevention methods should be ensured, “why” 
prevention methods should be offered, “how” decisions should be made, and “how” access to 
prevention methods should be ensured. Where necessary, sub-dimensions were developed to 
better accommodate the text. The remaining text was then clustered according to emerging 
dimensions (see Appendix 1 for the detailed tabulated coding).  
 
The review of ethics guidelines will hopefully help identify recommendations for guideline 
developers and will be used to compare ethics recommendations with actual practices in 
HVTs. To ensure reliability of coding, a second expert researcher in HIV prevention ethics 
coded a sample of ethical standards in guidance documents. Discrepancies were discussed 
until consensus was reached.  
 
3. Ethics guideline recommendations for standards of prevention in HVTs 
 
3.1 Why should prevention methods be provided? The ethical rationale  
Neither the MRC (2003) nor GPP (UNAIDS/AVAC, 2011) guidelines explicitly refer to any 
of the four ethical principles of beneficence, non-maleficence, justice or respect for autonomy 
(NCPHSBBR, 1979) when presenting a rationale for providing prevention methods to trial 
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participants. According to MRC guidelines (2003, p. 28) “reducing the risk of HIV infection 
among participants is an essential ethical component of HIV preventive vaccine trials. This is 
especially critical given that phase III efficacy trials rest on some exposure to HIV infection.” 
GPP guidelines (UNAIDS/AVAC, 2011, p. 49) specify, “helping trial participants reduce 
their risk of acquiring HIV is a key ethical obligation of research teams.”  
 
UNAIDS/WHO (2012) identifies beneficence and non-maleficence as the rationales for 
providing HIV prevention methods to participants. These principles require that potential 
benefits to participants be maximised and that potential risks be reduced to a minimum. Since 
HIV infection is the measured endpoint in HIV prevention trials (Lagakos & Gable, 2008), 
helping enrolled participants remain HIV-uninfected by ensuring access to prevention 
interventions is in line with the principles of beneficence and non-maleficence. However, 
there is little consensus amongst ethicists on the ethical rationale for ensuring access to 
standards of prevention (see Chapter 5). Furthermore, not all ethicists agree that beneficence 
mandates access to all state-of-the-art prevention methods (Philpott et al., 2011), with some 
arguing that beneficence places certain limits on obligations (see Chapter 5).  
 
3.2 Who should receive HIV prevention methods? Prevention services for non-trial 
participants  
 
3.2.1 Recommendations for trial volunteers who screen out  
Some trial volunteers will be screened for trials but found ineligible (Ngongo, Priddy, et al., 
2012) against the trial’s eligibility criteria (screen-outs). MRC (2003) has a statement (not 
specific to prevention) that where relevant, protocols should specify referral processes for 
screen-outs. UNAIDS/WHO (2012, p. 43) guidelines state that “there should be an ongoing 
iterative consultative process to facilitate local or national decision-making about the 
appropriate level of support, care, and treatment provided to potential and enrolled 
participants.” In the guidance point on the standard of prevention, UNAIDS/WHO (2012, p. 
46) recommends, “ways should be explored with local authorities to provide trial volunteers 
and participants with information about HIV prevention and treatment services available in 
the community.” UNAIDS/AVAC (2011) has no statement on the HIV prevention methods 




3.2.2 Recommendations for the partners of trial participants 
MRC (2003) guidelines state that trial participants should be provided with information on 
how to obtain STI treatment for their partners. UNAIDS/WHO (2012) guidelines do not 
specify what, if anything, should be provided to the partners of participants. GPP guidelines 
(UNAIDS/AVAC, 2011) require that in discussions and negotiations on the HIV prevention 
package, research teams and relevant stakeholders should consider which HIV prevention 
services will be ensured for participants’ partners. However, neither MRC (2003) nor GPP 
(UNAIDS/AVAC, 2011) guidelines specify how access to potential HIV prevention services 
should be ensured for partners, that is, provided on-site or through referrals to local 
healthcare facilities.  
 
3.2.3 Recommendations for host communities  
For host communities, MRC (2003) states in the guidance point on care and treatment, that 
the capacity of the healthcare system should be developed in order to improve the delivery of 
services to the host community (MRC, 2003). UNAIDS/WHO (2012) specifies in the 
guidance point on care and treatment, that the health conditions of the community and even 
the host country should be improved by integrating clinical trials into national plans: “clinical 
trials should be integrated into national prevention, treatment, and care plans so that services 
provided through clinical trials or arrangements brokered for trial participants serve to 
improve the health conditions of both the trial participants and the community from which 
they are drawn, and (to) support and to strengthen a country’s comprehensive response to the 
epidemic” (pp. 49-50). GPP guidelines (UNAIDS/AVAC, 2011) have no statement on HIV 
prevention services for the host community.  
 
The above review suggests that there is little consistency between ethics guidelines on access 
to prevention services for non-trial participants. In addition, the available guidance is vague 
regarding exactly which HIV prevention interventions should be ensured for these groups, if 
any. Only MRC (2003) specifies a mechanism for ensuring access to prevention services for 
screen-outs and this is limited to referral. However, statements in both MRC (2003) and 
UNAIDS/WHO (2012) imply that screen-outs should get the standard of prevention that is 
available in the local healthcare system.  
 
Apart from the statement in GPP guidelines (UNAIDS/AVAC, 2011), there is little direction 
provided in ethics guidelines on exactly what is owed to partners of participants, their 
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families, the host community and the host country. Most often, guidelines require that HIV 
prevention responsibilities to non-trial participants are satisfied by developing the capacity of 
the healthcare system for the benefit of host communities, which will include partners and 
families. Given the general silence in guidelines on what is owed to non-trial participants, it 
has been recommended that such decisions be made in consultation with local stakeholders 
(Tarantola et al., 2007). 
 
3.3 What should be provided to trial participants? The substantive ethical standard  
South African guidance asserts that the “most appropriate risk-reduction counselling and 
access to preventive methods should be provided to all trial participants” (MRC, 2003, p. 28). 
UNAIDS/WHO (2012, p.45) requires that “researchers, research staff, and trial sponsors 
should ensure that appropriate counselling and access to all state of the art HIV risk-reduction 
methods are provided to participants.” GPP guidelines (UNAIDS/AVAC, 2011, p. 48) do not 
outline a substantive position but do define the standard of prevention as “the package of 
comprehensive counselling and state of the art HIV risk reduction methods provided or made 
available to participants in biomedical HIV prevention trials.”  
 
Ethics guidelines advocate for access to optimal (MRC, 2003) or state-of-the-art 
(UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) prevention methods. MRC (2003) and 
UNAIDS/WHO (2012) guidelines contend that access to prevention methods should be 
ensured for trial participants and that “appropriate” risk-reduction counselling is provided. 
The obligation to provide ‘access’ is weaker than the obligation to actually provide 
prevention interventions (Lie et al., 2006) – ‘actual provision’ entails that researchers 
themselves should ‘actively provide’ the intervention (Lie et al., 2006) whereas ‘access’ 
entails either direct on-site provision of services or referral (Philpott et al., 2011; 
UNAIDS/AVAC, 2011) through established partnerships, and ensuring that no barriers 
(economic or other) impede uptake by participants (Lie et al., 2006). Further, guidelines 
(MRC, 2003; UNAIDS/WHO, 2012) do not indicate what is meant by “appropriate” risk-
reduction counselling. This term may be interpreted, and thus implemented, differently by 
different stakeholders.  
 
Guidelines (UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) do not define ‘state-of-the-art’. 
This critical concept is left open to interpretation. It is possible that the state-of-the-art will 
differ by locale. However, given that UNAIDS/WHO (2012) guidelines aim to minimise 
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double standards between developed and developing countries (Haire et al., 2013), it is likely 
that state-of-the-art is not intended as context-dependent but defined according to the best 
available standard anywhere in the world.  
 
All ethics guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) address 
the issue of the standard of prevention that should be provided to trial participants in HVTs. 
Given the more recent introduction of the term ‘standard of prevention’ (cf. Macklin, 2008), 
issues of HIV prevention are dealt with under risk-reduction interventions in the MRC (2003) 
guidelines.  
 
3.4 What should be provided to trial participants? The components of the package 
Guidelines specify that the following HIV prevention interventions should be included in the 
standard of prevention package:  
• Comprehensive risk-reduction counselling (MRC, 2003; UNAIDS/AVAC, 2011; 
UNAIDS/WHO, 2012), including partner and couples counselling (UNAIDS/AVAC, 
2011). Comprehensive counselling should include basic principles of safer sexual 
practices and safer injecting practices; education concerning general health and 
treatment of STIs; reproductive health; and strategies to reduce domestic violence 
(UNAIDS/WHO, 2012) 
• Access to male and female condoms (MRC, 2003; UNAIDS/AVAC, 2011; 
UNAIDS/WHO, 2012), with appropriate instructions and demonstrations 
(UNAIDS/AVAC, 2011) 
• Testing for (UNAIDS/AVAC, 2011) and treatment of STIs (MRC, 2003; 
UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) 
• VMMC, where applicable (UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) 
• Counselling about the potential benefits and risks of PEP and how it can be accessed 
(MRC, 2003; UNAIDS/WHO, 2012) 
• Access to PEP (UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) 
• Sterile injecting equipment and medical substitution therapy for IDUs 
(UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012)  




There is some consistency across guidelines regarding the prevention components that should 
be included in the package. While the above components are listed in the commentary section 
of various guidance points, it is also required that this package will be enhanced as new 
prevention methods are found effective (see 4. below).  
 
Components identified in MRC (2003) are somewhat outdated given evolutions in HIV 
prevention. However, the statement that “preventive methods should include, but not 
necessarily be limited to” the list of specified interventions, suggests that MRC (2003, p. 29) 
sets a minimum standard of prevention that could be ratcheted up. This is in contrast to 
UNAIDS/WHO (2012) which establishes a ceiling (state-of-the-art) to be negotiated down. 
Further, recommendations that new methods should be added to the package as they are 
discovered and validated (MRC, 2003) indicate latitude to include prevention methods that 
are not on the list of identified components.  
 
While MRC (2003) states that investigators are morally compelled to provide optimal risk-
reduction methods, this guidance document does not require the actual provision of PEP. 
Since PEP is only accessible in limited circumstances (occupational exposures and sexual 
assault) in the South African context, this may suggest that these guidelines benchmark 
optimal in relation to national rather than international standards.  
 
UNAIDS/WHO (2012) also identifies components related to reproductive healthcare under 
the standard of prevention. However, the standard of prevention seems like an inappropriate 
category for these ancillary care services. GPP guidelines (more appropriately, it could be 
argued) contend that sexual and reproductive healthcare are examples of non HIV-related 
care, and “not directly related to HIV prevention” (UNAIDS/AVAC, 2011, p. 55). 
 
3.4.1 Specific requirements for risk-reduction counselling 
MRC (2003) and UNAIDS/WHO (2012) guidelines specify several requirements for risk-
reduction counselling, including that counselling should be based on reliable information 
about the prevailing social and behavioural characteristics of the research population. 
However, there is some concern that relying on research staff to provide risk-reduction 
counselling and HIV prevention interventions to participants while conducting a trial that 
uses HIV infection as an endpoint introduces a conflict of interest or “researchers’ dilemma” 
(de Zoysa et al., 1998; Slack et al., 2000). For this reason, guidelines (MRC, 2003; 
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UNAIDS/WHO, 2012) recommend that consideration be given to providing counselling and 
other risk-reduction interventions through an independent agency. However, it has been 
argued that this “may in fact compromise rather than strengthen researchers’ abilities to meet 
ethical obligations to trial participants” (Chatterjee, de Zoysa, Farley, Hankins & Mane, 
2006, p. 2). Further, empirical studies of care and prevention in microbicide trials concluded  
that concerns that research staff would compromise risk-reduction efforts in order to facilitate 
research, were unfounded (Heise et al., 2008).  
 
MRC (2003) also requires that counselling should be conducted in accordance with national 
guidance, and should be appropriate to the participant’s language, age and gender. 
UNAIDS/WHO (2012, p. 47) requires that the “community-government-investigator-sponsor 
partnership should agree on the technique, frequency and message content of counselling 
sessions.”  
 
GPP guidelines (UNAIDS/AVAC, 2011) suggests that risk-reduction counselling should 
include both partner and couples counselling and that local and community stakeholders 
make inputs into counselling approaches during protocol development.  
  
3.5 How decisions should be made on what to provide? The current package  
Various factors to be considered in decision-making about the standard of prevention are 
identified in guidelines including stakeholder consultation, input from RECs, post-trial 
continuity and support, and government and sponsor policies, as detailed below.  
 
3.5.1 Stakeholder consultation 
All guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) endorse 
consultation with stakeholders, including the community, on the HIV prevention methods to 
be provided to participants in HIV prevention trials. These include consultations on: 
• The design of an effective risk-reduction strategy (MRC, 2003; UNAIDS/WHO, 
2012) 
• Determining the components of the HIV prevention package (UNAIDS/AVAC, 
2011) 
• Input into appropriate risk-reduction interventions (MRC, 2003) 
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• The method and process for monitoring risk-reduction interventions (MRC, 2003; 
UNAIDS/WHO, 2012) 
• Implementation and monitoring of risk-reduction interventions, including uptake and 
standards of referral services (UNAIDS/AVAC, 2011) 
• Tailoring the design, implementation, and oversight of risk-reduction interventions 
(UNAIDS/WHO, 2012), and 
• Establishing the type, scope, and process by which participants are provided with, or 
referred to, services to access the full HIV prevention package (UNAIDS/AVAC, 
2011). 
 
MRC (2003) identifies a role for stakeholder consultation in decision-making before 
(designing interventions) and during (monitoring interventions) the research process, with 
stakeholders having a role in determining ‘what’ prevention methods should be provided to 
participants as well as ‘how’ to monitor them.  
 
UNAIDS/WHO (2012, p. 13) identifies a role for stakeholder consultation in terms of 
designing, implementing and monitoring risk-reduction interventions. In addition, these 
guidelines state that “prevention trials should not be conducted when agreements have not 
been reached among all research stakeholders on ... the standard of prevention.” Therefore, 
stakeholders have a role in determining ‘what’ prevention methods to provide and ‘how’ to 
implement them. 
 
UNAIDS/AVAC (2011) also identifies a role for consultation in determining ‘what’ 
prevention methods are provided and ‘how’ to implement them.  
 
Consultation regarding mechanisms for implementation of prevention methods is ethically 
uncontroversial. However, the procedural requirement for consultation on the standard of 
prevention package is incongruous given the substantive standard is that trial participants 
should be provided with access to all state-of-the-art (UNAIDS/AVAC, 2011; 
UNAIDS/WHO, 2012) prevention methods. Such consultation may inadvertently lower the 
substantive standard when the ethical goal is to determine ‘what’ should be provided to 
participants (Essack, Slack, et al., 2010; Haire et al., 2012). There is no guidance on how the 
substantive and procedural standards must work together or how to resolve any tensions 
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between these standards. Furthermore, given that stakeholders may have vastly different 
perspectives, there may be instances where agreement cannot be reached on what standard of 
prevention to provide participants. In such cases, UNAIDS/WHO (2012) guidelines 
recommend that trials should not be conducted. This very rigid recommendation may impede 
the discovery of effective and needed prevention interventions. In addition, guidelines (MRC, 
2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) require consultation with various 
stakeholders on the standard of prevention but none provide any ethical rationale for 
consulting stakeholders on this issue. It seems plausible that this requirement is based on the 
principle of respect for communities, which “confers on the researcher an obligation to 
respect the values and interests of the community in research and, wherever possible, to 
protect the community from harm” (Weijer, Goldsand & Emanuel, 1999, p. 275). 
 
A further criticism is that certain guidelines (MRC, 2003; UNAIDS/WHO, 2012) only 
specify the outcomes of consultation. They provide little direction on how to operationalise 
stakeholder consultations, including which stakeholder groups should be included or the 
content of such consultations. While guidelines require that some decisions should be made 
via discussions (UNAIDS/AVAC, 2011) and negotiations (UNAIDS/AVAC, 2011; 
UNAIDS/WHO, 2012), there is little direction on what format the consultations should take 
(e.g., large stakeholder meetings). There is also a paucity of information on the feasibility of 
stakeholder consultations before every trial, given the requisite time commitments and cost 
implications.  
 
A gap in both the MRC (2003) and UNAIDS/WHO (2012) guidelines is that relevant 
stakeholders are not always identified or when stakeholders are specified, they seldom 
include all research stakeholders. Further, involving all research stakeholders in decision-
making has not been common practice to date (McGrory et al., 2010). There is also concern 
that in multi-centre trials, consultations may actually “lead to different recommendations and 
expectations about the type of prevention package that should be provided” (McGrory et al., 
2010, p. 30) at each site, creating potential differences in outcomes for participants. Of course 
vague guidelines permit trial implementers some flexibility and “it is often a virtue to leave a 
guideline intentionally somewhat vague, in order to enable decision makers to make different 
determinations depending on the circumstances. That is a better strategy than having to make 
exceptions to rules that are too rigidly defined in advance” (Macklin, 2012, p. 32). 
Nevertheless, vagueness may create challenges for implementation.  
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Despite these criticisms, stakeholder consultation may be valuable for making decisions 
about how to implement the established substantive standard, for example, by making inputs 
into whether local providers are capacitated to provide risk-reduction services and 
understanding the cultural nuances that may affect participant uptake of prevention services 
(cf. Mark et al., 2012). 
 
3.5.2 REC input  
MRC (2003) guidelines specify a role for RECs in approving both the risk-reduction strategy 
and plans for monitoring risk-reduction interventions.  
 
According to UNAIDS/WHO (2012, p. 57) “the appropriateness of plans to monitor risk-
reduction interventions should be determined by the scientific and ethical review committees 
that are responsible for providing prior and continuing review of the trial.” However, 
UNAIDS/WHO (2012) does not explicitly require that RECs approve the risk-reduction 
package and these guidelines omit the ‘standard of prevention’ in the list of items for 
scientific and ethical review. However, given recommendations to review informed consent 
procedures and information sheets which are required to include information on risk-
reduction interventions, it could be argued that RECs should review standard of prevention 
packages. Generally, it is accepted that ethics review of HVT protocols considers the 
standard of prevention to be provided to participants (Tarantola et al., 2007).  
 
UNAIDS/AVAC (2011) has no explicit requirement that RECs actually review and approve 
the risk-reduction package.  
 
3.5.3 Post-trial access to prevention methods  
There are general statements in MRC (2003) and UNAIDS/WHO (2012) stating that access 
to services, specifically counselling, should be available post-trial, for example, participants 
should be provided with “supportive counselling for the duration of the trial, and appropriate 
referral after the trial is completed”(UNAIDS/WHO, 2012, p. 18). 
 
3.5.4 Government and sponsor policies  
All guidelines consider governments and sponsors as key research stakeholders to be 
involved in consultations on the standard of prevention. However, only UNAIDS/AVAC 
(2011) acknowledges that national-legal restrictions and funding-body restrictions may 
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influence the prevention package provided to participants. Where funding restrictions limit 
which prevention methods can be covered by the study budget, the onus is on the research 
team to find alternative ways to ensure access to these prevention methods (UNAIDS/AVAC, 
2011). 
 
3.5.5 Trial design and population 
GPP (UNAIDS/AVAC, 2011) is the only guideline that requires consideration of the 
“appropriateness for the trial design and population” (UNAIDS/AVAC, 2011, p. 50) when 
making determinations about the prevention package. So, for example, the provision of sterile 
injecting equipment should be considered in relation to whether the trial population includes 
IDUs or not.  
  
4. How should decisions be made on adding new methods to the prevention 
package?  
From the guidelines, three criteria should be used to make decisions on adding new methods 
to the prevention package, namely, scientific validity, regulatory approval and stakeholder 
consultation.  
 
MRC (2003, p. 29) suggests that adding new methods should be determined by considering 
scientific evidence: “As new methods of prevention are discovered and validated, these must 
be added to the preventive methods offered to trial participants.” There is no role identified 
for regulatory approval and stakeholder consultation in making decisions on the enhancement 
of the prevention package.   
 
UNAIDS/WHO (2012, p. 45) recommends consideration of scientific validity, normative 
approval and stakeholder consultation when making decisions on adding new prevention 
methods: “…new methods should be added, based on consultation among all research 
stakeholders, as they are scientifically validated or approved by relevant authorities.”  
 
GPP (UNAIDS/AVAC, 2011, p. 49) states that “research teams may need to review the HIV 
prevention package regularly, taking into consideration new HIV counselling models and risk 
reduction methods that are scientifically validated and, when appropriate, approved by 




Requirements across UNAIDS companion guidelines (UNAIDS/AVAC, 2011; 
UNAIDS/WHO, 2012) are inconsistent: approval is recommended as an alternative to 
scientific validation (UNAIDS/WHO, 2012) as opposed to in addition to scientific validation 
(UNAIDS/AVAC, 2011). Further, while UNAIDS/WHO (2012) recommends approval by 
relevant authorities, UNAIDS/AVAC (2011) recommends approval by national bodies. Such 
inconsistencies may create implementation challenges for HVTs.  
 
Further, none of the ethics guidelines address what criteria constitute “scientifically 
validated” or “approved by relevant authorities”. While enabling flexibility in decision-
making, such vagueness may create practical challenges for implementation.  
 
UNAIDS/WHO (2012, p. 47) specifies that when making decisions on an evolving standard 
of prevention, negotiations should consider the following scientific criteria: “feasibility, 
expected impact and the ability to isolate the efficacy of the biomedical HIV modality being 
tested”. It has been argued that this latter procedural requirement (i.e., negotiation) is the 
solution to concerns that providing participants with all state-of-the-art prevention methods is 
infeasible and impractical (cf. Macklin, 2009). Given that these are the only specified 
considerations for consultation, it is unclear whether resource constraints or cultural and 
religious objections to the provision of prevention methods would be considered legitimate 
objections to a state-of-the-art package in terms of feasibility. It is also unclear why all 
research stakeholders should be consulted on such decisions, when only a few stakeholder 
groups, like scientists and statisticians, may possess the requisite skills to make such 
feasibility determinations (cf. Haire et al., 2013). Further, stakeholders may object to the 
addition of prevention methods like VMMC for religious or cultural reasons. If VMMC is not 
provided, then consultation would have lowered the substantive standard of ensuring access 
to all state-of-the-art prevention intervention (UNAIDS/WHO, 2012), and would arguably 
compromise the welfare of individual research participants. If VMMC is provided despite 
these objections, then stakeholder consultation is tokenistic and does not appropriately satisfy 
the principle of respect for communities. This illustrates the tension between having 
established substantive standards in conjunction with procedural requirements for 
consultation on substantive standards. It also highlights the tension between protecting 
individual research participants as espoused in most research ethics frameworks, versus the 
promotion of societal or community health goals advocated in public health frameworks 
(Buchanan & Miller, 2006).    
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5. What should be in the protocol? 
The research protocol should:  
• Specify referral processes for those persons excluded from the trial (MRC, 2003) 
• Outline potential risks, and steps that will be taken to reduce these risks to a 
minimum. Risk minimisation measures include providing participants with risk-
reduction interventions (MRC, 2003; UNAIDS/WHO, 2012) 
• Set out mechanisms for negotiation among all research stakeholders, including the 
community, about the standards for enhancement of the risk-reduction package 
(UNAIDS/WHO, 2012), and  
• The prevention standard should be defined in the study protocol (UNAIDS/WHO, 
2012).  
 
UNAIDS/AVAC (2011) has no statement on what should be included in the protocol. 
 
Study protocols are blueprints of research and provide detailed descriptions of the plan for 
conducting the HVT, including the purpose of the study and ethical considerations. Protocols 
are also submitted for ethical and scientific review and therefore should be comprehensive 
enough so that review bodies can make valid determinations. As a particularly complex and 
contentious ethical issue (cf. Macklin, 2008), it is critical that the standard of prevention is 
included in the study protocol.  
 
6. What should be in the informed consent form and process? 
MRC guidelines (2003, p. 18) state that “participants must be informed of and should 
understand the risks and risk minimisation measures that will be taken, and these measures 
should be included in the informed consent form.” However, including the standard of 
prevention in the informed consent form (ICF) does not absolve trialists of the responsibility 
to counsel participants on the risk-reduction efforts that are available. To this end, the 
guidance point on informed consent specifies that “each prospective participant must be 
counselled, using appropriate language and techniques, to understand ...that they will receive 
counselling and access to the means of risk-reduction...” (MRC, 2003, p. 22).  
 
UNAIDS/WHO (2012, p. 45) states that “if the study aims to test a product by comparing its 
additive effects to those of routinely practiced prevention, in all cases this prevention 
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standard should be defined in the study protocol as well as in informed consent documents.” 
Similarly to MRC (2003) guidelines, “each prospective participant must be informed... that 
they will receive counselling concerning how to reduce their risk of HIV exposure and access 
to risk-reduction means (in particular, male and female condoms, clean injecting equipment, 
and where relevant, male circumcision)...” (p. 54). 
 
While UNAIDS/AVAC (2011) is silent on whether details on the standard of prevention 
should be included in the consent form or process, MRC (2003) and UNAIDS/WHO (2012) 
contain very clear guidance that the prevention measures that will be provided to participants 
should be outlined in both the ICF and the informed consent process.  
 
7. How should access to prevention methods be ensured?  
Various mechanisms are identified in guidelines regarding ensuring access to prevention 
methods, namely, research, capacity building, partnership, referral, and advocacy, as detailed 
below. 
 
7.1 Formative research on HIV prevention interventions available in the trial 
community 
MRC (2003) requires that risk-reduction “counselling should be...based on reliable 
information about the prevailing social and behavioural characteristics of the research 
population” (p. 29). However, these guidelines do not recommend that formative research 
should be conducted to ensure that prevention methods are acceptable to, and can be accessed 
by participants during the trial.  
 
While there is no recommendation to conduct formative research on the services currently 
available in the local community, UNAIDS/WHO (2012, p. 49, italics added) requires that 
“trial sponsors and researchers should collaborate with governments in low- and middle-
income countries to explore, develop, and strengthen national and local capacity to deliver 
the highest possible level of HIV prevention, care, and treatment services.”  
  
UNAIDS/AVAC (2011, p. 50) states that “research teams determine which stakeholders 
already provide HIV prevention interventions, what types of services they provide, and their 
capacity to provide adequate services.” Such formative research is important in mapping the 
existing prevention services available in the community, areas where the capacity of local 
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providers needs to be developed, and “will enable research teams to provide optimal referrals 
and make linkages when necessary” (UNAIDS/AVAC, 2011, p. 50).  
 
7.2 Capacity building 
Ethics recommendations pertaining to capacity building in MRC (2003) guidelines focus 
mostly on risk-reduction counselling and specifically require that the capacity of community 
members to be counsellors should be developed and that risk-reduction counsellors should 
receive adequate training, supervision and support. There is also a general statement in the 
guidance point on care and treatment that “sponsors and investigators should build capacity 
of trial linked healthcare centres to deliver services to the host community” (MRC, 2003, p. 
31) and that the “capacity of trial-linked healthcare service centres in the host community 
should be strengthened” (p. 33). These guidelines do not prescribe how such capacity should 
be developed. Therefore, capacity building may include a range of strategies from 
information sharing to the provision of resources.  
 
UNAIDS/WHO (2012) guidelines make recommendation to build capacity to deliver 
prevention methods by training counsellors to provide culturally acceptable and sustainable 
risk-reduction counselling. In addition, “researchers should guarantee that all communities 
engaged in biomedical HIV prevention trials have state of the art reproductive healthcare 
services” (UNAIDS/WHO, 2012, p. 45). These guidelines also recommend that local and 
national capacity should be developed to improve health conditions of both trial participants 
and host communities by integrating clinical trials into national prevention plans 
(UNAIDS/WHO, 2012). Further, “trial sponsors and researchers should collaborate with 
governments in low- and middle-income countries to explore, develop, and strengthen 
national and local capacity to deliver the highest possible level of HIV prevention, care and 
treatment services through strategic investment and development of trial-related resources” 
(UNAIDS/WHO, 2012, p. 49). These guidelines prescribe that capacity development should 
include strategic investment and development of trial-related resources.  
 
In terms of the standard of prevention, UNAIDS/AVAC (2011) limits capacity building to 





While both MRC (2003) and UNAIDS/WHO (2012) contain specific capacity building 
requirements to facilitate and/or enhance the delivery of prevention services to trial 
participants, UNAIDS/WHO (2012) also addresses capacity building efforts to improve 
access to services for the host community and even for the host country.  
 
7.3 Partnership 
MRC (2003) is silent on establishing partnerships with other stakeholders in order to ensure 
access to prevention methods for trial participants.  
 
UNAIDS/WHO (2012) identifies partnership mechanisms to ensure provision of prevention 
services. However, these recommendations are located in different guidance points across the 
document. These guidelines recommend collaborating with governments to explore, develop, 
and strengthen national and local capacity to deliver the highest possible level of HIV 
prevention. They recommend collaborating with local authorities to explore ways to provide 
trial volunteers and participants with information about the HIV prevention interventions 
available in the community. In addition, they recommend that the responsibility to ensure 
access to prevention services is shared, and located primarily with the local health system.  
 
UNAIDS/AVAC (2011) recommends making linkages with, and consulting local service 
providers in order to ensure optimal referral networks.  
 
Empirical research studies on care (MacQueen, McLoughlin, Alleman, McClain Burke & 
Mack, 2008; Slack, 2014) have identified partnerships as a critical strategy in ensuring access 
to services in HIV prevention trials. Future revisions of MRC (2003) guidelines should 
consider providing some direction on strategic partnerships in ensuring access to prevention 
interventions.  
 
7.4 On-site provision and referrals 
HIV prevention interventions may be provided to participants directly (on-site) or through 
referrals (UNAIDS/AVAC, 2011).  
 
MRC (2003) states that referral networks should be established for those who screen out of 
the trial. For participants, referral networks should be monitored and appropriate referrals 
should be made post-trial for access to ongoing counselling. However, there is no explicit 
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recommendation that referral mechanisms should be established for participants during the 
trial. 
 
UNAIDS/WHO (2012, p. 46) has clear guidance on referrals for trial participants stating that 
“referral mechanisms should be established and follow-up mechanisms instituted to ensure 
quality case management services.” These guidelines also specify that trials should only be 
conducted in communities where participants can be referred to ongoing psychosocial 
services. 
 
UNAIDS/AVAC (2011, p. 51) recommends that “research teams and relevant stakeholders 
discuss and negotiate the comprehensive HIV prevention package, taking account....the HIV 
prevention services and options that will be offered through referral mechanisms.”  
  
Except the recommendation to outsource risk-reduction counselling, none of the guidelines 
specify which prevention services should be provided on-site and which should be referred. 
By stating that researchers should ensure access to prevention services (UNAIDS/WHO, 
2012), either strategy may be utilised to provide prevention services. However, when 
prevention interventions are ensured through referrals, it is incumbent on researchers to 
ensure that participants actually access these services. This lack of specification seems 
appropriate because the availability of prevention services in local communities is not 
standard or static. These recommendations suitably allow access strategies to be informed by 
the local context.  
 
7.5 The role of advocacy in ensuring access to prevention interventions  
UNAIDS/WHO (2012) identifies a role for advocacy in ensuring access to prevention 
services, particularly those considered illegal in some contexts, e.g., provision of clean 
needles. MRC (2003) states in the guidance point on vulnerability that advocates could play a 
role in addressing the needs of legally marginalised communities like IDUs, and GPP 
(UNAIDS/AVAC, 2011) requires consideration of current national laws in making 
determinations on the prevention package. It has been argued that when it is not legally 
permissible to provide participants with HIV risk-reduction interventions like clean needles, 
researchers should consider the appropriateness of conducting HIV prevention trials with 
IDUs in such contexts (Mamotte, 2012). The closure of PrEP trials in Cambodia and 
Cameroon provide important evidence of the role of advocacy in trials and the consequences 
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of failure to provide an optimal prevention package (Singh & Mills, 2005). There are many 
opportunities to advocate for the provision of better HIV prevention interventions such as the 
CDC PrEP trial in Thailand among IDUs where participants were provided with counselling, 
condoms, STI treatment, and follow-up in a methadone drug treatment programme but not 
with clean needles. Some contend that access was restricted by US government policy that 
prohibited provision of clean needles (Haire, 2011).  
 
8. What should be monitored?  
The monitoring of risk-reduction interventions forms part of an entire guidance point in both 
MRC (2003) and UNAIDS/WHO (2012) guidelines. MRC (2003) recommends that 
consideration should be given to employing an independent agency to monitor risk-reduction 
interventions in order to avoid conflict of interest concerns, while UNAIDS/WHO (2012) 
recommends that the clinical trial monitor should monitor counselling standards.  
 
GPP guidelines (UNAIDS/AVAC, 2011, p. 51) recommend ensuring the quality of referral 
mechanisms as well as monitoring the uptake of prevention services during the trial. 
 
All three guidelines require that risk-reduction interventions and referral mechanisms should 
be monitored, for example, “before a trial commences, researchers, trial sponsors, countries, 
and communities should agree on a plan for monitoring the initial and continuing adequacy of 
the informed consent process and risk-reduction intervention, including counselling and 
access to proven HIV risk-reduction methods (UNAIDS/WHO, 2012, p. 56).  
 
9. What should be documented?  
Only GPP guidelines (UNAIDS/AVAC, 2011) require certain aspects of the trial and related 
discussions to be documented. With regard to standards of prevention, these guidelines 
specify that “research teams maintain clear written records of discussions and agreements. 
This includes recommendations, actions taken by the research team, and any unresolved 
issues that require follow-up” (p. 51). 
 
Given the emphasis on stakeholder consultation across all the guidelines, the absence of 
recommendations for documentation of these discussions is a major oversight. Further, since 




10. Summary  
This chapter reviewed ethics recommendations on standards of prevention in three HVT-
specific ethics guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). 
These standard of prevention norms will be used as a basis of comparison for standard of 
prevention practices identified in the empirical component of this study. In the main, these 
guidelines are fairly consistent in their HIV prevention requirements. These similarities are to 
be expected because MRC (2003) is an adaptation of UNAIDS (2000) guidelines – an earlier 
version of UNAIDS/WHO (2012) – and UNAIDS/WHO (2012) and UNAIDS/AVAC (2011) 
are companion documents. Nevertheless, there are a few (but not insignificant) differences on 
standard of prevention norms between guidelines.  
 
All guidelines indicate the standard of prevention that should be provided to participants. 
However, South African guidelines (MRC, 2003) set a minimum standard of prevention that 
could be ratcheted up while UNAIDS/WHO (2012) guidelines establish a ceiling to be 
negotiated down.  
 
The ethical rationale for ensuring access to standards of prevention in trials is not consistent 
across guidelines, and only UNAIDS/WHO (2012) explicitly identifies ethical principles of 
beneficence and non-maleficence as underpinning obligations to ensure access to all state-of-
the-art prevention interventions.  
 
Ethics recommendations for non-enrolled persons (participants’ partners, families, and host 
communities) are fairly fragmented. Exactly what standard of prevention is owed to these 
moral groups, if anything, is not adequately articulated in guidelines.  
 
Guidelines also make recommendations for the enhancement of the prevention package, 
requiring scientific validation (MRC, 2003; UNAIDS/AVAC, 20112) and/or approval by 
relevant authorities (UNAIDS/WHO, 2012) or national bodies for use (UNAIDS/AVAC, 
2011). This difference between national and the broader “relevant authorities” may be of 
relevance during implementation. The use of indeterminate concepts may create challenges 
for implementation – stakeholders may be unclear about what is required of them, or may 




The next chapter reviews some frameworks/criteria for operationalising ethics guideline 




A REVIEW OF FRAMEWORKS FOR OPERATIONALISING 
STANDARD OF PREVENTION DECISION-MAKING  
 
There are several models for ethical decision-making in various professions and disciplines 
including, medical practice and psychology. However, there are very few models for 
decision-making in research, and even fewer for clinical research.  
 
The available normative framework for decision-making about standards of prevention in 
HVTs is ethics guidelines. As outlined in Chapter 3, ethics guideline requirements for the 
standard of prevention include access to ‘optimal’ or ‘state-of-the-art’ HIV risk-reduction 
interventions. In addition, new tools should be added to the prevention package as they are: 
• Discovered and validated (MRC, 2003) 
• Scientifically validated or approved by relevant authorities (UNAIDS/WHO, 2012) 
• Scientifically validated and when appropriate approved by national bodies for use 
(UNAIDS/AVAC, 2011).  
 
Further, UNAIDS/WHO (2012, p. 47) requires a process of stakeholder consultation when 
adding new tools which considers the “feasibility, expected impact, and the ability to isolate 
the efficacy of the biomedical HIV modality being tested.” There is some concern that such 
consultations may result in suboptimal prevention packages and undermine the substantive 
standard that the package be state-of-the-art (Essack, Slack, et al., 2010; Haire et al., 2012).  
 
As identified in Chapter 3, guidelines propose concepts for determination of the standard of 
prevention (e.g., state-of-the-art, scientific validation, consultation, negotiation) that are 
equivocal, and difficult to operationalise. Guidelines do not specify the criteria that constitute 
‘scientifically validated’ or ‘approved by relevant authorities’. This is problematic because 
these conditions are defined differently by different regulatory and normative bodies (Philpott 
et al., 2011) and can be interpreted as delineating different phases of product development 
(Jay et al., n.d.).  
 
An unpublished framework (Jay et al., n.d.) arguably the most developed (although not yet 
piloted to determine its pragmatic value) is reviewed below. It is relevant because of its 
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potential to facilitate decision-making on the enhancement of the prevention package. A set 
of ‘consensus’ criteria are also reviewed (McGrory et al., 2010; Philpott et al., 2011). These 
criteria were developed at an international workshop on standards of prevention, in which the 
present author participated.  
 
There are available (and contested) procedural approaches for making decisions, e.g., 
“accountability for reasonableness” (Daniels, 2000, p. 1300). This chapter also reviews a 
framework that delineates the process (and content) for stakeholder consultation (Tarantola et 
al., 2007) that appears to be endorsed by guidelines (cf. UNAIDS/WHO, 2012) and by others 
(cf. Hankins, Osmanov & Gutnick, 2009). 
 
1. The three-step framework for making decisions on the standard of prevention  
One of the key complexities with the standard of prevention is how to make decisions on the 
enhancement of the prevention package. This issue has become especially pertinent as new 
HIV prevention interventions have been proven effective, including VMMC and more 
recently, PrEP.  
 
1.1 Aims of the framework 
This framework aims to address some of the vagueness, ambiguity and inherent tensions in 
ethics guidelines (see Chapter 3). It delineates when a new prevention intervention should 
presumptively be provided to participants and when this obligation may be modified on 
scientific grounds (Jay et al., n.d.). However, it is not intended as a substitute for processes 
requiring stakeholder consensus on clinical trial designs (Jay et al., n.d.).  
 
1.2 The three phases 
 
1.2.1 Step 1: Validation for clinical use 
The key question driving step one is: has the new prevention intervention been validated for 
use? The framework clearly articulates when not to, and when to, add new prevention 
interventions to the prevention package. New prevention interventions should not be provided 
to participants:  
• too early: before its effectiveness (benefit) is conclusively established;  
• too late: only after it is introduced in the local healthcare system; nor  
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• in a haphazard manner: without consideration of appropriate combinations.  
 
Instead, new prevention methods should be included in the prevention package when the 
intervention has been validated for clinical use in the context where the trial is being 
conducted and among the enrolled populations. Several criteria are outlined as relevant to 
determinations of clinical validation, namely:  
• Data on safety and efficacy in comparable populations as well as the strength of data 
especially when the data from multiple trials conflict;  
• The similarity between the study populations and those who will be participating in 
the planned trial;  
• Behavioural considerations which could amplify or decrease the value of the 
intervention, either alone or in combination with other modalities;  
• The acceptability and desirability of the intervention among the populations(s) 
participating in the planned trial; and 
• Considerations of cost and delivery which could influence the real-world applicability 
and scalability of the prevention intervention.  
 
The concept of clinical validation is helpful in clarifying some of the nebulousness related to 
guideline (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) recommendations for 
scientific validation. While it is acknowledged that this approach does not make decision-
making easy, the validation requirement clarifies the relevant criteria to consider and the 
limits to researcher’s obligations. Such clarity may be helpful for trial implementers and may 
also subvert the potential of multiple interpretations, and therefore limit variability in the 
standard of prevention (when such variability is driven by challenges with interpretation 
rather than context-specific determinations). Furthermore, it is not required that researchers 
routinely provide all available prevention interventions without a careful appraisal of benefits 
to participants nor does it mean that researchers can merely rely on modalities available in the 
public healthcare system.  
 
The framework describes that validation is not dependent on regulatory approvals. In this 
way, it may be helpful in clarifying potential challenges identified in Chapter 3 regarding the 
equivocal and inconsistently applied concept of regulatory approval, including whether any 
approval or national approval is a prerequisite for the enhancement of the prevention 
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package. In resource-constrained contexts, it is argued that if the prevention intervention is 
considered an appropriate, realistic practice but has not been instituted in the local healthcare 
system only due to cost, the validation threshold is satisfied (Jay et al., n.d.). In these 
circumstances, research may serve to ‘ratchet up’ the local system. However, in cases where 
the provision of the intervention would severely tax the current and foreseeable capacity of 
the local healthcare system, and is perceived as unsustainable and an inappropriate use of 
clinical resources, then that prevention intervention is not considered validated. The authors 
contend that researchers should not introduce long-term prevention modalities knowing that 
these would not be sustained post-trial (Jay et al., n.d.). However, others have argued that the 
immediate potential benefit of reduced HIV infection risk for participants is a legitimate trial-
related benefit (Haire et al., 2013). 
 
1.2.2 Step 2: Methodological necessity 
Step 2 is driven by the question of methodological necessity: is withholding the prevention 
intervention methodologically necessary to answer the study question(s)? Once the 
prevention intervention is validated for clinical use (Step 1 above), ethically, it must be 
provided to trial participants (Jay et al., n.d.). However, the authors specify that prevention 
interventions “may be withheld when methodologically necessary to address a compelling 
public health question” (Jay et al., n.d., p. 11), subject to the agreement of the community. 
 
Methodological necessity is explained as only existing when “it is impossible to answer the 
study question while providing the most clinically reasonable prevention package to all 
participants” (Jay et al., n.d., p. 11). This is similar to the feasibility threshold described in 
guidelines (UNAIDS/WHO, 2012) and highlights the tension between researcher’s scientific 
and ethical responsibilities in that:  
• the study intervention cannot be adequately evaluated in combination with the newly 
validated modality because their mechanisms of action are too similar; 
• the newly validated modality is so effective that showing an added effect from the 
study intervention will require a sample size and/or duration that is substantially 
misaligned with a reasonable allocation of resources; or 
• the newly validated modality cannot reasonably be procured, due to issues relating to 
manufacturing or licensure. (When an unlicensed product can be obtained, regulatory 
status alone does not create methodological necessity for withholding it.) 
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It is recommended that feasibility determinations should consider alternative trial designs, 
including the use of active controls (cf. Haire, 2014) designed to demonstrate superiority of 
the experimental product as compared to the control. This will permit sample sizes 
comparable to recent efficacy trials.  
 
1.2.3 Step 3: Compelling public health need 
The key question driving step three is: does the study address a compelling public health need 
in the setting where it will take place? While the authors anticipate that the standard of 
prevention would be resolved at one of the first two steps, in some instances if the provision 
of a clinically validated prevention intervention is not methodologically possible, the social 
value of the research is considered. Only in circumstances where research addresses a 
compelling public health need in the host community, can withholding an otherwise ethically 
required prevention intervention be justified (Jay et al., n.d.). A compelling public health 
need is defined as contributing to prevention efforts and offering “the prospect of a true 
‘game-changer’ with respect to the local epidemic” (Jay et al., n.d., p. 13). Of course, such 
judgements may rely on the opinions of experts, which may differ.  
 
In addition, a suboptimal prevention package is only acceptable with thorough consultation 
and the express agreement of host communities and other local stakeholders such as health 
officials and local RECs in accordance with processes outlined in GPP guidance 
(UNAIDS/AVAC, 2011). Figure 4 graphically captures the three decision-making steps when 















Figure 4: The three-step framework for making decisions on the standard of prevention (Jay 
et al., n.d.). 
 
This framework provides a promising model for making decisions about when and how to 
add new tools to the prevention package. It helps clarify requirements in ethics guidelines by 
delineating requirements for clinical validation and attempting to clarify considerations 
regarding the feasibility threshold.  
 
2. Criteria for decision-making on standards of prevention 
In 2009, a consultation on standards of prevention was held in Uganda to explore challenges 
with operationalising existing guidelines and develop criteria to help research stakeholders 
implement guidance (Philpott et al., 2011). Meeting delegates established specific criteria to 
guide standard of prevention deliberations, as follows:  
1. If an international normative body and/or a national policymaking process 
recommends the use of a new method or strategy for HIV prevention for the 
population group enrolled in the trial, the presumption is that all trial participants 
should be ensured access to the method. Any departure from this recommendation 
must be clearly and persuasively justified on scientific and ethical grounds in the 
study protocol. 
2. In settings in which high-quality prevention services are available in the 
community, it may be appropriate to provide access to new prevention tools either 
by direct provision at the trial site or by referral. If participants receive access to 
new prevention tools through referral, researchers and trial sponsors must use a 
system of active referrals to monitor access and to ensure quality care. Consistent 
with the commentary to guidance point 13, participants agreed that sponsors need 
not always provide prevention methods directly. Access to new tools could be 
achieved through referral to existing high-quality HIV prevention and care 
services rather than through direct provision by the trial. 
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3. It is the responsibility of the researchers and trial sponsors to ensure that new HIV 
prevention tools included as part of the standard prevention package are made 
available at no additional cost to study participants. The meeting participants 
agreed that to protect participant safety and maximise benefit, trials must cover 
the cost of the service as necessary, actively support referrals and ensure suitable 
levels of quality (Philpott et al., 2011, p. 246).  
 
However, some of these criteria may result is similar ambiguities as guidelines, for example, 
criterion 1 requires international normative body and/or a national policymaking process. 
Some trial implementers may wait for national guidelines before offering newly validated 
tools while others may offer prevention interventions based on international normative body 
approval. There is also little direction on how to ensure access to prevention interventions in 
circumstances where they are not available in the public healthcare sector and where sponsor 
funding policy prohibits the provision of such interventions (cf. UNAIDS/AVAC, 2011).  
 
Meeting delegates also developed a set of seven questions to guide stakeholder decision-
making during stakeholder consultations on standards of prevention (when regulatory 
approvals are pending). These questions consider the evidence to support the safety and 
scientific validity of the intervention; pragmatic/logistical considerations regarding 
availability and access to the intervention; and scientific design/statistical considerations. The 
specific questions follow: 
1. What is the strength of evidence for efficacy/effectiveness of the new HIV 
prevention tool, including: 
a. the point estimate and confidence limits for any estimate of effect;  
b. the consistency of the data across different trial sites (contexts) and in 
different study populations; and  
c. the number and type of clinical trials demonstrating an effect. 
2. Has the efficacy/effectiveness of the new HIV prevention tool been demonstrated 
in comparable populations and for comparable modes of transmission? 
3. Are there any safety concerns or other unanswered questions that could question 
the appropriateness of the new HIV prevention tool for the trial participants (e.g., 
antagonistic interactions with other components of the prevention package (cf. 
Dawson, 2012), concerns about frequency or duration of use, or cultural practices that 
could affect safety)? 
4. Have the safety and efficacy or effectiveness data been reviewed and accepted by 
experts other than the trial investigators? 
5. Is there general agreement in the public health community that the new HIV 
prevention tool would likely provide some protective benefit for the population 
enrolled in the trial? 
6. Will it be feasible to provide trial participants with the new HIV prevention tool 
given local availability and accessibility, manufacturing and importation restrictions, 
or other relevant factors? 
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7. Will adding the new method undermine the trial’s ability to isolate the efficacy of 
the HIV modality being tested? (Philpott et al., 2011, p. 246) 
 
In circumstances where a newly validated prevention intervention is not included in the 
standard of prevention of trials, research stakeholders (including researchers, sponsors, 
national government, and community advocates) should develop a communication strategy 
(cf. UNAIDS/AVAC, 2011) to explain the clinical, scientific, and/or ethical justifications for 
not including the prevention tool in the standard prevention package (Philpott et al., 2011).  
 
These criteria expounded by meeting delegates for consideration by stakeholders in 
determining the enhancement of the prevention package consider complicated statistical and 
scientific design issues, difficult for those without technical expertise (Haire et al., 2013; 
Koen et al., 2013) and require stakeholders to determine agreement among experts, which is 
difficult to achieve and evaluate (National Bioethics Advisory Commission, 2001).  
 
3. The good governance model for stakeholder consultation  
Stakeholder consultation is often recommended as a mechanism for decision-making in ethics 
guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). Further, it is 
recommended that trials should not be conducted until agreement has been reached on key 
ethical and scientific design issues, including the standard of prevention, (UNAIDS/WHO, 
2012). However, guidance (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) 
provides no direction on how to operationalise such consultations (Philpott et al., 2011) and is 
not consistently explicit about which stakeholder groups should be consulted and at what 
points in the trial process.   
 
The good research governance model (Tarantola et al., 2007) spells out a process for 
operationalising stakeholder consultations. The rationale for selecting this model is that it has 
informed the drafting of UNAIDS/WHO (2012) and UNAIDS/AVAC (2011) guidelines, has 
been applied to issues of care and treatment in HVTs, and its authors contend that it can be 
adapted for standard of prevention decision-making (Tarantola et al., 2007).  
 
The good research governance model is the result of several consultations held by the WHO 
and UNAIDS that aimed to “map out current guidance and approaches being applied in 
practical field situations, define obligations to provide care as well as constraints to the 
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provision of care and treatment in the context of vaccine trials, and identify potential creative 
mechanisms and approaches to the attainment of the highest possible synergy between 
scientific quality, outcome of research, and protection of trial participants” (Tarantola et al., 
2007, p. 4863).  
 
There are different principled approaches to making decisions about obligations to 
participants in clinical trials including distributive justice (which focuses on the outcome) and 
procedural justice (which focuses on the process) (cf. Daniels, 2004). Ethical decision-
making in research requires a deliberative process (HPTN, 2009). Daniels (2004) argues that 
outcomes arrived at through a fair deliberative process are likely to be perceived to have 
moral legitimacy. Social psychological research also suggests that people’s perceptions of 
procedural fairness impacts on their evaluation of the outcome, that is, people are more 
willing to accept decisions if they believe that they were reached through a fair process, even 
if the outcome is not personally favourable (Tyler, 2000).  
 
As mentioned above, one model for making procedural decisions in the context of HIV 
vaccine research is the good governance model (Tarantola et al., 2007). The good governance 
model proposes to involve all research stakeholders, including the community, in a 
structured, participatory and transparent decision-making process, that will allow agreement 
(cf. UNAIDS/WHO, 2012) to be reached on core obligations in settings where HVTs are 
planned (Tarantola et al., 2007). It identifies the ethical goal of such consultation as ensuring 
that “the needs and legitimate expectations of trial participants are appropriately met, 
obligations towards them are delivered and, as a result, ethical research is facilitated in the 
interest of public health” (Tarantola et al., 2007, p. 4863). The need to involve all research 
stakeholders in a transparent and deliberative decision-making process can also be justified 
on the basis of ensuring a fair process and is in line with the philosophical principle of respect 
for communities (cf. Weijer et al., 1999). In justifying the need for a decision-making model, 
Tarantola et al. (2007) argue that while ethical principles, like beneficence and reciprocal 
justice, obligate sponsors and investigators to provide care, treatment and prevention, these 
ethical principles are not always easy to apply. Further, Tarantola et al. (2007) contend that 
while ethics guidelines have also been developed to address key ethical complexities, they are 




The purpose of good research governance is two-fold. Firstly, as a process it aims to (i) 
ensure participation in decision-making, transparency and mutual accountability and (ii) 
document terms of agreement and responsibilities prior to initiation of the trial (Tarantola et 
al., 2007). Secondly, as an outcome it aims to (i) ensure compliance with international and 
national scientific and ethical standards and (ii) achieve a fair balance between community 
expectations and the provision of services to trial participants.  
 
This model identifies a comprehensive list of research stakeholders who should be included 
in decision-making, namely: volunteers, trial participants, communities, researchers, funders, 
sponsors, health systems, employing organisations, community-based organisations (CBOs) 
and NGOs, care organisations, responsible care professions, regulatory authorities and RECs. 
According to Tarantola et al. (2007) these stakeholders must consider four questions in their 
deliberations, namely: 
1. who should benefit from care, namely, potential trial participants excluded from a 
trial, enrolled participants, and/or other community members?;  
2. what type of care should they receive, namely, diseases targeted specifically by the 
vaccine being studied, diseases diagnosed as part of the trial design, diseases 
unrelated to the purpose of the trial?;  
3. what level of care should they receive, where level of care refers to the array of 
diagnostic, therapeutic and monitoring procedures relevant to a particular type of 
care?; and  
4. who should bear the cost of providing care?  
 
In addition, Tarantola et al. (2007) stipulate that four sets of criteria (normative, factual, 
evaluative and prospective) should be considered in decision-making. Firstly, normative 
criteria include established international, national and local norms and standards. Here 
stakeholder decisions should take into consideration ethics guidelines, sponsor and 
government policies, norms for scientific and ethical review, research governance and 
regulatory processes, guidelines on transparency and mutual accountability, national norms 
and practices regarding effective participation in decision-making as well as the requisite 
knowledge and skills that consultation participants should have in order to make effective 




Secondly, factual criteria include consideration of all the background evidence relevant to 
decision-making, including scientific and technical validity of the research design, the burden 
of the target disease, the required care and treatment necessary to satisfy study design 
requirements, ensuring participant safety during the study, existing and new collaborative 
partnerships, community expectations, and other context-specific considerations.  
 
Thirdly, evaluative criteria consider expectations and the effectiveness of policies, structures 
and services, including technical feasibility of care and treatment options, costs and cost-
effectiveness, national priorities and equitable access, and attention to vulnerable populations.  
 
Finally, prospective criteria are concerned with projection of resources, mechanisms, 
resource needs and impact for each optional approach, including estimating the resources 
required for each approach and who will pay for them, who will manage resources, the 
sustainability of approaches post-trial, impact on existing health systems, impact on disease 
burden, social benefits, monitoring and accountability, communication and community 
involvement, establishing a precedent, and review.  
 
Can this model be applied to standards of prevention? While the model has been proposed for 
setting standards for care and treatment in HIV vaccine research, the authors articulate that 
“standards of prevention form an integral part of the study protocol. As for standards of care 
and treatment, these should be established through broad-based stakeholder consultation. The 
model proposed for setting standards of care and treatment may prove a useful tool adaptable 
to achieve this aim” (Tarantola et al., 2007, p. 4865). A procedural approach focused on 
structured negotiating processes was also perceived as the optimal strategy for addressing 
several contentious issues including evolving standards of prevention, by participants at a 
UNAIDS workshop (Hankins et al., 2009). However, there are no published reports of 
adaptations of this model to standards of prevention. The authors justify their focus on care 
and treatment by arguing that prevention standards are commonly defined in the scientific 
design of vaccine trials whereas access to care is often insufficiently defined (Tarantola et al., 
2007). However, in a review of two trial protocols (see Chapter 7), the standard of prevention 
was only explicitly defined in one protocol in terms of study design. Further, even when 
standards of prevention are defined in protocols, ethics guidelines (MRC, 2003; 
UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) require that all research stakeholders should 
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be consulted on the standard of prevention and there are few sets standards for making 
decisions (cf. Essack, Slack, et al., 2010).  
 
3.1 Applying the four questions to standards of prevention 
The first question refers to who should benefit from care, namely, screen-outs, enrolled 
participants, and/or other community members. This is also an important consideration for 
standards of prevention, that is, who should receive prevention methods, and is especially 
critical given that guidelines are generally silent on this issue (see Chapter 3).  
 
The second question considers what type of care they should receive, namely, diseases 
targeted specifically by the vaccine being studied, diseases diagnosed as part of the trial 
design, or diseases unrelated to the purpose of the trial. This question does not map neatly 
onto standard of prevention considerations and will need to be adapted because, by definition, 
the standard of prevention refers to the prevention package provided to all participants in a 
trial to lower their risk of HIV (the target disease). Therefore, of particular concern is the 
question of which HIV prevention methods should be included in the standard of prevention 
package, including the incorporation of newly validated methods in the prevention package. 
This is considered a burning issue in standards of prevention (see Chapter 5). So, for this 
question it would be more appropriate to consider which HIV prevention methods should be 
provided to each moral group identified in question one above.  
 
The third question refers to what level of care they should receive, where level of care refers 
to the array of diagnostic, therapeutic and monitoring procedures relevant to a particular type 
of care. Here this question could be easily adapted to consider the level of HIV prevention 
interventions in terms of diagnostic, therapeutic and monitoring procedures for each type of 
HIV prevention method.  
 
The final question regarding who should bear the cost of providing care, is also applicable to 
HIV prevention, a question which is considered particularly contentious (see Chapter 5). 
 
Stakeholder consultations on standards of prevention should therefore consider:  
(1) Who should receive HIV prevention interventions?  
(2) Which HIV prevention interventions should they receive? 
(3) What level of HIV prevention should they receive? 
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(4) Who should bear the cost of providing HIV prevention interventions? 
 
Table 1 provides a decision-making matrix that considers these four questions as applied to 
standards of prevention. The left column of Table 1 addresses questions one and two. The 
column on the right deals with questions three and four, and some selected criteria for 
consideration. These questions will have to be addressed for each eligible moral group and 
applied to each HIV prevention intervention during decision-making, making it a potentially 
cumbersome exercise given the various stakeholder groups involved.  
 
Table 1.  
Decision-making matrix adapted from Tarantola et al. (2007) 
Decisions on responsibilities for prevention in the context of vaccine trials 
HIV prevention 
interventions for: 
Questions to consider for each moral group: 
1. What HIV prevention interventions should be provided 
(including consideration of newly validated interventions)? 
2. For how long? (feasibility study, phase I, II and III, post-
trial) 
3. Who will deliver HIV prevention interventions?  
4. What prevention will be offered through existing services? 
5. What are government and sponsor policies on the standard 
of prevention? 
6. Who will provide the resources? 
7. Who will administer the resources? 
8. What will be the monitoring and accountability 
mechanisms? 
9. What will be the complaint and arbitration mechanisms? 
10. When, under what conditions and how will standards of 
prevention be re-evaluated? 
1. Trial participants 
2. Participants who are 
screened out 
3. Partners of 
participants 
4. Families of 
participants 
5. Host communities 
 
 
The value of this framework in relation to ethics guidelines (MRC, 2003; UNAIDS/AVAC, 
2011; UNAIDS/WHO, 2012) is evaluated below.  
 
3.1.1 Who should receive HIV prevention interventions?  
Ethics guidance (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) varies in 
identifying eligible groups for prevention services. While all agree that participants should 
receive HIV prevention interventions, there is inconsistency on whether screen-outs, 
participants’ partners, and/or host communities should get access to HIV prevention 
interventions. Therefore, this model will be useful in helping to clarify who, apart from trial 
participants, should receive prevention interventions, what prevention interventions they 
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should receive, and how these prevention services should be accessed (on-site provision 
versus referral) by other eligible populations. Ethics guidance (MRC, 2003; 
UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) does not provide adequate direction on these 
issues – as described in Chapter 3.  
 
3.1.2 Which HIV prevention interventions should be provided? 
The prevention interventions offered to participants in HVTs is a somewhat controversial 
topic. Ethics guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) have 
established substantive standards and spell out the components of prevention that should be 
ensured for trial participants. However, all guidelines endorse consultation with stakeholders, 
including the community, regarding the HIV prevention interventions that should be ensured 
(MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). There is potential for conflict 
between substantive and procedural norms, as detailed in Chapter 3. Given that one purpose 
of the model is to ensure compliance with international and national scientific and ethics 
standards, consultations on ‘what’ should be provided to participants seem superfluous given 
that these are already established in guidelines. Further, consultation on ‘what’ to provide 
may result in several outcomes, some more ethical than others, namely, it may ratchet up the 
standard of prevention, it may endorse the current substantive standard, or it may actually 
undermine the substantive standard that this package be ‘state-of-the-art’ (Essack, Slack, et 
al., 2010; Haire et al., 2012). It appears as though the substantive ethical standard and the 
procedural requirement for consultation are based on different ethical principles, namely, 
beneficence/non-maleficence and respect for communities, which may be in tension with 
each other when making decisions. It is also unclear about how best to resolve these tensions.  
 
It is considered unethical to withhold prevention services from trial participants that they 
could obtain outside the trial (Macklin, 2009). However, neither the ethics guidelines (MRC, 
2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) nor the model provide any guidance 
on what to do if the community argues for a publically available prevention service (e.g., 
VMMC) not to be provided in the trial due to strong religious and cultural objections. 
Beneficence (and respect for the autonomy of individual participants) would imply that 
researchers should offer these services to participants. At the same time, if we are to take 
seriously the principle of respect for communities (Weijer, 1999), then these services should 
not be offered to participants. However, the latter position opens researchers to criticism for 
putting community concerns ahead of concerns about individual participants. 
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3.2 Strengths and weaknesses of the model 
This model allows for deliberative decision-making that considers many relevant criteria, 
especially pragmatic consideration about how best to implement prevention services. Further, 
this model is helpful in identifying exactly which moral groups are entitled to which HIV 
prevention interventions. Apart from obligations to trial participants, what is owed to screen-
outs, partners and the host community is not clearly articulated in guidelines (MRC, 2003; 
UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). 
 
Unlike some ethics guidelines (MRC, 2003; UNAIDS/WHO, 2012), it is not left to the 
discretion of the reader as to who should be involved in consultations. Nonetheless, it may be 
impractical and infeasible to involve each of these stakeholders on every decision, for every 
clinical trial (cf. Koen et al., 2013; McGrory et al., 2010).  
 
Some authors have cautioned that in the absence of clear norms, consultation using this 
structured approach to consensual decision-making to clarify core obligations, merely 
delegates “the difficult struggle with norms and standards to consultative meetings” (Stobie 
& Slack, 2010, p. 151). For example, determining which moral groups are entitled to 
standards of prevention is a normative undertaking best addressed by normative philosophical 
analysis, rather than via stakeholder consultation. Canvassing the opinion of stakeholders is 
morally respectful and not morally definitive (Essack, Slack, et al., 2010; Grady et al., 2008; 
Slack & Stobie, 2010). So, while consensus may be an important tool for making procedural 
decisions, these decisions should be made in a way that does not undermine substantive 
norms and standards.  
 
This model lacks theoretical coherence. While it seems to resonate with the fair process 
approach (Daniels, 2000; 2004), this is not specified in the model. Unlike this model, the fair 
process approach is only used when there is a lack of set standards, and consultation would 
not be required to determine what to include in the package because there is already an 
established substantive standard. The ethical rationale for consultation is also not clear, but it 
appears congruent with the principle of respect for communities (Emanuel et al., 2004; 





Making decisions about the prevention services to provide to trial participants is complex and 
while guidelines provide some direction on how decisions should be made (MRC, 2003; 
UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012), these recommendations are vague and the 
processes necessary to operationalise guideline recommendations are not delineated. Some 
frameworks have been developed to facilitate decision-making about adding new tools to the 
standard of prevention package in a way that clarifies broad concepts such as scientific 
validity and regulatory approval (Jay et al., n.d.; McGrory et al., 2010; Philpott et al., 2011), 
and to operationalise ethics guideline recommendations for stakeholder consultation 
(Tarantola et al., 2007). While these frameworks offer detailed and helpful direction in 
operationalising recommendations, in some instances, e.g., feasibility determinations, they 
are subject to the same flaws as guidance. Further, these frameworks have not been piloted or 
evaluated for use as tools in standard of prevention decision-making. Empirical data on the 
implementation of these frameworks in HVTs and other prevention trials may help illuminate 
the pragmatic value of such frameworks, and identify how they could be strengthened.  
 
The ensuing chapter provides an overview of the debates and complexities regarding 




REVIEW OF DEBATES ON THE STANDARD OF PREVENTION 
 
As already shown, the standard of prevention is a prominent ethical concern within the 
context of HIV prevention trials and has become a recent topic of intense debate and 
consultation (e.g., Essack, Slack, et al., 2010; Haire et al., 2013; Macklin, 2008; Philpott et 
al., 2011). Much of this tension emanates from standard of prevention norms outlined in 
ethics guidance (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) reviewed in 
Chapter 3. Further, the ethical rationale for providing HIV prevention interventions to trial 
participants remains unsettled, the decision-making process is fraught with gaps and 
complexities, and there are several other objections to providing participants with a state-of-
the-art standard of prevention. This chapter reviews the debates regarding standards of 
prevention and the objections to providing a state-of-the-art standard of prevention to trial 
participants. It concludes with a review of previous empirical research and situates the 
present study within the empirical literature on standards of prevention.    
 
1. Standard of prevention norms in ethics guidelines 
Relevant ethics guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) on 
standards of prevention in HVTs were reviewed in Chapter 3. These guidelines assert that 
participants should be provided with access to ‘optimal’ (MRC, 2003) or ‘state-of-the-art’ 
(UNAIDS, 2012; UNAIDS/AVAC, 2011) HIV risk-reduction interventions. However, some 
contend that the ‘state-of-the-art’ standard may be too aspirational and not practically feasible 
(HPTN, 2009; Macklin, 2009; Rennie & Sugarman, 2010) especially in resource-constrained 
contexts with limited access to high quality prevention modalities (Macklin, 2010). It has 
been argued however, that the state-of-the-art standard is “an ethical aspiration, rather than an 
unwavering mandate” and that in circumstances where less than a state-of-the-art package is 
provided to participants, “this deviation must be strongly justified by a higher, competing 
obligation” (DAIDS, 2010, p. 10). Given that ethical aspirations are considered morally 
praiseworthy or commendable rather than ethically obligatory (cf. Rennie & Sugarman, 
2010), it is unclear why exceptions would require a strong ethical justification, nor which 




Ethics guidelines also recommend inter-stakeholder collaboration, and numerous engagement 
activities, to ensure access to the highest standard of prevention (MRC, 2003; 
UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). They make a range of recommendations 
about the standard of prevention in trials, including what should be declared in protocols and 
ICFs; which prevention interventions should be included in the prevention package; that 
prevention interventions should be monitored and documented; and about how decisions 
should be made on what to provide and when to add new tools to the prevention package. 
These recommendations have been argued to set a very high standard (Essack, Slack, et al., 
2010). Complexities with specific standard of prevention norms in HVT-specific ethics 
guidelines are also explored throughout this chapter.  
 
2. The ethical rationale for standards of prevention  
The ethical rationale underpinning the provision of HIV prevention interventions to 
participants is not settled. There is no published literature arguing that HIV preventive 
interventions should not be provided to trial participants. There is wide ethical consensus that 
participants should be provided with prevention interventions to reduce their risk (Macklin, 
2008; Slack et al., 2000; Rennie & Sugarman, 2010). However, various justifications for 
providing participants with a standard of prevention have been offered thus far. 
 
One rationale is that since participants in late-phase trials are at high-risk for HIV infection, 
they should be provided with prevention interventions to help reduce their risk (Essack, 
Slack, et al., 2010; MRC, 2003). Another rationale is that factors that place participants at 
high risk for HIV also increase their vulnerability, and that there is an ethical obligation to 
protect the vulnerable (de Zoysa et al., 1998). Further, the experimental nature of HVTs, the 
fact that some participants receive placebo, and that HIV is incurable, all underlie obligations 
to provide prevention interventions to trial participants (IAVI, 2005). Commentators have 
noted that standard of prevention obligations are founded on the provision in the Declaration 
of Helsinki that the researcher’s primary obligation to minimise risk for participants is 
paramount over consideration of future beneficiaries of research (Haire et al., 2012). Finally, 
prevention services should be provided to participants in order for researchers to satisfy their 




2.1 Bioethics frameworks and the standard of prevention 
McGrory et al. (2010) report on a review of what various bioethics frameworks would outline 
as researchers’ HIV prevention responsibilities, including principalism, standard of care, 
therapeutic obligation and equipoise, and duty of rescue. Lie et al. (2006) explore three 
potential ethical rationales for the provision of VMMC in HIV prevention trials, including 
behavioural disinhibition, reciprocal justice and the Good Samaritan argument. These 
potential ethical rationales for the provision of HIV prevention interventions to trial 
participants are outlined below.  
 
2.1.1 Principalism 
The first ethics framework from which potential ethical rationales for the provision of HIV 
preventive methods to trial participants are derived, is principalism. After a series of research 
abuses, the US government established a commission in the 1960s mandated to develop 
guidelines for the ethical conduct of research with human participants. The resultant 
document, the Belmont Report, expounded three ethical principles for research, namely, 
respect for persons, beneficence and justice. These principles, or ‘prescriptive judgments’, 
were envisaged to provide a moral framework to guide the ethical conduct of research with 
human participants and resolve any resultant ethical dilemmas (NCPHSBBR, 1979). 
 
Respect for persons requires that all participants be treated with respect, that individuals be 
treated as autonomous human beings, and that those with diminished autonomy are entitled to 
extra protection (NCPHSBBR, 1979). Beneficence/non-maleficence requires that all potential 
risks to participants be minimised and potential benefits maximised (NCPHSBBR, 1979). 
The principle of justice or fairness requires that the benefits and burdens of research are 
equitably distributed (Wassenaar, 2006) and that study participants and trial communities are 
not exploited (McGrory et al., 2010). 
 
Beneficence and non-maleficence have been offered as ethical rationales for providing 
prevention interventions to participants. These principles require that researchers recognise 
the potential vulnerability of trial participants and then design trials to minimise this risk and 
maximise benefits (McGrory et al., 2010; Slack et al., 2000). It is often assumed that this 
translates to a duty to protect participants’ welfare and “provide services known to reduce the 
risk of HIV infection and accepted as the standard of care” (de Zoysa et al., 1998, p. 571). 
Further, researchers cannot withhold HIV prevention interventions from participants if they 
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exist within the trial community (Macklin, 2009). Similarly, UNAIDS/WHO (2012) 
guidelines assert that beneficence and non-maleficence underpin the obligation to provide 
prevention interventions to participants. These principles obligate researchers and sponsors to 
reduce “the risk that any trial participant will acquire HIV infection during a biomedical HIV 
prevention trial” (UNAIDS/WHO, 2012, p. 45).  
 
However, there are limits to this obligation and not all ethicists concur that it is the principle 
of beneficence that compels researchers to provide participants with access to all established 
effective HIV prevention methods (cf. Lie et al., 2006; McGrory et al., 2010; Philpott et al., 
2011). Firstly, rather than a risk of study participation, HIV acquisition may occur due to 
behavioural, contextual or structural-level risks (cf. Haire et al., 2012). It has been 
empirically shown that HIV incidence among trial participants tends to decrease because of 
“sustained risk-reduction counselling and provision of effective HIV prevention tools” 
(UNAIDS/WHO, 2012, p. 12). Secondly, the metaethical principle ‘ought implies can’ 
dictates that researchers are morally required “to do what they are capable of doing, or what 
is reasonable to ask” (van de Graaf & van Delden, 2009, p. 37). This means that ethical 
standards must be feasible or implementable in practice (van de Graaf & van Delden, 2009, p. 
37). A case in point is that while many ethicists contend that VMMC should be provided to 
participants when researchers can afford to do so, some argue that this obligation does not 
extend to circumstances where circumcision is not yet established and accepted by the local 
community (HPTN, 2009; McGrory et al., 2010).  
 
Another rationale for providing preventive interventions is based on reciprocal justice where 
participants are “rewarded” with preventive interventions because the trials in which they 
enrol contribute social benefits, such as improved prevention methods (Lie et al., 2006). Here 
researchers would be required to evaluate the overall risks and benefits of participation and 
demonstrate that the provision of preventive interventions is fair compensation for 
participation (Lie et al., 2006). Since trial participants give more of themselves it is suggested 
that they do indeed qualify for special treatment in the form of access to services or benefits 
not available to others – researchers’ obligations to the larger society do not surpass their 
responsibilities to individual participants (Heise & Wood, 2005).  
 
Still, Tarantola et al. (2007, p. 4863) argue that while ethical principles, like beneficence and 
reciprocal justice, “create certain obligations on researchers, sponsors and public health 
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authorities... these obligations are poorly defined in practical terms, inconsistently understood 
or inadequately applied.”  
 
2.1.2 Behavioural disinhibition 
Behavioural disinhibition/risk compensation captures the potential for participants to place 
“undue faith in the protective effects of the intervention or technology under study” and 
compensate by increasing their risky behaviour (Woodsong et al., 2012, p. 786). Such risk 
compensation may occur due to three fundamental misconceptions: an overestimation of the 
potential effectiveness of the experimental HIV prevention intervention, belief that one is 
assigned to the experimental arm, and that prevention trials are intervention programmes 
(Cassell, Halperin, Shelton & Stanton, 2006; Chakrapani, Newman, Singhal, Nelson & 
Shunmugam, 2013; Gray et al., 2013). Therefore, an obligation to provide preventive 
interventions could be justified because of the potential for increased risky behaviour in such 
trials (cf. Lie et al., 2006). Although, HIV incidence typically decreases among HIV 
prevention trial participants, some increases in risk behaviour have been observed in HIV 
vaccine research (Chesney, Chambers & Kahn, 1997). Still others have argued that there is 
little evidence for behavioural disinhibition (Slack et al., 2000; Lie et al., 2006) and that 
limited data from HIV vaccine and other HIV prevention trials has generally not indicated 
any overall increase in risk behaviour amongst trial participants (Agot et al., 2007; Gray et 
al., 2013; Guest et al., 2008). Recent research also found no evidence for risk compensation 
among participants in an HIV vaccine efficacy trial conducted in South Africa (Gray et al., 
2013). Further, participants are counselled at every study visit on how to reduce their risk. It 
is also emphasised during counselling that participants should not assume that they are 
protected from HIV infection given that the product is experimental and assignment to the 
experimental and control arms is double-blinded (cf. MRC, 2003). Therefore, it is argued that 
the potential for behavioural disinhibition provides a weak justification for the provision of 
prevention services (Lie et al., 2006). 
 
2.1.3 Standard of care 
A third potential rationale for providing participants with HIV prevention interventions is that 
it is ethically abhorrent for trial participants to receive care or prevention services not on par 
with the established standard of care (McGrory et al., 2010). However, there is disagreement 
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on whether the established standard of care should reflect the best-proven interventions 
available globally or whether this should be locally defined6 (Dawson, Klingman & Marazzo, 
2014; Haire et al., 2013; McGrory et al., 2010). Each has its own drawbacks. Most ethicists 
and researchers agree that providing the locally established standard of care which may 
comprise only a few, if any, prevention interventions is wholly inadequate (McGrory et al., 
2010). At the other extreme, providing an internationally established state-of-the-art standard 
of prevention may not be feasible in some developing country contexts (Macklin, 2010; 
Rennie & Sugarman, 2010). Determining the appropriate standard of prevention is complex 
because entitlements to health services vary by country, and even in well-resourced countries, 
participants are not entitled to all available, effective (or state-of-the-art) interventions 
“because justice necessitates establishing priorities” (Emanuel et al., 2004, p. 933). While 
providing a locally relevant standard of prevention is argued to compromise generalisability 
to other contexts (Haire & Jordens, 2013), results that are irrelevant to the host community 
are unethical (Emanuel et al., 2004). As long as the study is socially valuable (especially to 
the host community), providing a standard of prevention beyond that to which participants 
are entitled or that are feasible and sustainable may be unethical if it undermines scientific 
validity or makes “the results irrelevant to the community” (Emanuel et al., 2004, p. 933).  
 
In their review of HIV prevention trials, Padian, McCoy, Balkus and Wasserheit (2010a) 
found that most of the services provided to participants in the control arm were not sustained 
post-trial nor were there plans to do so. Given that the experimental product is not compared 
to the standard in the local setting, this compromises the study methodologically (Padian et 
al., 2010a). These authors suggest that the standard of prevention offered in trials should be 
on par with the established local standard “or the provision of a feasible, well documented 
plan for the sustainability of proposed new services as a measure of both the ethical and 
methodological appropriateness of interventions in control groups” (Padian et al., 2010b, p. 
2299). On the other hand, it is argued that even if the ethical criterion of sustainability 
(Padian et al., 2010b) is not realised post-trial, the immediate potential benefit of reduced 
HIV infection risk for participants (and their sexual partners) is a legitimate trial-related 
benefit (Haire et al., 2013), that may have ongoing impacts on HIV incidence (Haire & 
Jordens, 2013). Another suggestion is to provide as high a standard of prevention as possible 
                                                             
6 Readers are referred to Alex London’s seminal work (London, A. J. (2000). The ambiguity and the exigency: 
clarifying 'standard of care' arguments in international research. Journal of Medicine and Philosophy, 25(4), 
379-397), which attempts to disambiguate the concept of a 'standard of care'. 
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while ensuring that this is not infeasible for researchers, or unachievable and/or unsustainable 
in the local context (HPTN, 2009; McGrory et al., 2010). Further, if the local standard of care 
is poor, efforts should be made to “ratchet up” available services (Shapiro & Benatar, 2005).  
 
2.1.4 Therapeutic obligation and clinical equipoise 
The therapeutic obligation and clinical equipoise may also ground researchers’ obligations to 
provide participants with a standard of prevention (McGrory et al., 2010). The therapeutic 
obligation compels physicians (and by extension physician-researchers) to act in their 
patients’ best interests (McGrory et al., 2010). Clinical equipoise requires genuine uncertainty 
about whether an experimental vaccine is better or worse than the existing standard of care 
(Haire & Jordens, 2013; McGrory et al., 2010). Given the uncertainty about the experimental 
intervention coupled with obligations to act in participants’ best interests, it follows that 
researchers are obligated to provide participants with effective HIV prevention interventions. 
However, some commentators contend that the concept of clinical equipoise is itself 
defective, incoherent (Miller & Brody, 2003, 2007) and irrelevant (Veatch, 2007). Since 
researchers are not primary-care physicians (Miller & Brody, 2003, 2007) and services 
provided in HIV prevention trials differ from medical care typically received by patients, the 
therapeutic obligation may not be a sound argument for framing researchers’ HIV prevention 
responsibilities to trial participants (McGrory et al., 2010).  
 
2.1.5 The duty of rescue 
Like the principle of beneficence, the duty of rescue (or Good Samaritan argument) requires 
that potential benefits are maximised and potential risks minimised (McGrory et al., 2010). 
Therefore, the provision of preventive measures could be morally justified “based on the 
fundamental ethical requirement for any person to do what they can to help others in need” 
(Lie et al., 2006, p. 523). It follows that researchers are obligated to provide participants with 
some care beyond that required for the conduct of the study, although this obligation too has 
limits (McGrory et al., 2010). This ethical obligation implies that certain scientific and 
logistical considerations must be satisfied such that the intervention should have proven 
effectiveness and can be justified in terms of acceptable and reasonable costs in relation to 
the magnitude of benefits that one could expect (Lie et al., 2006). If the prevention tool is 
both effective and economical given the context, then researchers will be ethically obligated 
to promote it and perhaps even ensure access to it as part of trial costs (Lie et al., 2006). 
However, the availability of a cost-effective prevention tool will likely create an even 
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stronger moral obligation on health authorities to include this tool as part of the public 
healthcare system; if the prevention tool is already in the public domain researchers would be 
obliged to provide information about the tool, remove barriers to access, and encourage 
participants to access it (Lie et al., 2006). As long as the costs of providing such preventive 
care do not compromise the trial, there is “no compelling reason why the researchers do not 
have an obligation to provide as many additional medical and social services to study 
participants as possible” (McGrory et al., 2010, p. 11). 
 
In summary, all commentators agree that there is an ethical mandate to provide participants 
with preventive interventions. However, this obligation is derived from various ethical 
principles and frameworks and the ethical reasoning informing guidelines and 
recommendations on the standard of prevention is not clear (McGrory et al., 2010) or 
explicit. Even within one framework, e.g., principalism, there are different potential 
rationales for providing preventive interventions to participants. “Ethics guidelines and 
frameworks can provide broad principles but rarely provide a ‘one size fits all’ set of 
recommendations on the types and levels of prevention and care services within individual 
research trials” (McGrory et al., 2010, p. 11).  
 
3. Complexities regarding the standard of prevention 
There is little clarity about how decisions should be made about standards of prevention in 
trials. The decision-making process is unclear (Cohen, Mastroianni & Macklin, 2014; Essack, 
Slack, et al; 2010; Philpott et al., 2011); the incorporation of newly validated prevention 
interventions in the standard of prevention is fraught (Cowan & Macklin, 2014; Dawson, 
2012; Haire et al., 2012; Macklin, 2012; Philpott et al., 2011; Rennie & Sugarman, 2010); 
and there is little certainty about exactly which stakeholders are ethically responsible for 
ensuring implementation of the standard of prevention and covering the costs of prevention 
interventions (Essack, Slack, et al., 2010; Macklin, 2008). These decisions are complicated 
by many factors including vague guidance, a paucity of (evaluated) operational frameworks 
for decision-making, and an absence of established standards for decision-making.  
 
It has been mentioned that there is increasing consensus regarding the provision of state-of-
the-art HIV prevention interventions in trials (Macklin, 2008). However, debate remains 
about what services should be included in the package of prevention. Currently, male and 
female condoms, VMMC, STI diagnosis and treatment, education and risk-reduction 
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counselling, PEP, the provision of clean needles and medical substitution therapy, treatment 
as prevention, and PrEP are available tools for HIV prevention (see Chapter 2). To add to the 
current prevention arsenal, many new technologies are being tested. Recent developments in 
HIV prevention research include positive trial outcomes for oral and topical PrEP and 
treatment as prevention, and while these findings are welcomed and celebrated, they create 
ethical and scientific challenges for future HIV prevention trials.  
 
While there is broad agreement (McGrory et al., 2010; Slack et al., 2000; UNAIDS, 2000) 
that participants should receive access to certain HIV risk-reduction interventions (such as 
condoms, counselling and STI treatment), there has been some disagreement about 
obligations to ensure access to other interventions such as VMMC (cf. Lie et al., 2006; 
HPTN, 2009), PEP (UNAIDS, 2000) and PrEP (Cowan & Macklin, 2014; Dawson, 2012; 
Haire et al., 2012; Haire, 2014; McEnery, 2012; Sugarman & Mayer, 2013). Ambiguities in 
guidelines about what should be included in the prevention package are manifested in 
practice – the standard of prevention offered to participants in HIV prevention trials is 
variable (Haire & Jordens, 2013; Heise et al., 2008; Ngongo, Priddy, et al., 2012). A further 
complexity is that there are no established standards for decision-making (Kim et al., 2010) 
and variable standards have been used across trials and stakeholder groups (cf. Essack, Slack, 
et al., 2010; Haire & Jordens, 2013; Philpott et al., 2011).  
 
As newly validated HIV prevention tools emerge, there has been increasing debate about 
whether they should be added to the standard of prevention, including whether a state-of-the-
art package would include VMMC and a partially effective vaccine or microbicide if such 
methods are proven effective (Macklin, 2009). The requirement to provide access to all state-
of-the-art prevention interventions has been argued as setting a very high standard (HPTN, 
2009; Macklin, 2009) and as creating concerns about the feasibility of future trials (Macklin, 
2008).  
 
Ethics guidelines provide some direction on the addition of new prevention interventions to 
the prevention package. Firstly, new tools should be added when they are scientifically 
validated (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). A second criterion 
for adding new tools is approval by relevant authorities (UNAIDS/WHO, 2012) or national 
bodies for use (UNAIDS/AVAC, 2011). As described in Chapters 3 and 4, ethics guidelines 
do not outline the criteria for “scientifically validated” or “approved by relevant authorities” 
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which is problematic because these conditions are defined differently by different regulatory 
and normative bodies (McGrory et al., 2010). For example, in terms of scientific validity, 
with VMMC normative bodies required evidence from three RCTs before issuing guidance 
but male condoms were recommended as an effective strategy based only on observational 
data (Philpott et al., 2011). In terms of normative/regulatory approval, some trials provided 
VMMC based on scientific evidence while others only included VMMC in the prevention 
package after the introduction of VMMC in national guidelines (Essack, Slack et al., 2010; 
Haire & Jordens, 2013). Furthermore, when considering whether a new prevention 
intervention is scientifically validated, the requirements for new tools far exceed what was 
previously accepted (Padian et al., 2008). For some tools, e.g., condoms and PEP, there is 
only data from observational studies yet for new tools the requirement is evidence from at 
least two RCTs. Regulatory requirements for two RCTs have been criticised as unduly 
delaying the introduction of effective prevention interventions in high-risk populations (Haire 
et al., 2012) although this was rebutted because it would be irresponsible (and arguably 
unethical) to provide prevention interventions to participants based on inconclusive evidence 
(Dawson, 2012).  
 
Given the evidence for efficacy of PrEP (oral Truvada), in relation to the operational criteria 
for clinical validation (Jay et al., n.d.) and scientific validity (Philpott et al., 2011), PrEP can 
be considered scientifically validated. For this reason, it has been argued that PrEP should be 
included in the standard of prevention in future HIV prevention trials (Cowan & Macklin, 
2014) or as an active comparator (Haire, 2014). Further, “[w]ith the FDA now having 
approved PrEP for HIV prevention, under the UNAIDS guidelines there is a prima facie 
requirement to provide PrEP as standard of prevention, as PrEP clearly meets the definition 
of “state-of-the-art,” having been approved by a normative body” (Haire, 2014, p. 6). 
However, while PrEP has been approved as an effective prevention strategy by the US FDA, 
it is yet to be approved in any other country in which trials were conducted (Haire, 2013; 
Hankins & Dybul, 2013). Denying participants access to a prevention intervention simply 
because it has not been registered in the country where they live, has been argued to be 
ethically problematic (Cowan & Macklin, 2014). However, it has also been argued that 
interventions should not be provided as part of the standard of prevention in trials when they 
have not been approved by national regulatory authorities (cf. Philpott et al., 2011). 
Disagreement on this issue is enabled by vague guidelines, for example, while Haire (2014) 
contends that there is a prima facie requirement to provide PrEP, she also notes (Haire, 2013) 
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that UNAIDS guidelines are ambiguous and it is not clear whether approval would be 
required from national authorities or whether any regulatory or normative body approval 
would suffice. Therefore, it is difficult to imagine that in contexts where PrEP is not 
approved, inaccessible, or cannot be reasonably procured (Jay et al., n.d.) that it could be 
considered unethical by UNAIDS ethics guideline standards not to provide this intervention 
to HVT participants.  
 
These ambiguities on ethical concepts in guidance are further complicated by requirements 
that the prevention package be determined via a process of consultation with all research 
stakeholders (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012), that trials should 
not be conducted unless all stakeholders agree on the standard of prevention before a trial 
commences (UNAIDS/WHO, 2012), and that the prevention package should be negotiated 
(UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). It is specified that negotiations should 
consider the impact of enhanced standards of prevention on trial feasibility and the ability to 
isolate the effect of the experimental intervention (UNAIDS/WHO, 2012).  
 
Several concerns have been raised regarding these procedural requirements. Firstly, 
guidelines do not provide direction on how to operationalise these decision-making 
mechanisms (Cohen et al., 2014; Philpott et al., 2011). Secondly, commentators have noted 
that these requirements present pragmatic complexities since many HIV prevention trials are 
designed well in advance of their implementation (Haire et al., 2013) and for multi-site trials, 
protocol development is often centralised (UNAIDS/AVAC, 2011). Therefore, extensive 
consultation and stakeholder input on the design of the standard of prevention may not 
always be possible, and is further compounded by low levels of literacy which may constrain 
discussions on standards of prevention (Haire et al., 2013). Thirdly, as identified in the 
review of standard of prevention norms in HVT-specific guidelines (Chapter 3) procedural 
requirements may conflict with substantive standards requiring access to ‘state-of-the-art’ 
prevention interventions and in some instances this may undermine the substantive norm and 
lower the prevention package (Essack, Slack, et al., 2010; Haire et al., 2012). Similar tensions 
have been noted by Philpott et al. (2011) who recommend additional work in order to clarify 
how the substantive standard that the package be state-of-the-art (UNAIDS/WHO, 2012) 




In terms of the negotiation recommendation (UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012), 
theoretical concerns have been raised about how structural power inequities between 
communities and researchers, and between resourced and resourced-constrained contexts may 
limit the ability to negotiate (Haire, 2013; West Slevin, Ukpong & Heise, 2008). 
Recommendations to ‘negotiate’ have also been criticised as serving the interests of the 
research elite rather than communities (Haire, 2013) given their consideration of statistical, 
scientific and technical issues. Given these limitations, it has been recommended that 
“standard prevention packages should be provided in line with clearly defined guidelines as a 
responsibility of researchers to the research participant. The utilisation of GPP 
(UNAIDS/AVAC, 2011) as a practice guide in the design and implementation of HIV 
prevention research is expected to better systematise community engagement and promote 
greater ownership of research by communities” (Haire et al., 2013, p. 6). This 
recommendation, however, does not resonate with empirical findings that some standard of 
prevention recommendations outlined in GPP guidelines (UNAIDS/AVAC, 2011) are 
considered challenging to implement (Moorhouse et al., 2014). 
 
As indicated in Chapter 4, another complexity relates to the resources to fund prevention 
interventions (Kim et al., 2010) and which stakeholders should pay for the provision of these 
interventions to participants (Macklin, 2008). It is argued that the burden should not fall on 
sponsors and researchers alone; nor is it affordable for poorly resourced governments on their 
own (Macklin, 2008). It is accepted that “researchers are not solely responsible for meeting 
healthcare related needs of trial participants” and while they are obligated to ensure access to 
adequate healthcare, this does not entail that researchers should provide it themselves (Heise 
& Wood, 2005, p. 35). However, who pays for prevention interventions is complex because it 
may be constrained by sponsor funding policies (Philpott et al., 2010; UNAIDS/AVAC, 
2011) and the local healthcare context (Macklin, 2010). One suggestion has been to 
incorporate costs into budgets supported via public-private partnerships and that skilled 
negotiators be utilised in brokering such arrangements (Macklin, 2008). Ethics guidelines 
also suggest that researchers and sponsors should collaborate with host country governments 
to ensure access to the highest standards of prevention and care because these efforts should 
be envisaged as a shared responsibility (UNAIDS/WHO, 2012). 
 
Considerations related to the local context of the planned HVTs have also been argued as 
important (Rennie & Sugarman, 2010), including feasibility, accessibility and sustainability 
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of the intervention. It has been argued that newly validated tools should not be added to the 
prevention package when they are not widely available in the host context, not approved by 
national regulatory bodies and not sustainable in the local context after the trial (cf. HPTN, 
2009; Philpott et al., 2011). On the other hand, it is argued that the immediate potential 
benefit of reduced HIV infection risk for participants (due to the addition of a new prevention 
intervention), is a legitimate trial-related benefit (Haire et al., 2013). Finally, potential 
interaction effects between the vaccine and other prevention interventions require careful 
assessment (Dawson, 2012), and may also affect licensure of the experimental vaccine.  
 
4. Objections to providing a state-of-the-art standard of prevention 
There have been a slew of objections to ethics recommendations to provide access to all 
state-of-the-art HIV prevention interventions including that it sets the bar too high, introduces 
significant inequities between trial participants and communities, may result in undue 
inducement, and increased behavioural disinhibition (HPTN, 2009). Further, since large-scale 
efficacy studies are often conducted in developing country contexts where there is a high 
burden of disease, there is some concern that strict adherence to ethics guidelines may be 
challenging, given limited access to state-of-the-art prevention packages in these contexts 
(Macklin, 2010). Concerns regarding undue inducements, creating inequities between trial 
participants and communities, and the potential impact on trial feasibility are described 
below.  
 
4.1 A state-of-the-art standard of prevention is an undue inducement 
There is concern that a state-of-the-art standard of prevention will create an undue 
inducement to participate in trials (de Zoysa et al., 1998; HPTN, 2009; cf. UNAIDS/WHO, 
2012). Undue inducements are “offers of a desirable good in excess such that it compromises 
judgment and leads to serious risks that threaten fundamental interests” (Emanuel, Currie & 
Herman, 2005, p. 337). Proponents of the argument that a state-of-the-art standard of 
prevention is an undue inducement suggest that offers of medical care, not generally 
available, may unduly influence people to participate in risky clinical research (HPTN, 2009). 
Similarly, it may be argued that providing participants with a comprehensive prevention 
package may serve to compromise participants’ abilities to evaluate the risks of their 
participation. It is argued that “offering an extensive array of HIV prevention methods when 
these methods are not generally available in the community may also constitute undue 
inducement to participate” (HPTN, 2009, p. 44). However, some argue that undue 
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inducement should not be a concern in clinical research as long as RECs approve the research 
and the risks are reasonable in and of themselves (Emanuel, 2004; Emanuel et al., 2005). 
However, approval of research by RECs may not absolve the researcher of undue inducement 
concerns as RECs are sometimes not capacitated to evaluate risks competently (Martin, 2005; 
Milford et al., 2006). Others have contended that the provision of services and care beyond 
what is necessary to conduct the trial should not be understood as undue inducements because 
inducements are only “undue” and problematic when they are so attractive that they impair a 
volunteer’s ability to employ proper judgment and leads them to discount risks (Heise & 
Wood, 2005). Further, as with the provision of ART, it is plausible that access to benefits like 
HIV prevention interventions may be based on rational choice and are not evidence of 
distorted decision-making (Slack et al., 2005). Further, it is argued that “because there is not 
an enormous amount of risk associated with participating in HIV prevention trials, offering 
real benefits to participants is unlikely to constitute an ‘undue inducement’” (McGrory et al., 
2010, p. 29). 
 
4.2 A state-of-the-art standard of prevention introduces local inequalities 
If the state-of-the-art standard is benchmarked against international best practice, in some 
contexts, this standard would be higher than the available local standard. Providing HIV 
prevention strategies to trial volunteers when they are unavailable to the larger community in 
which the trial is situated, has been considered unethical and as creating “serious inequities 
between research participants and community members with similar needs” (HPTN, 2009, p. 
46). However, the principle of reciprocal justice deems it appropriate that participants receive 
services that may not be available to the broader community (Heise & Wood, 2005). It is 
argued that researchers should always endeavour to minimise inequities but that such 
disparities exist in most contexts (Heise & Wood, 2005). Efforts to provide benefits and 
improve the lives of some (even if not all), is not morally problematic (Heise & Wood, 2005). 
National guidelines (MRC, 2003) also suggest that participants should receive services that 
they would not otherwise obtain and while this may introduce local inequalities, it reflects 
active protection and fair treatment of participants. This resonates with the position in 
UNAIDS/WHO (2012) guidelines that social justice concerns do not fully appreciate that “all 
scale-up programmes involve temporary inequalities in the community until universal access 




4.3 A state-of-the art standard of prevention may negatively impact on trial 
feasibility 
As described in Chapter 2, HIV prevention efficacy studies are conducted to determine 
whether the experimental prevention method can decrease the risk of HIV infection more 
than the standard of prevention provided to participants in both arms of the study (de Zoysa et 
al., 1998). In these trials, the primary endpoint is HIV infection. However, even in areas of 
high HIV incidence, HIV infection is a relatively uncommon occurrence (Lagakos & Gable, 
2008). Therefore, prevention trials are often complex and expensive to conduct as they 
require enrolling and retaining several thousand HIV-negative participants over several years 
(Hankins, 2006). Furthermore, researchers are ethically obligated to provide all participants 
with prevention interventions to reduce their risk of HIV acquisition (MRC, 2003; 
UNAIDS/WHO, 2012; UNAIDS/AVAC, 2011) thus decreasing HIV incidence in both the 
experimental and control arms of trials (UNAIDS/WHO, 2012).  
 
Clinical trials must demonstrate that the experimental intervention has a benefit above that of 
the risk-reduction methods being provided. The more effective the prevention package 
provided to participants, the lower the incidence, and the less power the trial has to detect 
beneficial effects of the experimental intervention (Lagakos & Gable, 2008). This is not a 
theoretical concern. For example, in the MIRA diaphragm trial, diaphragms plus condoms 
were compared against condoms alone. Since HIV transmission rates were similar in the 
intervention and control arms, “it was interpreted widely that diaphragms were ineffective. A 
more correct interpretation was that they might have been equally efficacious as condoms, as 
condom use in diaphragm group was uncommon, despite encouragements for their use” 
(Vermund et al., 2009, p. 271). In their review of 37 HIV prevention RCTs reporting on 39 
unique interventions, Padian et al. (2010a) reported that nearly 90% of these trials produced 
‘flat’ results, many of which may be attributed to trial design and/or implementation issues. 
In many of the studies with no effect, the intensity of risk-reduction services offered in both 
arms is a key consideration with most of these studies providing a prevention package that 
exceeded the standard available in the local community (Padian et al., 2010a). This may 
dramatically reduce the ability to detect the effect of a new and effective intervention (Padian 
et al., 2010a).  
 
As newly validated prevention interventions emerge, “researchers worry that requiring a 
prevention package containing state-of-the-art methods will thwart their ability to obtain 
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meaningful results of trials” (Macklin, 2008, p. 285). In order to counter such decreases in 
statistical power, trial sample sizes will need to increase, resulting in longer, more expensive 
trials (cf. Essack, Slack, et al., 2010; Haire, 2014). Trial implementers must consider how to 
incorporate new tools in their protocols, in a context of inflationary increases, resource-
intensive trials, and diminishing investments (RTWG, 2013; 2014).  
 
The standard of prevention may create tension between scientific validity and exploitation, 
that is, between a clinical trial’s scientific aim to obtain meaningful results and ethical 
requirements to minimise risks and not withhold effective interventions from participants. 
Withholding proven interventions from participants (even if they are not available in the local 
context) may raise concerns about exploitation (MacQueen, 2011). However, enhanced 
prevention packages may result in futile trials and may undermine the real-world applicability 
of the data (Rennie & Sugarman, 2010). Furthermore, incorporating new prevention 
interventions in trials changes the questions that can be answered by the trial (Dawson, 2012). 
These tensions have been particularly pronounced in terms of decisions on evolving standards 
of prevention. On the one hand, protecting the welfare of trial participants is paramount and 
necessitates providing all validated prevention interventions. However, for research to be 
ethical it must produce scientifically valid and socially valuable results (Dawson, 2012; 
Emanuel et al., 2004). Therefore, any analysis of trial designs must consider the protection of 
participants in relation to the threshold at which the provision of enhanced standard of 
prevention packages invalidates trials (Emanuel et al., 2004; Essack, Slack, et al., 2010) and 
impedes the development of increasingly effective interventions (Sugarman & Grace, 2010). 
If the feasibility of obtaining meaningful results from the trial is adversely impacted by the 
addition of new HIV prevention methods, then the ethical obligation to provide all state-of-
the-art methods is weakened because participants will be exposed to risks and inconvenience 
for no social benefit and valuable resources will be wasted (Emanuel et al., 2004; Essack, 
Slack, et al., 2010; Lie et al., 2006). Furthermore, “the production of irrelevant research is 
both a scientific and ethical concern” (Rennie & Sugarman, 2010, p. 812). However, the 
threshold at which adding new methods will invalidate trials has yet to be clearly defined and 




5. Previous empirical studies on prevention in HIV prevention trials 
There has been some empirical investigation of the standard of prevention provided to 
participants in HIV prevention trials (Haire & Jordens, 2013), microbicide and diaphragm 
studies (Heise et al., 2008; McGrory et al., 2010) and HVTs (Ngongo, Priddy, et al., 2012).  
 
5.1 Findings on standard of prevention decision-making 
In terms of HIV prevention decision-making practices, findings reflect that variations in the 
standard of prevention across trials could be accounted for by several factors including “local 
guidelines and standards; trial design considerations; the services and resources available in a 
local site setting; providers’ knowledge, comfort, training, and beliefs; and when the study 
started” (McGrory et al., 2010, p. 24). The Global Campaign for Microbicides’7 (GCM) 
review of policies and guidance documents found that while only a few donor policies set a 
minimum standard of prevention for trial participants, there were many examples “where 
general policies or uncertainty about donor expectations influenced decisions about what care 
to provide trial participants” including restrictions on HIV prevention interventions (Philpott 
et al., 2010, p. 223). For example, funding from the NIH prohibits the use of federal funds for 
the procurement of drugs or the provision of care not required for the scientific conduct of the 
trial or to ensure participants’ safety (Philpott et al., 2011). Protocol omissions of strategies to 
ensure care services in HIV prevention trials in order to comply with sponsor funding policy 
have been identified in empirical studies (Philpott et al., 2010; Heise et al., 2008; Slack, 
2014). In contrast, Haire (2013) found that donor policies positively influenced the provision 
of standards of prevention. 
 
Interview data (Heise et al., 2008) suggest that external bodies like RECs and donors do 
influence aspects of the standard of prevention such as messages around condom use. For 
example, in one study, a US REC required that investigators add a statement to the consent 
form that, “the only way to prevent HIV/STIs is not to have sex”— despite the fact that being 
sexually active was an eligibility criterion (Heise et al., 2008, p. 36). While ethics guidelines 
recommend consultations with stakeholders, including inputs from the community on 
standards of prevention prior to the initiation of the trial, Heise et al. (2008) found little 
evidence of this. Only one site consulted community members and advisory groups about the 
prevention services that should be provided to participants prior to study approval – mostly, 
                                                             
7 http://www.global-campaign.org/  
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inputs were obtained from communities after the study was approved (Heise et al., 2008). 
While there was little interrogation of why inputs from the community were rarely obtained 
prior to the approval of the study, the authors reinforced that the standard in ethics guidelines 
should be adhered to in that “community voices should be sought and integrated into 
standards of care decision-making at every stage of the trial design and implementation” 
(Heise et al., 2008, p. 67).  
 
5.2 Findings on standard of prevention implementation practices 
The GCM mapping study found that participants received intensive quality counselling, 
unlimited free male condoms and quality STI services. However, female condoms were not 
actively promoted with some site staff reporting perceptions that female condoms were 
expensive and inaccessible (Heise et al., 2008). An abbreviated mapping study, also 
conducted by GCM, explored the HIV prevention services offered to participants across a 
wider range of HIV prevention trials including herpes suppression, PrEP and HVTs; 18 HIV 
prevention trials in total. Of these, three were HVTs (HVTN 204, HVTN 502 and HVTN 
503) with HVTN 204 and HVTN 503 having trial sites in SA. In HVTN 204, the standard of 
prevention for all participants comprised male condoms, female condoms if available in the 
community, referral for STI treatment and clean needles if requested. In HVTN 502 (or 
STEP), the prevention standard included male condoms and STI treatment if indicated. 
HVTN 503 (or Phambili) provided the most HIV prevention interventions for trial 
participants including male and female condoms, treatment of STIs, STI treatment for 
partners, PEP and VMMC (CDC/GCM/UNAIDS, 2009). While there was some 
standardisation in terms of general categories like condom promotion and risk-reduction 
counselling, the type and intensity of prevention services provided to participants varied 
greatly –  “the ‘standard of prevention’ between and within HIV prevention trials is anything 
but ‘standard’” (McGrory et al., 2010, p. 24). 
 
Standards of prevention and care8 were explored at ten IAVI-affiliated research centres in 
East and Southern Africa to understand variations, similarities and gaps in services provided, 
recipients of services, referral systems, and barriers to referral uptake (Ngongo, Priddy et al., 
2012). Findings indicated variability in the provision of services. While HIV risk-reduction 
counselling, male condoms and management of STIs were provided consistently, female 
                                                             
8 A review of the care findings is beyond the scope of this study.  
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condoms, VMMC, and PEP in the case of rape were less consistently provided. Referral 
systems were established for VMMC and PEP at most research centres but challenges with 
referral uptake were reported (Ngongo, Priddy, et al., 2012). Research centres endeavoured to 
provide a variety of services to non-trial participants but there was concern that this might 
constitute an undue incentive or make conducting research prohibitively expensive (Ngongo, 
Priddy, et al., 2012). Based on these findings and consideration of scientific priorities, 
contextual realities, community expectations, equity and cost-effectiveness, the authors 
developed a set of required and recommended services to be provided on-site or via referrals 
(Ngongo, Priddy, et al., 2012). For prevention interventions not widely available, it was 
recommended that research centres consider either training site staff or identifying 
organisations in the community that could provide such services. In particular, it was 
recommended that research centres ensure referral for PEP in cases of rape based on national 
guidelines or international guidelines where there is no national policy; or provide such 
services on-site (Ngongo, Priddy, et al., 2012). Some informal evaluation of the quality of 
referral networks was recommended in terms of the provision of specific services such as 
VMMC, since referrals were to public healthcare services where formal evaluations were not 
common practice (Ngongo, Priddy, et al., 2012). In terms of prevention interventions, these 
authors distinguished between those that are required on-site or through referral and those 
only recommended (see Table 2). 
 
Table 2.  
Recommended and required standard of prevention interventions for IAVI-affiliated clinical 
research centres 
Standard of prevention intervention On-site provision Referral 
HIV VCT Required  
Basic social support counselling Required  
Professional social support counselling  Required 
Male condoms Required  
Female condoms Recommended  
Syndromic management of STIs Required  
STI diagnosis Recommended (if available)  
Information and education on VMMC Required  
Surgical procedure: VMMC  Required 
PEP (occupational exposure) Required  
PEP (in cases of rape) Recommended Required 
STI diagnosis and treatment for 





From Table 2, it is clear that the authors have identified different obligations for different 
prevention interventions and different moral groups, although they have not specified their 
rationale for such distinctions. For example, male condoms are required while female 
condoms are only recommended; access to the only female-initiated method approved for use 
in many settings is not even required through referral. This weak obligation is even 
superseded by responsibilities to ensure access to STI treatment for participants’ partners for 
whom on-site provision is recommended but at a minimum referral is required. Further, there 
is no consideration of the use of PEP for all risky sexual exposures.  
 
South African researchers have investigated the uptake of circumcision by male participants 
in an efficacy trial (Phambili) and found that 17.7% of those eligible underwent the procedure 
(de Bruyn et al., 2009). The authors argue that an uptake of this magnitude may decrease 
incidence rates and consequently influence sample size requirements. Factors such as 
feasibility may play an important role in decision-making about what services to provide to 
participants and when to add new prevention tools to the standard of prevention.  
 
5.3 Stakeholder perspectives on the standard of prevention 
Few empirical studies have investigated the perspectives of research stakeholders on the 
standard of prevention in HVTs. These are significant yet missing perspectives since ethics 
guidelines require negotiation with all key stakeholders on the standard of prevention, and 
different stakeholders may have vastly different opinions on factors to consider when making 
decisions about what to include in the prevention package (McGrory et al., 2010).  
 
At a consultation on standards of prevention held in Uganda in March 2009, representatives 
of various (though not all) stakeholder groups presented their perspectives. The South 
African MCC reported that typically, significant results in two RCTs are required before a 
product/intervention is approved (McGrory et al., 2010).  
 
DSMBs noted that their obligation is to trial participants and an important consideration for 
them would be whether withholding a successful intervention from participants is ethical. 
They are not however responsible for considering if and how their decisions about halting or 




From the perspective of RECs, the risk-benefit ratio is an important consideration. With 
regard to HIV prevention, RECs typically expect that researchers provide trial participants 
with nationally approved and available prevention methods. Researchers must be explicit 
about how often the risk-reduction intervention will be provided to participants, the study 
staff responsible for delivering the service, and the required infrastructure. There is still 
reportedly some debate among RECs regarding whether a new proven method must be made 
part of the prevention package if it has not been tested or implemented in the community 
where the trial is planned (McGrory et al., 2010).  
 
Investigators discussed the tension between their desire to provide participants with a range 
of interventions and services, including new risk-reduction methods, versus providing a core 
package of risk-reduction interventions consistently and well (McGrory et al., 2010). While 
some investigators argued that new efficacious interventions should be provided to 
participants, others suggested that investigators fulfil multiple roles with limited resources, 
which may make requirements to add new tools to the prevention package unrealistic. Those 
of the latter view also argued that given the absence of guidelines for the type of prevention 
package that must be provided, it would be more feasible to develop a core evidence-based 
prevention package with enough flexibility to be adapted for different trials and trial contexts 
(McGrory et al., 2010).  
 
Principal Investigators (PIs) (n=14) of phase IIB/III HIV prevention trials were interviewed 
to identify practices and perspectives regarding the negotiation of standards of prevention in 
trials (Haire & Jordens, 2013). Findings revealed disparate views of PIs on standards of 
prevention, and that little consensus on the standard of prevention existed, even among these 
key decision-makers. In particular, differences in opinion were noted regarding whether the 
standard of prevention should be the best available anywhere, justified as ethically and 
epistemologically sound; or whether it should approximate local realities justified on 
scientific validity grounds. In practice, decisions to add VMMC were made based on variable 
criteria: some PIs reported that the decision was based on the scientific evidence while others 
had waited for national guidelines. Respondents appeared more restrained in terms of their 
views on whether PrEP should be included as part of the standard of prevention. Respondents 
in this study negotiated complex systems that structured what was and what was not possible 
in their particular trials, including funding constraints, regulatory systems, ethics guidance, 
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ethics review processes and requirements, and healthcare systems in the host country (Haire 
& Jordens, 2013). 
 
From the community perspective, it was observed that several approaches have been utilised 
for community consultations, some more effective than others. However, the common 
denominator is that all consultation efforts were employed with the purpose to ‘consult’ 
communities whereas more recent ethics guidelines (UNAIDS/AVAC, 2011; 
UNAIDS/WHO, 2012) require ‘negotiation’ with research stakeholders. Concerns have been 
raised regarding the feasibility of negotiation given apparent power differentials between 
researchers and CABs (Haire et al., 2013; McGrory et al., 2010; West Slevin et al., 2008). 
Given the strict timelines within which trials are conducted, there is a need to explore 
multiple mechanisms for achieving the requirements of consultation and negotiation outlined 
in ethics guidelines, so that complex and sometimes technical decisions can be made 
timeously (McGrory et al., 2010). It was also argued that “while it may not be practical from 
a substantive or logistic standpoint to consult with all research stakeholders on all issues, it 
may be more feasible and realistic to outline which organisations or entities among 
stakeholders are well placed to address different aspects of a trial” (McGrory et al., 2010, p. 
22). 
 
A recent qualitative study explored ethical and participatory issues related to the conduct of 
biomedical HIV prevention trials among marginalised populations in Thailand (Allman et al., 
2014). This study considered findings in relation to GPP guidelines (UNAIDS/AVAC, 2011). 
Suggestions were made to improve ethical and participatory practices related to standards of 
prevention, informed consent, communication and human rights. Regarding the standard of 
prevention, respondents reflected on the normativity of ethics, some of whom perceived 
ethics as “culturally dependent, embodying elements of morality and enforceability that 
varied with nation, community and institutional context” (Allman et al., 2014, p. 2), even 
questioning the applicability of international ethics guidelines to the Thai context. When 
international ethics guidelines are implemented in different prevention trial contexts, 
international standards of prevention may supersede local services (raising concerns about 
unethical standards); in other cases, international standards may be inadequate depending on 
the study population (Allman et al., 2014). Discrepancies between norms in ethics guidelines 
and actual practices are possible. For example, while sterile needles for IDUs are considered 
an important component of the standard of prevention in HIV prevention trials 
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(UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012), some sponsor policies might restrict their 
provision (Allman et al., 2014; UNAIDS/AVAC, 2011). It was argued that despite 
international guidance, community expectations of the standard of prevention in the local 
context might differ from “what researchers and trial sponsors were willing to offer” based on 
interpretations of local laws and policies, as well as international donor funding restrictions 
(Allman et al., 2014, p. 3). 
 
5.4 Stakeholder perspectives on ethics guidelines 
The introduction and/or revision of HVT-specific guidelines has been accompanied by some 
exploration of stakeholder perspectives of guidelines. An assessment of the global 
implementation of GPP guidelines (UNAIDS/AVAC, 2011) found increases in support and 
awareness of these guidelines but gaps in practices related to documentation of engagement 
activities and stakeholder input in trial protocols (Hannah, Warren & Bass, 2012). A 
quantitative assessment of GPP guideline (UNAIDS/AVAC, 2011) implementation at HIV 
prevention research clinical centres (Ngongo et al., 2012), found lower support for guidance 
points on standards of prevention at baseline, but this was found to improve after an 
evaluation workshop which sought to identify the strengths and limitations of these 
guidelines.  
 
At two regional workshops to pilot test training curricula developed by WHO, UNAIDS, and 
the African AIDS Vaccine Programme (AAVP), key stakeholders, including REC members, 
researchers, advocates, policymakers, research sponsors, government representatives, and 
regulators exchanged perspectives on the UNAIDS/WHO (2012) guidance document. 
Stakeholders argued for a procedural approach focused on structured negotiation processes as 
the best strategy to make complex decisions, including on access to evolving standards of 
prevention (Hankins et al., 2009).  
 
South African HVT stakeholders (site staff, CABs and RECs) (n=98) participated in a 
quantitative assessment of their perspectives on ethics recommendations (UNAIDS/AVAC, 
2011; UNAIDS/WHO, 2012) on standards of prevention and care (Moorhouse et al., 2014). 
Respondents rated each of 20 ethics recommendations on prevention (n=10) and care (n=10), 
on five dimensions, namely, familiarity, ease of understanding, ease of implementing, 
perceived protection, and agreement. Ethics recommendations on care and prevention were 
rated highly overall, with recommendations regarding informed consent rated most highly. 
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However, in comparison to recommendations on care, standard of prevention 
recommendations were rated significantly less positively. Actually, five of the lowest scored 
recommendations were on standards of prevention (Moorhouse et al., 2014). Respondents 
considered the ethics recommendation that the protocol should outline how stakeholders 
negotiate adding new methods to the prevention package (UNAIDS/WHO, 2012) as 
problematic in terms of ‘familiarity with’, ‘ease of implementing’, and ‘perceived protection’ 
(Moorhouse et al., 2014). The recommendation that new prevention tools should be added to 
the package as they are validated or approved by relevant authorities (UNAIDS/WHO, 2012) 
was rated as most problematic in terms of ‘ease of understanding’. The recommendation that 
new tools should be added to the standard of prevention based on consultation among all 
research stakeholders (UNAIDS/WHO, 2012) was rated as most problematic on the 
dimension of ‘agreement with’. Importantly, stakeholders’ perspectives indicated concerns 
about the implementability of certain guideline recommendations. The authors recommend 
that standard of prevention norms in ethics guidelines be prioritised for refinement 
(Moorhouse et al., 2014).  
 
6. Remaining gaps 
Previous empirical studies have explored standard of prevention practices and/or perspectives 
in HIV prevention trials, including in South Africa (Haire & Jordens, 2013; Heise et al., 
2008; Moorhouse et al., 2014; Ngongo, Priddy, et al., 2012).  
 
The empirical data gathered in the GCM mapping study and accompanying abbreviated study 
(Heise et al., 2008; McGrory et al., 2010) documented practices at sites, and explored 
(somewhat) the extent to which actual practices corresponded with ethical norms. While this 
research acknowledged the value of data for ethics guidelines (cf. Heise et al., 2008), 
recommendations aimed to bring practices closer to ethical ideals rather than to critically 
reflect on both practices and norms in ethics guidelines.  
 
The exploration of standards of prevention (Ngongo, Priddy, et al., 2012) documented 
standard of prevention practices at IAVI-affiliated research centres, and used this data to 
develop a “standardised” prevention package. This study did not aim to compare practices 




Haire (2013) conducted empirical research with PIs to explore standard of prevention 
negotiation practices and perspectives. This study did not aim to document standard of 
prevention services provided in those trials nor to systematically compare practices, 
perspectives and complexities with related norms in ethics guidelines. Based on study 
findings, it was recommended that further empirical research be undertaken on standard of 
prevention practices and perspectives, in order to inform deliberations about whether, or how, 
to incorporate newly validated prevention interventions (Haire et al., 2013).  
  
Moorhouse et al. (2014) responded to a gap in the literature regarding perceptions of standard 
of prevention guidance, and in light of findings of this quantitative assessment, recommended 
that further qualitative research be undertaken to explore in-depth, stakeholder reservations 
about implementing ethics recommendations. 
 
To date, there has been no systematic empirical assessment of actual practices at South 
African HVT sites. There has also been limited empirical investigation of how stakeholders 
in HVTs make decisions on what services to provide or what they perceive to be the 
challenges in making these complex decisions (Essack, Slack, et al., 2010). Further, there is 
little information about how individual trial networks and trial sites address questions on the 
standard of prevention (cf. Macklin, 2008) nor on whether norms in ethics guidelines are 
implementable in practice (Macklin, 2010). As such, it has been recommended that the 
prevention services offered to HVT participants and decision-making practices should be 
assessed (Essack, Slack, et al., 2010). Further, such research should explore whether practices 
at sites correspond with norms in ethics guidelines (Essack, Slack, et al., 2010; Macklin, 
2010) and whether ethics guidelines provide any direction on the dilemmas faced by 
researchers (Essack, Slack, et al., 2010). 
 
To address these gaps, this research aimed to 1) identify standard of prevention norms in 
guidelines (Chapter 3) and 2) gather data about standard of prevention practices and 
perspectives in South African HVTs (Chapters 7-9). It aimed to collect data that would 
inform the ethical debate about whether a high standard of prevention is feasible in practice 
(HPTN, 2009; Macklin, 2009), especially in resource-constrained contexts (Macklin, 2010). 
It aimed to explore the challenges experienced regarding standards of prevention by HVT 
stakeholders and whether ethics guidance provides adequate direction regarding these 
concerns. Further, this study examined perspectives on selected standard of prevention norms 
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in ethics guidelines (Chapter 10). Overall, this study aimed to generate knowledge that might 
strengthen site practices, inform revisions of normative guidance and better engage affected 
stakeholders.  
 
Part 3 (Chapters 6-11) of this thesis focuses on the empirical study. The following chapter 
details the research methodology and outlines the research questions and aims. It justifies the 
use of empirical approaches to bioethics, considers the philosophical underpinnings of the 
study, and describes the data collection and analyses strategies. Ethical considerations related 







This chapter describes the research questions and aims of the study. It begins by situating this 
study within the ‘empirical turn’ in bioethics (Borry, Schotsman & Dierickx, 2005), followed 
by a description of the research design, methodology and the philosophical underpinnings of 
this study. The sampling, data collection and data analysis procedures are presented and the 
rationale for adopting particular approaches explained. Considerations regarding the quality 
of data and ethics are also discussed (see Table 3 for an overview of the research 
methodology and process).  
 
1. Research aims and questions  
This study was guided by three primary research questions: (1) To what extent do standard of 
prevention decision-making and implementation practices (current and evolving) resonate 
with recommendations in ethics guidelines? (2) To what extent do ethics guidelines address 
the concerns of key stakeholders about standards of prevention? (3) What are the perspectives 
of HVT stakeholders on evolving standards of prevention and selected standard of prevention 
norms in ethics guidelines? 
 
This study specifically aimed to: 
1. Critically review HVT-specific ethics guidelines to identify stakeholders’ standard of 
prevention responsibilities in HVTs.  
2. Review HVT site documents (e.g., protocols, standard operating procedures, meeting 
minutes, consultation reports) in order to identify standard of prevention practices at 
sites. 
3. Explore reported standard of prevention decision-making and implementation 
practices, perspectives and challenges in HVTs (current and evolving). 
4. Explore stakeholder perspectives on selected standard of prevention recommendations 
in ethics guidelines. 
5. Explore a) correspondence between ethics guideline recommendations and reported 
practices; and b) whether ethics guidelines anticipate empirically identified concerns.  
6. Make recommendations for strengthened practices and improved ethics guidance on 
standards of prevention (cf. Kon, 2009a). 
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Table 3.  
Overview of the research methodology and process 
EMPIRICAL APPROACHES TO BIOETHICS 
PARADIGMATIC ASSUMPTIONS 
Paradigm Critical realism (ontology) 
Interpretive/discursive (epistemology)  
Methodology Qualitative  
RESEARCH DESIGN 
Type of study Descriptive, exploratory and applied 
Sampling strategies  Purposive and snowball sampling  
DATA SOURCES AND DATA PROCESSING 
Data sources Desk review of site documents  
Semi-structured interviews with key stakeholders 
Data processing Verbatim transcription including laughter, speech 
repetitions and emphases 
DATA ANALYSIS 
Hybrid inductive-deductive approach (Fereday & Muir-Cochrane, 2006) 
Critical thematic analysis (Braun & Clarke, 2006) 
DATA QUALITY 
Credibility, transferability, dependability and confirmability 
ETHICAL CONSIDERATIONS 
As per Emanuel et al.’s (2004) framework for conducting research in developing country 
contexts 
 
2. Empirical approaches to bioethics 
Methodological approaches to bioethics have, over recent decades, taken an ‘empirical turn’ 
from predominantly normative philosophical analyses to the increasing use of empirical 
research methods (Borry et al., 2005)9, called ‘empirical bioethics’ or ‘evidence-based ethics’ 
(Ashcroft, 2003; Borry et al., 2005). This empirical turn has been accompanied by increasing 
interest in the relationship between bioethics and social sciences, evinced by dedicated 
special issues in journals. For example, Contributions of Psychological Science to Empirical 
Bioethics (American Journal of Bioethics Primary Research, 2013); Bioethics and Empirical 
Research (Healthcare Analysis, 2003); and The View from Here: Bioethics and the Social 
Sciences (Sociology of Health and Illness, 2006), among others. The Journal of Empirical 
Research on Human Research Ethics is exclusively dedicated to empirical research on issues 
of research ethics. Further, the Wellcome Trust Biomedical Ethics Programme was launched 
in 1997 with the aim of fostering an approach in bioethics that combined normative 
                                                             
9 It is beyond the scope of this thesis to fully consider the rationale for the increasing use of empirical research 
in bioethics. Readers are referred to Haimes, E. (2002). What Can the Social Sciences Contribute to the Study of 
Ethics? Theoretical, Empirical and Substantive Considerations. Bioethics, 16(2), 89–113. 
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philosophical inquiry with social science methodologies (Draper & Ives, 2007). The 
empirical turn was principally instigated by the increasing dissatisfaction with normative 
bioethics, demonstrated by the ‘social science critique’ (Hedgecoe, 2004) which criticised 
bioethics as being speculative given its theoretical basis, too broad and abstract, and as failing 
to take into account everyday realities.  
 
Empirical approaches to bioethics acknowledge that empirical data can influence normative 
bioethics questions and this issue has received considerable attention in the literature (e.g., 
Borry et al., 2005; de Vries, Turner, Orfali, & Bosk, 2006; Draper & Ives, 2007; Goldenberg, 
2005; Kon, 2009a; Leget, Borry & de Vries, 2009; Miller, 2002; Miller, 2013; Smajdor, Ives, 
Baldock & Langlois, 2008; Sugarman, 2004). There has been intense debate between 
bioethicists using classical philosophical inquiry versus those conducting empirical studies on 
bioethics issues (Kon, 2009a) regarding how empirical research conducted in the social 
sciences can contribute to bioethics (Frith, 2012). Research in the social sciences is 
concerned with how the world is (or is perceived to be) and the analysis of such perceptions 
and experiences, while bioethics is concerned with how the world ought to be (Draper & 
Ives, 2007). Some authors argue that “an evidence-based approach is incompatible with 
bioethics' normative mandate” (Goldenberg, 2005, p. 2) while others contend that empirical 
data and philosophical inquiry are complementary, and that empirical research can 
significantly facilitate the refinement of ethical norms (Kon, 2009b; Carter, 2009) by 
revealing ethical problems experienced in practice (Draper & Ives, 2007; Kon, 2009a; 
Essack, Koen, et al., 2010) or by enabling the development of contextualised and responsive 
ethical recommendations (Carter, 2009; Kon, 2009a).  
 
2.1 Types of empirical studies in bioethics 
Empirical research in bioethics can be categorised in three (non–mutually exclusive) 
categories, social science for bioethics, social science of bioethics and social science in 
bioethics (Draper & Ives, 2007). In social science for bioethics, empirical methods are used 
to substantiate existing theory or identify novel ethical issues that require resolution through 
normative analyses (Draper & Ives, 2007).  
 
In the social science of bioethics, “bioethical debate, the way in which bioethical discourses 
interact with people and institutions, and the way in which bioethical discourses are acted out, 
are themselves subject to sociological analysis” (Draper & Ives, 2007, p. 322). This category 
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studies bioethics as a social phenomenon rather than an abstract philosophical discipline 
(Frith, 2008). Studies that consider the application of ethical theory in practice, and how 
scientists perceive ethical issues arising from their research would fall into this category. A 
social science of bioethics has proved valuable for studies on the factors that influence and 
moderate ethical decision-making in practice (Frith, 2008).  
 
These two categorisations maintain clear delineations between social sciences and bioethics.  
 
Social science in bioethics aims to dissolve the boundary between empirical data and 
philosophical inquiry and develop a more bottom-up approach where the development of 
ethical theory is informed by empirical data, rather than removed from it – ethical theory is 
“informed directly by the values, experiences, and perspectives of real people – and not 
solely by the philosopher in his ivory tower” (Draper & Ives, 2007, p. 326). Studies in this 
category are designed and conducted to document and identify specific responses (e.g., 
perspectives, issues, practices) which themselves will inform specific ethical debate (Draper 
& Ives, 2007).  
 
Some studies may seek to address issues at more than one level, and since categories are not 
mutually exclusive (Frith, 2008), the present study could be argued to incorporate elements of 
all three approaches to empirical research in bioethics. It incorporates some elements of a 
social science for bioethics in that it seeks to identify standard of prevention complexities 
experienced by stakeholders. Through exploring their perspectives on key standard of 
prevention issues, this research may also identify ‘nuances’ to existing ethical complexities. It 
also incorporates some elements of a social science of bioethics in its exploration of how 
standard of prevention decisions are made in practice and the assessment of correspondence 
between norms in ethics guidelines and stakeholder practices. The thesis also has elements of 
a social science in bioethics in that it aims to examine standard of prevention practices 
(empirical data) in relation to norms, and make recommendations for strengthened practices 
and refinements to ethics guidelines. Further, this research seeks to identify standard of 
prevention practices and perspectives to inform further normative analyses of this topic.  
 
An alternative framework for classifying empirical research in bioethics is identified by Kon 
(2009a). Kon (2009a) distinguishes between four hierarchical levels of empirical research 
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that inform bioethics, and the aims of this study align with some of the categories defined by 
Kon (2009a).  
 
Lay of the land research is the first level of inquiry. It aims to document current practices, 
opinions and beliefs (Kon, 2009a). Generally, lay of the land research is descriptive and 
explanatory in nature and may be driven by predefined assumptions (Kon, 2009a). 
Documenting standard of prevention practices and complexities at HVT sites (Aim 3) could 
be considered as falling in this category. Data at this level can be useful for the development 
of policies, can facilitate provider decision-making and help inform future research (Kon, 
2009a).  
 
Ideal versus Reality studies explore the extent to which actual practices reflect ethical ideals 
(Kon, 2009a). However, the premise is that the ethical ideal is uncontested, so this level aims 
to effect changes to the current practices that deviate from ethical norms. The present study, 
in its assessment of correspondence between actual practices and norms in ethics guidelines 
(Aim 5), can also be categorised at this level with the exception that, this study did not 
uncritically accept ethics norms as uncontested. In this way, this study makes 
recommendations (Aim 6) that could helpfully inform levels three and four below.  
 
The third level of empirical research, Improving Care, considers how to best align actual 
practices with ethical ideals, in other words, to address complexities identified at the Ideal 
versus Reality level (Kon, 2009a). Studies at this level typically design and evaluate methods 
or interventions to help clinicians improve care practices so that they are better aligned with 
ethical norms.  
 
Finally, at the highest level of the hierarchy are empirical studies on Changing Ethical Norms 
(Kon, 2009a). Through a review and bioethical analysis of multiple empirical studies, 
changes are recommended to ethical norms (Kon, 2009a). However, such studies do not 
indicate that norms hinge on public opinion but that empirical research helps develop 
“realistic ethical constructs” (Kon, 2009a, p. 62).  
 
This hierarchical framework (Kon, 2009a) however, is not without critics (e.g., Emerson, 
Upshur & Daar, 2009; Sugarman, Kass & Faden, 2009). In considering that empirical data 
indicate what ‘is’, this framework is accused of inadequately considering the limitations of 
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empirical research (e.g., validity, reliability, generalisability) and failing to acknowledge that 
empirical research cannot produce a mirror of reality, but rather theoretically informed 
arguments of a particular version of reality (Carter, 2009; Dunn & Ives, 2009). In this study, 
respondent reports on standard of prevention practices are not seen as direct reflections of 
standard of prevention practices at sites, but as different perspectives/accounts of the various 
ways in which the social world (reality) is experienced (Snape & Spencer, 2013). The quality 
of the data is also explored, as are study limitations. Secondly, while normative theories offer 
frameworks for interpretation of empirical data, it is argued that they can also be produced in 
empirical studies (Carter, 2009). Finally, this framework has been criticised for failing to 
consider research in developing country contexts (Emerson et al., 2009). In such contexts, 
empirical research at lower levels of Kon’s (2009a) hierarchy may be able to promote 
normative changes reserved only for higher levels, in a way that considers ethical reform 
from the bottom up (Emerson et al., 2009). This study considers this criticism, and provides 
recommendations for strengthened practices and improved guidance (see Chapter 12).  
 
3. Methodological approach 
This thesis interconnects several disciplines in its use of empirical social science methods to 
explore an ethical issue in a clinical research context.  
 
The present study was conceptualised within the critical realist ontology (the nature of 
reality). Critical realists assume that data can provide information on an external reality, 
although unlike realists, it is not understood as a mirror image of reality (Snape & Spencer, 
2013). In other words, it is assumed that an external reality exists independently of an 
individual’s subjective understanding but that it is only accessible through socially 
constructed meanings, that is, via respondents’ interpretations (Snape & Spencer, 2013). In 
this way, language is used to construct social realities (Sims-Schouten, Riley & Willig, 
2007). Therefore, respondents’ own interpretations of the relevant research issues are 
important, with different perspectives indicating different vantage points, reflective of the 
various ways in which the social world (reality) is experienced (Snape & Spencer, 2013). The 
assumption that an external reality exists however, does not entail that “absolute knowledge 
of the way it works is possible” (Scott, 2005, p. 634). Therefore, interview data cannot be 
taken as literal representations of an external reality; but they do provide important 
perspectives about a phenomenon that exists outside the interview context (standards of 
prevention in HVTs). Accordingly, it is argued that “we need not hear interview responses 
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simply as true or false reports on reality. Instead, we can treat such responses as displays of 
perspectives of moral forms” (Silverman, 1993, p. 107).  
 
Epistemologically, this study adopted the perspective that “the way of knowing reality is by 
exploring the experiences of others” (Nieuwenhuis, 2010, p. 55). As follows, this study 
incorporated the two quintessential interpretive principles of understanding in context 
(verstehen) and the positioning of the researcher as the primary instrument/medium in data 
collection and analysis (Merriam, 2002). Although the research was predominantly guided by 
interpretive principles, where relevant, the researcher adopted a more critical (discursive) 
approach towards interpreting and understanding respondents’ accounts. In marrying these 
approaches, the research position varied between first-person and third-person perspectives – 
in understanding stakeholders’ standard of prevention practices, perspectives and challenges, 
the researcher primarily adopted an empathic epistemology; however, by implementing 
Ricouer’s (1973) concept of distanciation, the analysis was able to offer a more critical 
interpretation, where relevant. Discourse analysis centres on the way knowledge is produced 
through talk, (e.g., ethical discourse, medical discourse) or through implicit theories so as to 
make sense of social action (e.g., culture, power, gender relations). Discourse analysis may 
also focus on the details and dynamics of the interaction, including, in terms of respondents’ 
use of representations and rhetorical devices (Silverman, 2005). 
 
Such dual approaches have been previously applied in research on masculinity (Davies & 
Eagle, 2007; 2010), women and motherhood (Sims-Schouten et al., 2007) and volunteering in 
child abuse services (Alexander, 2011). The resultant critical thematic analysis (Braun & 
Clarke, 2006) appeared to consolidate these theoretical orientations in a way that 
accommodated the perspectives and experiences of respondents as well as the discursive 
contexts in which they attach their meaning systems.  
 
4. Research design 
This study, which focused on standards of prevention in HVTs, was embedded in a larger 
project on HIV care and prevention in South African HVTs. The related studies qualitatively 
examined applicable ethics guidance and the provision of ancillary care services in HVTs 
(Slack et al., 2014); and quantitatively explored stakeholder perspectives on care and 




This study was descriptive, applied and exploratory. Firstly, a descriptive approach was 
selected because a key aim of this study was to describe stakeholder practices regarding the 
standard of prevention in HVTs.                                                                     
 
Secondly, a review of the literature revealed a paucity of empirical studies on standards of 
prevention in HVTs generally, and in South Africa, especially in relation to norms in relevant 
ethics guidelines. As such, an exploratory approach was adopted since exploratory research is 
useful when there is limited knowledge about a particular topic (Durrheim, 2006). 
 
Thirdly, given its pragmatic focus on actual practices in HVTs and its assessment of 
correspondence between practices and ethics guidelines, this study had an applied 
component. Further, it was anticipated that findings from this study would contribute towards 
improving decision-making and implementation practices in HVTs as well as strengthening 
standard of prevention recommendations in ethics guidelines. This is in line with one of the 
primary aims of applied research which is to collect and generate data that can improve 
understanding of real-world problems (Guest, Namey & Mitchell, 2012) and its potential for 
generating actionable outcomes (Ritchie & Spencer, 2002).   
 
Given the exploratory and descriptive nature of the study, a qualitative research approach was 
selected (Mouton & Marais, 1991). Qualitative research is generally inductive and flexible in 
nature. As defined by Denzin and Lincoln (1994, p. 2), “qualitative research is multimethod 
in focus, involving an interpretive, naturalistic approach to its subject matter. This means that 
qualitative researchers study things in their natural settings, attempting to make sense of, or 
interpret phenomena in terms of the meanings people bring to them.”  
 
A qualitative methodology is well suited for descriptive and exploratory research because it 
permits an open-ended and flexible approach, which allows for further probing and enables 
interviewees to respond in their own words, rather than to a set of predetermined categories 
(Mack, Woodsong, MacQueen, Guest & Namey, 2005). An open-ended approach also 
enables responses that are both meaningful and culturally relevant to the respondent, largely 
unanticipated by the researcher, and rich and explanatory in nature (Mack et al., 2005). In 
addition to the “what”, it allows for exploration of the “why”, the “who”, and the “how” 




Furthermore, qualitative research is described as well suited to exploring the ethical issues 
experienced in practice (Sanker & Jones, 2008). Qualitative research can help identify how 
‘bioethics’ is achieved in practice by illuminating “the practical ethical work being 
undertaken through the day-to-day choices, priorities, decisions, and actions taken by 
[people]” (Spallone, 1999, p. 21). By producing rich descriptions of actual practice, 
qualitative research may reveal novel ethical concerns (Essack, Koen, et al., 2010; Sankar & 
Jones, 2008). Furthermore, qualitative research takes people’s subjective experiences 
seriously, and in so doing, can improve perceptions of the credibility of HVTs (Essack, Koen, 
et al., 2010).  
 
4.1 Sampling 
Stakeholder groups, namely HVT site-staff (e.g., clinicians, counsellors, PIs), CAB members, 
REC members and research network representatives were selected due to their involvement 
in the implementation, review, and coordination of HVTs. Respondents10 from key 
stakeholder groups were purposively sampled (Mason, 2002). This sampling strategy is 
“based on careful selection of cases that are typical of the population being studied” and is 
“often used to create small, relevant samples in qualitative research” (Terre Blanche, 
Durrheim & Painter, 2006, p. 563). Some respondents were also selected using snowball 
sampling techniques (Biernacki & Waldorf, 1981), for example where respondents made 
suggestions of other suitable interviewees. 
 
At the time this research was undertaken, there were five trial sites conducting prophylactic 
HVTs in South Africa, and two trials were ongoing. This study explored standards of 
prevention practices for both trials (phase I and phase IIB) at all five sites. The phase I trial, 
conducted at two sites, investigated the safety of a vaccine in HIV-uninfected participants at 
low risk for HIV. The phase IIB trial, conducted at five sites, investigated the safety and 
efficacy of a vaccine in HIV-uninfected participants at high risk for HIV.  
 
Forty-four interviews (prevention-specific, care-specific or combined) were conducted with 
36 respondents. Prevention-specific interviews were conducted with 14 respondents and 
general interviews were conducted with 15 respondents. Additional relevant data came from 
                                                             
10 The terms interviewee and respondent indicate those who participated in interviews for the present study, 
while the term participant is used for individuals who participate in HVTs. 
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15 care-specific interviews with 14 respondents, where prevention-related references were 
made. Because this research was qualitative, pre-defined sample size calculations were not 
warranted. Rather, sample size was determined by respondents’ willingness to participate. 
Therefore, the number of respondents in each stakeholder group and across different sites 
varied. Breakdowns of the sample by stakeholder group/interview type and across sites are 
captured in the Tables 4 and 5 below.  
 
Table 4.  
Number of interviews by stakeholder group 
Interview type RECs CABs Site Staff Network  Total 
General 8 6 1 - 15 
Prevention-specific - - 12 2 14 
Care-specific - - 12 3 15 
Total 8 6 25 5 44 
 
Table 5.  
Number of interviews by site 
Stakeholder Site 1 Site 2 Site 3 Site 4 Site 5 
CAB: General 1 1 1 1 2 
Site Staff: 
Prevention  
3 4 1 1 3 
Site staff: 
Combined 
- 1 - - - 
Site Staff: Care 2 2 2 4 2 
Total 6 7 4 4 7 
 
Table 6. 
Characteristics of the study sample 
Role Male Female 
Principal Investigators 1 5 
Site leadership (Directors, Sub-investigators, 




Study clinicians 0 1 
Community Liaison Officers 1 1 
Counsellors 0 2 
Network leadership  2 2 
CAB members 2 4 
REC members (including 4 REC chairs) 7 1 
104 
  
4.2 Data collection strategy 
The empirical component of this study explored standard of prevention practices in two trials 
using primary sources (semi-structured interviews with HVT stakeholders) and secondary 
sources (review of documents, e.g., protocols, ICFs, standard operating procedures [SOPs]).  
 
A letter requesting site documents and outlining the safeguards for trial sites was sent to PIs 
at all sites (Appendix 2), who granted permission for the release of site documents.  
 
To formally introduce the study to all sites, identify concerns, and collaboratively determine 
the most appropriate methods for inviting potential respondents to participate in interviews, 
sensitising visits were undertaken to all sites (Appendix 3). REC chairs were contacted by 
email, and their permission sought to contact REC members for an interview. Similarly, a 
network representative was contacted to determine the most suitable approach for inviting 
network representatives for interviews. Through this initial outreach, a list of potential 
respondents was developed.  
 
An information sheet on the study was emailed to all potential respondents, along with an 
invitation to participate (Appendix 4). Some CAB members did not have access to email, and 
were contacted telephonically, informed of the study, and invited to participate in an 
interview. 
 
4.2.1 Semi-structured interviews 
This study used a combination of face-to-face and telephone interviews to collect data. The 
sample was geographically diverse (Opdenakker, 2006), and so telephone interviews 
provided a useful method to minimise the cost of travel and to access participants outside of 
South Africa (at the research network). Except for the loss of ability to access social cues 
(e.g., body language), telephone interviews “may provide information quite comparable to in-
person interviews” (Sturges & Hanrahan, 2004, p. 116).  
 
Interviews were semi-structured, broadly guided by key questions and offered “an adaptable 
and reliable means to gather the kind of data needed to conduct empirical bioethics research” 
(Sankar & Jones, 2008, p. 117). Where relevant to the research questions, additional 
questions (probes) were used to get respondents to elaborate on particular issues. Semi-
structured interviews are often used in qualitative research and serve as a guide that can be 
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adapted to interviewees and circumstances (Babbie & Mouton, 2001). Semi-structured 
interviews provide an intermediary between the need to collect similar kinds of information 
from all respondents while allowing each respondent to express their unique perspectives and 
experiences (Sankar & Jones, 2008).  
 
Site-staff participated in prevention-specific interviews (Appendix 5) while all other 
stakeholder groups participated in general interviews (Appendix 6). The prevention-specific 
interview schedule was developed to explore HIV prevention decision-making and 
implementation practices, perspectives on ethics guidelines, and challenges and successes in 
conducting HVTs. The general semi-structured interview comprised an exploration of 
interviewees’ perceptions of general issues regarding HIV prevention practices, their 
perspectives on ethics guidelines, and challenges and successes. The interview guides 
evolved over the duration of the study as findings of new prevention interventions became 
available and based on important issues identified in earlier interviews. Interview guides were 
also tailored to specific stakeholder groups.  
 
Respondents provided their individual informed consent to participate in interviews and for 
the audio recording of interviews (Appendix 4). Typically, interviews lasted between 45-60 
minutes.  
 
The desk review of documents occurred between July 2009 and August 2012, and interviews 
were conducted between August 2010 and August 2012. 
 
4.3 Data processing and analysis  
Given time constraints, the present researcher transcribed a sample of interviews but the 
majority were outsourced to a service-provider, who was guided by transcript conventions. 
Interviews were transcribed verbatim to capture pauses, speech repetitions and overlapping 
talk (Appendix 7). 
 
Standard of prevention practices in documents and interviews were coded using descriptive 
methodologies. A descriptive analysis (Sandelowski, 2000) was undertaken with the aim of 
describing which HIV prevention interventions were provided, to whom, how these services 
were accessed, who covered the cost of providing these services, why HIV prevention 
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interventions were provided and how decisions were made. The analysis was descriptive 
because it was devoid of a theoretical framework (Sandelowski, 2000).  
 
Text was also coded using a critical thematic analysis of the data (Braun & Clarke, 2006). 
Thematic analysis is well suited to revealing the specific way in which individuals or groups 
conceptualise the phenomenon under study (Joffe, 2011). It is not intrinsically linked to a 
particular paradigm and can be accommodated by a range of epistemological approaches 
(Joffe, 2011), including critical realism (Braun & Clark, 2006) and interpretivism (Terre 
Blanche, Durrheim & Kelly, 2006). The analysis broadly followed stages of analysis 
identified by Braun and Clarke (2006) and Terre Blanche et al. (2006), as detailed below. 
However, the process was iterative rather than occurring in six discrete phases.  
  
4.3.1 Familiarisation and immersion  
Prior to this study, the present researcher completed a conceptual review of HIV prevention 
responsibilities in HVTs (Essack, Slack, et al., 2010), and participated in consultations related 
to this issue (e.g., Heise et al., 2008; Philpott et al., 2011). Before data collection commenced, 
relevant literature and ethics guidelines on standards of prevention were reviewed. Therefore, 
initial ideas about standards of prevention were developed early on, and informed the 
development of semi-structured interview guides, facilitated probing in interviews, and 
influenced the subsequent coding and analysis of data.  
 
In and of itself, the process of collecting data allows the researcher to develop initial analytic 
insights and thoughts (Braun & Clarke, 2006; Terre Blanche et al., 2006). While most of the 
relevant data came from interviews conducted by the present researcher, some additional 
relevant data came from interviews conducted by another researcher, illuminating the 
importance of multiple readings of the text as a first step in analysis.   
 
The process of transcription offers another opportunity to become acquainted with the data 
(Braun & Clarke, 2006). Since some of the transcription was outsourced, to ensure accuracy, 





This process of repeated reading of the text, listening to original recordings (Braun & Clarke, 
2006) and making annotations, resulted in thorough immersion with the data and enabled 
preliminary codes/analyses to be developed.  
 
4.3.2 Generating initial codes 
The preliminary codes, developed through the process of immersion and familiarisation, were 
systematically applied to the data using a hybrid inductive-deductive approach (Fereday & 
Muir-Cochrane, 2006). Through this process, new codes were also developed. Although 
interpretive and exploratory approaches generally employ inductive coding techniques, 
because this study aimed to explore the extent to which practices corresponded with standard 
of prevention norms, a flexible hybrid inductive-deductive approach (Fereday & Muir-
Cochrane, 2006) was used. The research questions and ethics framework informed an a-
priori coding template. Text was also inductively coded to identify emerging themes. Some 
sections of text were assigned multiple codes while some were not coded if they were 
considered irrelevant to the research question. At this preliminary phase, codes were 
identified by highlighting text in different colours on printed transcripts. Annotations were 
made linking codes to ideas raised in the literature and to the normative framework. 
Preliminary interpretations of the data were also made.   
 
4.3.3 Identifying themes 
After step two, a long list of codes was generated. In this stage, related codes were clustered 
and re-clustered as necessary, to form coherent overarching themes (Braun & Clarke, 2006).  
 
According to Boyatzis (1998), themes may be identified at a semantic (explicit) level or at a 
latent (interpretive) level. This analysis predominantly focused on identifying themes at a 
semantic or surface level (the what, why, who and how) to facilitate thick description of 
standard of prevention decision-making and implementation practices. However, even at this 
level, there was an attempt to interpret themes in relation to previous literature and normative 
frameworks to explore broader meanings and implications (cf. Braun & Clarke, 2006). This 
analysis is largely the approach adopted in Chapters 7-10.  
 
In Chapter 11 (Discussion), the analysis is conducted at the latent level to explore the 
underlying ideas or assumptions that inform stakeholders’ reports of complexities with 
standard of prevention decision-making and implementation. Rather than descriptive, latent 
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analysis is interpretive (Braun & Clarke, 2006). When thematic analysis is focused at the 
latent level, it starts to intersect with discourse analysis (Braun & Clarke, 2006), generating a 
critical thematic analysis. Figure 5 below provides an example of the relationship between 





















State-of-the-art needs localisation 
Endorsing national regulatory approval 
Availability in the public healthcare sector 
Ensuring access to VMMC across trials (funding for VMMC) 
Initiating PEP using non-government guidelines 
Endorsing national regulatory approval 
Guidelines are vague 
Endorsing scientific validity and national regulatory approval  
Adding VMMC to the prevention package (based on scientific validity 
only) 
Variable thresholds being used for risk-reduction interventions 
State-of-the-art is vague 
Operationalising scientific validity  
Semantic themes: 







Current versus evolving 




Figure 5: The relationship between sub-themes, semantic themes and latent themes 
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4.3.4 Reviewing themes 
Phase 4 involved refining the preliminary themes developed in phase 3, and occurred in two 
stages: coded data extracts were examined to identify whether they cohered with the 
overarching theme. Once this was achieved, the coherence of themes in relation to the data 
set as a whole was considered (Braun & Clarke, 2006). Themes were also considered in 
relation to each other, and merged or separated if warranted by significant overlap or 
differences. Some themes were discarded. Sub-themes (or themes within a theme) were also 
identified during phases 3 and 4. Once this process was complete, each interview was then 
coded electronically using QSR NVivo 10 (qualitative data management software). Once all 
interviews were coded electronically, further amendments were made to the coding 
framework as necessary (see Appendix 8 for final coding framework).  
 
4.3.5 Defining and naming themes  
During this phase of analysis, names of each theme were finalised and definitions were 
developed (cf. Braun & Clarke, 2006).  
 
4.3.6 Interpretation and writing up  
The final phase of analysis involved consolidating themes with the aims and research 
questions to inform the final interpretations of the data (Terre Blanche et al., 2006). Finally, 
writing up the findings involved the careful selection of compelling supporting extracts for 
themes. In some instances, text used in supporting extracts was slightly edited through the 
deletion of text (indicated by ellipses) in order to improve readability without altering the 
meaning. The relevance of themes identified in this study was highlighted through linkages to 
available research, literature and normative frameworks. Further, interpretations were used to 
formulate emerging answers to the research question and draw conclusions from the data 
(Braun & Clarke, 2006). The scholarly report of the analysis is consolidated in remaining 
chapters of this thesis. 
 
5. Ethical considerations 
This section details the ethical considerations of this study, according to Emanuel et al.’s 
(2004) widely cited (354 Google Scholar citations by August 2014) framework for 




5.1 Collaborative partnerships  
The principle of collaborative partnerships encourages researchers to develop research in 
collaboration with relevant stakeholders (Emanuel et al., 2004). Prior to the implementation 
of the study, a national consultation was held with 23 representatives (mainly PIs and CABs) 
from all sites to inform them about the study and obtain their inputs. Consultation participants 
made recommendations for improvements to the study and expressed concerns about 
potential risks to sites (e.g. less developed sites being “penalised”). Measures to reduce such 
risks were discussed.  
 
5.2 Social value 
The social value of research lies in its ability to address questions that are of value to society 
or generate knowledge of benefit to participants and/or society (Emanuel et al., 2004; 
Wassenaar & Mamotte, 2012). In responding to calls in the literature (Essack, Slack, et al., 
2010; Haire et al., 2013; Macklin, 2010) to explore standards of prevention in trials, and their 
correspondence with ethics guidelines, this study hopes to generate knowledge of potential 
benefit to ethics deliberations on standards of prevention in HVTs. An explicit aim of this 
study is to identify recommendations for improved practices and guidelines, and, in this way, 
this study hopes to be of benefit to study respondents.  
  
5.3 Scientific validity 
This principle emphasises the importance of scientifically sound research design, sampling 
strategies, and data collection and analysis processes, since research that is not scientifically 
valid is not ethical (Emanuel et al., 2004). The measures implemented in this study to 
enhance rigour, validity and reliability are explained below and summarised in Figure 6.  
 
This study adopted a critical realist ontology, assuming that there is an underlying reality 
which can be studied but that data provides a representation of that reality that is perspectival, 
rather than absolute (Scott, 2005). While the concepts of reliability and validity were 
developed for positivist research, in their broadest conception, they are applicable to 
qualitative research (Lewis & Ritchie, 2013). Several strategies were used to ensure to 
reliability and validity in this study.   
 
Rather than validity in the quantitative sense of measuring what the researcher claims to 
measure, in qualitative research validity is understood in terms of the credibility and 
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transferability of the data (Lincoln & Guba, 1985). In qualitative research, reliability is less 
concerned with whether a replicated study would produce similar findings but with the 
'trustworthiness' (Glaser & Strauss, 1967), 'consistency' (Hammersley, 1992) or 
'dependability' (Lincoln & Guba, 1985) of the data. Efforts to ensure credibility and 
consistency are detailed below. Issues of transferability (generalisability) and reflexivity are 
discussed in Chapter 11.  
 
5.3.1  Triangulation 
Triangulation is the use of multiple methods to study the same phenomenon or the analysis of 
the research question from multiple perspectives to enhance the credibility of research 
(Guion, Diehl & McDonald, 2011). This study employed several strategies of triangulation 
including data triangulation, methodological triangulation and investigator triangulation.  
 
Data triangulation involves using different sources of information/data (Guion et al., 2011). 
In this study, document review and semi structured interviews were used as sources of data. 
Data triangulation can also be considered in terms of categories of time, space, and person 
(Begley, 1996). In this study, data triangulation of space and person were used. Space 
triangulation was used by collecting data from multiple HVT trial sites and different RECs 
(Begley, 1996). In terms of person (stakeholder) triangulation, semi-structured interviews 
were conducted with various stakeholders involved in HVTs, and within sites, staff with 
differing responsibilities were sampled, e.g., PIs, clinicians and counsellors. By conducting 
interviews with multiple representatives of stakeholder groups, this study was able to get 
different accounts and perspectives on standards of prevention practices. Unit of analysis 
triangulation (Begley, 1996) entails employing two or more approaches to analysis. This 
study employed descriptive, interpretive and critical approaches in the analysis of data.  
 
The use of different researchers during the coding process (investigator triangulation) was 
used to ensure reliability of coding and to enhance the credibility of the research. The coding 
framework for decision-making was jointly developed with a second independent coder 
based on a reading of a sample of transcripts, key literature, and ethics guidelines. Where 
there were discrepancies in coding, these were resolved through reconciliation discussions 
(Boyatzis, 1998). Codes identified in the initial reading of transcripts were consolidated into a 
coding framework. The development of the coding framework was iterative. The preliminary 
coding framework was used to code two additional transcripts, and after reconciliation 
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discussions, amendments were made as necessary, where some codes were merged and others 
discarded altogether (see Appendix 8).   
 
The present researcher developed the coding framework for implementation practices and 
perspectives. To enhance reliability of coding, a portion of interview data (STI treatment) 
was co-coded by a second researcher and followed the same process of reconciliation 
discussions to resolve disagreements (Boyatzis, 1998). Similarity in the identification of 
themes and interpretations of this data were also compared.  
 
In order to ensure the reliability of analysis in qualitative research, it is recommended that 
researchers present actual data from respondents rather than their own inferences when 
presenting the final analysis (Silverman, 2005). For this reason, extracts from interviews are 
used to support interpretations of the data (see Chapters 7-10).  
 
5.3.2 Respondent validation  
Respondent validation (member checking) requires that the researcher’s account or 
interpretation of the data is compared to respondents’ to determine correspondence (Mays & 
Pope, 2000). Respondent validation is considered valuable for ensuring the credibility of a 
study’s findings (Lincoln & Guba, 1985). The range of feedback to respondents varies and 
may include sending transcripts or quotes to respondents to verify accuracy, or providing an 
opportunity for respondents to comment on the interpretations of draft reports (Lacy & Luff, 
2012). In the present study, the feedback consultation with stakeholder representatives, 
including some respondents, could be argued to serve as a strategy for respondent validation. 
The aim however, was not to verify results, but to feed key findings back to stakeholders (as 
ethically required), and obtain their inputs/feedback on study conclusions/implications.   
 
5.4 Fair selection of participants 
The ethical principle of justice (Beauchamp, 2008) requires that study participants are 
selected fairly. Participants should be selected from populations to which the research 
question is relevant (Emanuel et al., 2004; Wassenaar & Mamotte, 2012). As described 
above, the study sample was purposively selected and included representatives from HVT 
stakeholders involved in the planning, implementation and oversight of HVTs. The sample 




5.5 Favourable risk/benefit ratio 
The ethical principles of beneficence and non-maleficence require that potential risks be 
identified and minimised and benefits maximised (Wassenaar, 2006). It was anticipated that 
some respondents might experience anxiety about their reported practices being judged as 
inadequate and potentially resulting in negative consequences for them or their organisation. 
As such, the research was presented as a collaborative problem-solving endeavour around a 
shared concern. Prefacing each interview, respondents were informed that their 
confidentiality would be protected and it was emphasised that respondents could refuse to 
answer certain questions. Further, to emphasise that this research was undertaken in the spirit 
of collaboration rather than as an audit, no direct observations of practices were undertaken. 
Few direct benefits for respondents were expected from this research. However, this research 
aimed to make recommendations for improvements to practices and ethics guidance.  
 
Respondents who participated in interviews were offered R50 (+/- $5). It is considered ethical 
to compensate participants in research for their time and inconvenience (Koen et al., 2008). 
This payment was not considered to offset risk (Wassenaar & Mamotte, 2012).  
 
5.6 Independent ethics review  
This study received ethics approval from five RECs with jurisdiction over trial sites, as 
follows (approval numbers in parentheses): Biomedical Research Ethics Committee, 
University of KwaZulu-Natal (BE 241/09); Human Research Ethics Committee (Medical), 
University of the Witwatersrand (M091140); Medunsa Research Ethics Committee, 
University of Limpopo (Medunsa Campus) (MREC/P/13/2010: CR); Human Research Ethics 
Committee, University of Cape Town (REF 476/2009) and The Committee for Research on 
Human Subjects (Medical), Walter Sisulu University (089/009).  
 
All respondents were informed of the ethics review process and were provided with the 
contact details of the Biomedical Research Ethics Committee (UKZN), should they have any 
questions pertaining to ethical issues in the study (Appendix 4). 
 
5.7  Informed consent 
Autonomy and respect for the dignity of persons is operationally expressed in the 
requirements for informed consent in research (Wassenaar, 2006). Individual informed 
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consent was obtained from all respondents for both their participation in interviews and the 
audio recording thereof (Appendix 4).  
 
5.8 Ongoing respect for communities and study participants 
Participants should be treated with respect during and after a study by ensuring 
confidentiality, allowing them to withdraw at any time and informing them of study findings 
(Emanuel et al., 2004; Wassenaar & Mamotte, 2012). In terms of confidentiality, each 
interview respondent was assigned a code that was recorded on their interview transcript. 
Records of respondent and organisational identifiers were stored separately from the data. 
Identification of respondents and their organisations was omitted from public reports. Site 
data was aggregated to form a national picture. However, since this study sample was 
relatively small, in some cases individual responses may be identifiable through the use of 
rich text extracts to support interpretations. This limit to confidentiality was outlined to 
participants in information sheets (Appendix 4) and every effort was made to reduce this risk.  
 
A post-research consultation was held in November 2012, where preliminary results were 
presented to stakeholders such as sites, CABs and RECs. The aim of this meeting was to 
provide feedback to stakeholders on the study findings, get their inputs, and stimulate 
discussion on the implications for practices and ethics guidelines. A manuscript on standard 
of prevention practices at sites was published (Essack, 2014), and circulated to all 

























Figure 6: Ensuring rigour in the design and conduct of the study  
Data Triangulation: 
Desk review of documents 
Semi-structured interviews 
with HVT stakeholders 
Stakeholder Triangulation: 
• Site-staff 
• CABs  
• RECs 
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MEASURES TO ENHANCE SCIENTIFIC VALIDITY 
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This chapter outlined the methodology used for this study. This study is located in the 
‘empirical turn’ in bioethics and uses qualitative empirical research to address debates on 
standards of prevention in HVTs. Specific study procedures, approaches, data collection 
methods and instruments, and data analysis processes were detailed. The next chapters 
present findings on standard of prevention practices and perspectives in relation to norms in 





STANDARD OF PREVENTION DECISION-MAKING PRACTICES 
AND PERSPECTIVES  
 
"In theory, there is no difference between theory and practice. But, in practice, there is" –  
Jan L.A. Van de Snepscheut 
 
This chapter presents empirical data on standard of prevention decision-making practices and 
perspectives. It begins with stakeholder perspectives on the rationale for providing prevention 
services to trial participants (the why). Standard of prevention decision-making practices and 
perspectives are then presented according to the various stages at which decisions are made, 
namely protocol development, protocol review and protocol implementation. For each phase, 
the analysis considers the stakeholders involved in decision-making (the whom), their related 
practices and perspectives, the decision-making processes that are utilised (the how), and the 
challenges experienced. Given that most standard of prevention decisions do not occur at site 
level, this chapter only presents comparisons between sites and stakeholder groups, where 
relevant. Data in this chapter were analysed using critical thematic analysis (Braun & Clarke, 
2006) which involved consideration of discursive undertones where relevant. Decision-
making practices are compared with relevant HIV prevention recommendations in ethics 
guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012).  
 
1. Why provide prevention interventions to trial participants? The rationale 
While there is broad consensus that participants must be provided with effective preventive 
interventions to reduce their risk of acquiring HIV (Rennie & Sugarman, 2010), there is little 
consensus on the ethical rationale for doing so (Philpott et al., 2011). Several ethical 
frameworks have been advocated as justifying the provision of a standard of prevention 
package (see Chapter 5). Respondents in this study were also asked for their perspectives on 
why access to prevention services should be ensured for participants, as detailed below.  
 
1.1 To keep participants HIV-negative 
Some respondents argued that trial participants should be provided with a prevention package 
because of the obvious need to maintain their HIV-negative status. Since HVTs enrol HIV-
negative individuals with the overarching aim to identify an effective vaccine to prevent HIV 
119 
 
infection, keeping trial participants negative was argued to be congruent with this aim.  
 “…as researchers we need to remind ourselves of the bigger picture. That whilst 
we’re doing our trials and whether it’s vaccine trials or microbicide trials or 
whatever, you know at the end of the day we’re wanting to reduce individuals 
becoming infected so we therefore need to, focus on that at times. It’s important for us 
to actually send out the prevention messages because that’s the ultimate goal” (Z22, 
site staff, site 1).  
  
 “I think since the criteria is explained that we need an HIV-negative, we need to 
maintain them being their negative status throughout the trial. I think that’s the 
commitment that the sites have to make to the participant which make it upon us that 
we’ll maintain your HIV-negative status” (Z2, site staff, site 1).  
  
 “I think it can help them to stay negative. It is important.” (Z19, CAB, site 4).  
 
The old idiom that ‘prevention is better than cure (treatment)’ was also evoked to justify the 
provision of prevention interventions in trials. It was argued that “…prevention is what you 
always aim for…the health of the people is the supreme law.” (C17, REC). 
 
1.2 An ethical obligation 
Many respondents purported that providing a standard of prevention satisfies an ethical 
obligation or “moral duty” (Z17) to trial participants:  
  “I think it’s critical, it’s an ethical obligation of ours. They’re participating in our 
trials and uhm gosh uhm it’s the right thing to do (laughs). I don’t know what else to 
say” (Z13, network representative).  
  
 “I think it’s our obligation as ethical individuals (laughs), as ethical, um, 
researchers, to provide access…there are a number of guidelines as to how to 
conduct research in communities… all of them are very clear about providing the 
highest level of prevention available… We do these trials which are incredibly 
expensive, right, it boggles the mind how expensive they are. Uhm if we didn’t provide 
a level of care, if we were working in an ethics-free environment, we could do a trial 
in eight people…we’d vaccinate four people, we wouldn’t vaccinate four people, we’d 
introduce HIV and see what happens…for God’s sake, that would be a quick way to 
find out, wouldn’t it? But you know, that’s not the way we do things, and still look at 
ourselves when we get up in the morning” (Z9, network representative).  
 
 “…even at a moral level, I then have to move to say… I will put at your disposal the 




Some respondents were able to articulate this ethical obligation in relation to ethical 
principles. Like UNAIDS/WHO (2012) guidelines, beneficence and non-maleficence were 
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described by one REC respondent as the justification for providing prevention interventions 
in that researchers are obligated to maximise benefits and minimise foreseeable harms to trial 
participants – “…in HIV prevention trials the foreseeable risk is seroconversion so that 
researchers have an obligation to access and provide the best available standards of 
prevention.” (C19, REC).  
 
However, like ethicists (Philpott & Heise, 2009), not all respondents considered beneficence 
to ground standard of prevention obligations.  
 
1.4 Reciprocal justice 
The rhetoric used by many respondents (owe, sacrifice, reciprocate, thanking, voluntary 
contribution) resonates with the ethical principle of reciprocal justice. Participants were 
deemed as deserving a standard of prevention because research relies on their involvement 
and they voluntarily risk their well-being to contribute to the development of an HIV vaccine, 
which if effective, would be of great scientific and social value (Lie et al., 2006). For such 
contributions, researchers and sponsors, and to a more limited extent society, were argued to 
have a moral duty in protecting the welfare of participants in these trials.  
 “…it’s the reciprocity principle. And, in this regard, you find that if somebody is 
willing to risk their life, and put their life on the line in the interests of science, then 
it’s an ethical requirement that society or science in general, the scientific community, 
and sponsors, and everybody who’s part of that, you know, the sector that is going to 
receive the knowledge, that they actually reciprocate. And, they actually end up, 
obviously compensating them for whatever it is that they need if they do get infected, 
or they are provided with relevant prevention measures (.) beforehand.” (Z12, REC).  
  
 “I mean our lives depend on the study… We all rely on the information or whatever 
that they give, because eventually the findings that come from the research will be 
answer to all of us.” (Z1, CAB, site 1).  
  
 “…these are participants who are participating voluntarily and you know just 
because of their passion about wanting to make a contribution to the academic. So the 
least that we can do is to offer them the best that we can…” (Z22, site staff, site 1).  
  
 “(laughs) I think we owe it to them. … we are begging them, to come and help us 
improve this knowledge. ((Vaccines)) are going to help the very same community 
anyway, but at this point, there are no real benefits for them. So, an obligation… with 
all that they give to us, they give us their bodies, they give us their information, they 
give us their time. I think this is personally, and I think it is based upon some 
literature that, we, we owe it to them….that’s the least we can do.” (Z11, site staff, 




 “I think because without participants a site will not have research.” (Z20, CAB, site 
5).  
 
Reciprocal justice was an implicit rationale for providing a higher standard of prevention to 
trial participants than those in the local community or the general population:  
 “…because of the special sacrifice that research participants in HIV prevention trials 
are making for the community and for the future of the population that they do, I don’t 
think there’s any special worry that they might be receiving a higher standard of 
prevention than people in the community.” (C19, REC). 
 
Obligations to non-trial participants are discussed in chapter 9 on standard of prevention 
implementation practices and perspectives.  
 
1.5 Therapeutic obligation and clinical equipoise 
A few respondents argued that the provision of prevention interventions satisfied the 
investigator’s obligations to act in the best interests of their participants – akin to clinicians’ 
obligations to their patients. It was also justified based on the uncertainty of the efficacy of 
the experimental vaccine in comparison to the existing standard of prevention. 
 
The provision of a prevention package was argued to not only be for the benefit of trial 
participants but also as servicing the intrinsic needs of clinician-investigators by satisfying 
their clinical obligation to save lives and by feeding their self-perceptions as “ethical 
researchers”:  
 “I think probably the most fundamental reason is it fulfils our responsibilities of 
investigators.” (Z6, site staff, site 2). 
  
 “…it’s one of those two things, you know, that, often, push back in ethical, kind of , 
discussions, is that it feels good, it looks good to provide a great prevention, you 
know, intervention along with the trial, because it makes you feel like you’re saving 
people.” (C5, REC).  
 
1.6 Standard of care 
Access to prevention options for trial participants was also justified on the grounds that it is 
scientifically relevant to compare new prevention interventions against currently available 
prevention interventions. It would be unethical to deny participants’ access to available HIV 
prevention options as this would mean that participation in HVTs would potentially increase 




1.7 To counteract behavioural disinhibition 
Although dismissed as a weak rationale by some ethics commentators (see Lie et al., 2006), 
providing access to prevention interventions in HVTs was also argued to minimise the 
potential that participants will increase their risk behaviour because of false perceptions that 
the vaccine is protective.  
 
1.8 To moderate community mistrust of research 
Finally, the provision of a standard of prevention was perceived as tempering community 
mistrust of research. Some respondents reported that given the history of research in 
apartheid South Africa (Baldwin-Ragaven et al., 2000; Barsdorf & Wassenaar, 2005), 
community mistrust of research and researchers still prevailed. It was noted that many 
communities were still suspicious that HIV vaccine research increased participants’ risk of 
acquiring HIV.  
 “…because the last thing that you want is to have a situation where the community 
views our research as actually/ because we’re doing prevention research it’s like 
therefore especially where you’re finding that HIV infection is your endpoint. Now if 
we do not offer good risk-reduction counselling that can be easily viewed as that we 
are encouraging women to become infected so we can reach our endpoint and that is 
definitely not the aim.” (Z22, site staff, site 1). 
  
 “…most of the questions that are asked by people ‘is this research of yours not going 
to give us more HIV?’ So that is where now we have got to explain to say ‘the 
research is trying its utmost to reduce the incidence of HIV, so there is no way that 
you can get more HIV in the community.’” (Z3, CAB, site 2).  
  
 “…at the moment here people are very suspicious and then because of our history. 
When things come like this they are suspicious – ‘they want to take my blood, what is 
it? What are they going to do with it and all that.’ And the suspicion that the vaccine 
that they are going to use: ‘are they not going to infect me with HIV’ and so on so, it 
takes time to win the trust of the community…” (C12, CAB, site 3).  
 
 “It’s so they don’t think that whatever we doing here, we are giving them the 
diseases. I think it’s very critical.” (Z8, site staff, site 4).  
 
1.9 Comparison of perspectives on the rationale for providing access to prevention 
interventions with ethics guidelines 
National ethics guidelines (MRC, 2003) require the provision of risk-reduction interventions 
in trials on the basis that phase III trials will involve some exposure to HIV infection while 
the GPP guidelines (UNAIDS/AVAC, 2011), like many respondents in this study, merely 
articulate that providing a standard of prevention to participants is an ethical obligation. 
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Beneficence and non-maleficence stated as ethical rationales in UNAIDS/WHO (2012) 
guidelines and by various commentators, were also suggested as rationales by some 
respondents. The lack of agreement on the ethical rationale supporting the provision of 
prevention services to participants in trials (McGrory et al., 2010) was also reflected in the 
variable justifications provided by respondents in this study.  
 
Many of the responses to the question of why prevention services should be provided to trial 
participants were peppered with laughter. Laughter seemed to serve several purposes in the 
research interview. Some of the laughter appeared to suggest the perception that the ethical 
rationale is obvious and that even asking the question was nonsensical, for example “Mmm, 
uhm:: what do you mean? I mean for obvious reasons …” (Z7, site staff, site 1) and “…uhm 
gosh uhm it’s the right thing to do (laughs). I don’t know what else to say” (Z13, network 
representative). The perception that the rationale is obvious did not resonate with the fact that 
there is no consensus on the ethical rationale for providing prevention interventions 
(McGrory et al., 2010), nor with this data, which identified multiple rationales.  
 
For other respondents, the laughter appeared to ease tension. Given that this question was 
posed by a researcher affiliated with an ethics unit, for some respondents, it may have 
generated a moderate degree of anxiety. For example, “you’re cleverer than me about all the 
words like beneficence and all the other things” (Z18, site staff, site 5). Nevertheless, many 
respondents appropriately articulated their perspectives in a way that closely mapped with 
positions identified in related ethics guidance.  
 
In addition to the rationales of beneficence/non-maleficence, reciprocal justice, standard of 
care, behavioural disinhibition, the therapeutic obligation and clinical equipoise (McGrory et 
al., 2010) mentioned above, respondents identified community mistrust of research as a 
rationale for providing prevention interventions. 
 
South African trial communities have been particularly sceptical about clinical trials and 
mistrust of research has been perpetuated by various myths and misconceptions including that 
researchers infect participants with HIV (Ramjee et al., 2010) and that HIV/AIDS was 
manufactured to decrease the numbers of the Black population in South Africa to support the 
return of the apartheid regime to power (Sivelä, 2012). Such myths and misperceptions find 
fertile ground in a complex history where under apartheid “black people were targeted as 
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research participants due to their obvious vulnerability” (Barsdorf & Wassenaar, 2005, p. 
1087). Widely publicised and sensationalised media reports that trial participants are used as 
‘guinea pigs’ in HIV prevention research (cf. Ramjee et al., 2007) has further fuelled such 
mistrust of research. Respondents in this study argued that the provision of a prevention 
package to participants would help defuse such mistrust and that active efforts to take care of 
trial participants would engender less scepticism in future trials. GPP guidelines 
(UNAIDS/AVAC, 2011) acknowledge that efforts to reduce risk of HIV acquisition among 
trial participants is of great concern to community stakeholders and that negotiation with 
these stakeholders about the prevention package is likely to impact on community 
perceptions of the trial.  
 
2. Protocol development practices and perspectives 
For every HIV prevention trial, deliberations must occur regarding the standard of prevention 
to be provided to participants. Accordingly, standards of prevention are an integral 
component of the study design (Tarantola et al., 2007). Deliberations about the standard of 
prevention are both ethically and scientifically relevant: the provision of a standard of 
prevention is ethically mandated (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 
2012) and has critical scientific implications for trial design (Padian et al., 2010). Different 
approaches to standard of prevention discussions were described in interviews, including 
consultations between the sponsor, network and investigators as well as iterative, informal 
dialogue among various research stakeholders. 
 
Standard of prevention deliberations primarily occurred during the protocol development 
process:  
 “I think probably the main stakeholder, certainly in that particular clinical trial [the 
phase IIB trial], and I would say clinical trials in general, is the protocol committee. 
… And, I think really, the main decisions around what will be in, and what won’t be 
in ((the prevention package)), is at that level.” (Z18, site staff, site 5). 
 
The protocol committee was represented as the leading decision-making body in terms of 
establishing the standard of prevention for most trials.   
 
For each trial, a draft study protocol was circulated to members of the protocol committee for 
review, three weeks preceding a one and a half day face-to-face meeting. The protocol 
125 
 
development meeting was described by a network representative as intensive, methodical and 
structured:  
 “So, the protocol’s distributed to us about three weeks before, and we have three 
weeks to review it. We bring people into a room and it’s a very structured process, so, 
the first half day…we literally go through the protocol and everybody provides 
comments. It’s a round-robin, anybody can provide as many comments as they 
want…everybody is providing input at that point, and then we break into functional 
groups… our functional group is assigned a couple of different sections, and we are 
assigned to resolve all the issues that have been raised in that section, and, that’s 
down in the second half of the first day, and then, at the end of the day, everybody 
presents back what the resolutions are. That night, staff members from our office 
complete all the changes in the protocol, and the beginning of the next day, there is a 
fresh protocol put in front of everyone, with all the changes incorporated, and there’s 
basically a reading period by which everybody in the room reads through and makes 
sure that it meets all their requirements, and then, there’s a sign off.” (Z9, network 
representative). 
 
The above quotation emphasises the collaborative nature of protocol development. It was 
suggested that all stakeholders represented on the protocol committee were afforded an 
opportunity to make a meaningful and substantive contribution, including regarding the 
standard of prevention.  
 
2.1 Stakeholder ‘negotiation’ of the prevention package  
GPP guidelines (UNAIDS/AVAC, 2011) affirm that research teams and relevant stakeholders 
should negotiate the HIV prevention package during protocol development. The protocol 
committee comprised diverse stakeholders including representatives from the sponsor/funder, 
the coordinating network, site investigators and the host community.   
 
2.1.1 The sponsor’s role in standard of prevention decision-making  
The sponsor was reported to have representation on all protocol committees:  
 “.. the [sponsor’s] medical officer sits on every protocol team and sits on every 
protocol safety review team and is sort of intimately involved in the development of 
the science and in overseeing the operations of the protocol” (C10, network 
representative). 
 
The ‘intimate’ involvement of the sponsor in making decisions on all phases of the trial is in 
line with the sponsor’s role of “taking primary responsibility for the initiation, management, 
and/or financing of a clinical trial. It ensures that the design of the study meets appropriate 
standards and that arrangements are in place to ensure appropriate conduct and reporting” 
(Tarantola et al., 2007, p. 4864).  
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2.1.2 Complexities with sponsor funding policy 
Many respondents in this study perceived the sponsor as having supreme decision-making 
authority. In some circumstances, the sponsor was even portrayed as dictatorial and self-
serving by limiting the prevention options that could be made available to trial participants. 
The rhetorical device of ‘othering’ (Johnson et al., 2004) was observed in discussions about 
the sponsor who was perceived as the stakeholder “not on the same boat” (Z5, site staff, site 
2) with regard to the welfare of participants (see Chapter 11).  
 
A sentiment shared by some respondents was that the sponsor was solely promoting their 
own interests:   
 “…there are the donors driving, funder driving. If the funder said I need 1, 2 and 3, 
you can’t go beyond that” (Z2, site staff, site 1).  
 
 “One of the stakeholders I think it’s the sponsor. Sponsors structure trials according 
to what they want to study. And beyond that they are not fully committed…So there 
are some stakeholders who are in the same room but uhm what I've noticed is that 
sponsors are not in the same boat as everybody.” (Z5, site staff, site 2) 
 
 “I guess it’s the pharmaceuticals, that’s another industry altogether. We are a site, 
they are pharmas. They design. They have strict budgets. They say, ‘What we want is 
this.’ (R: ‘We’ll pay for this.’ Ja11) ‘We’ll pay for this. Anything else. No’. You could 
negotiate some of those things… but they would not go beyond certain brackets. 
(laughs). And, I think, sponsors have realised that South Africa is picking up when it 
comes to clinical trials. They’ve got options. Um, if you put in weird budgets, they will 
just not take you into their trial and go to [other local sites] (laughs). And they will 
find a PI there who is willing. PIs must also agree, on certain/ to say, ‘This is what we 
need, or it’s not happening.’… They’re just concerned about their trial, so I think 
cracking that gap would be another mission. Because they could say, ok, South 
Africa’s not co-operating when it comes to this, let’s just move it to Zimbabwe, move 
it to another country.” (C3, site staff, site 2). 
 
  “So for example unless an STI test is mandated by the research we cannot cover the 
cost of that test. So if it’s, for example, you know a participant retention tool that they 
can do sort of one-stop shopping for their care…that funding needs to come from 
elsewhere. We cannot use the money for that. Not that we wouldn’t like to but we 
can’t.” (C10, network representative, emphasis added) 
  
 “So, we were saying to the sponsor I think you’d better pay for the drugs [for STI 
treatment]…they wouldn’t budge, they wouldn’t. And we were like, ‘Ok find a 
pharmaceutical company that can sponsor’. But then that was also another red-tape, 
                                                             
11 ‘Ja’ is a colloquial term for yes.  
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because you can’t do it, you have got to do it via the government, and what-not.” 
(Z11, site staff, site 2).  
 
The above extracts highlight that as the funder and financer of the trial, the sponsor was 
perceived to command most of the decision-making power. This was characterised by the 
perception of a relatively non-negotiable sponsor policy and the uneasy acquiescence of other 
stakeholders with this policy. Still, a few respondents expressed frustration at the funding 
thresholds imposed by sponsors and the lack of commitment to compromise – with 
compromise considered a critical aim of negotiation. There was some concern expressed that 
sponsor policies were intractable and that it was difficult “to change their [sponsor’s] mind-
set” (C17, REC). Sponsor policy dictated for example, that federal funds could not be used to 
purchase drugs or support care services that are not required for scientific validity or 
participant safety (Philpott et al., 2010).  
 
While concerns expressed by respondents related primarily to sponsor policy not to fund non-
research activities (also described in chapter 9), one respondent was concerned about sponsor 
decisions to utilise particular guidelines that may not necessarily be “helpful”: 
 “Like I was mentioning before, I found the CDC guidelines…to not be particularly 
helpful which is a little disappointing because that’s a requirement that we use the 
CDC guidelines” (Z13, network representative). 
 
Given sponsor policy, there was an obvious chasm between what sponsors were willing to 
provide and what ethics guidelines prescribe for trial participants. This gap was bridged via 
complex arrangements between other key stakeholders as described below.  
 
2.1.3 The investigator’s role in standard of prevention decision-making  
Investigators were represented on the protocol committee and played a pivotal role in 
determining the standard of prevention, particularly for the phase IIB trial. It was described 
that protocol development included vociferous discussions on the components of the 
prevention package, including whether to provide trial participants with access to VMMC 
(which was not widely available at the time) and STI treatment despite funding frameworks, 
for example:  
 “…in consultations during protocol development…the investigators felt very strongly 
that circumcision should be provided…and STI syndromic management…and, [the 
protocol chair] pushed very hard in that because the initial response was, ‘We can’t 
pay for this.’ You know… we all agree that this is a fine idea but our funding is 
restricted to research. And, since … circumcision and provision of STI syndromic 
128 
 
management, isn’t part of our mandate. We can’t fund that kind of thing. We’ll have 
to figure out something else. But, you know, we can’t really put it in the protocol 
because all of our funding comes from the [sponsor].’ So, [the protocol chair] pushed 
very hard to have that added. And, pushed us very hard to find funding…” (Z9, 
network representative).  
 
 “…sites insisted on having a list of things available for their participants” (Z17, site 
staff, site 5).  
 
Concerns raised by some respondents that being too demanding would serve to deter funders, 
did not appear to dissuade investigators from strongly advocating for the welfare of trial 
participants. Sponsors may be perceived to hold the upper hand in decision-making: they 
control the funding while investigators from resource-constrained contexts compete for that 
funding. This data indicates that investigators showed resolve in ensuring a ‘state-of-the-art’ 
prevention package for trial participants. This advocacy from researchers to ensure a high 
standard of prevention further undermines concerns that researchers may provide substandard 
prevention interventions to ensure study endpoints (cf. McGrory et al., 2010).  
 
2.1.4 The role of the network in standard of prevention decision-making 
The network coordinated the protocol development process and was represented on the 
protocol writing committee. Respondents in this study sometimes conflated the 
funder/sponsor and the co-ordinating network. However, network representatives were 
careful to distinguish themselves from the sponsor:  
 “The way I understand it is that the X is in most cases the sponsor for our trials with 
some exceptions… Now in most cases the trial sponsor delegates to [the network] 
some of the authority, so some of the regulatory responsibilities and/or some of the 
operational responsibilities that a sponsor typically takes on…. and those 
responsibilities are delegated very clear in the arrangements between the [sponsor] 
and the [network]…” (Z9, network representative).  
 
This distinction is ethically relevant because while the network must subscribe to and enforce 
the policies of the sponsor, they reportedly made great efforts to fulfil their moral 
responsibilities to participants. One possible reason for network representatives to highlight 
this distinction may have been to distinguish themselves from the practices of the sponsor – 
some of which were criticised by respondents in this study.  
 
In contrast to the somewhat negative portrayal of the sponsor in relation to funding policies, 
the coordinating network was reported to have made a significant contribution to ensuring 
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access to a high standard of prevention by securing alternate funding for a ‘state-of-the-art’ 
prevention package, for example:  
 “…a lot of these trials are funded by federal government, and the US government has 
some quite strict rules about what they can and can’t fund, um, so, you know, where, 
aspects of the standard of prevention cannot be funded by the sponsor, other funds 
have to be found. Now, in the case of the [network], they might raise the money 
themselves. So, make the, you know, those funds available separately.” (Z18, site 
staff, site 5) 
  
The network was perceived by some respondents as highly committed to ensuring a high 
standard of prevention both in terms of their role in decision-making and implementation:  
 “I can speak from personal experience with working with the [network]. They are 
extremely diligent in providing prevention services because they have made sure that 
we have implemented the male circumcision programme and then everything else… 
they are quite serious about it.” (Z7, site staff, site 1).  
 
 “Actually the [network protocol] is one of the best protocols I’ve ever worked on 
because you know they’ve actually paid for medical circumcision on the protocol and 
that’s quite expensive.” (C2, site staff, site 1).  
 
Network representatives also reflected on the efforts initiated to satisfy standard of prevention 
requirements for the phase IIB study:  
 “So, I can tell you that at the time of protocol development we didn’t have any 
mechanisms in place to support the sort of two care elements there, the, the um STI 
treatment, and the circumcision….we had to negotiate. We had to find funding and 
negotiate for it because…it’s not part of the mandate from the [sponsor] and they 
can’t support it. So that required some hoop-jumping (laughs) but, um, not 
impossible…” (Z9, network representative).  
 
 “…I suspect what happens is it’s a discussion between very high levels of the 
[network] and very high levels of the vaccine manufacturer to say look this is 
something that the local investigators feel very strongly about. We’d like for you/ 
could you identify some money to basically /I cannot verify this in any way but my 
understanding is that our leadership goes knocking on doors to try and find the 
money.” (C10, network representative).  
 
In this way, the network was able navigate the complex terrain between satisfying 
investigators’ demands and meeting ethics guideline requirements while still honouring the 
sponsor’s mandate. It was anticipated by a network representative that these negotiations for 
alternative funding would become common practice for future trials, especially as new tools 




However, for the phase I trial, the network was not able to source alternate funding for 
VMMC or STI treatment and no reference to these prevention interventions was made in the 
ethical considerations section of the phase I trial protocol:  
 “Well, I can tell you that, for the largest trial that we’ve done so far in South Africa, 
we offered circumcision (R: Yep), um, er/ we’ve done a couple of low-risk trials since 
then, which, um::, we weren’t able to offer circumcision as part of this…” (Z9, 
network representative). 
 
This suggests that standard of prevention determinations may depend on the phase of the 
trial. Distinctions in prevention options offered to participants in different trials are described 
in chapter 8 on the evolving standard of prevention in relation to relevant criteria for 
decision-making.  
 
2.1.5 The role of CABs in standard of prevention decision-making 
Community engagement has been defined as “a transparent and meaningful participatory 
process” of stakeholder involvement in the trials process, from the design of protocols to the 
dissemination of results (UNAIDS/WHO, 2012, p. 17). Ethics guidelines also recommend the 
involvement of community representatives in designing risk-reduction interventions. Some 
respondents reported that CABs were represented on the protocol committee and on key 
network bodies, namely the ethics working group and the scientific steering committee – the 
network’s primary decision-making body:  
 “…in advance of protocol team meetings, someone from our office coordinates… 
discussions with the community members about what their concerns are, so that they 
are sort of collated, and coordinated in a way…” (Z9, network representative).  
 
 “…each site has its own community advisory board and they nominate one person 
from the community advisory board, from the local community advisory board to sit 
on a global community advisory board. So that G-CAB as we call it is made up of 
representatives from each site and then from the G-CAB we call upon a 
representative to sit on our sort of governing body. So that includes the protocol 
committee which is what reviews all concepts and all protocols; the scientific 
advisory group which reviews, it’s sort of a slightly different take on the protocol 
committee, they do slightly different reviews in terms of sort of scientific prioritisation 
so the protocol committee looks very closely at both.” (C10, network representative). 
  
 “I’m not sure how much the sponsors er, commit, but I know that our community 
representatives sit on those global boards, and they do, express the interests of their 






2.1.6 Complexities with stakeholder negotiation of the standard of prevention 
 
2.1.6.1 Inherent power dynamics  
One of the key challenges with authentically and meaningfully engaging communities in 
protocol development is the presence of an “inherent power dynamic” between scientists and 
the lay community (C10, network representative). In recognition of this potential imbalance 
of power, CAB representatives on the protocol committee were reported to have received 
network-provided support, including on the standard of prevention (see Chapter 11).  
 
2.1.6.2 Perceptions of top-down decision-making  
While some respondents in this study perceived protocol development to be a collaborative 
and inclusive process, other respondents expressed concern that decisions regarding the 
standard of prevention made during protocol development occur in a top-down fashion with 
minimal inputs from people on the ground such as site staff and CAB representatives. This 
criticism has previously been levelled against ethics deliberations, including on the standard 
of prevention (Heise et al., 2008).  
 
For the phase IIB trial, it was reported that the protocol committee was not entirely 
representative of all implementing sites. By implication then, determinations on key standard 
of prevention decisions were not necessarily consultative and inclusive, for example:  
 “… what I’ve realised with [the phase IIB trial] was that basically you’d find that it 
will be the national PI who eventually would have done all that…when they come to 
other sites and then you find that basically the main negotiations have already been 
done” (C16, site staff, site 3).  
  
 “I have really no idea how we came up with that package. Uhm the [network] 
obviously came up with it. We didn’t really have an input in it.” (Z7, site staff, site 1).  
 
 “… how the whole um thing developed is that our site together with [site X] were the 
last ones to get on board and so, because I remember you know by the time our site 
was ready, the protocol was almost finalised” (Z22, site staff, site 1).  
 
However, the involvement of selected sites/investigators was not deliberately exclusionary 
but reflected a practical challenge in that the participating sites may not all have been 
identified as early as the protocol development phase:  
 “…we have a face-to-face protocol team meeting although at that time, to be quite 
honest with you, some of the sites have not really been decided upon so it might be 
difficult to, at that point in time, get input from the local investigators because they’re 
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not, they haven’t actually generally been picked for the trial…” (C13, network 
representative).  
 
Most CAB respondents perceived a more limited role for the CAB in making substantive 
inputs into standard of prevention determinations generally, and particularly regarding 
decisions taken during protocol development. This may relate to the way in which 
community representatives were selected to be on the protocol committee:  
 “…typically we start with that chairperson’s site, identifying the community member 
and staff member and CAB representative. But, if no one from that site is available, 
then we branch out.” (Z9, network representative).  
 
Rather than a sense of inclusivity, selecting a CAB representative from one or two sites to be 
on the protocol committee, fostered a sense of marginalisation amongst some CAB 
respondents. It highlighted that these particular CAB members did not enjoy the same levels 
of engagement and involvement in HVT decision-making as CAB members at other sites, for 
example:  
 “….it [the protocol] came as final deal, as a done deal to them.” (Z2, site staff, site 
1).  
 
 “The CAB has complained they were not involved in the protocol. [The PI] explained 
that we were the last site to be involved in [the phase IIB trial] and not even the 
researchers had input….But other sites seem to involve their CAB more…one member 
is in the scientific protocol development team, another on ethics team” (C1, site staff, 
site 1).  
 
 “You know, we’ve got the theory part and the practical part, huh? The theory part is 
that you develop the protocol with them [the community], but practically, as you may 
be aware that, these protocols are developed at a very high level” (Z11, site staff, site 
2).  
 
 “As you say, at the moment our PI’s are having to consult communities. I guess, you 
know, the criticism is it’s after the fact. You know, you’re presenting them with a 
protocol. You know, you’re not going in and saying let’s develop a protocol, which I 
think does have very practical problems.” (C6, REC). 
 
Some CAB respondents expressed a strong desire to be involved in decision-making and at 
one site, a request was made of a fellow researcher to facilitate the involvement of the CAB 




2.2 Defining the standard of prevention in protocols (the what) 
Ethics guidelines make specific recommendations for the protocol regarding the standard of 
prevention. Both MRC (2003) and UNAIDS/WHO (2012) guidelines require that risk-
minimisation measures should be outlined in the study protocol.  
 
In line with ethics guideline recommendations, the standard of prevention was defined in the 
ethical considerations section prefacing both study protocols. The phase I protocol specified 
that risk-reduction counselling would be provided to participants. No other prevention 
interventions were specified. The phase IIB protocol stated that the research network “is 
committed to ensuring that all trial participants receive access to the highest standard of 
prevention which may include, but is not limited to, access to risk reduction counselling, 
provision of male and female condoms, access to syndromic management of STDs, 
information regarding male circumcision and referral to services that can provide male 
circumcision and post-exposure prophylaxis when indicated”.  
 
Neither protocol however, delineated mechanisms for stakeholder negotiation regarding 
standards for enhancement of the risk-reduction package as per UNAIDS/WHO (2012) 
specifications.  
 
Apart from the statement in the ethical considerations section, there was little other detail in 
protocols regarding the standard of prevention, including regarding the implementation of the 
prevention package, except that VMMC should be provided via referral. This silence was 
initially flagged as problematic during the document review process. However, it became 
increasingly clear during interviews that the statements on the standard of prevention were 
appropriate and well considered, including the lack of detail regarding how best to implement 
prevention services at sites. Such detail was argued to necessitate additional levels of 
oversight and monitoring as well as a consistent approach to implementation across sites, 
despite different socio-cultural and economic contexts – “if you prescribe it in the protocol, 
any deviation from that is an actual deviation from the protocol” (C14, network 
representative). Rather than in protocols, such details were reportedly captured in documents 
such as the manual of operations.  
 
Given the changing HIV prevention landscape, the sponsor/network did not have an 
established policy on the standard of prevention. Instead, the standard of prevention was 
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determined on a “protocol by protocol” basis. Defining the standard of prevention in the 
ethical considerations section of the protocol was reported to ensure that it was debated and 
discussed during the protocol development process. Respondents au fait with the protocol 
development process highlighted that the standard of prevention, and other ethical issues, 
were considered as important as the science, and that the ethical considerations section was 
interrogated to the same extent and with the same rigour as the rest of the protocol.  
 “The ethical considerations…that section will be evaluated just as carefully as the 
statistical section, as the procedures section…that one line that you were reading 
from the ethical considerations section [referring to the standard of prevention]…that 
is where we put it to ensure that that discussion comes up in the protocol…in other 
words, we didn’t put it in an SOP at the sites, we didn’t put it er, in a policy statement 
that isn’t reviewed by every protocol, we put it right in the protocol so that it is 
reviewed by everybody… (Z9, network representative). 
 
2.3 Defining the standard of prevention in informed consent forms  
With regard to informed consent, MRC (2003) and UNAIDS/WHO (2012) both require that 
risk-minimisation measures should be detailed in the ICF. Further, participants should be 
counselled that they will receive access to risk-reduction counselling and proven prevention 
interventions (MRC, 2003; UNAIDS/WHO, 2012).  
 
ICFs for both studies specified that prevention counselling would be provided to participants 
to help them avoid getting infected with HIV. However, ICFs provided no information about 
access to other prevention interventions. It was reported that this may either be an oversight 
or deliberate to allow for flexibility in REC review, for example: “the other thing we don’t 
want to do is be too specific so, every time there’s a change to the consent form, obviously it 
has to go back to the ethics committee for review” (Z9, network representative).  
 
While ICFs do not meet guideline requirements in terms of defining the standard of 
prevention, interviewees reported that the prevention package was described to participants in 
the informed consent process. 
 
This data indicated that with regard to the content of ICFs, practices deviated from guideline 
recommendations. Sites provided substantially more to participants (see Chapter 9 on 
implementation practices) than was specified in ICFs. Concerns that providing detail on 
standards of prevention in these documents would curb flexibility in REC review is not 
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predicted by ethics guidelines, which instead underscore the importance of full disclosure to 
RECs. 
 
2.4 Comparison of protocol development practices with ethics recommendations 
The standard of prevention for both trials was largely determined by the protocol writing 
committee, which included representatives from the sponsor, the coordinating network, and 
selected trial sites and host community representatives. This resonates with requirements in 
ethics guidelines that HIV prevention packages be ‘negotiated’ by the research team and 
relevant stakeholders during the protocol development phase (cf. UNAIDS/AVAC, 2011) and 
that the community participates in protocol development (cf. MRC, 2003; UNAIDS/WHO, 
2012). While ethics guideline requirements were generally satisfied, several challenges were 
reported regarding standard of prevention determinations during protocol development, 
particularly pertaining to funding and community involvement.  
 
The potential for sponsor policies to impact on standards of prevention have been reported in 
other empirical studies. Philpott et al. (2010) found that donor policies that restricted how 
research funds may be used, limited the level of care provided to trial participants. Ethics 
guidelines too (UNAIDS/AVAC, 2011) acknowledge that potential funding restrictions may 
influence the provision of a comprehensive standard of prevention. To this end it is 
recommended that “when funding-body restrictions limit which prevention methods can be 
paid for by trial funds, research teams have the responsibility to find other ways to provide 
these methods, such as through alternative funding streams or linkages with non-
governmental organisations or community-based organisations” (UNAIDS/AVAC, 2011, p. 
49).  
 
Consulting the community on protocol development and informed consent has been argued to 
have protective benefit for communities (Weijer & Emanuel, 2000) and is entrenched in 
ethics guidelines. The most common mechanisms for achieving community inputs in HIV 
vaccine research is through CABs (Boulanger et al., 2013; Marsh, Kamuya, Rowa, Gikonyo 
& Molyneux, 2008; Morin et al., 2008). While it could be argued that ethics guideline 
requirements were satisfied by the involvement of selected CAB representatives on the 
protocol writing committee, some respondents did not equate this representation with 
meaningful community participation. While ethics guidelines require community inputs on 
the standard of prevention, they do not delineate the process for such engagement – it was 
136 
 
perceived by some respondents that the engagement mechanism of involving selected CAB 
representatives was inadequate.  
 
Perceptions of inadequate community engagement in this study are consistent with previous 
findings. An exploration of the role of CABs in health research in South Africa (Reddy et al., 
2010, p. 6), found that “CABs had limited influence on the substantive decisions of the 
research project.” The standard of care mapping study at microbicide trial sites, including 
South Africa, also found that at all sites, except one, community members and advisory 
groups were not consulted about the prevention package before protocols were approved. 
Their input was occasionally sought when the protocol had already gone through the approval 
process (Heise et al., 2008). Findings from the present study are also consistent with research 
that identified stakeholder input in trial protocols as a gap between GPP guidelines and site 
practices (Hannah et al., 2012) and which found a perceived low relevance of GPP guidelines 
regarding stakeholder engagement in both protocol development and the standard of 
prevention (Ngongo, Priddy, et al., 2012b).  
 
The lack of community engagement on standards of prevention during protocol development 
found consistently across studies, begs the question of why this ethics requirement is not 
realised in practice. While the reasons for this discrepancy between guidelines and practices 
have not been elaborated upon in previous empirical studies, this study found that there were 
practical challenges with meaningfully engaging all communities on the standard of 
prevention in trials. The thorough engagement of all affected CABs was constrained by the 
fact that not all sites were selected as implementing sites prior to the protocol development 
stage. This challenge is anticipated in guidelines (UNAIDS/AVAC, 2011) which state that in 
some instances opportunities for community input during protocol development might be 
limited.  
 
3. Protocol review practices and perspectives 
While decisions about which prevention interventions to include in the standard of prevention 
predominantly occurred at the protocol development phase, protocol review presented an 
opportunity for the HIV prevention package to be “vetted” by other research stakeholders 




Once the protocols were developed, they underwent sequential scientific and regulatory 
review by the sponsor. The sponsor provided comments on the protocols and the research 
network coordinated responses from the protocol team, including “community 
representatives and site level representatives” (C10, network respondent).  
 
The master protocol and supporting documents, including template ICFs, were then sent to 
sites. Before implementation at sites, protocols were submitted to several bodies for review, 
namely CABs, RECs and the regulatory authority (the MCC).  
 
The document review process found no substantive differences between master protocols and 
site-specific protocols for the two trials, suggesting that few amendments were made to these 
protocols before being distributed CABs and RECs for review.  
 
The prevention package offered in the two trials (see Chapter 9) indicates a discrepancy 
between what was provided to participants in trials and what was spelled out in both ICFs and 
protocols. Essentially this implies a disjuncture between what CABs and RECs approved as 
the standard of prevention and what was actually provided in trials. This may not be ethically 
concerning since the standard provided to trial participants exceeded what was committed to 
paper. Protocol and ICF drafting practices reported in this study do not align with the 
perspectives of REC stakeholders at the Ugandan consultation (McGrory et al., 2010) which 
argue that researchers must be explicit about how often the risk-reduction intervention will be 
provided to participants, the study staff responsible for delivering the service, and the 
required infrastructure. However, given ethics guideline recommendations that RECs should 
approve the risk-reduction package, it is especially pertinent that all the available information 
is provided to RECs, in a way that still permits flexibility for researchers. Failing this, RECs 
would have to approve amendments to the protocols.  
 
CAB and REC members were interviewed on their practices and perspectives pertaining to 
the review of HVT protocols, particularly concerning standard of prevention considerations.  
 
3.1 CAB review of protocols 
Ethics guidelines recommend that community representatives participate in the review of the 
trial protocol (UNAIDS/WHO, 2012) and make inputs into the informed consent process 
(MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) to ensure that the “research is 
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informed by the concerns and priorities of the community in which the study is to take place” 
(UNAIDS/WHO, 2012, p. 23). Protocol review presents another opportunity for community 
representatives to make inputs into the design of the standard of prevention as required by 
guidelines (cf. MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). 
 
In efforts to involve the community in all phases of the research process, CABs were 
involved in the review of study protocols/protocol summaries and informed consent 
materials. Two primary purposes of CAB review of protocols were identified in interviews. 
Firstly, review allowed for CAB oversight of research, ensured that the protocol represented 
the community’s interests, and was ethical:  
 “…before we even go out to a community, we actually get them [the CAB] to go 
through the protocol. Together with them, we do a community diagnosis or 
community mapping to say what are the feelings, what is the feel, what is the attitude 
out there, you know for the community” (Z8, site staff, site 4).  
 
 “Particularly with the history of research, we all know how people were, were used 
and hurt, in the name of getting successful researches… hence the involvement of the 
community in research and the informed consent to say everybody must be aware of 
what is being researched and how it is going to be done so that at the end of it all, 
things are done ethical, that is to say things are done in a way that nobody gets hurt 
in the name of research.” (Z3, CAB, site 2).  
 
It was argued that community oversight of research was critical in helping researchers 
maintain ethical standards, especially with regard to ensuring that researchers “don’t over-
research” (Z3, CAB site 2).  
  
Secondly, protocol review developed CAB competency on the protocol which facilitated their 
community education and outreach activities. In addition, the review of protocols and/or ICFs 
also enabled CAB “oversight on ethical issues related to protecting the interests of the 
participants” (Reddy et al., 2010, p. 3) and ensured community representativity on issues 
pertaining to the standard of prevention.  
  
While many of the CAB respondents could detail their concerns regarding issues of HIV care 
and treatment, the standard of prevention was not consistently noted as a concern by CAB 
respondents nor was it described as a critical element of the review process. The complexities 




3.1.1 Complexities with CAB review 
 
3.1.1.1 CABs’ perception of review process as tokenistic  
Perceptions about the CAB’s ability to impact on and meaningfully contribute to decision-
making during protocol review were mixed. CAB representatives at most sites felt that the 
protocol review process provided an opportunity for them to interrogate the protocol and 
accompanying documents and that their recommendations were seriously considered. Rather 
than aspects relating to the standard of prevention, most CAB interviewees described that 
they scrutinised the eligibility criteria, risks and benefits, and the language and wording of 
ICFs. The focus on the latter issues was in line with the specific roles and responsibilities 
identified for CABs (NIAID, 2009).  
 
A CAB representative at one site reported that despite the imperative to involve the CAB in 
the review of all study protocols, there was an uneven approach to engaging CABs in 
protocol review, with the CAB only reviewing selected protocols. Opportunities for review 
may vary by trial, especially in multisite trials (UNAIDS/AVAC, 2011) like the phase IIB 
trial where protocol development was a largely centralised exercise. It has also been 
acknowledged that “extensive grassroots consultations prior to conclusion about the content 
of the standard of prevention packages for research may not, and indeed cannot, always 
occur” (Haire et al., 2013, p. 6).  
 
At another site, the review of protocols was perceived by some as tokenistic – undertaken 
merely to tick the relevant boxes of community engagement. It was reported that the CAB 
felt that they had little power to demand changes to the protocol because CAB and REC 
reviews occurred concurrently:  
 “The CAB is not involved in developing the protocol, and the CAB has no power to 
change things – the protocol has already been sent to ethics” (C1, site staff, site 1). 
 
 “…it’s already in the protocol by the time you send it out to the community to review 
what you’ve already written.” (Z5, site staff, site 2).  
 
The review of ICFs accords with CAB insider-knowledge of the community and their 
understanding of the dynamics and nuances of the community. Such review contributes to 
culturally astute informed consent processes and effective health research. Despite 
community representativity on RECs, there were reports that CABs identified issues with 
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ICFs that were not always recognised by RECs, indicating their critical role in the review 
process.  
 
Despite concerns that concurrent review by CABs and RECs may result in the contributions 
of the CAB being overlooked, it was reported that relevant CAB concerns have resulted in 
amendments to the protocol, even post REC approval:  
 “…half the time this [CAB review of protocols] happens at the same time that your 
research ethics is reviewing the protocol. But what has struck me, in fact what I like, 
is that we have these multi-site, you know, trials. And, the protocol goes to your [X 
REC], it goes to your [Y REC], and goes to your [Z REC]. We’ve had the 
community’s inputting onto the protocol, such that we had to change. It didn’t matter 
which site you were at, that they look at this and say, ‘This cannot happen this way.’ 
And it’s impacted on all. Some of the protocols had already been approved by the 
research ethics, but once the communities read this, the various sites had to put their 
heads together to say, ‘This has come up, and they think we need to look at this and 
we need to change’. So, ja, as much as the theory says, at the development, they come 
in very late, after the protocol has been developed, but I’ve observed that they still 
have an impact on/ ja.” (Z11, site staff, site 2).  
 
Some CAB representatives have problematised their role as the link between researchers and 
communities by arguing that certain site-level decisions, including the name of the CAB, 
negatively impacts on the ability of the CAB to protect the interests of the participating 
community:  
 “There is a big tension here about the brand-name – it is called a CRSG – a 
Community Research Support Group. There have been questions about this – why this 
name? The answer was “advisory” and “board” means that they can say no and 
nothing will happen! CSRG implies support for the researchers. I was trying to probe 
this issue. To me, they are the advisory board. They advise on community values etc. 
The power of advising has been taken away.” (C1, site staff, site 1).  
 
At another site, the term advisory was perceived as not all-encompassing but limited to their 
expertise on the community: “…the advisory don’t advise the researchers on what research 
to do, but we tell them about the nature of the community.” (Z3, CAB, site 2).  
 
The quality of the relationship between sites and CABs differed across sites. At sites where 
CAB members enjoyed a close working relationship with site staff, including the PI, their 
perceptions of their engagement was more positive. Good relationships between PIs and CAB 
members have been reported as a critical element of effective CAB functioning (Strauss et 




Another key concern expressed by most CAB respondents related to their ability to serve as a 
“watchdog for the participant so that participants are not abused or taken for a ride” (C21, 
REC). At most sites, CABs were denied access to trial participants by sites with the view to 
protecting participants’ confidentiality. Again, this was perceived as limiting the role of the 
CAB in terms of advocating for trial participants: 
 “…the CABs are there to ensure that the trial participants are not abused or exploited 
… But on the other side, there is this big word confidentiality which blocks the whole 
relationship now. It says black and white that you there as an advocate, but then 
again in practice, the trial participant is not given a chance due to the confidentiality 
issues that they talk about, that they cannot discuss these matters with the CABs, they 
cannot meet with the CABs in person. So we don’t know when really in practice you 
become an advocate.” (Z1, CAB, site 1).  
 
The fact that the CAB was often called upon when the site experienced major challenges and 
“something that has exploded” (Z1, CAB, site 1) may have surreptitiously conveyed to 
CABs that sites determine the CABs’ oversight role and that mostly, it was their role in 
support of research that took precedence. At the one site where CAB access to participants 
was permitted (after signing confidentiality agreements) and highly regarded, the CAB 
respondent reported a positive relationship with the site: “What works well is that you know 
as CAB members we do follow up to participants.” (Z3, CAB, site 2).  
 
3.1.1.2 Disengagement of CABs 
Still for other CAB respondents, review of protocols did not appear to be a priority. These 
respondents found it difficult to describe whether they have reviewed protocols and ICFs, and 
what they looked for during the review. These ambivalent perspectives suggest that 
individual CAB representatives may have different conceptions of their roles. For some CAB 
representatives, their role in supporting research took precedence over their role in 
advocating for trial participants. This disengagement by some CAB members was also 
articulated by a site staff member at one site:  
 “I think the community advisory boards play a really important role within the 
function of the site. We certainly you know uh hold them in high regard…they have a 
real status and um we provide them with whatever support they need to function. 
However uh under the life span of a site, CABs go through good times and bad times 
and uh you know we have our fair share of those. Um so it’s great when the CABs are 
committed, energetic, enthusiastic, supportive, engaged it’s wonderful uh but when 
they are disengaged, uninterested, uh don’t care um and I’ve got into big trouble from 
when I dared suggest that CAB members just come to eat the food/[for] a pair at our 
site we thought that was certainly true and they’d arrive just at the end of the meeting 
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so that they could be counted and get access to the food provided just afterwards um 
so but that’s the life of a CAB uh and that’s not unexpected” (C18, site staff, site 4).  
 
At another site a CAB respondent noted that the negative results from the phase IIB trial and 
the consequent reduction in the frequency of CAB meetings, were discouraging for the CAB 
and “the morale of the CAB took a dip” (C12, CAB, site 3). Given that the medical and 
scientific experience of individual CAB members differed widely, infrequent meetings may 
reverse any gains in research literacy.  
 
Some CAB members also expressed some dissatisfaction with static reimbursement 
allowances not on par with inflation, as well as with the lack of a budget for CAB activities 
including community education workshops.   
 
3.1.1.3 CAB understanding of scientific concepts 
To meaningfully contribute during the review process, CAB members were trained to review 
protocols and received support for this task from sites. This resonates with ethics guideline 
requirements (MRC, 2003) to build the capacity of community representatives to contribute 
to the development and review of HVT protocols. However, such site-provided support is 
criticised as potentially tainting CAB independence (Koen et al., 2013). Given that CAB 
involvement in research, albeit voluntary, provides them with otherwise scarce opportunities 
for capacity building and travel, CABs may be unlikely to criticise a study, even when such 
criticism is warranted (Koen, 2010). By virtue of being supported and educated by sites, there 
was also some concern that CABs could be perceived as potentially biased towards the 
research organisation (Koen et al., 2013). Nevertheless, the present study found that CABs 
were free to, and often did, consult external experts on aspects of the protocol at their 
prerogative.  
 
It was reported that CABs may experience challenges in understanding some of the scientific 
concepts described in protocols, which may impede their review of standards of prevention. 
The standard of prevention is intimately related to the science of the trial and the background 
prevention package impacts on the statistical power of the trial and efficacy determinations. 
Such statistical concepts are complex to understand:  
 “You’re having to work with probabilities… people aren’t understanding what actual 




CAB respondents concurred that some scientific concepts were difficult to comprehend. Even 
during interviews, CAB representatives demonstrated some confusion regarding these issues. 
Most were unclear about the standard of prevention implemented at their respective sites 
despite having reviewed the protocol and consent material. 
 
3.1.1.4 Cultural taboos  
CAB discussions regarding components of the standard of prevention were sometimes 
hindered by cultural norms and practices. Discussing sexual activity and related issues among 
CAB members of different genders was argued to be inappropriate, for example:  
 “…in our culture we can’t talk something like that too much because if we are around 
the men they can’t talk with those things” (Z19, CAB, site 4). 
  
 “…it’s difficult [to discuss male circumcision]. The other person doesn’t want to 
speak in front of a peer that’s a girl.” (Z21, CAB, site 5).  
 
 “Uhm it’s not a usual thing in our community… it’s also the norm that women don’t 
talk to men about it [circumcision]” (Z17, site staff, site 5).  
 
The need to challenge some cultural prescriptions was noted and it was argued that 
communities need to be empowered “to openly talk about these things…So unless we make 
these talks open in all our institutions, we really gonna take a while before we are there” 
(Z5, site staff, site 2).  
 
3.2 REC review of protocols 
All ethics guidelines mandate the ethical review of research protocols (cf. MRC, 2003; 
UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). RECs review protocols to determine 
whether they meet ethical and scientific standards for conducting research with human 
participants. The REC has the power to approve, request modification, or disapprove a 
research protocol. Independent review is one of eight principles identified for conducting 
ethical research in developing country contexts (Emanuel et al., 2004). This entails 
mandatory review by bodies without stake in the research, such as RECs and regulatory 
authorities. RECs were perceived by site staff and network representatives as critical 





Ethics review of HVT protocols typically considers the prevention package that will be 
promoted in trials in order to comply with ethics recommendations as well as with the 
scientific imperative to determine the safety and efficacy of the experimental vaccine “against 
the background of established, ongoing or planned prevention modalities” (Tarantola et al., 
2007, p. 4865). Ethics guidelines require that RECs approve the standard of prevention 
(MRC, 2003) as well as plans for monitoring risk-reduction interventions (MRC, 2003; 
UNAIDS/WHO, 2012).  
 
REC respondents described that when reviewing protocols they generally considered the 
“presence or absence of risk-reduction” (Z16, REC). In addition, some REC respondents 
reported that there was a minimum standard of prevention that must be provided to 
participants in HVTs, namely condoms, STI treatment and risk-reduction counselling. This is 
on par with the minimum standard of prevention offered in most HIV prevention trials (cf. 
McGrory et al., 2010). REC respondents reported to rarely weigh in on the intricacies of the 
standard of prevention but reported occasionally influencing standard of prevention 
implementation practices: “…we were one of those who actually pushed for the syndromic 
approach” (C21, REC). The two protocols reviewed in this study did not specify plans for 
monitoring risk-reduction interventions and REC interviewees confirmed that they did not 
review plans for monitoring risk-reduction interventions. More often, RECs required 
assurance that researchers would take steps to help keep participants HIV-uninfected and paid 
less attention to the actual components of the package or related implementation practices. 
These findings conflicted with assertions that RECs expect researchers to specify “the 
frequency, mode, and personnel responsible for delivering the service and the infrastructure 
used” (McGrory et al., 2010, p. 17).  
 
REC respondents generally reported having an excellent working relationship with South 
African HVT investigators developed on a foundation of trust that investigators “completely 
want to do the right thing in terms of standards of prevention” with the affirmation that “… I 
haven’t had in…my years of being the chair of the committee any acrimonious arguments 
around standards of prevention issues” (C19, REC). Investigators too, described the 
relationship with RECs as good and founded on “good communication and mutual respect” 
(C11, site staff, site 5). It was described that in some circumstances investigators have 
approached RECs prior to protocol development regarding challenges with sponsor policy in 
order to “flag what they think we…would have a look at” (C17, REC). In cases where 
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sponsors and other stakeholders are unwilling to commit to providing a high standard of 
prevention, such prior discussions may prompt RECs to probe this reluctance.  
  
3.2.1 Complexities with REC review 
 
3.2.1.1 Applying variable standards in reviewing protocols 
One challenge in meeting ethics guideline requirements of approving the standard of 
prevention package was that REC respondents reported applying variable standards in the 
review of protocols. Essentially the level of review was reported to be dependent on the 
quality of the members present at the particular meeting, for example:  
 “I wonder if we don’t tend to apply relatively uneven lenses or uneven standards in 
critiquing protocols and what we expect out of protocols… I think the REC standards 
are themselves quite variable, and that’s not malice or to slight the REC it’s just, it 
depends on who reviews it and who's at the committee meeting on that day and how 
interested they are.” (Z16, REC).  
  
 “Uh to be quite frank we’ve got nothing laid down. I think it’s really an ad hoc 
response of the people at the meeting at the time” (C17, REC).  
  
 “…there isn’t a specific thing that a committee would look for…” (C19, REC).  
 
3.2.1.2 Lack of ethics capacity on RECs 
Other reasons purported for this variability included a lack of capacity as well as resource and 
time constraints, which inhibit the ability of RECs to interrogate major substantive issues as 
rigorously as they should:  
 “…we are not educating…our committee members, you know we’re falling very short 
there. You know, we’re busy educating everybody else, (laughs) but not locally… 
unless you’re familiar with the UNAIDS guidelines, you don’t know what is expected 
really and we are back to this issue of nit-picking informed consent forms. You know, 
too much time is spent on that sort of thing as opposed to the really substantive 
ethical issues” (C6, REC). 
  
 “…usually you find many of the people who serve on the ethics committee don’t have 
ethics training… whatever they’ve learnt about ethics is what they’ve just read about 
or come across by chance or by doing their own literature review search. But you 
know if you are doing your own literature review search… if you don’t know what 
ancillary care is you’re not going to go and look for ancillary care, and find out what 
it means. So, I think that, in the context of RECs in South Africa and elsewhere, it 
depends on who the member is, and what their training is, and so you’ll find that, in 
my opinion, it widely differs…” (Z12, REC).  
 
 “…it depends on the skill of the reviewer as to how much of that is picked up…we 
would send to expert reviewers in the field, who mightn’t pick up or make issues out 
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of the ethical issues of referral. That would have to be picked up by the committee, 
which has only read often the synopsis, at a full committee meeting. So unless I have 
made an effort to look, or somebody picks it up, it might fall between the cracks.” 
(C6, REC)  
 
3.3 Comparison of protocol review practices with ethics recommendations 
Community representatives and local RECs are required to review HVT protocols and 
informed consent materials regarding the standard of prevention and the monitoring thereof 
(cf. MRC, 2003; UNAIDS/WHO, 2012). In congruence with ethics guideline 
recommendations, it was reported that for both trials, community representatives (in the form 
of CABs) and RECs reviewed the protocols and related consent materials. However, practices 
deviated from guidelines in terms of REC review of risk-reduction monitoring plans – such 
plans were not included in protocols or ethics applications.  
 
In terms of protocol review, several complexities with CAB review were noted including the 
perception of the review process as tokenistic, the disengagement of some CAB members, a 
lack of research literacy and understanding of science as well as cultural taboos (see Chapter 
11). Ethics guidelines address some of these identified concerns. The need to build research 
literacy as an essential component of stakeholder engagement is recommended by guidelines 
(UNAIDS/AVAC, 2011). While engaging community stakeholders is argued to increase the 
socio-cultural relevance of the research (Boulanger et al., 2013; Marsh, Kamuya, Parker & 
Molyneux, 2011; Tindana et al., 2007), guidelines do not anticipate that cultural taboos may 
deter key standard of prevention considerations. These socio-cultural norms and practices 
create tension in terms of the CAB’s role in making inputs into the design of the standard of 
prevention and deserve further detailed exploration.   
 
REC review of standards of prevention in protocols and ICFs was limited to ascertaining the 
presence of such a package (see Chapter 11 for detailed discussion).  
 
4. Protocol implementation practices and perspectives 
The standard of prevention was determined during protocol development and approved 
during protocol review. However, for the phase I trial conducted at two sites, the actual 
standard of prevention provided to participants in the trial exceeded the determined and 
approved standard of prevention (see the Chapter 9). Furthermore, for both trials, several 
factors during implementation impacted on the actual standard of prevention provided to 
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individual participants. These factors included site-level decisions, provider decisions to 
promote services and participant decisions to take up services. These are briefly described 
below.  
 
4.1 Site-level decision-making 
To some extent, decisions on the standard of prevention were made on a site-by-site basis. 
More experienced sites, with better finances and/or well-developed referral networks, 
reported having an established standard of prevention which they were able to offer all 
participants regardless of what was outlined in the protocol and/or funded by sponsors:  
 “…are we going to make the standard of prevention, countrywide? And, what is going 
to be the standard of prevention for our research protocols? Um, and is that going to 
be community-specific? Or is that going to be country-specific? Or is that going to be 
protocol-specific? And so I think, you know, um, I’m not sure that I have all those 
answers at the moment. I mean, currently, there has been a level of site-specificity to 
this… to illustrate this I will put as an example iPREX. So, the iPREX MSM study that 
we’ve just participated in, the standard of prevention that was offered in the protocol 
was, condom, you know, male condoms, lubrication, regular testing with risk-
reduction counselling… We then mentioned that we have in our standard of 
prevention, post-exposure prophylaxis. And it was agreed that we could offer post-
exposure prophylaxis, even though that was not across all sites…So, I thought it was 
a nice example of how a protocol, um, modified itself, if you like, to take into account 
a site’s own standard of prevention.” (Z18, site staff, site 5).  
 
The network also acknowledged permitting some site flexibility with regard to standard of 
prevention implementation.  
 “…because we don’t know the capacity of each site…our template consent is phrased 
in a way that is um you know is basically for the site that cannot provide that but 
rather will refer for that um and sites are always free to change that consent and 
make it site specific and if they’re able to do that that’s more power to them” (C13, 
network).  
 
While for some respondents, site-level decision-making enabled the individual nuances of 
each trial context to be accommodated, others contended that it created unwelcomed 
differences between participants enrolled in the same trial at different sites (see Chapter 11). 
Recommendations in UNAIDS/WHO (2012) ethics guidelines were intended to minimise 
double standards between developed and developing countries (Macklin, 2009; Haire et al., 
2013) and indeed some respondents have argued that this was achieved for the phase IIB 
trial: “They are providing first world care in a developing country…” (Z7, site staff, site 1). 
However, actual practices at sites may inadvertently perpetuate double standards between 
better-resourced and less-resourced sites within the same country. 
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In contrast, some respondents perceived that there was an existing established standard 
package of prevention which was a routine “part of the protocol” (Z5, site staff, site 2):  
 “… there’s now kind of a standard that everybody has to comply to…It’s kind of we 
do standard things that people know, it doesn’t even get discussed, it must be in, in 
the protocol.” (Z17, site staff, site 5).  
  
 “…there's all of these things that are part of the package and that’s how it will stay. I 
suppose the way to address your question is to say what’s next, ‘cause we aren’t 
going to peel things off” (Z6, site staff, site 2).  
 
Despite the perception by some that protocols complied with an established standard of 
prevention, the standards of prevention outlined in the phase I and phase IIB protocols were 
distinctly different. It was suggested by a network representative that in future, the 
implementation of standards of prevention may be systematised and formalised to ensure 
uniformity as the number of South African sites expand for a large-scale efficacy trial of the 
Thai RV144 vaccine (cf. Esparza, 2013). 
 
4.2 Provider decision-making 
Providers have a central role in determining which prevention interventions were actually 
offered to participants. Provider-promotion of components of the standard of prevention is a 
focus of Chapter 9 on standard of prevention implementation practices. It was highlighted 
that some providers may suffer a general apathy towards ensuring the well-being of 
participants, may exercise their own preferences in counselling participants on certain 
prevention modalities, or may be inadequately trained:  
 “…if the very people that are supposed to give it don’t know much about it, it’s 
pointless. We give information to the communities, and the communities are so bright 
and they know about these and they get there, and people are looking at them like, 
huh? The same thing happened with female condoms. The female condoms expired in 
storerooms (laughs).” (Z11, site staff, site 2).  
 
 “… at whatever site you are at there are healthcare nurses, they can’t make a 
diagnosis. I think it’s got to do with maybe laziness or lack of insight, or no 
innovation happening at a site level.” (C4, site staff, site 2).  
 
 “Another thing which perhaps I think is important is the person who gives these 
people the preventative measures, whether the person is properly or was properly 
trained…Now to some extent measures might fail not because of the participant but 
because of the people who deal with the participant. So you have to question yourself 
time and again. You just say they are wrong, you don’t know, you were not there 
when you know they trained, you were not there when they offered these condoms to 
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the person but you don’t know what really went on. There’s no way, there’s no 
criteria, there’s no way you can check …” (C12, CAB, site 3).  
 
As the available prevention arsenal expands, it was described that there may be increased 
opportunities for providers to play a more active role in standard of prevention decision-
making at an implementation level – by tailoring prevention packages to suit individual 
participant’s needs. This would involve customising the standard of prevention to carefully 
developed risk-profiles of participants – in a manner analogous with women choosing the 
best contraceptive method from a basket of options.  
 “Then of course, um, there’s the whole piece of deciding well, what would be a good, 
prevention package for this individual. And, so how do I tailor my risk-reduction 
counselling, or my prevention package for this individual, is the next step. And I think, 
this is probably because we have only recently moved in the paradigm, of 
understanding that, you know, it’s not just A, B, C for everyone…So, I think as we 
move more strongly into a paradigm of prevention packages, um, healthcare workers 
are going to have to become, um skilled at deciding which package is best for an 
individual, and an individual is going to have to be skilled up, to be able to, you know, 
help make those choices, or decide what’s best for them. …you can either present a 
set menu, or you can present an à la carte menu, and so the individual may pick and 
choose what they think is going to work for them, with your guidance. Or else you’ll 
say, you are a young adolescent with the following risk profile, I suggest you use the 
following, you know…” (Z18, site staff, site 5).  
 
4.3 Participant decision-making  
Ultimately, the individual trial participant decides which prevention services to take up. 
Issues pertaining to participant uptake of specific prevention services are described in 
Chapter 9. Of critical importance to participants’ overall decision-making ability, respondents 
across stakeholder groups emphasised participants’ autonomy in making decisions in line 
with their personal values and preferences, for example:  
 “…it can’t be forced on anyone anyway… you can provide it, but…there’s no 
guarantee anybody’s going to definitely use it, or want to take it up” (Z12, REC).  
 
 “…you still have the people that are not going to be using, even if it’s available and 
accessible…” (Z11, site staff, site 2).  
 
 “…you offer it, you offer the best, and if, um, it is up to them to either refuse or accept 
it” (Z10, site staff, site 5).  
 
 “…on the other hand it’s important that you know not everybody’s the same, you 
know so people have different beliefs and different preferences. So it is important to 
have different things available for people to access.” (Z17, site staff, site 5).   
  
Enabling participant preferences in terms of which prevention options to take up is in line 
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with the ethical principle of respect for autonomy (see Chapter 11).  
 
5. Summary 
This chapter addressed the research question of the extent to which actual standard of 
prevention decision-making practices correspond with related recommendations in ethics 
guidelines. In resonance with the literature, none of the respondents in this study argued 
against the provision of a standard of prevention package. Rather, respondent perspectives on 
the rationale for providing risk-reduction interventions to participants were diverse and many 
individual respondents articulated multiple rationales.  
 
Data from this study indicated that the primary standard of prevention deliberations occurred 
during the protocol development process. The protocol committee was positioned as the 
leading decision-making body with regard to establishing the standard of prevention package 
for every trial. The standard of prevention was also approved during protocol review. At 
these phases, sponsors, investigators, communities and RECs had the opportunity to make 
inputs into the design of the standard of prevention. Given that these different stakeholders 
represent different interest groups, the determination of the standard of prevention during 
protocol development was fraught.  
 
Some respondents across stakeholder groups perceived the sponsor as dominating decision-
making, particularly in relation to intractable sponsor policies on funding for research. 
Investigators on the other hand were perceived as strong activists protecting the welfare of 
participants in stark contrast to the perception by a few that they need independent 
monitoring to ensure their compliance with ethical norms. The network was viewed as 
committed to ensuring a high standard of prevention in trials by securing alternate funding for 
the standard of prevention.  
 
There was a disjuncture between community representatives’ perceptions of their impact on 
the standard of prevention during protocol development and review versus perceptions of 
their involvement by sponsors and researchers. The lack of inclusivity of all sites in decision-
making processes has had the unfortunate yet predictable result of some CAB representatives 
feeling alienated and disengaged from the decision-making process. While CABs sought 
more decision-making authority, RECs possessed such power but did not necessarily appear 
to maximise it for the standard of prevention.  
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REC review practices did not wholly satisfy ethics guideline requirements in terms of 
approving the standard of prevention and plans for monitoring prevention interventions. 
Several complexities were described in meeting these recommendations including a lack of 
set standards for critiquing protocols and a lack of ethics capacity on RECs which favours the 
discussion of procedural rather than substantive issues.  
 
Major thematic complexities of power, partnerships/funding and culture will be examined in 
the discussion (Chapter 11). The following chapter will focus on the critical and relevant 





THE EVOLVING STANDARD OF PREVENTION: DECISION-
MAKING PRACTICES AND PERSPECTIVES 
 
The preceding chapter detailed respondents’ standard of prevention decision-making 
practices and perspectives. This chapter presents respondents’ practices and perspectives 
regarding the evolving standard of prevention, and focuses on the criteria respondents’ 
considered relevant when making decisions on adding new tools to the prevention package. 
Data in this chapter were analysed using critical thematic analysis (Braun & Clarke, 2006) 
which, where relevant, involved consideration of discursive undertones. Decision-making 
practices and perspectives were compared with relevant HIV prevention recommendations in 
ethics guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012), and decision-
making frameworks (Jay et al., n.d.; Philpott et al., 2011; Tarantola et al., 2007), where 
relevant.  
 
1. Criteria for the enhancement of the standard of prevention  
With every positive HIV prevention trial outcome, there is increasing concern about 
standards of prevention, particularly regarding how and when to add new tools to the 
prevention package (Essack, Slack, et al., 2010; Haire, 2014; Macklin, 2009; McGrory et al., 
2010; Philpott et al., 2011). During data collection, positive results for topical and oral PrEP 
trials became available. In addition, the treatment as prevention trial (HPTN 052) 
demonstrated the success of early ART initiation among serodiscordant couples. Amidst 
these positive results, the FEM-PrEP trial designed to assess the efficacy of daily oral 
Truvada among women was closed for reasons of futility, as were the oral Truvada and the 
Tenofovir gel arms of the VOICE trial (Hankins & Dybul, 2013). In July 2012, just prior to 
the conclusion of data collection, the FDA approved Truvada for use as an HIV prevention 
drug for those at high risk of HIV infection and who may engage in sexual activity with HIV-
infected partners (FDA, 2012). At the time, the South African regulator (the MCC), had not 
reviewed the data nor approved Truvada for use as an HIV prevention intervention.  
 
As the available prevention arsenal increases, some commentators have recommended that 
efforts be made to understand how decisions are made on the enhancement of the prevention 
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package (Essack, Slack, et al., 2010). To this end, respondents were asked their perspectives 
on the criteria that should be considered when adding new tools to the standard of prevention.  
While positive HIV prevention trial results were largely welcomed by respondents, some 
noted that decision-making has become increasingly complex. The ever-evolving HIV 
prevention landscape was perceived as creating uncertainty as to the appropriate standard of 
prevention:  
 “…the landscape is changing all the time as new data comes in and my impression is 
that it’s becoming increasingly quite a complicated issue for all the players involved. 
So in other words I think it’s very difficult for communities to know what to demand 
as the minimum standard of prevention and I think it’s very difficult for investigators 
to know what they’re obliged to provide and I think it’s very hard at the moment for 
ethics committees to know what they should insist as a minimal standard of 
prevention” (C19, REC).  
 
Reflecting the dynamic and evolving nature of the HIV prevention landscape, respondents’ 
perspectives on the relevant criteria for the enhancement of the prevention package were 
varied, as described below.  
 
1.1 Endorsing scientific validity  
Most respondents endorsed that new prevention tools should be added to the prevention 
package when they are scientifically validated (MRC, 2003; UNAIDS/WHO, 2012) and 
articulated that there should be definitive scientific evidence to support the addition of new 
tools, for example:  
 “I think there has to be definitive evidence that these interventions work” (Z16, REC).  
  
1.1.1 Complexities with scientific validity 
 
1.1.1.1 Variable thresholds being used for risk-reduction interventions 
The need for clear, definitive evidence advocated by respondents for new interventions was 
not uniformly applied to all prevention modalities in the current prevention package. While 
respondents were steadfast in their endorsement of evidenced-based prevention, some 
conceded that evidence for some of the current tools, e.g., PEP, was not scientifically 
convincing. This tension between requiring a high standard of evidence for new tools versus 
making concessions for current tools is aptly captured in the quotes by one respondent below:  
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 “…when we’re talking about state-of-the-art prevention obviously as long as we’re 
talking about prevention modalities that have been validated, that have been 
proven…to show effect I have no problems with that” (Z22, site staff, site 1).  
 
 “I would still encourage to an extent post-exposure prophylaxis. I mean ehm just ja 
um like you can see I’m not really convinced [that it is effective] (laughs) but it’s just 
that you know if it can be made available to participants you know I always 
encourage them to take that” (Z22, site staff, site 1).  
 
1.1.1.2 Operationalising scientific validity  
Respondents’ endorsement of scientific validation was qualified by a degree of uncertainty 
(e.g., “It’s hard to really know”; “I guess”) as to when a new tool would be considered 
scientifically validated: 
 “It’s really hard to know what the threshold is at which a particular prevention 
modality becomes obligatory because I think it’s a complex dance between is there 
enough scientific data to justify efficacy” (C19, REC). 
 
This uncertainty reflected a lack of clarity about how to operationalise scientific validity and 
interpret complex scientific data, especially for partially efficacious interventions: 
 “…I think that they [the REC] would consider the available data at the moment [for 
Tenofovir gel] and be just as confused as every HIV researcher is as to whether it’s 
effective or not and therefore not include it in the package of care” (C20, REC).  
 
 “[The decision to add microbicides and PrEP to the prevention package]… is really a 
difficult one …is that data sufficient enough to move that already [to] the standard of 
care? You know those are the debates that are ongoing but once data is sufficient 
enough like it came up with the circumcision issue, once we have reached that point 
then you will have no choice, we’ll have no choice but to make it the standard of 
care” (Z15, site staff, site 3).    
  
Ethics guidelines only partially facilitate decision-making, and the difficulties suggested with 
operationalising scientific validity reflect the vagueness of guidelines and the absence of 
coherent frameworks for decision making:  
 “…I don’t think at the moment investigators or ethics committees have got any logical 
tools to help them make firm recommendations…” (C19, REC). 
 
A few respondents attempted to operationalise scientific validity in relation to the effect size, 
the trial phase, and the number of the clinical trials required before a tool is considered 
validated. Evidence from one RCT was not considered definitive, for example:  
 “…so there’s been, you know, a fair bit of push-back…to all the announcements 
about the gel...because of…the fairly limited effect, and the kind of hype around it, 
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and people saying, ‘Well, we don’t even have the right study that we need, and there 
might be a small effect and dadadada’. (C5, REC). 
 
 “And the classical example is that here we had 004 showing some level of efficacy 
39% but… VOICE and the daily Tenofovir has shown no effect so it really just 
emphasises the importance of always confirming a trial before we can move into any 
policy changes or something like that. And so for 004 it just over emphasizes how 
critical it is for the FACTS study to go on so we then can compare apples to apples.” 
(Z22, site staff, site 1).  
 
 “I guess unless something jumped out so clearly that this is so clearly a big leap 
forward, and we have to make sure that it’s included….my guess is that it would just 
become part of this gradual, advance, and it would gradually become accepted 
scientifically, and then it would gradually become accepted at an international level, 
and then gradually, the government would decide to pay for it, and then gradually we 
would move towards expecting that as a standard of prevention. Um, so I think it 
would need to make a dramatic leap forward for us to/ (R: Yes. It would have to be a 
slam-dunk, and so scientifically convincing for you), right, right, to say like, even if 
the government doesn’t pay for it, you have to do it, because it’s just so clearly gonna 
make a difference.” (C5, REC).  
 
1.1.2 Comparing practices and perspectives on scientific validity with ethics 
recommendations 
Ethics guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) set a 
substantive standard that new HIV risk-reduction methods should be added to the prevention 
package when they are scientifically validated (MRC, 2003, UNAIDS/WHO, 2012, 
UNAIDS/AVAC, 2011). Scientific validation could be defined as evidence of efficacy of a 
prevention intervention as demonstrated in a clinical trial (Haire, 2013). However, while 
guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) establish the 
standard, they do not define the conditions for scientific validity. Whether scientific 
validation requires data from “one trial, or two, or more” is not articulated in guidelines 
(Haire, 2013, p. 168). Like respondents in this study, some commentators argue that 
determinations of scientific validity will require consideration of the strength of evidence 
generated from the efficacy trial, the degree to which results can be extrapolated to other 
populations and contexts, the conclusiveness of the data, the number of trials that have 
demonstrated an effect, the need for further confirmatory trials, and the safety profile of the 
candidate product (van de Wijgert & Jones, 2006; Philpott et al., 2011). Some direction can 
also be gleaned from regulatory requirements. Regulators, including the South African MCC, 
typically require that for a new product to be licenced, it should be tested in at least two 
pivotal phase III efficacy trials (McEnery, 2009; McGrory et al., 2010). However, under 
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special circumstances, a single pivotal trial (well conducted, well designed and of sufficient 
size) that provides as much evidence of effectiveness as two trials would have, may suffice 
(Heise & Wood, 2005; McEnery, 2009). For example, the FDA approved a hepatitis A virus 
vaccine based on evidence from one phase III trial (McEnery, 2009). 
 
It is asserted that scientific validation is intentionally vague to permit decision-makers the 
flexibility to make different determinations depending on the particular circumstances 
(Macklin, 2012). However, data from respondents indicate that it is difficult to operationalise 
requirements in ethics guidelines because they are so vague. This lack of clarity is also 
reflected in recent debates in the literature on when to add PrEP to the standard of prevention 
(Cowan & Macklin, 2014; Dawson, 2012; Haire et al., 2012; Haire et al., 2013). Haire et al. 
(2012) were critical of delays in the introduction of partially effective HIV prevention 
products and argued for the relaxation of regulatory requirements in terms of the evidentiary 
standards for approving and licensing new products. Other commentators (Dawson, 2012) 
contested that early introduction of tools would be in participants’ best interest without 
sufficient supporting evidence; the need for data from two trials was substantiated by 
examples of where the first trial showed benefit but additional trials did not, e.g., CAPRISA 
004 and the Tenofovir gel arm in the VOICE study. When evidence about an HIV prevention 
intervention is inconclusive, “it would be irresponsible for researchers to use these methods 
as active controls, or for policymakers to roll out the technologies across whole populations, 
without further research; it is like placing the people at risk of acquiring HIV in an enormous 
game of Russian roulette—maybe the prevention method is actually effective, maybe it isn’t, 
who knows?” (Dawson, 2012, p. 33) – a perspective with which the present author agrees.   
 
Respondents’ comments suggest that there is a need for more logical tools for determining 
when the scientific validity threshold is satisfied, as echoed by other commentators (Haire et 
al., 2013; Philpott et al., 2011). The lack of consensus on whether PrEP should be considered 
standard of prevention in trials is not only reflective of ambiguities about regulatory approval 
but also of the absence of clear logical frameworks for decision-making (Haire et al., 2013). 
Some authors have proposed frameworks (Jay et al., n.d.) and criteria (Philpott et al., 2011) 
for decision-making, which may help expound scientific validity (see Chapter 5). For 
example, clinical validation considers whether the safety and efficacy of the prevention 
modality have been established for the trial population; the potential for behavioural factors 
to mediate this efficacy; the acceptability of the intervention to the trial population; cost and 
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deliverability; and the potential for interaction effects (Jay et al., n.d.). The pragmatic value 
of such frameworks for decision-making on the enhancement of the prevention package 
should be evaluated through piloting.  
 
1.2 Endorsing regulatory approval 
Respondents specified that once scientifically validated, there is another threshold for the 
addition of new tools to the prevention package – regulatory approval and licensure. 
 
It was further specified, primarily by REC respondents, that the intervention would need to be 
approved by the national regulatory authority in the host country before it could be provided 
to HVT participants:  
 “…now there’s FDA approval of Truvada as a prevention modality and then there’s 
the issue of even if it’s FDA approved is it feasible to provide it locally um [if] it’s not 
yet approved by our own regulator as a prevention modality…” (C19, REC).  
 
  “…the regulatory authority in that country, basically registering those 
interventions…” (Z12, REC).  
 
 R: …would it be quite important that a new methodology had been approved … 
by our own national authorities so it became part of our standard of prevention 
before it should be provided to participants? 
 C21: I think that answer is an affirmative yes. (C21, REC) 
 
1.2.1 Comparing practices and perspectives on regulatory approval with ethics 
recommendations 
Ethics guidelines recommend that new HIV prevention methods should be added to the 
standard of prevention based on approval by relevant authorities (UNAIDS/WHO, 2012) or 
national bodies for use (UNAIDS/AVAC, 2011). The approval requirement is recommended 
as an alternative to scientific validation by UNAIDS/WHO (2012) guidelines and to augment 
scientific validation by GPP guidelines (UNAIDS/AVAC, 2011). 
 
The recommendation for approval by relevant authorities is problematic because different 
regulatory and normative bodies use different criteria for approving prevention interventions 
(McGrory et al., 2010). Further, UNAIDS/WHO (2012) guidelines are unclear on whether 
approval would be required by the national regulatory authority, or whether any regulatory or 
normative body approval would suffice (Haire, 2013). GPP guidelines however, stipulate 
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national approval as a prerequisite for new tools to be added to the prevention package 
(UNAIDS/AVAC, 2011) (see Chapter 11 for detailed discussion).  
 
1.3 Stakeholder consultation 
UNAIDS/WHO (2012) guidelines also contain a procedural requirement for the enhancement 
of the standard of prevention which specifies that new HIV risk-reduction methods should be 
added to the prevention package based on consultation among all research stakeholders, 
including the community. Such consultations should consider (1) feasibility, (2) expected 
impact, and (3) the ability to isolate the efficacy of the biomedical HIV modality being tested 
(UNAIDS/WHO, 2012). Respondents in this study did not spontaneously endorse 
consultation with relevant stakeholders as a criterion for the enhancement of the prevention 
package. In a companion study that quantitatively explored perceptions of care and 
prevention norms in ethics guidelines (Moorhouse et al., 2014), respondents reported low 
agreement with the recommendation that new prevention methods should be added to the 
prevention package based on consultation with all stakeholders. This recommendation was 
also rated as problematic in terms of ease of implementation, ease of understanding and the 
degree to which it protected participants (Moorhouse et al., 2014).  
 
Respondents’ perspectives on the value of stakeholder consultation in standard of prevention 
determinations, is detailed in Chapter 10 which considers respondents’ perspectives on ethics 
guidelines.  
 
1.4 Additional criteria 
In addition to the ethics guideline requirements of scientific validation and regulatory 
approval, respondents identified additional criteria for consideration when making decisions 
about the enhancement of the prevention package, namely, availability in the public 
healthcare sector and the phase of the trial.  
 
1.4.1 Availability in the public healthcare sector 
Some respondents, particularly REC members, identified public sector availability as an 
additional criterion for consideration, that is, the new intervention should be available in the 
public healthcare sector before it is offered to participants in HVTs. In this way, respondents 
advocated for a localised standard of prevention:  
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 “…it’s always got to be seen in relation to whatever the local standard of care is and 
…my perception is that the national/the local standard of care is the one that prevails 
in local ethics committee determinations.” (C19, REC). 
  
 “I think the interventions have to be part of public sector practice. That is, if the 
government decides that for instance…they’re not going to make PrEP available in 
the public sector, I think then it would be hard to justify requiring it from a local 
ethics committee.” (Z16, REC).  
  
 “I think, number one, confirmatory results. Number two, preferably implementation 
trial results, and, I think, number three, obviously, the regulatory authority in that 
country (.) basically registering those interventions, or changing the indication of 
those interventions from treatment, to treatment and prevention. And I think when 
those three things, and when the intervention becomes available in the public sector, 
all four of those conditions then would pave the way for that to be offered to trial 
participants.” (Z12, REC). 
 
 “Now, and I think we should work towards whatever is being suggested as the state-
of-the-art prevention package should really form part of, part of the standard of care 
which is available in the public services” (Z15, site staff, site 3).  
 
Some respondents justified their endorsement of public sector availability as related to 
concerns about sustainable access to prevention interventions post-trial, for example:  
 “And the other question is that, should that site actually be a trial site at all if, once 
the study ends it’s not going to continue, or there’s no availability in the public 
sector.” (Z12, REC).  
  
 “I think it’s because research has a limit. There’s a duration of time. We are doing 
research for the 3 years. If you’re providing more services that is not in the public 
sector where is the participant going to get that because when they were exited they 
have to refer back to…their public health sectors.” (Z2, site staff, site 1).  
 
 “Sustainability is one of the things that we consider…we haven’t had to consider it as 
carefully up until now because of the availability of syndromic management, the 
availability of circumcision, but that will definitely be part of the discussion…when 
we’re considering our next big trial” (Z9, network representative).  
 
However, it was noted that some tools (e.g., PrEP) do not raise such sustainability concerns: 
 “PrEP is a little bit different from therapy in that someone can benefit from PrEP 
over a certain period of time and not access it again but still have that benefit for that 
period of time without” (Z16, REC).  
 
While REC respondents unequivocally endorsed public sector access as a pre-requisite for 
inclusion in the prevention package, some site staff were of the view that accessibility in the 
public sector would not always be a determining factor, granted that sponsors “are prepared 
to fund” the intervention (Z7, site staff, site 1).  
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1.4.1.1 Complexities with public sector access 
 
1.4.1.1.1 The politics of policy development 
Despite strong advocacy for a localised standard of prevention accessible in the public 
healthcare sector, it was acknowledged that the public sector might sometimes lag behind in 
introducing new prevention technologies. Particularly in South Africa, some respondents 
seemed weary of poor government policy decisions regarding HIV, given the history of AIDS 
denialism during former President Mbeki’s tenure (Jones, 2005; Patterson & Cole, 2006). For 
example: “…if the government is a stakeholder, and we were in the Mbeki era, we would be 
in big trouble” (C4, site staff, site 2) and “…that’s our government, they take time to deliver 
things” (J1, site staff, site 2).  
 
Therefore, relying on public sector access as a benchmark for the standard of prevention in 
HVTs could result in unnecessary delays on political grounds, as was the case with PMTCT 
(Dawson et al., 2014; Philpott et al., 2011). Similarly, despite VMMC being proven effective 
in three RCTs, rollout of this intervention in the South African public healthcare sector, was 
slow (Bateman, 2010). While UNAIDS/WHO recommended VMMC as an additional HIV 
prevention methodology in 2007, the South African national circumcision policy document 
was only launched in 2011 (cf. Mayosi et al., 2012).  
 
1.4.1.1.2 Disjuncture between national standards and local realities  
While public healthcare policy is often established at a national level, realities experienced at 
public healthcare facilities may differ. These differences are experienced both between and 
within facilities in various South African provinces (cf. Stuckler et al., 2011). Some 
respondents reported that variable access to prevention interventions was a characteristic of 
the South African public healthcare sector. For example:  
 “…the standard of care means different things to different people even if you’re 
looking just within the health system of one country. The standard of care in Cape 
Town is different than in Durban or Bloemfontein…it’s an interesting question to me, 
conceptually, to think about, do we owe them standard of care in Cape Town, or if 
they’re from the Eastern Cape, do we owe them that standard of care?” (C5, REC).  
 
 “I mean I think it comes down to, what’s the standard of prevention? And (.) 
obviously the clinical trial has to take that into consideration. Um, and that in itself is 
quite a vexed question, so, what are we going to make the standard of prevention, 
countrywide? And, what is going to be the standard of prevention for our research 
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protocols? Um, and is that going to be community-specific? Or is that going to be 
country-specific? Or is that going to be protocol-specific?” (Z18, site staff, site 5).  
 
 “…in many areas of South Africa, from what I understand, access to treatment for 
HIV-infected individuals can still be problematic in some areas. And (.) so, access to 
PEP or PrEP for prevention of HIV infection, while a laudable goal, may not be 
practical in South Africa…” (Z9, network representative).  
 
Two different dimensions of accessibility were distinguished, namely theoretical access 
(standard of prevention as in guidelines) and actual access (standard of prevention as in 
practice). It was suggested that “actual access” may not be a pre-requisite but that theoretical 
access was the actual determinant:  
 “…you also have theoretical access versus actual access, so you qualify for it, but 
then there’s a long waiting list, or you qualify for it but it’s not being provided in your 
area. So it’s the standard of care in the country, but when you go to a district, or 
even, a particular city level, it’s not available in that particular study, or that host 
community” (Z12, REC).  
  
 “…the two things that come up in the discussions often that are kind of points of 
contention, um, is one, when we mean ‘standard of care’, do we mean, what’s written 
down in the guidelines, or what actually happens in the…public health service.” (C5, 
REC). 
 
A contrary view was that the standard of prevention implemented in trials should be 
determined by actual availability in the particular context, rather than by the established 
national standard. If actual access was not available in a particular context, then the 
prevention intervention should not be added to the prevention package:     
 “I think that it’s true, they [participants] should be provided with everything but then 
you also have to look at the context of uh you know your settings. I mean they could 
have told us that we need to provide male medical circumcision but then if/ just say 
that our research site was in the Transkei or something, and there's no medical doctor 
there to actually provide the service…So in that case the nearest referral would be 
Durban and then we would still refer them to Durban but if there’s nothing available 
on-site or locally, then we wouldn’t be able to provide that service” (Z7, site staff, site 
1).  
 
1.4.1.2 Comparing practices and perspectives on public sector availability with ethics 
recommendations 
The criterion of public sector availability, endorsed by some respondents in this study, is not 
a requirement of MRC (2003) and UNAIDS/WHO (2012) guidelines. While GPP guidelines 
(UNAIDS/AVAC, 2011) suggest that research teams and relevant stakeholders consider the 
current standard of prevention available nationally and locally when discussing and 
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negotiating the HIV prevention package, they do not suggest that public sector availability 
should be the benchmark for the standard of prevention. Respondents’ views concurred with 
network-specific guidelines developed by the HPTN (2009) that the standard of prevention 
should be practically achievable, reasonably accessible, and locally sustainable. Similarly, 
respondents justified their endorsement of public sector availability based on ensuring 
sustainability of the standard of prevention post-trial. Concerns that new prevention 
interventions should not be added to the prevention package if they are not sustainable in the 
trial setting after the completion of the trial, is a sentiment supported by others (McGrory et 
al., 2010). Further, the strong endorsement by RECs in this study that new tools should be 
nationally approved and available corresponded with perspectives of RECs reported at the 
Ugandan consultation (McGrory et al., 2010). Respondents in an empirical exploration (Haire 
& Jordens, 2013) also suggested that implementing enhanced prevention services that cannot 
be sustained post-trial is ethically problematic. However, a competing view is that as long as 
the feasibility of the trial is not undermined by the addition of the new prevention modality 
“it can be argued that the immediate potential benefit of reduced HIV infection risk for study 
participants is a legitimate derivable benefit from the trial for the community, even if this 
cannot be sustained beyond the research” (Haire et al., 2013, p. 7).  
 
1.4.2 Phase of the trial 
Some respondents articulated different obligations to participants enrolled in different trial 
phases because participants’ risk of HIV infection differs. Trial participants in early-phase 
trials are at lower risk of HIV than participants in late-phase trials. If the ethical principles of 
beneficence and non-maleficence are considered, then it seems reasonable that participants’ 
risks of acquiring HIV should be offset by the provision of proven HIV prevention modalities 
– the higher the risk, the better the standard of prevention:  
 “…it obviously depends on the phase of the trial. It’s safe to say one or two you can’t 
do too much prevention. Phase three obviously becomes more difficult to show 
efficacy of the product if you have that many prevention strategies in place but I think 
it’s still our moral duty to do that even if it makes the study more difficult to do” (Z17, 
site staff, site 5).  
 
 “…because it’s a lower-risk protocol, the imperative to make sure it was in place was 
probably lower but it just happened that we were setting up those services anyway so 





 “Well, I can tell you that for the largest trial that we’ve done so far in South Africa, 
we offered circumcision. We’ve done a couple of low-risk trials since then, which, we 
weren’t able to offer circumcision as part of this…” (Z9, network representative).  
 
In the drafting of protocols, it appears that the phase of the trial influenced the standard of 
prevention – the phase IIB protocol specified risk-reduction counselling, male and female 
condoms, STI treatment, and access to PEP and VMMC while the phase I protocol only 
specified that risk-reduction counselling would be provided.  
 
An alternative view was that participants are owed the same standard of prevention regardless 
of the phase of the trial, because the risk of HIV infection is not only a function of participant 
behaviour but may also be related to the vaccine product. It was acknowledged that 
participants in early-phase trials may have lower uptake of prevention services, but that these 
should be consistently offered to participants in all trial phases.   
 “They should be provided with a high standard of care regardless of what phase 
they’re in, because the risks are basically the same. Because remember with…the 
adeno-5 vaccine that ended up causing people, or, possibly increasing the risk of 
them acquiring HIV. So, at the end of the day it didn’t matter if they were getting that 
vaccine in the context of a phase II or in the context of a phase III, the point is that 
they were getting that vaccine… it’s not necessarily a case of the higher the phase of 
trial, the more, or the better your standard of care should be, you should have 
standard of care from, whatever the, level of intervention is” (Z12, REC). 
 
 “I think you know we still offer all of the same care and prevention methods. Maybe 
there’s less uptake within those groups.” (Z13, network representative).  
 
1.4.2.1 Comparing practices and perspectives on the trial phase with ethics 
recommendations 
Ethics guidelines do not specify whether the obligation to provide prevention services differs 
according to the phase of the trial or risk-level of participants. However, UNAIDS/WHO 
(2012) guidelines mention in the guidance point on clinical trial phases that different trial 
phases present different scientific and ethical requirements. Some commentators (Slack et al., 
2000) have also hinted at this distinction by suggesting that since participants in efficacy 
trials are enrolled because they are at high-risk of infection, the principle of beneficence 
obligates researchers to reduce harm. Similarly, data from this study indicated that protocol-
writers accorded different obligations to early-phase and late-phase trial participants, a 
practice endorsed by some respondents in this study. However, consideration of participants’ 
susceptibility to risk may not accurately acknowledge context-specific and structural-level 
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risks, given that “a woman in Kwa-Zulu Natal in South Africa, for example, faces a 25% 
lifetime risk of HIV acquisition, while an Australian woman’s risk is less than one-
thousandth of that” (Haire et al., 2012, p. 28).  
 
1.5 Adding VMMC to the prevention package 
At the time of data collection, VMMC was the only new HIV risk-reduction intervention 
deliberately added to the prevention package. Respondents who were privy to the decision-
making process described the relevant criteria considered and the stakeholders involved in the 
decision to add VMMC to the prevention package.  
 
VMMC was reportedly added to the prevention package based on clinical trial findings that it 
significantly reduced male risk of contracting HIV during heterosexual sex (Auvert et al., 
2005), for example: 
 “…at the time we were doing protocol development for that, which was, November 
2005 I think…there were two trials. I can’t remember what the order was but there 
was…the circumcision trial from Kenya and the circumcision trial from Orange Farm 
in South Africa. One had been published and one hadn’t. So there was some debate 
about it but I think a lot of people knew the results of the second trial anyway, even 
though it hadn’t been published yet. So, we knew that this was coming, and we also 
knew that the protocol development process was going to take some time before it was 
approved, so we knew…by the time the protocol was final, we were likely to have 
circumcision as another prevention tool, in our toolkit.” (Z9, network representative).  
  
The initial decision to provide VMMC to trial participants based on the results of the South 
African trial was strengthened by the results of two additional trials (Bailey et al., 2007; Gray 
et al., 2007) which became available before the phase IIB trial commenced at sites (Essack, 
Slack, et al., 2010): 
 “Yeah so that [the decision to add VMMC] was driven by three studies and an 
increasing international acceptance of circumcision…so I think by the time it was 
included in the package of prevention care it was already becoming acceptable. So 
the WHO already had their meetings, they may not have released their documentation 
but they’d already had their meetings.” (C20, REC).  
 
Many respondents supported the offer of VMMC to participants based on the “overwhelming 
scientific evidence that it works” (Z7, site staff, site 1). In conjunction with ethics 
requirements to offer “all the available resources” (Z11, site staff, site 2) to participants, it 




Respondents reflected that despite the evidence of efficacy, there were objections to the 
rollout of VMMC in South Africa:  
 “…one of the persons who was against the rollout of the circumcision, 
disappointingly so, is an advocate, who is key in HIV research…there was a lot of 
ongoing, you know, backwards and forwards, and with some people for it, and some 
people just not supporting” (Z11, site staff, site 2).  
 
Conflicting perspectives on VMMC were noted to have impeded rollout – the provision of 
VMMC to participants sans accompanying scale-up in the public healthcare system was 
argued as “beyond the standard of care” (Z22, site staff, site 1). However, it was reported 
that given knowledge of the protective benefit of VMMC and that participation in HVTs is a 
voluntary endeavour, participants should be offered “the best care that is affordable” (Z22, 
site staff, site 1). Some ethicists have argued that researchers are not obligated to provide 
VMMC until it has become an established and accepted prevention intervention within the 
larger community. It can, however, be offered to participants when researchers can afford to 
do so (McGrory et al., 2010).  
  
As with overall standard of prevention determinations, the addition of VMMC was largely 
determined by the protocol committee (including representatives from the sponsor, network, 
local investigators, and CABs) during the protocol development stage (see Chapter 7). The 
inclusion of VMMC in the prevention package was reviewed and formally approved by all 
RECs with jurisdiction over trial sites as well as selected CAB representatives, and required 
the formal approval of all relevant RECs. The product developer, as the financer of VMMC 
in the phase IIB trial, was also a critical stakeholder in the decision to add VMMC. 
Respondents also reported informal discussions with government stakeholders.  
 
1.5.1 Complexities with adding VMMC to the prevention package 
 
1.5.1.1 Cultural implications of providing VMMC 
While adding VMMC based on scientific evidence was considered a sound medical decision, 
there was some concern that the cultural implications had not been as carefully considered. 
Given that not all sites and CABs were engaged in protocol development and review (see 
Chapter 7), the lack of widespread community consultation on VMMC was perceived by 
some as a challenge because of the related cultural ramifications. At one site, it was reported 
that some CAB members objected to the provision of VMMC as it “deviated” from their 
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cultural practices. Again, the perception that the CAB had limited ability “to change things” 
was reported:  
 “…some of the CAB members they do oppose the circumcision which is provided by 
the site because they said now we are deviating from the cultural norms because the 
[name of ethnic group] are not doing the circumcision. So meaning that if we are 
taking the participants for the circumcision, we have to inform the extended families 
so that they can do some ceremonies, all those things. What if they are coming from 
the poor background and they are not prepared to do those things? It was their [the 
CABs] concern but nothing was done about it because the participant were 
circumcised, they are the one who made the decision not their families.” (Z2, site 
staff, site 1).  
 
Nevertheless, a lack of cultural acceptability did not always translate into poor uptake by 
participants. At the site where some CAB respondents opposed the provision of circumcision, 
uptake of VMMC was reportedly high (see Chapter 9).  
 
1.5.1.2 Lack of REC input  
In reflecting on the decision to add VMMC to the prevention package, RECs were portrayed 
as having adopted a passive role in decision-making, for example:  
 R: To your knowledge was the REC involved in discussions with the researchers 
when male circumcision was added to the prevention package?                                       
Z16: Not to my knowledge, no. (Z16, REC). 
 
 “It was pretty much a discussion between the people implementing or preparing to 
implement the specific study in the site. The REC wasn’t really making any 
pronouncements or advocating for any particular position…but as a whole they’re 
not activists in the sense that you know I’ve yet to see them say you know ‘we think 
that your standard of care should include X’” (Z6, site staff, site 2).  
 
Rather than being intricately involved in the decision-making process, the role of RECs was 
perceived as limited to approval of the addition of VMMC to the prevention package.  
 
It was also reported that some REC members may not support the provision of VMMC 
because they have doubts about its efficacy:  
 “I know that there are members on [the REC] who are very much against medical 
male circumcision. They’ve taken a very strong line against it.” (Z12, REC).  
 
Importantly, unlike with provider beliefs of efficacy, REC perceptions on the efficacy of 
VMMC did not result in their disapproval of the prevention package. Rather, it was reported 
that RECs undertook to ensure that information on the risks and benefits of VMMC were 
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clearly outlined to participants. While such risks were not specified in ICFs, it was reported 
that participants were counselled on the risks and benefits of circumcision.  
 
1.5.2 Comparison of decision-making practices and perspectives with ethics guideline 
recommendations 
In line with the substantive requirement for scientific validity (MRC, 2003; UNAIDS/AVAC, 
2011; UNAIDS/WHO, 2012) which was also endorsed by respondents in this study, VMMC 
was added to the prevention package based on evidence of efficacy. However, VMMC was 
added to the package before its endorsement for use by national or international bodies (Haire 
et al., 2013) such as the WHO. In contrast, other empirical studies found that VMMC was 
only added to the prevention package of other HIV prevention trials after national guidelines 
were developed (Haire & Jordens, 2013; Ngongo, Priddy, et al., 2012). Such differences in 
approach may reflect ambiguities between companion guidelines, with one set of guidelines 
(UNAIDS/AVAC, 2011) advocating for both scientific validation and national approval and 
the other (UNAIDS/WHO, 2012) allowing for either condition.  
 
Insofar as the decision to add VMMC occurred during protocol development (which included 
select CAB representatives) and was reviewed by some CAB members and all relevant 
RECs, the procedural requirement for consultation among all research stakeholders, including 
the community (UNAIDS/WHO, 2012) was somewhat satisfied. However, guidelines do not 
prescribe the process for consultation. Structured decision-making processes (e.g., Tarantola 
et al., 2007) have been advocated for making determinations on the standard of prevention 
(Hankins et al., 2009; Philpott et al., 2011) but were not reported in decision-making 
regarding the addition of VMMC.  
 
While some respondents in this study supported the view that new prevention methods should 
only be provided to participants when they are available and accessible in the public 
healthcare sector, VMMC was offered to phase IIB trial participants at a time of limited 
accessibility in the public sector (de Bruyn et al., 2007). This practice appears to be in 
agreement with the three-step framework, which is explicit that new prevention tools should 
not be incorporated into the prevention package too late, that is, only after introduction in 
local healthcare systems (Jay et al., n.d.). Further, once a new prevention tool is considered 
validated, its addition to the prevention package should not be contingent on regulatory 
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approvals as long as it is considered appropriate and can be sustainably implemented in the 
local healthcare system (Jay et al., n.d.).  
 
The inclusion of VMMC in the phase IIB study protocol and not in the phase I protocol, 
underlines some respondent arguments that the phase of the trial is a critical consideration for 
standard of prevention determinations.  
  
2. Challenges with evolving standards of prevention  
 
2.1 Adding new tools may impact on trial feasibility 
The concern that adding new modalities to the prevention package will reduce HIV incidence 
was acknowledged in the phase IIB protocol – “although the HIV seroincidence in South 
Africa has been estimated to be more than 4% in most of these settings, for the purposes of 
this study we have assumed that the HIV infection rate will be reduced due to enhanced 
prevention activities" (p. 13). Such decreases in incidence may imperil the ability of the trial 
to generate meaningful results (Padian et al., 2010).  
 
Most respondents recognised that as new modalities are added to the prevention package, it 
may become increasingly difficult to conduct HVTs:  
 “…the irony is that it masks… the efficacy of a vaccine, you now potentially have 
other confounding factors that could be preventing HIV, if you take the current, or 
emerging standards of care. So now for example we have medical male circumcision, 
we have the issue of HIV drugs as prevention, we have microbicides, and if those 
become standard of care then you have all those potential interventions also as 
confounding factors or possible prevention blockages to HIV, rather than just the 
vaccine…” (Z12, REC).  
 
 “…it’s the Nancy Padian golden egg paper of 2010…if we reduce the incidence so 
markedly, we will not be able to tell the difference between products because of just 
creating, such a logistical difficulty. In other words, to power the study sufficiently to 
show a difference in your product and non-product, or strategy and no strategy means 
that the study will have to be so big, that it just becomes logistically impossible. And 
so the concern, is that, by increasing and increasing our standard of prevention, you 
make a population who, just have no chance of HIV acquisition, and therefore you 
reduce transmission to such an extent” (Z18, site staff, site 5).  
 
It was argued that given the potential to impact on the scientific validity of the trial, careful 
consideration should be given to the enhancement of the prevention package:  
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 “…to just willy nilly put in new things all the time will destroy the value of the study 
that’s going on” (C17, REC).  
 
Respondents agreed that concerns about trial feasibility were real, but some suggested that 
the potential impact has been somewhat inflated. Many respondents framed their discussions 
of feasibility as a tension between ensuring the scientific integrity of the trial and the need to 
ensure the welfare of trial participants, with most arguing in favour of protecting participants. 
Scientific integrity or the ability of the trial to generate meaningful results was noted as 
related to sample size – respondents implied that increasing sample sizes to ensure an 
adequately powered trial, although costly and demanding in terms of participant accrual, was 
a necessary evil:  
 “I think that [trial feasibility] is a real concern and it’s one that we should learn to 
live with…the suggestion or the possible idea that we should be denying participants 
prevention interventions in order to observe a higher HIV incidence is obviously 
untenable. So I think it’s a real concern but I think it’s, it's a fact and it’s a fact that 
we need to account for and adjust for. …I think the conflict is a little bit inflated by 
people and is a little bit less dramatic than some people think” (Z16, REC). 
  
 “…of course that makes it harder to find a difference, because if you’re effective in 
your other forms of prevention, the lower the rate of infection, and you’re gonna need 
more people in order to see a difference in terms of the design and I think that’s a 
perfectly reasonable trade-off” (C5, REC).  
 
 “…if it means increasing your numbers, then you’ll have to increase your numbers in 
the trial but I don’t think you can really not provide HIV prevention options for 
participants” (Z7, site staff, site 1).  
 
Enrolling large sample sizes is possible – the success of the Thai RV144 trial was not only 
that it was the first HVT to demonstrate proof of concept, but also that it enrolled over 16000 
participants and retained over 90% in a six-year period. Nevertheless, the inclusion of PrEP 
in the prevention package of HVTs would complicate trial design. Typically, HIV incidence 
rates of 3-6% have been found among trial populations in efficacy trials, and these may 
decrease further with the addition of effective HIV prevention strategies. Relatively low 
incidences limit the ability of detecting moderate efficacy in trials (Reynell & Trkola, 2012). 
For example, if a microbicide (e.g., CAPRISA 004) or product of similar efficacy is added to 
the standard of prevention, the incidence of HIV infection would decrease by at least 30–50% 
- “a trial such as RV144, which followed 16,402 participants for 3.5 years and detected only 
125 infections, would be under-powered to retrieve data for outcome analysis” (Reynell & 
Trkola, 2012, p. 5). 
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Withholding a scientifically validated prevention modality from participants solely to ease 
the burden of increased sample size and resultant expense was argued to be ethically 
abhorrent and likened to the infamous Tuskegee study:  
 “…the one thing that is obvious is that as more and more prevention modalities 
become available and form the prevention package, obviously for ethical reasons 
you’ve got to provide that to participants…The one thing that we’re gonna have to 
live with is that then it just means our trials are gonna get more and more expensive 
because we/ it therefore means we need to have bigger and bigger numbers to reach 
the endpoint that we’re looking for….as we advance in science…we gonna be getting 
more prevention modalities and we can’t then now deny/ otherwise we gonna end up 
with the Tuskegee trial situation where we want to say we gonna withhold this 
because otherwise we can’t achieve what we want to achieve in trials. And we can’t 
allow that to happen.” (Z22, site staff, site 1). 
 
Network representatives confirmed that the addition of PrEP to the prevention package would 
indeed amplify costs because of increased sample sizes but that this would not translate to 
withholding PrEP from participants: 
 “… ART as PrEP that also may come to be something that we need to offer in our 
trials. In which case we’re going to have to enrol like three times as many people as 
we thought (laughs)…It will get very interesting but if it’s the right thing to do, we 
should do it.” (C13, network representative). 
 
 “…I think it can impact on the feasibility. Sure uhm but I don’t think that’s a reason 
you know not to try and implement a full standard of prevention package and I do 
think/ I think at least the researchers that I’m aware of within [the network] work 
very hard to make sure that it’s done in a way that is feasible so the prevention 
packages can be included.” (Z13, network representative) 
 
A common view held by respondents was that regardless of logistical complexity and costs, 
“we aren’t going to peel things off” the standard of prevention (Z6, site staff, site 2). 
However, in a different study, some interviewees argued that there should be efforts to 
concentrate on the experimental product and “peel back from offering everything” (Haire & 
Jordens, 2013, p. 11). In contrast, none of the respondents in this study explicitly supported 
the latter view, although a few argued that enhanced prevention packages might severely 
cloud the effect of an experimental vaccine and might result in trial futility, for example: 
 “Well I mean we’ve already seen some ongoing studies being abandoned because the 
incidence of HIV in those studies was seen to be too low. So that’s the sort of thing 
where if it comes to an end, that’s a dead end and the information that we learn from 
that study is very limited” (Z6, site staff, site 2).  
 
Standards of prevention are based on the tenet that the researcher’s principal obligation is to 
reduce participants’ risk and prioritise their well-being over considerations of future 
171 
 
beneficiaries of research (Haire et al., 2012). Decision-making criteria (Philpott et al., 2011) 
and frameworks (Jay et al., n.d.) specify that when making determinations on adding tools to 
the prevention package, the impact on trial feasibility should be considered. A new 
prevention tool should not be added to the prevention package when it is so effective that 
showing an added effect from the study intervention will require a sample size and/or 
duration that is substantially misaligned with a reasonable allocation of resources (Jay et al., 
n.d.). For example, treatment as prevention has been found to be 96% effective in reducing 
HIV acquisition in serodiscordant couples (Cohen, 2011) and would likely dramatically 
reduce HIV incidence if provided to trial participants. Such an effective prevention 
intervention would require trials of significantly increased sample sizes to have sufficient 
power, at a level unlikely to be feasible (Haire, 2014). For this reason, future HIV prevention 
trials will be unlikely to recruit participants in serodiscordant relationships (Haire, 2014). 
 
Still, some respondents in this study considered providing sub-optimal prevention packages 
to ensure sufficient endpoints, untenable – rather one proposed solution was to conduct 
research with those populations who fail to implement current prevention interventions:  
 “…by making those provisions available to people, doesn’t mean that those people 
are going to take them…unless you force it down their throats…this is still going to 
come down to human behaviour. So, it may be, that in the future, we need to think of 
ways where we would enrol people who genuinely don’t want to use those strategies, 
or, we know that, even if we make them available to them, they won’t use those 
strategies…sadly in my own site, where I think we do excellent risk-reduction 
counselling, condoms are always available, I treat anybody who presents with an STI, 
I often test those people who ask for it, I still had an extraordinary incidence in that 
population. So, you know, I think, whilst that is a consideration, and there may come 
a time when we just put ourselves out of business because we cannot do efficacy 
studies, because the whole population is just preventing so well, well then, you know, 
then I’m hoping the HIV epidemic will be coming under control, and we will be, you 
know, not needing anything more going forward. The fact of the matter is that I think, 
around the world, there are lots of pockets of transmission going on, and we’re just 
going to have to find those pockets, and use those in our clinical trials going for/ I 
think it will get harder, because I think they’re gonna be more difficult populations to 
reach, they’re gonna be more difficult populations to inform, and to provide services 
for, but, you know, I think that’s the natural history of this thing. Um, I, honestly, at 
this stage, don’t believe that we can entertain for a moment that we would do some 
less standard of prevention, in order to conduct an efficacy study” (Z18, site staff, site 
5).  
 
2.2 Adding new tools is costly 
Implementing enhanced standards of prevention has implications for the costs of clinical 
trials because larger sample sizes, and therefore exponentially more funding, will be required 
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to meet study endpoints (Haire et al., 2012). This is further compounded by increasing 
research costs as a result of routine inflationary increases – all occurring in a context where 
research funding is stagnating (RTWG, 2013; 2014). 
 
A network respondent noted that funding may well be a consideration for standard of 
prevention determinations: “I think you know expense may sometimes come into the picture. I 
certainly hope that that’s not something that interferes though” (Z13, network 
representative). The reality, as described by many respondents, was that funding was a major 
determinant of standard of prevention decision-making, especially considering donor 
restrictions of funding. For example:   
 “And we’ve also discussed to what extent would these resources be applied to other 
prevention modalities…that it could be very costly…Truvada, oral PrEP, 
microbicides these are not typically interventions that [the sponsor] would pay for 
under study protocol costs, right? So you know that may be an issue in the future as 
some of these other interventions become the standard of care, yeah.” (C14, network 
representative).  
 
 “…it’s a funding issue…the largest trial that we conducted… [the product developer] 
actually provided the funding for the circumcision procedures, so those were not 
government dollars. The other trials that we’ve been doing have been… funded by the 
US government, but they’ve been South African products. And there just wasn’t 
money available for them.” (Z9, network representative).  
 
 “So the least that we can do is to offer them the best that we can…obviously within 
financial constraints…” (Z22, site staff, site 1).  
  
 “…there’s always been a bit of a discussion on things around you know what they can 
afford or what not. Especially because there’s always a financial issue… You know 
sites insisted on having a list of things available for their participants and you know 
the sponsors not being willing to provide it because then it would include a much 
bigger cost component to the protocol.” (Z17, site staff, site 5).  
 
2.3 Adding new tools may be an undue inducement to participate in HVTs 
Several respondents were concerned that the addition of new prevention interventions not 
otherwise available or affordable would constitute an undue inducement to participate in the 
HVT: 
 “I think that’s going to be problematic because then we’re doing something that’s not 
standard of care and I would be worried about the reasons why people would then 
take part in the study. Because it might be purely just because they want to access 
that. Ja no I won’t, I think it would be problematic if you add something that’s not 




 “I don’t think it’s fair. The only concern for me it’s mentioned that participation is 
voluntary. Now if you put such things there I don’t know whether I should say it but 
you know it entices people that if you come here you are going to get this and this. It 
doesn’t sound nice. It seems you are bribing people, you are telling people that now if 
you take part in this you are going to get this and this… For a study to be credible, 
people should not be bought to take part in it, but if you bribe people to come and 
take part the credibility of the study reduces.” (C12, CAB).  
 
 “…should we be providing an extra package just for participants and then there 
would also the, which is still really a debate the question of when we’re doing that 
isn’t that a conducive incentive? You know because then you know here you are for 
participants you’re providing what they otherwise would not have received” (Z22, 
site staff, site 1).  
 
 “I think that’s always a big concern is if they’re not available to the public are we 
offering an undue inducement to participate in the trial you know by providing them.” 
(Z13, network representative).  
 
Like these respondents, HPTN (2009) guidelines argue that offering a state-of-the-art 
prevention package, when such interventions are unavailable in the community, may create 
an undue inducement to participate. Concerns about undue inducement in research are not 
new (see Chapter 5), and some assert that this ethical concern has been “over used or misused 
in discussions of trial ethics” (McGrory et al., 2010, p. 29).  
 
2.4 Adding new tools may create inequities between trial participants and their 
communities 
Some respondents in this study were of the view that the evolving standard of prevention 
should be determined by the availability of the particular intervention in the public health 
sector.  
 
For a few respondents, there was concern that adding new tools, not otherwise available, to 
the standard of prevention would create inequities between trial participants and host 
communities. In this way, these respondents adopted a social justice perspective, which 
argues that the standard of prevention implemented in HVTs should not be so superior in 
comparison to the standard of prevention in the community that it could not be feasibly and 
timeously integrated into the local healthcare sector on completion of the trial (HPTN, 2009). 
Requiring that all new and validated tools be provided to participants in HVTs when they are 
otherwise unavailable or unaffordable would “create serious inequities between research 
participants and community members with similar needs” (HPTN, 2009, p. 33). Given the 
potential for social injustice some respondents argued that “…long-term there should be a 
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move towards having these available to all our…patients regardless of their participation” 
(Z15, site staff, site 3).   
 
While other respondents did not necessarily support this perspective, there was some 
acknowledgement that it could be a potential complexity:  
 “Because, you know, if something is not a standard of prevention in the country, and 
then it’s offered in a clinical trial, that could well have implications for that 
community, you know” (Z18, site staff, site 5).  
 
Still other respondents supported a reciprocal justice perspective (see Chapter 7), that trial 
participants are deserving of special treatment in the form of access to services or benefits not 
available to others, because of the risks they are exposed to. 
 
2.5 New tools may replace the old  
A concern for some respondents was that as new partially effective prevention modalities 
become part of the prevention package, participants may be less likely to use previously 
available prevention strategies like condoms: 
 “I think the challenge, is that when you introduce a new prevention method, the 
person thinks that ‘ok, I can get rid of what has been existing’…they’re thinking that 
the new methods that have been introduced are there to substitute the others” (Z2, 
site staff, site 1).  
 
 “…[if microbicides are added to the prevention package] it will change the whole 
thing…People are going to minus the condom part and use the gel.” (J1, site staff, 
site 2).  
 
It was emphasised that clear counselling messages on the importance of condom use, despite 
the availably of new efficacious products, should be imparted to participants. For example:  
 “… it would also go with a lot of education for the community and the study 
participants because they would obviously need to understand very clearly that if they 
do get a microbicide added to a vaccine trial and the microbicide efficacy was shown 
to be say 63%...it’s not 100% effective…don’t think because you’re using microbicide 
you won’t get HIV infection. Still use your condoms, still you know practice safe sex 
you know all those things they need to understand…” (Z17, site staff, site 5).  
 
Given that an HIV prevention modality with full efficacy is unlikely, participants should be 




3. Summary  
This chapter addressed the research question on what are the perspectives and practices of 
HVT stakeholders on evolving standards of prevention. Ethics guidelines specify two 
substantive standards for the addition of new HIV prevention interventions to the prevention 
package. Firstly such interventions should be scientifically validated (MRC, 2003; 
UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). Secondly, they should be approved by 
regulatory authorities (UNAIDS/WHO, 2012) or national bodies for use (UNAIDS/AVAC, 
2011). UNAIDS/WHO (2012) also specifies that new tools should be added based on 
consultation among all research stakeholders, including the community.  
 
Respondents largely agreed with ethics guideline recommendations that new tools should be 
added when they are scientifically validated, although the operationalisation of scientific 
validity was identified as a complexity, particularly considering that guidelines are vague. 
Scientific validity was also reported as the basis of the decision to add VMMC to the 
prevention package. The need for clearer operational frameworks for researchers, RECs and 
regulatory authorities was also identified.  
 
In line with UNAIDS/AVAC (2011) guidelines and a more stringent interpretation of 
UNAIDS/WHO (2012) guidelines, respondents reported that a new prevention modality 
would need approval of the national regulatory authority in the host country before it is 
offered to HVT participants.  
 
Public sector availability and the phase of the trial were also articulated as relevant to 
determinations on the enhancement of the standard of prevention. Neither of these criteria are 
explicitly spelled out in ethics guidelines. Data from this study support the perspective that 
researchers should provide participants with proven, nationally approved and available 








STANDARD OF PREVENTION IMPLEMENTATION PRACTICES 
AND PERSPECTIVES 
 
This chapter presents respondents’ reports on the HIV prevention interventions provided in 
two HVTs at five South African sites. It describes ‘which’ prevention interventions were 
provided, to ‘whom’ (participants, volunteers at screening, participants’ partners or the wider 
community) and ‘how’ (implementation practices). Respondent perspectives on standard of 
prevention challenges and complexities are also presented. HIV prevention practices at sites 
are compared with relevant HIV prevention recommendations in ethics guidelines (MRC, 
2003, UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). Findings in this chapter were 
published in Public Health Ethics (Essack, 2014).  
 
1. Which HIV prevention interventions were ensured in HVTs?  
An analysis of site documents and interviews revealed that risk-reduction counselling, male 
and female condoms, STI treatment, VMMC and PEP (where indicated), were provided at the 
five South African HVT sites.  
 
Implementation practices and complexities are presented below according to each prevention 
intervention for trial participants and then for non-trial participants.   
 
1.1 Ensuring access to risk-reduction counselling  
There is broad consensus from multiple stakeholders that participants in HIV prevention trials 
should be provided with behavioural risk-reduction counselling (Lagakos & Gable, 2008). 
While some behavioural risk-reduction interventions have been proven effective in reducing 
self-reported risk behaviours and even STIs, to date there is no evidence showing significant 
reduction in HIV infections (Lagakos & Gable, 2008; Lie et al., 2006). However, risk-
reduction counselling is invaluable for enhancing knowledge of HIV/STIs, enhancing skills 
for condom use and increasing the effectiveness of biomedical interventions (Heise et al., 
2008; Lagakos & Gable, 2008). 
 
Ethics guidelines recommend that trial participants should be provided with risk-reduction 
counselling (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). Both study 
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protocols and interviews at all five sites, indicated that on-site risk-reduction counselling was 
provided to participants at every study visit. Risk-reduction counselling was reported to be 
“in-depth”, taking “plus-minus 30 to 45 minutes” (Z4, site staff, site 2) up to two hours to 
complete, depending on individual participant needs. Given that phase I trial participants 
were at lower risk compared to those in the phase IIB trial, it was reported that the length and 
“nature of those discussions may be different” (Z6, site staff, site 2). Counselling was 
conducted “in the language of the participant’s choice” (Z10, site staff, site 5).  
 
Across all sites, counselling was conducted by trained counsellors who were part of the site 
staff complement. While the baseline training of counsellors varied, it was reported that 
counsellors have undergone intensive network-driven training on risk-reduction counselling 
in efforts to systematise counselling across study protocols and trial sites. For example:  
 “…our counsellors undergo the training of risk-reduction counselling which was 
offered [by] the [network]” (Z2, site staff, site 1). 
  
 “… most recently…there was an effort to try and create standardised training 
material that was made available to sites so that all of the counsellors who are 
participating in the HIV prevention trials… could have a similar training experience 
so that at least from a [sponsor] perspective there would be a common platform you 
know when we say risk-reduction counselling, those counsellors have been through a 
common experience…” (Z6, site staff, site 2). 
 
Some interviewees, including counsellors, commented positively that counselling was “in 
depth” and intensive. While risk-reduction counselling was primarily provided by a 
designated counsellor, at some sites it was reported that additional counselling on specific 
issues (e.g., access to PEP) was provided by other study staff (e.g., clinicians, nurses, etc.).  
 
The master protocols for both trials specified that counselling should follow the US Center 
for Disease Control (CDC) guidelines for HCT unless alternative procedures are approved or 
mandated by the local REC. Interviewees described that risk-reduction counselling was 
developed in accordance with CDC guidelines but tailored to the South African context. 
Risk-reduction counselling was argued by one interviewee to be an “upgraded” (Z2, site 
staff, site 1) version of South African guidelines while another contended that South African 
guidelines were “excellent … I found them much more comprehensive than what I could find 
the CDC” (Z13, network representative). Given that sexual activity is an enrolment criterion, 
at one site, the mantra of ABC was reported to be incompatible with trial requirements:  
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 “They follow DoH counselling guidelines and CDC, but ABC in reality does not 
work! It is a song the counsellor needs to sing. Participants can’t abstain – we need 
the risk behaviour. They can’t say the ‘A’” (C1, site staff, site 1).  
 
Interviewees described counselling sessions as a “personalised” risk-assessment where the 
counsellor could “dig more details” (Z4, site staff, site 2) about a participant’s risk behaviour 
and jointly develop risk-reduction plans. In addition, detailed behavioural risk-assessments 
(cf. Andrasik et al., 2013) were conducted by members of the research team. According to the 
phase IIB protocol, behavioural risk-assessments were completed at screening and in all but 
five study visits. The phase I protocol indicated that the behavioural risk-assessment 
questionnaire was only administered at screening. Phase IIB site documents revealed that an 
interviewer-administered risk-assessment tailored to males and females was administered to 
all participants. The risk-assessment comprised questions on sexual practices including 
number of sexual partners, HIV status of partners, sex of partner, condom use, type of sexual 
activity (vaginal, oral or anal), recent STIs, alcohol and drug use, transactional sex and forced 
sex.  
 
From interviews, multiple objectives of risk-reduction counselling were identified. 
Interviewees at some sites described that counselling aimed to reduce unsafe sexual practices 
that may result from misperceptions of vaccine efficacy (i.e., behavioural disinhibition), for 
example:  
 “…they [participants] were told to stick to condoms… because the study is a 
research, it’s not approved” (Z1, CAB, site 1).  
  
 “…we try our level best to make sure that they [participants] understand it…every 
time when they come for follow ups that we should still try to ask them few questions 
to make sure that they do remember that while they are participating it’s not really 
protecting them. It’s a trial” (Z15, site staff, site 3). 
  
The value of counselling for improving uptake of prevention interventions was also 
highlighted. Key aims of risk-reduction counselling included assisting participants in 
identifying their risk behaviours, helping participants reduce their risk (i.e., protect 
participants), and educating participants about potential risks.  
 
When indicated, it was reported that participants were referred to psychologists or social 




In both trials and at all sites, risk-reduction counselling was guided by a network-provided 
risk-reduction worksheet which was a comprehensive “menu-based list of options that are 
explored with the participants” (Z6, site staff, site 2). This worksheet comprised an 
assessment of the participant’s subjective perception of his/her HIV risk plus an objective 
exploration of potential risks for HIV/STI acquisition, including drug and alcohol use, sexual 
activity and type of sexual partners. It also involved developing plans for how the participant 
will reduce his/her risk behaviours and identifying any sources of support including referrals. 
The worksheet required that counsellors review with participants the changes that the 
participant had made post the last study visit, as well as any potential for risk 
compensation/behavioural disinhibition. Risk-reduction counselling is distinct from 
behavioural risk-assessments in that the focus is on identifying and minimising risk 
behaviours. Worksheets were also reported to serve as a guideline for counsellors:  
 “…we also have our worksheets which helps guide/ it sort of sets up the pieces that 
need to be covered during sessions and we’ve done training on the worksheets so that 
adds to it as well” (Z13, network representative). 
 
The risk-reduction worksheet permitted “chart-noting” of counselling sessions, serving as a 
possible tool for documenting counselling sessions. In terms of monitoring practices, at some 
sites, respondents reported that the quality of risk-reduction counselling was assessed and that 
all risk-reduction documentation was quality controlled: 
 “…trials are monitored the way they are monitored? So, whatever they come, and 
they’ll look at your counselling forms. They’ll look at your chart-notes” (Z11, site 
staff, site 2).  
  
 “... we have a programme that staff members get assessed on a regular basis. So 
somebody would sit in a counselling session and actually write down you know, make 
notes of what’s said and what was left and you know what was missed and things like 
that and people then get retrained...” (Z17, site staff, site 5). 
 
However, at some sites it was reported that supervision of counselling sessions, while ideal, 
was not possible due to staff shortages: 
 “…if we had enough counsellors, like… it will make more sense that you have 
somebody that sits in from time to time, but we are so constrained. Like in the/ in all 
the projects that I’ve worked in, I was the only professional counsellor” (Z11, site 






1.1.1 Complexities with risk-reduction counselling  
 
1.1.1.1 Relying on self-report by participants 
At some sites there was concern that risk-assessments relied on self-reports which are 
notoriously subject to social desirability bias (Chillag et al., 2006; van de Mortel, 2008), 
referring to the tendency of participants to respond in a way that presents a favourable image 
of themselves (King & Bruner, 2000). The participant may believe their self-report to be 
accurate (self-deception) or they may ‘fake good’ to conform to socially acceptable values, 
avoid criticism, or gain social approval (King & Bruner, 2000). 
 
Since site staff build relationships with participants focused on reducing risk, participants in 
HVTs may have responded to questions about their risky behaviour in such a way as to please 
site staff or gain their approval, and may therefore not have reported their risky behaviours. 
For example:  
 “So most cases we find people mention that they are using protection. At the end of 
the day, they not using protection because you find them with STIs, the others are 
pregnant, others are infected with HIV” (Z4, site staff, site 2).  
  
 “The common problems, you know, everybody used a condom, and everybody’s 
pregnant.” (Z11, site staff, site 2)  
 
 “…if the doctor wants an answer that’s yes, I’m going to say yes. That is the answer 
that the doctor wants.” (Z10, site staff, site 5). 
 
Gendered stereotypes and cultural taboos were also noted to complicate self-reporting of 
risky behaviours, for example:  
 “… she just said she was scared to mention more than one partner. So that is why she 
keep on lying. She was so scared to mention more than one partner in her age and 
she’s a female. It was going to be better if she was a male.” (Z4, site staff, site 2).  
 
Still, some interviewees argued that socially desirable reporting decreases as relationships 
between counsellors and participants develop. Because counselling was tailored to 
participants’ risk profiles, socially desirable reporting was described as an obstacle to 
effective risk-reduction counselling.  
 




 “…I think people themselves have a lot of trouble perceiving their own risk…” (Z18, 
site staff, site 5). 
 
1.1.1.2 Participants’ implementation of risk-mitigation plans 
In contrast, some interviewees reported that participants were forthcoming about their risk 
behaviours but the challenge was participants’ failure to implement risk-mitigation plans:  
 “...I'm usually of the view that people are telling us what they’re doing but I guess it 
is an issue whether or not they are then able to translate whatever insights they reach 
through the counselling process into some practical steps when they’re outside of the 
clinic” (Z6, site staff, site 2).  
 
 “…they are not practicing [safe sex] all of them because as a result they become 
pregnant, they seroconvert…because of their risk behaviour ‘uh, I was drunk, I went 
to the party, the condom burst and all that.’ They came up with the package of the 
excuses why they become infected” (Z2, site staff, site 1). 
 
 “…we offered an excellent standard of prevention. As I mentioned, sadly, we still had 
an extraordinary incidence rate. So, you know, it’s sobering that even when you offer 
all of those services, you still see a lot of HIV transmission.” (Z18, site staff, site 5).  
 
A respondent at one site noted that a potential difficulty with changing behaviours, 
particularly for men, related to cultural conceptions of masculinity and cultural practices of 
multiple partners:  
 “…‘cause men are the people, I don’t want to say stubborn, they still believe in their 
what? Is it inheritance? Where they’re coming from. They coming from polygamous 
families, so it’s very hard to change a person like that who’s born in a family where 
there’ve been five grannies, five mothers.” (Z1, CAB, site 1).  
 
1.1.1.3 Supporting counsellors 
The importance of providing continuous mentoring, training and psychosocial support for 
counsellors was mentioned: 
 “The first challenge with risk-reduction, or any counselling, is that you need to have a 
certain type of personality to provide the counselling itself, so that’s challenge 
number one. Training people, er, mentoring them, and supporting them throughout, 
because what we tended to realise is that you train people, and the first two weeks 
after the training, you go into the counselling session, you know, you are very 
impressed with the way the counselling goes on. Come month three, you go in, 
sometimes you don’t even believe it’s the same counsellor that you trained that is 
offering the counselling… Because everybody that comes in offloads onto the… 
counsellors, and by the end of the week the counsellors have absorbed so much that, 
you know, they don’t even look forward to go into the next week” (Z11, site staff, site 
2).  
 
 “…our counsellors I think they have a very challenging job and it can be very hard on 
them emotionally and we’ve had to work on addressing that. And interestingly that 
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was in the area that was very much appreciated, that was one of their favourite topics 
with the training that we did.” (Z13, network representative).  
 
One respondent also noted that despite the important role of counsellors in HIV prevention 
research, their salaries were not commensurate with their responsibilities in trials:  
 “…you get counsellors…they’re highly trained, they’re highly motivated, but if you 
look at counsellors throughout the country, if you look at their salary structure, and 
the important role that they are playing in your HIV prevention trials then you have to 
say, really… counsellors are very lowly paid, and that is a major concern…that is a 
demotivating factor” (Z10, site staff, site 5).  
 
In support of counsellors, a mentorship programme was instituted at sites that elected to 
implement it. Counsellors’ mentors were responsible for training counsellors, debriefing them 
and providing general support, helping them deal with “difficult clients or participants” (Z2, 
site staff, site 1), and reviewing “chart-notes” of counselling sessions.  
 
1.1.2 Comparing risk-reduction counselling practices with recommendations in ethics 
guidelines 
All HVT sites satisfied ethics guideline requirements (MRC, 2003; UNAIDS/AVAC, 2011; 
UNAIDS/WHO, 2012) that comprehensive risk-reduction counselling be provided to 
participants. MRC (2003) guidelines require that counselling be conducted in accordance 
with national guidelines. The South African guidelines for HCT (DoH, 2010) provide little 
direction on HIV prevention counselling. However, they do require that counselling be 
conducted in a language that the client understands, and that when HCT is conducted in the 
context of research, all participants “must be informed about HIV prevention through 
practicing safe sex, and effective treatment or referral must be provided for STIs” (DoH, 
2010, p. 13). In addition, all clients who test HIV-negative should be offered a 
comprehensive prevention package that includes information about VMMC, TB screening, 
risk-reduction and the correct and regular use of condoms (DoH, 2010). Further, like ethics 
guidelines, national guidelines specify that counselling should be conducted by “an 
appropriately trained, mentored, and supervised counsellor...” (DoH, 2010). CDC guidelines 
recommended for use in both study protocols state that counselling should involve a risk-
assessment based on the unique characteristics of the client as well as the development of 
concrete risk-reduction goals (CDC, 2001). It is also recommended that counselling be 
provided on-site by trained counsellors and that counselling should be monitored for quality 
183 
 
(CDC, 2001). In practice, trial participants in both trials received risk-reduction counselling 
in accordance with CDC guidelines and South African national guidelines.  
 
The provision of psychosocial support for counsellors was also identified as critical in 
previous research (Heise et al., 2008). Given their ongoing relationship with trial participants 
over the course of the trial, counsellors may experience high job stress and burnout and there 
is a need for increased support of counsellors through opportunities to debrief and 
counselling (Heise et al., 2008).  
 
Key reported concerns with social desirability are anticipated by select guidelines which 
outline that site staff should be cognisant of the potential for social desirability bias and 
recommend the use of neutral advisors and trained counsellors (MRC, 2003). Previous 
research has recommended that ongoing assurance of confidentiality to participants may 
circumvent some concerns that full disclose may result in stigma, ridicule and gossip (Chillag 
et al., 2006). Given cultural barriers to discussing sex with older persons and persons of a 
different gender, it was recommended that where possible, same-gender and similarly aged 
research staff should be selected (Chillag et al., 2006). Reported complexities also reflect 
broader concerns with the efficacy of counselling to reduce HIV risk and underscore the 
search for an expanded array of prevention options that combine biomedical and structural 
interventions with behavioural interventions (Hankins & de Zalduondo, 2010).  
 
1.2 Ensuring access to male and female condoms 
If used correctly and consistently, condoms are an effective strategy for preventing HIV. 
Ethics guidelines specify that trial participants should receive access to male and female 
condoms (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012), with appropriate 
instructions and demonstrations (UNAIDS/AVAC, 2011). 
 
In practice, at all five sites, and for both trials, male and female condoms were reportedly 
provided to participants during risk-reduction counselling sessions and participants were 
counselled to use condoms with every sex act. According to interviewees across sites, 
condoms were available outside counselling sessions, for example, at reception, in restrooms 
and waiting areas. The availability of male condoms at sites was also observed by the 




At all sites, participants received condom demonstrations using a penile model. At one site it 
was reported that while vaginal models were also used, female condom use was only “halfly” 
demonstrated (Z2, site staff, site 1).  
 
At all sites, condoms were procured from the DoH at no cost to sites. At one site it was 
reported that condoms were also sourced from a donor. The risk-reduction worksheet used by 
all sites required “chart-noting” (recording) of condom provision, which was also reported to 
facilitate feedback to the DoH on the number of condoms issued.  
 
1.2.1 Complexities with condoms  
 
1.2.1.1 Ensuring adequate supplies from government partners 
At two sites, shortages of government-issued male condoms were reported:  
 “Sometimes you find that the condoms are not available from the provincial office...” 
(Z8, site staff, site 4).  
 
 “Well there are times when it’s not available...it would relate to the general shortage 
of condoms” (Z10, site staff, site 5).  
  
However, at these sites, staff did not explicitly report that shortages in supply resulted in 
instances where no condoms could be provided to participants.  
 
There were reports about particularly poor accessibility of female condoms at all sites, for 
example:   
 “…the majority are really male condoms because you know to access female condoms 
is a mission and they are expensive” (Z22, site staff, site 1) 
 
 “…we didn’t have as many female condoms. I think we had a problem getting the 
condoms, and we had demands” (Z11, site staff, site 2).  
 
Given the limited availability, at some sites it was reported that female condom provision was 
capped or only provided on request because they “…are provided very sparingly from the 
Department of Health with the proviso that only females who request it are actually 
dispensed those condoms…” (C7, site staff, site 4).  
 
1.2.1.2 Counsellor promotion of condoms 
Interviewees at some sites reported that condom use was emphasised:  
185 
 
 “We actually encourage them to use condoms… we emphasise that they must use 
condoms” (Z8, site staff, site 4). 
 
The emphasis on condom promotion was partially driven by the requirement to record or 
“chart-note” condom provision on the risk-reduction worksheet:  
 “When you counsel someone you have to issue condom, and you have to …chart-note 
that I issue so much condom to the participant” (Z2, site staff, site 1). 
 
Since risk-reduction worksheets were reviewed by mentors, it was reported that participants 
may be pressured by counsellors to take condoms, for example, participants “cannot get out 
of the [counselling] room without a condom” (C1, site staff, site 1). Condom provision was 
described as a tick-boxing activity by one respondent - “it became a quantitative issue, not a 
qualitative thing” (C1, site staff, site 1).  
 
1.2.1.3 Low acceptability and uptake by participants 
At two sites it was reported that participants had complained that “the Department of Health 
is not providing worthy condoms” (Z3, CAB, site 2). Complaints included that these Choice 
condoms break, are too small and may cause allergic reactions. Trial participants were 
reportedly unhappy that they were provided with “the same condoms as in the public service 
[sector]” and they “expect that the researchers need to give them the best” (C1, site staff, 
site 1). To remedy concerns, one site secured condoms from an international donor while at 
the other site some participants reportedly opted to purchase their own condoms: 
 “Yes, so they don’t want it at all…they prefer to go and buy the condom from the 
pharmacy” (Z4, site staff, site 2). 
 
 “I’m providing condoms, since we are using the government condoms, the Choice 
condoms, so if a particular person says, you know what, I don’t want condoms, I do 
go to the garage and buy them, you write down in a chart-note that I’ve offered 
condoms to this particular participant but he said he’s ok, he’s using the expensive 
condoms…” (J1, site staff, site 2). 
 
It was noted that participant acceptability of condoms may be related to the cultural 
perceptions of the inadequacy of Western medicines which may inhibit condom uptake, 
especially by male participants:  
 “…you get the very very traditional guys they don’t believe in Western medicines, 




There were reports of poor uptake of female condoms at most sites. Respondents across sites 
described various reasons for poor uptake including that it is “not comfortable” (Z7, site 
staff, site 1), “it makes a lot of noise” (Z15, site staff, site 3) and “is too big for them” (Z4, 
site staff, site 2). Further, female condoms “are not user friendly, you’ve got to put them on 
quite earlier on, and so those messages are not attractive” (Z22, site staff, site 1).   
 
1.2.2 Comparing condom practices with recommendations in ethics guidelines 
Consistent with ethics guidelines, access to male and female condoms was ensured for trial 
participants (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). Obligations to 
ensure access to condoms entail that they should be available at or in close proximity to the 
trial site, and there should be no economic or other barriers to their attainment (Lie et al., 
2006). Therefore, it could be argued that at most sites, obligations to ensure access to female 
condoms were not wholly satisfied (see Chapter 11 for detailed discussion). While guidelines 
are silent on issues of poor uptake, national guidance requires that risk-reduction 
interventions be monitored for quality, specifically the “availability of adequate supplies of 
barrier methods” (MRC, 2003, p. 31).  
 
Collaborating with host country governments in ensuring the highest standard of prevention 
is a requirement of ethics guidelines (UNAIDS/WHO, 2012). Trial sites have indeed 
partnered with government stakeholders (namely, DoH) to ensure access to free condoms for 
participants. The reported challenges with procuring condoms from government partners 
suggest that constant engagement with such stakeholders is critical. Further, sites should plan 
for inadequate supply by government partners, given reports that in 2010/11 the DoH fell 
short of their targets for the distribution of both male and female condoms (DoH, 2011). 
While one strategy may be to seek supplies from international donors, it must be ensured that 
these condoms comply with South African Bureau of Standards (SABS) requirements.  
 
The concerns by some participants that Choice condoms are of inferior quality may relate to 
the recall of these condoms by the South African government (Moszynski, 2007), three times 
in less than five years. In August 2007, 20 million condoms were recalled after it was learned 
that a testing manager at the SABS had accepted money from the manufacturer in exchange 
for certifying defective condoms (Reuters, 2007, in Moszynski, 2007). In October 2007, an 
additional five million condoms were recalled after a sample failed the airburst test (BBC, 
2007, in Moszynski, 2007). Further, Lindegger, Solomons, Essack and Blackbeard (2007) 
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found that young men were reluctant to use freely available government condoms because 
they believed that these condoms did not help them sustain a particular image or status. In 
keeping with reports in this study of participants opting to purchase their own “expensive” 
condoms, “the use of a brand label helped create and maintain status and repute for young 
men in relation to partners and social reference groups” (Lindegger et al., 2007, p. 26). More 
recently, the DoH acknowledged “condom fatigue” among target users as well as the 
perception that Choice condoms are “uncool” (BBC News, 2 April 2014). In response, the 
DoH planned to introduce colourful and flavoured condoms (BBC News, 2 April 2014).  
 
1.3 Ensuring access to STI treatment 
STIs are proven cofactors that significantly increase vulnerability to HIV (WHO, 2003). 
Ethics guidelines require that access to STI treatment should be ensured for trial participants 
(MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) and that risk-reduction 
counselling should include education on general health and the treatment of STIs 
(UNAIDS/WHO, 2012).  
 
At all sites and for both trials, participants were counselled on how to prevent STIs. In 
concordance with the phase IIB protocol, it was reported that sites followed South African 
national guidelines for STI treatment, i.e., syndromic management (DoH, 2008). Syndromic 
management entails identifying symptoms and providing treatment for all infections that 
could cause those particular symptoms, for example:  
 “…if they have a symptomatic episode they’ll be examined and their history taken by 
one of the study clinicians and an assessment made.... A clinician will make an 
assessment by what kind of syndrome they have and apply the (unclear) syndromic 
management” (Z6, site staff, site 2).  
 
 “For each visit our participants require physical examination…it is a symptom-
directed physical exam... if a participant complains specifically of a discharge, warts 
or whatever it may be, even if they’re unsure, then I would do genital exam, a genital-
urinary exam to exclude an STI or if the participant complains of a discharge then I 
would examine the participant, confirm that they do have a discharge which requires 
STI treatment and then I would treat them for it” (Z7, site staff, site 1). 
 
At four sites participants received STI treatment on-site, for example “…the site provides STI 
treatment” (C9, site staff, site 4) and “we provide STI treatment on-site” (Z17, site staff, site 
5). At one site, participants were referred to public healthcare facilities: “STIs we don’t 
provide that on-site… We sending them to a local clinic to get that” (Z15, site staff, site 3).  
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If an STI remained unresolved post-treatment, participants were referred to the public 
healthcare sector for further care, for example:  
 “…if there’s a sort of treatment failure in that regard, then they would be referred to 
the local clinic” (Z10, site staff, site 5).  
  
 “...for those that we could not treat we were still referring it’s either to the/ depending 
on the severity, it was to the hospital or to the clinics where they would treat” (C8, 
site staff, site 4). 
 
Respondents described that donor restrictions prohibited the use of research funding for care 
services (detailed in the section on complexities below). Various strategies were therefore 
adopted at sites to enable on-site treatment, including procuring STI drugs from the DoH, and 
site-funded treatment. It was reported that where the site was unable to devise its own 
strategy, the network was able to support certain sites to provide on-site treatment:  
 “…but because of the cost of these being quite minimal we’re able to procure 
resources if the sites themselves are not able to do so. Usually the sites themselves are 
able to procure sufficient resources for something like that” (C14, network 
representative). 
 
For the phase I trial conducted at two sites, it was reported that STIs were addressed by on-
site treatment, with the drugs being funded by the affected sites, for example: “… we 
purchase it ourselves as an organisation” (Z17, site staff, site 5).  
 
1.3.1 Complexities with STI treatment 
 
1.3.1.1 Sponsor restrictions of funding 
A key reported challenge was that trial funds come with restrictions – certain sponsors do not 
permit the use of funds for non-research activities, including the procurement of drugs:  
 “But [sponsor] money is restricted in that it has to be used for research. It cannot be 
used for care and that is a very clear distinction. That’s a distinction that takes a 
[government] to change… So for example unless an STI test is mandated by the 
research we cannot cover the cost of that test” (C10, network representative).  
 
 “The research costs are of course all-encompassing within these protocol costs but 
other costs such as you know treatment of medical issues not directly related to the 
protocol defined objectives can be problematic and this includes treatment of STIs for 
example. Unless we’re doing a prevention study that’s focusing on comparing the 
treatment of certain STIs versus others so payment for drugs that is not study product 
is usually not allowed…” (C14, network representative).  
 
Concerns about funding restrictions were also raised by respondents at sites, for example:  
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 “…there is a clause from the [sponsor] that they cannot spend their money on 
drugs…at some level it feels a bit like a cop-out…it just seems to be one of those 
things that you just can’t raise and discuss, you know, so it gets stuck...” (C11, site 
staff, site 5).  
 
1.3.1.2 Using the syndromic management approach 
Interviewees at some sites reported complexities with syndromic management, for example: 
“STIs are really over and under treated in our population” (Z7, site staff, site 1) and if “they 
don’t report symptoms, we don’t know.” (Z6, site staff, site 2). It was argued that there is a 
need to develop better methods to diagnose STIs.  
 
Cultural barriers with discussing sexual activity and related issues, especially with someone 
of the opposite sex, may also impede self-reporting of STI symptoms, for example:  
 “…one of the participants, I mean he’s been coming here for three years and then he 
tells me the other day that you know he’s been having a urethral discharge. So I say 
you know when did it start? So he says no about four or five months ago. I’m like 
gosh and I saw you in between that time and you didn’t tell me about it. So he says no. 
I think he was just embarrassed because he’s male and maybe I’m female. I think it’s 
a barrier sometimes with [name of ethnic group] men” (C2, site staff, site 1).  
 
However, others contended that syndromic management is a better approach in trials:  
 “I think it’s working well because laboratory support is not always what it should be. 
It’s much better in research… It enables you to start treatment for a participant prior 
to getting a laboratory result” (C7, site staff, site 4).  
 
 “I mean for [the phase IIB] we did go back and forth quite a bit on to what extent do 
we screen and diagnose and treat STIs and prescribe that in the protocol... if going to 
really diagnose it then you need to collect sufficient samples and you need to culture 
it in a variety of ways, you need to have the diagnostic infrastructure sufficiently on 
the ground” (C14, network representative). 
 
1.3.2 Comparing STI treatment practices with recommendations in ethics guidelines  
All sites satisfied guideline requirements by counselling participants on how to prevent and 
treat STIs (UNAIDS/WHO, 2012) and ensuring access to STI treatment (MRC, 2003; 
UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012).  
 
STI treatment can be ensured in through syndromic management based on self-report of 
symptoms or by testing for all STIs (intensive diagnostics). MRC (2003) and UNAIDS/WHO 
(2012) do not prescribe whether diagnostic tests or the syndromic management approach 
should be adopted. While UNAIDS/AVAC (2011) specifies that STI testing should be 
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discussed, and its appropriateness for the trial design and population assessed, the provision 
of syndromic management is in line with WHO (2003) recommendations and South African 
STI treatment guidelines (DoH, 2008).  
 
The over-diagnosis and over-treatment of STIs as a result of syndromic management are 
acknowledged as a potential disadvantage in the literature (Altini & Coetzee, 2005) which 
has implications for increased drug costs and potential drug resistance, among others. 
Further, it has been argued that South African guidelines of syndromic management may be 
inadequate or not in participants’ best interests (cf. Essack, Koen & Slack, 2009). However, 
the syndromic approach permits healthcare providers to make a timeous diagnosis without 
specialised skills, and sophisticated and costly laboratory tests (Altini & Coetzee, 2005). In 
South Africa, syndromic management of STIs is free, integrated into primary health centres, 
and available in public health clinics (DoH, 2008; Heise et al., 2008).  
 
1.4 Ensuring access to VMMC 
Three RCTs of VMMC found that male risk of contracting HIV during heterosexual 
intercourse is halved when circumcised (Weiss et al., 2008). In 2007, WHO and UNAIDS 
issued recommendations on VMMC as an additional HIV prevention strategy based on strong 
and consistent scientific evidence. International ethics guidelines also require that access to 
VMMC be ensured for participants, where indicated (UNAIDS/AVAC, 2011; 
UNAIDS/WHO, 2012). 
 
At all affected sites, interviewees reported that participants in the phase IIB trial were 
informed of the benefits of VMMC and that it was provided to all male participants who 
requested it. At the time the trial was initiated, VMMC was not widely rolled-out in the 
public sector: 
 “You know it’s not regularly available. If you referred someone to [public hospital] 
they’re going to wait for over a year to have a circumcision done.” (Z7, site staff, site 
1).  
 
Given the poor availability of VMMC at the time (de Bruyn et al., 2007) and the prohibition 
on the use of donor funding for care services, circumcisions were paid for via funds sourced 
from the product developer for the phase IIB trial: 
 “We have a sponsor [the product developer] that’s paying for male circumcision…” 
(Z17, site staff, site 5) 
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 “…the largest trial that we conducted… [the product developer] actually provided 
the funding for the circumcision procedures” (Z9, network representative).  
 
For the phase I trial, VMMC was not paid for by the sponsor nor were alternative funds 
secured. However, it was reported in interviews at both sites conducting the phase I trial, that 
VMMC was made available if requested. 
 
At four of five sites, VMMC was ensured through referral to the private sector, for example:  
 “You know they [the network] provided the money so our participants could get 
circumcision in private but because it was (not) being rolled out uh (R: nationally) in 
the public sector, ja, at that time.” (Z7, site staff, site 1) 
  
 “…the circumcision we made an arrangement with a local GP, we were not sending 
them to the public sector, we were having that special arrangement with the GP who 
has to do that for our participants.” (Z15, site staff, site 3) 
 
 “Well the one classic one that we do quite a bit of is our circumcision. So our 
circumcisions are done by a private practitioner, a private surgeon, and that’s just 
because then it’s just easy. It’s just been easier and cleaner.” (C11, site staff, site 5). 
 
At one site, VMMC was provided on-site by a trained individual:  
 “…for our site you know it’s easiest to implement in a situation where uhm you know 
a trained individual uhm came and performed the procedures for trial participants 
who wanted to be circumcised” (Z6, site staff, site 2).  
 
It was argued that referral to the private sector was a strategic decision in order to avoid the 
challenges of the public healthcare system:  
 “...we initially thought of going through the public system…but it’s a mission…people 
are put on theatre lists and you know how it gets when somebody doesn’t pitch and 
they don’t get operated that day it’s a mission. So we went the private route which is 
much easier” (Z17, site staff, site 5). 
 
 “…we were aware of what the limitations were of the local health services and uh 
that just telling people about it wouldn’t/ might mean that they’d have to wait years, if 
ever, to get a procedure” (Z6, site staff, site 2).  
 
1.4.1 Complexities with VMMC  
 
1.4.1.1 Ensuring access to VMMC across trials (funding for VMMC)  
Interviewees at one site asserted that paying for VMMC in one trial, and not in others, created 
differences between participants at different sites or in different protocols, for example:  
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 “[The phase IIB trial] also funded circumcision for males and none of our other 
planned or current vaccine trials actually support that. So we do refer people to the 
public sector with counselling but we don’t have any influence over how soon that 
care is accessed…” (C7, site staff, site 4). 
 
However, such concerns may decrease over time as referral for VMMC becomes increasingly 
acceptable, given scale-up in the public healthcare system – from one VMMC site in 2010 to 
over 80 sites by 2012 (Rech et al., 2014) – so sites “…would probably in the future deal with 
participants wanting circumcision by referring them” (Z6, site staff, site 2).  
 
1.4.1.2 Provider-promotion of VMMC 
Respondents at some sites expressed concern that low uptake may reflect poor provider-
promotion of circumcision, for example: “…there was even a joke of saying that maybe it’s 
because the investigator sometimes may not really be for circumcision…” (Z15, site staff, 
site 3). It was asserted that sound counselling was key to improving uptake of prevention 
interventions: “…if the participants are counselled adequately then the uptake will be good” 
(Z7, site staff, site 1) and “If they’re just given everything, and they’re not counselled about 
what the implications are of taking it or not taking it, then you’ve got a problem” (Z12, REC 
member).  
 
1.4.1.3 Participant acceptability and uptake of VMMC 
At certain sites, the uptake of VMMC was reportedly good. Some even reported the provision 
of circumcision as a success: “I think it’s the one thing I can say it’s a highlight” (Z2, site 
staff, site 1) and “in terms of things that have worked well, I mean I think definitely in our 
hands offering male circumcision has been taken up quite widely” (Z6, site staff, site 2).  
 
However, at two sites, interviewees reported lower uptake, attributed to preferences for 
traditional circumcisions in the wider community: “...you have to realise that we live in a 
community where male circumcision is part of a custom” (Z10, site staff, site 5). Therefore, 
many participants may already be circumcised or may prefer traditional circumcision: “many 
people feel they don’t want to come do it on-site, so they will wait for the right opportunity 




Despite initial concerns about low acceptability and stigma due to cultural taboos around 
circumcision, interviewees reported a high uptake of VMMC in those areas with the lowest 
baseline circumcision prevalence:  
 “…when we told [the investigator]…that we were doing circumcision, I remember 
her eyebrows shot up, um, and she was sort of surprised, and thinking, ‘Oh. Well 
that’s never, you know, that’s never/ we’re never going to be able to get much uptake 
of that…ironically, and I think happily for her, she was wrong, there was a good 
uptake” (Z13, network representative).  
 
 “…we were actually very surprised [by the high uptake of VMMC] because you know, 
all the stigma that’s attached to being circumcised here” (Z7, site staff, site 1). 
 
While concerns about the cultural acceptability of circumcision are widely published (Eaton 
& Kalichman, 2009; Khumalo-Sakutukwa et al., 2013; Mark et al., 2012), a few respondents 
in this study expressed some concern that circumcision served as an inducement to 
participate, even in contexts where circumcisions are not traditionally practiced.  
 
1.4.2 Comparing VMMC practices with recommendations in ethics guidelines  
In concordance with international guidelines (UNAIDS/AVAC, 2011; UNAIDS/WHO, 
2012), VMMC was provided to all willing participants, where indicated. South African 
guidance (MRC, 2003) was drafted before the VMMC results became available. Therefore, 
they do not specify that VMMC be provided but they do require that new tools should be 
added to the prevention package as they are discovered and validated.  
 
Low uptake reported at some sites (attributed to cultural objections) resonates with 
complexities theorised to be of some importance by ethics commentators (cf. Lie et al., 2006; 
HPTN, 2009) including that VMMC presents “fundamental cultural issues for 
implementation” (Haire et al., 2012, p. 23). Low uptake at sites located in traditionally 
circumcising communities was also consistent with research findings (Mark et al., 2012) and 
acceptability is likely to be context-specific and influenced by local cultural norms and 
practices (Eaton & Kalichman, 2009). Mark et al. (2012, p. 571) found that while the 
majority of men in the sample were aware of the preventive benefit of VMMC, most were 
“unwilling to undergo a medical circumcision or allow their sons to do so, because of 
religion/culture, notions of manhood, and social disapproval.” Other research in traditionally 
circumcising communities in Tanzania found that despite a preference for VMMC, traditional 
circumcisions are still practiced due to social pressures in the community (Wambura et al., 
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2011). However, the uptake of VMMC reported by interviewees in this study, albeit low in 
traditionally circumcising communities, suggests that for some individuals offers of VMMC 
may still be accepted. Therefore, access systems for such services should be considered 
regardless of the cultural context. Offers of VMMC should not be censored based on 
predominant social, cultural or religious values in a community (Haire, 2013).  
 
1.5 Access to PEP 
Emergency PEP with antiretroviral drugs is the standard of care for occupational exposures to 
HIV through infected tissues or fluids, and is increasingly used for nonoccupational 
exposures (Tolle & Schwarzwald, 2010). Across all trial sites, and for both trials, 
interviewees reported that PEP was provided to participants on-site for all risky sexual 
exposures. During counselling sessions, participants were reportedly informed that they need 
to report to the site “within 72 hours” (Z7, site staff, site 1). Some sites reported 
implementing strategies to facilitate prompt reporting.  
 
For the phase IIB trial, it was reported that at most sites PEP packs were available on-site 
(procured from the DoH or other sources like PEPFAR), for example:  
 “…I was privileged that within [name of trial site] we also had a treatment/ an HIV 
treatment programme which then made ehm provision of eh post-exposure 
prophylaxis easy because we had antiretroviral drugs on-site” (Z22, site staff, site 1).  
 
In some instances, arrangements were brokered with other sites to facilitate access to PEP. 
For the phase I trial, interviewees at both sites reported that the site covered the cost of PEP 
provision.  
 
One respondent noted the potential for participants to misuse PEP: “it’s like uh TOP 
[termination of pregnancy], you know, some people don’t use contraception, they just go 
have TOPs all the time, it’s the same thing, you know” (Z7, site staff, site 2). However, 
another respondent noted that PEP is unlikely to be abused due to severe side effects:  
 “…even within our SOP, we would not hand out post-exposure prophylaxis 
repeatedly… and then you know, they could do this again, and possibly even again 
(laughs) but there’s a point at which the staff would really step up with their risk-
reduction counselling, and to be honest…it’s not my experience that people abused 
this service, or kept using this service…” (Z18, site staff, site 5).  
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In line with the latter view it was reported that the uptake of PEP was low: “it’s not the most 
popular thing” (Z18, site staff, site 5) and “I can’t remember the numbers exactly, but I think 
it was pretty small” (Z9, network representative).  
 
1.5.1 Complexities with PEP  
 
1.5.1.1 Initiating PEP using non-government guidelines 
The national protocol for the provision of PEP in the public sector is limited to sexual 
assaults and not for other risky sexual exposures, like condom failures. However, for the two 
trials sampled in this study, PEP was provided on-site for all sexual exposures:  
 “...in South Africa it’s usually given in the public sector for post-rape, post-needle 
stick injuries, or whatever, but because we’re funded by [the network]and…they 
follow the US sort of guidelines with regard to HIV prevention” (Z7, site staff, site 1).  
 
 “…in fact offering PEP is over and above what somebody would get in the public 
sector at the moment” (Z18, site staff, site 5). 
 
Given the South African PEP protocol (DoH, 2008), some interviewees questioned the 
provision of PEP for all sexual exposures:  
 “…things like post-exposure prophylaxis, we don’t in fact provide to everyone who’s 
having unprotected sexual intercourse, and we provide it in very limited situations, 
mainly the context of sexual assault. So it’s not clear to me in South Africa whether or 
not post-exposure prophylaxis is in fact an appropriate thing to provide in a vaccine 
trial” (Z16, REC member).  
 
An interviewee at one site stated that offering PEP in the phase IIB trial created an 
incongruity amongst participants enrolled in different protocols:  
 “I think the one challenge I’ve experienced and this had been a difference between 
[the phase IIB] trial and our other vaccine trials is that in [the phase IIB trial] we 
provided post-exposure prophylaxis for risky sexual contact, it didn’t have to be a 
sexual assault. But for all our other protocols we follow the national department of 
health guidelines because PEP is not provided by the protocol budget…as a 
consequence we can only refer people for post-exposure prophylaxis if there’s been 
an actual sexual assault…” (C7, site staff, site 4).  
 
1.5.1.2 Provider-promotion of PEP 
Some interviewees expressed concern about the lack of evidence from RCTs to support the 
efficacy of PEP as well as safety concerns. One interviewee stated: “…we don’t have direct 
evidence that it works” (Z6, site staff, site 2). Another remarked that PEP provision is “not 
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necessarily in the patient’s greatest safety interests” (Z16, REC member). However, others 
suggested there was sufficient evidence to support the use of PEP, for example:  
 “…my own belief around this is that there is sufficient evidence to believe that it is 
effective” (Z18, site staff, site 5).  
  
 “… we are living in such a high prevalence you know eh environment of HIV and so 
really I would still encourage to an extent post-exposure prophylaxis.” (Z22, site 
staff, site 1).  
 
An interviewee at one site reported that PEP was provided inconsistently because of 
provider-beliefs about efficacy: “some people provide it, some people don’t” (Z6, site staff, 
site 2) and described PEP as “a very un-standard part of the study” (Z6, site staff, site 2). At 
two sites, it was reported that the use of SOPs may help improve standardisation.  
 
Even the level of counselling on PEP at two sites was reportedly not as intensive as for other 
preventive interventions, for example:  
 “So participants were counselled on the availability of PEP and then when we saw 
that… we were getting more and more seroconversions, then we counselled them for a 
second time to let them know that PEP is available here” (Z7, site staff, site 1). 
 
 R: And do you discuss uhm post exposure prophylaxis in your risk-reduction 
counselling? 
 Z4: No::t that much. Not that much. (Z4, site staff, site 2).  
 
1.5.1.3 Facilitating timely access to PEP 
The requirement that PEP be provided within 72 hours of exposure was reported as 
challenging:  
 “…after 72 hours, we feel that the benefit, is not, um, sufficient for the side-effects 
and the risks, so we don’t offer it after 72 hours. So it does mean the individual has to 
recognise their risk, and get into the clinic within 72 hours, and that is, tricky for a lot 
of people” (Z18, site staff, site 5).  
 
A few respondents noted that some participants reported sexual exposure when it was too late 
to intervene, some only at seroconversion. In anticipation of problems with late reporting, 
some sites employed strategies to facilitate prompt reporting, for example:  
 “...sometimes we’d have participants who during holidays and over the weekend have 
contacted our site, uh but we did make the provision that we have a 24 hour cell 
phone available, so if a participant wants to contact us over the weekend and then we 




 “Yes because they even call if maybe the condom was break. They even call over the 
phone then we’ll tell them come to the clinic” (Z4, site staff, site 2). 
  
1.5.2 Comparing PEP practices with recommendations in ethics guidelines  
South African guidelines (MRC, 2003) require that participants be informed about the 
benefits of PEP and where it can be accessed, while international guidance requires that 
participants are actually ensured access to PEP, where indicated (UNAIDS/AVAC, 2011; 
UNAIDS/WHO, 2012). All sites satisfied international ethics guideline requirements by 
providing on-site access to PEP in the event of a known likely sexual exposure, and not only 
for sexual assault. This exceeded South African guideline recommendations (MRC, 2003) 
and the national protocol for PEP access in the public sector (DoH, 2008).  
 
The provision of PEP at sites appears to be in line with the ethical vision of UNAIDS/WHO 
(2012) guidelines to prevent double standards between well-resourced and resource-
constrained contexts (Haire et al., 2013). However, at an earlier regional consultation on 
ethical issues in preventive HVTs (UNAIDS, 2000, p. 20) it was argued that PEP “should be 
offered to trial participants to the degree that it has become the standard practice in the host 
country.”  
 
There are some concerns with providing participants with access to PEP for all sexual 
exposures when this is not routinely available in the public healthcare sector. Firstly, some 
contend that providing PEP to participants when it is unavailable to the general population 
may be an inappropriate inducement to participate in the trial (UNAIDS, 2000). Secondly, it 
may increase disparities between trial participants and the local community (HPTN, 2009). 
However, UNAIDS/WHO (2012) justifies access to prevention services not locally available 
on the basis that participants bear greater risk than other community members by exposure to 
an experimental intervention (Haire et al., 2013). Still, as indicated by the data in this study, 
efforts to reduce disparities in the standard of prevention between well-resourced and 
resource-constrained contexts, may inevitably create differences between trial participants 
(see Chapter 11), both within and across sites. Thirdly, it is not sustainable post-trial. 
However, the immediate potential benefit of reduced HIV infection risk for trial participants 
is a legitimate benefit for the community, even when such services are not sustainable post-
trial (cf. Haire et al., 2013). This perspective is espoused given that researchers should 
endeavour to ‘ratchet up’ care in the local community (Shapiro & Benatar, 2005), where 
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feasible, and where the provision of such prevention services does not negatively affect the 
scientific validity of the trial.  
 
1.6 Ensuring access to HIV prevention interventions for non-enrolled persons 
Ethics guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) are generally 
silent on the specific prevention services owed to persons not enrolled in trials, except for the 
provision of couples counselling (UNAIDS/AVAC, 2011) and informing participants about 
how to obtain STI treatment for their partners (MRC, 2003). In addition, UNAIDS/AVAC 
(2011) recommends consultation on the specific HIV prevention interventions that will be 
available to participants’ partners. There are also general statements that those volunteers 
who screen out of the trial should be referred, where relevant (MRC, 2003) and provided with 
information about HIV prevention interventions available in the community 
(UNAIDS/WHO, 2012). 
 
All sites reported providing some prevention services to persons not enrolled in trials, 
namely, volunteers at screening, participants’ partners and the wider community. HIV 
prevention education was a commonly reported practice across all trial sites, for example:  
 “… we’ve got an obligation, of making sure that when we leave the community…they 
are better off…and one of the resources that we have, it’s knowledge. So we share 
information with the communities and the participants…” (Z11, site staff, site 2).  
 
CAB interviewees also described their various HIV prevention education activities in the 
broader community, for example:  
 “With HIV prevention, I'm talking to people. As a teacher, I'm talking to the parents 
when we have parents meeting, talking to the children about HIV, how people can 
prevent HIV” (Z1, CAB, site 1).  
  
 “… there was intensive education given to people … And when we say ongoing 
counselling on risk-reduction…it’s extensive shall I say education or enlightenment. 
Because now education would sound like one stream but we do dialogue with the 
communities and also guiding them to you know, the best practice that they could do, 
to prevent HIV and AIDS.” (Z3, CAB, site 2). 
 
Both study protocols stated that risk-reduction counselling was to be provided to all 
volunteers at screening. In addition, some sites reported providing counselling to participants’ 
partners via couples counselling, and to community members at the level of VCT as part of 




Condoms were reportedly made available to partners in that participants were free to access 
male and female condoms. Condoms were also dispensed at community events and 
community members could access condoms at sites, for example:  
 “…on a monthly basis we have an activity that involves the community advisory 
group… where we do condom distributions.” (Z8, site staff, site 4).  
 
According to both study protocols, volunteers underwent a physical exam at screening. 
Volunteers presenting for the phase I trial were screened for syphilis and if infected, were not 
enrolled. For the phase IIB trial, some sites reported that volunteers with STIs at screening 
were enrolled after successful treatment. Various mechanisms for ensuring access to STI 
treatment for volunteers were adopted across sites and for both trials, including, on-site 
provision (where funds permitted), or referral to a co-located or public healthcare facility, for 
example:  
 “Well we do offer STI and contraception services to anybody who accesses screening 
so it’s not quite the broader community but it’s broader than just the study sample 
that we’re looking at…” (C7, site staff, site 4).  
 
 “If they have an STI we would treat, because we have very much a policy of you, you 
know, don’t squander your opportunity” (C11, site staff, site 5). 
 
 “So what we would either do is, if the participant is comfortable buying the 
medication themselves, we would do the prescription here, but if, they cannot afford 
that, we would refer to the clinic, for STIs, it would be the clinic (C3, site staff, site 2).  
 
Some interviewees reported that participants were informed about where their partners could 
access STI treatment. However, most respondents across all sites reported that partners were 
referred to the public sector, with a ‘yellow card’ or referral letter/slip, for example: “…we 
give an STI referral slip for partners…” (C7, site staff, site 4). A few interviewees at some 
sites reported that, where possible, partners were provided with STI treatment on-site while 
others described lack of resources as an obstacle to on-site provision: 
 “We, unfortunately, do not have in place yet the STI treatment for partners which is, 
we’re planning to do that next year it’s just a bit of a resource issue because none of 
the sponsors will that pay that extra for partners because you know some people 
might five or six partners” (Z17, site staff, site 5).  
 
For the phase IIB study, a circumcision assessment was conducted at screening and it was 




 “…we informed everybody about the benefits of circumcision, we did do that. So even 
if they screened out and/ they were informed about circumcision so they could have 
gone to their local hospital but we didn’t actively refer them if they were screened 
out” (Z7, site staff, site 2).  
  
 “Ja as soon as they enter the pre-screen protocol. That includes information about 
circumcision, how to prevent HIV in general, you know condoms and teach for 
behaviour, they get pre- and post-HIV test counselling, they get risk-reduction 
counselling” (Z17, site staff, site 5).  
 
At one site, it was reported that where female participants requested circumcision for their 
partners, they were referred to a local clinic. Access to PEP was ensured for enrolled 
participants only, at all sites.   
 
Some REC respondents commented on researchers’ obligations to non-enrolled persons. The 
general sense was that there were limited obligations to these moral groups, including 
education on HIV prevention and referral to appropriate services:  
 “…for me there’s not ancillary care obligations to the wider community, except to 
maybe do engagement sessions and invite anybody who wants to come to them. And in 
those engagement sessions, speak about risk-reduction etcetera.” (Z12, REC).  
 
 “I think there is a moral hazard here that one will attract people…once you know a 
site is offering a very good screening service, you know, you may well be/ you could 
have a condition and go there purely to get screened…So, here you’ve got a kind of, 
an on-site service (.) so I think there’s that danger…obviously if it’s a heart 
transplant, you know, you would refer (laughs). If it’s a simple, you know, treating an 
STI, again I think we’re into/ I think, your obligations are less at this stage, but there 
are obligations to refer, to either your own ST/ and if you are already running your 
own onsite service to treat the common primary healthcare things and maybe (.) 
again have a strict referral thing.” (C6, REC).  
  
 “… there are things which are maybe perhaps should be obligatory and there are 
things which would be nice but not mandatory. And I think the principal obligation is 
in fact to the participant. I don’t know that it’s appropriate to make a broader 
community based contribution required of any trial but I do/ it would be nice and it 
would be part of the indirect benefit of the study’s existence…” (Z16, REC). 
 
1.6.1 Complexities with ensuring prevention interventions for non-enrolled persons 
 
1.6.1.1 Limited funding and resource allocations 
As previously described, there were restrictions on the use of donor funding for non-research 
activities or care elements, including the provision of certain prevention services not 
considered necessary for the conduct of research. Further, some interviewees stated that the 
201 
 
provision of prevention services to non-enrolled persons was dependent on the trial budget, 
and that in a context of constrained budgets, it was difficult to ensure access to such services, 
for example:  
 “…you can have theoretically, you’re saying that standard of care must be provided 
to the whole study community… in real life it doesn’t actually doesn’t work like that. 
You know, you, you go and tell PEPFAR that, they’ll laugh in your face, they’ll say 
‘Sorry, we’re not going to fund it.’ Or NIH is going to say, ‘We definitely don’t fund 
this.’” (Z12, REC). 
 
 “…I think it depends on the funding. You know, if the funding they would say, “Just 
service everybody”, then it would be nice. So, now we just have to depend on the 
other services, especially the government services, to refer them [non-trial 
participants] to.” (J1, site staff, site 2).  
 
 “We would like to add the STI treatment and you know just in general so anybody can 
come and get treated because then you know at least they do get treated but ja it’s a 
resource issue. It’s also very labour intensive.” (Z17, site staff, site 5).  
 
1.6.1.2 Difficult to define partners 
The presence of multiple partners was noted by some respondents as a key risk factor among 
the trial population. Some interviewees said that it was difficult to define obligations to 
partners because conceptions of partners may differ practically and culturally from theoretical 
definitions, and may infringe on participants’ rights or the rights of their partners:  
 “And in partners in particular I think there're concerns because how participants 
define and choose to identify their partners to study staff is up to them, and in fact 
there’s the potential…for a study that wishes to engage with partners to be intrusive 
and to violate the rights of an individual participant.” (Z16, REC) 
 
 “…what if they have five sexual partners? What do you do if they have five sexual 
partners and a wife, or, you know a statutory wife, a common law wife, a customary 
wife, and a girlfriend? Where do you draw the line?” (Z12, REC) 
  
 “…. we try to offer services to partners. People have got multiple partners…not 
everybody has got a stable relationship…And, the communication that happens within 
those relationships, it can never be the same, and can never be standardised…as 
much as we are open to offering to partners, how we define partners as researchers 
or academics is completely different from what is happening on the practical basis.” 
(Z11, site staff, site 2).  
 
1.6.2 Comparing HIV prevention practices for non-enrolled persons with 
recommendations in ethics guidelines  
Site practices for non-enrolled persons generally exceeded requirements in ethics guidelines 
by providing access to selected HIV prevention interventions.  
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Consistent with GPP guidelines (UNAIDS/AVAC, 2011), some sites reported providing 
couples counselling. Sites exceeded guideline recommendations that participants should be 
informed how to obtain STI treatment for their partners (MRC, 2003) by actually referring 
partners and volunteers at screening with referral letters to the local clinic, and where 
possible, providing on-site STI treatment.  
 
Although the ethical principles of justice as equality, reciprocity and beneficence may be 
used to justify access to HIV prevention interventions for trial participants, guidance remains 
unclear on the standards of care/prevention for individuals who are not enrolled in the trial 
(cf. Tarantola et al., 2007). REC interviewees in this study were of the view that there were 
limited obligations to persons not enrolled in trials and that the provision of such services was 
morally praiseworthy rather than obligatory.  
 
Previous empirical research has found that in practice trial sites endeavour to provide a 
variety of services to non-enrolled persons including partners and screen-outs (Ngongo, 
Priddy, et al., 2012). However, there was some concern that offering services to non-trial 
participants might constitute an undue inducement and/or make conducting research 
prohibitively expensive (Ngongo, Priddy, et al., 2012). Similarly, in this study, resource and 
budget constraints were reported as impeding the provision of HIV prevention interventions 
to non-trial participants. It has been recommended that researchers and sponsors, in 
consultation with relevant stakeholders (Tarantola et al., 2007), should determine which 
services would be provided in trials, the expected beneficiaries of each service, and which 
services will be made available via referrals (Ngongo, Priddy, et al., 2012). 
 
1.7 Access strategies for ensuring HIV prevention interventions  
In practice, access to HIV prevention methods was ensured either via direct on-site provision 
of services or by referral to private or public healthcare services.  
 
1.7.1 On-site provision of HIV prevention interventions 
At all five sites, risk-reduction counselling, male and female condoms and PEP were 
provided to participants on-site. Four of five sites also provided STI treatment on-site. It was 




 “...a lot of it’s required and the site needs to be doing it themselves. So counselling we 
require that the sites are doing it themselves and we do know that that’s happening. 
When they refer for something like circumcision there are people here at [the 
network] who are aware of how the sites are handling different issues like that... we 
require that sites provide condoms and STD treatments” (Z13, network 
representative).  
 
Another interviewee concurred that certain services should be provided on-site but that others 
are more appropriately provided via referral:  
 “I think there's some things that are just logistically so simple that they should be 
required of research staff so condoms, you know and the counselling and basic 
counselling certainly. But things which are more complicated like male circumcision 
it might be hard to justify making a vaccine trial provide male circumcision services 
when at the most it might only be used by roughly half your participants, at the 
absolute most, and there’s a/ it's a surgical intervention there's safety issues and other 
things, and it may in fact be in the participants best interests to be referred” (Z16, 
REC).  
 
The general position favouring on-site provision of HIV prevention interventions may stem 
from the benefits of direct provision identified during interviews. Firstly, given the potential 
for risk-reduction interventions to reduce HIV incidence in the trial and impact on the study 
design and outcomes, providing prevention interventions on-site was reported to permit better 
monitoring and control:  
 “…obviously if the services are provided by the research centres then there’s 
better/there would be better processes to monitor” (Z22, site staff, site 1).  
 
 “I think it’s also wise to treat on-site, because the lifestyle and the wellbeing of a 
participant, you’ll have a track record. You know, of what has been happening in this 
particular patient. …most of them who are coming, they come in for STI treatment. It 
helps us, for us to know that they’ve been at risk…” (J1, site staff, site 2).  
 
 “I think it’s just better to monitor uhm ja it has been given and it has been taken if 
they do get it on-site” (C9, site staff, site 4).  
 
It was argued that direct provision of prevention interventions facilitates better record-
keeping and tracking of participants as opposed to referrals, where follow-up of participants 
is sometimes difficult, for example:  
 “…that’s why it’s important for us to actually provide those services on-site because 
if they’re in a study and you refer them you actually don’t know whether they’re going 
to go you know until their next visit that they tell you.” (Z17, site staff, site 5).  
 
On-site provision was also reported to facilitate participant retention and permit the efficient 
delivery of services. Interviewees across most sites referred to the benefit of a “one-stop 
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shop” where participants could access a multitude of HIV prevention interventions. On-site 
provision was even argued to result in better data as it allows the development of rapport with 
participants who in turn are more disclosing of their risky behaviour. Further, having an on-
site pharmacy offering a variety of treatments was argued by some to be a basic requirement 
for a trial site and convenient for participants:  
 “…this to my mind is a basic prerequisite for prevention studies, that you do provide 
a one-stop shop… it just makes perfect sense, in terms of a good trial, because 
obviously it helps for retention, for monitoring participants…” (C11, site staff, site 5)  
 
 “...we wanted to have it on-site so that it can really be one-stop for the patients” 
(Z15, site staff, site 3).  
 
1.7.1.1 Complexities with on-site provision 
 
1.7.1.1.1 Participant dependence on the site 
At most sites it was reported that participant dependence on the site was a challenging 
consequence of direct provision of services, for example:  
 “So they tend to sort of want [to] depend on the trial site you know. Not really 
wanting to go to a normal primary healthcare system that is available.” (C3, site 
staff, site 2). 
  
 “I think there’s still a perception on behalf of participants, that they can access total 
care at a research site…” (C7, site staff, site 4). 
 
 “…at times you’ll find out that the participant has STI but it’s difficult for him to go 
to the local clinic. He will tell you he is not going to get the service, the one expected 
in the local clinic. It’s better to come here…even if maybe the participant got 
headache, he will run quickly here.” (Z4, site staff, site 2). 
 
There was some concern expressed that participants may perceive the site as a “service 
provider” rather than as a research centre, which may create challenges because participants 
are expected to utilise public or private healthcare facilities at the trial’s conclusion.  
 
1.7.1.1.2 Concerns regarding the researchers’ dilemma 
Despite several identified benefits of on-site treatment, one argument for ensuring access to 
prevention services via referral relates to concerns about the researcher’s dilemma or 
conflicts of interest. However, most interviewees argued that concerns that researchers will 
dilute prevention efforts in order to increase HIV incidence in trials, by nature of the design 
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of clinical trials, is a theoretical concern rather than a concern that plays out in actual 
practice, for example:   
 “It is a theoretical concern because it goes back to the question of do people 
understand how we then assess efficacy. …whatever risk-reduction methods of 
counselling that we are doing, we do it across the board and we’re all double-
blinded…” (Z15, Site staff, site 3).  
 
 “I mean I understand the principle. Um, and it’s hard for me to imagine that someone 
would provide weak counselling and other prevention because they hope the person’s 
going to get infected, you know, and then we can test the vaccine…I can see it as a 
hypothetical risk, but it’s hard for me to imagine concretely, how that would actually 
play out” (C5, REC member).  
 
 “…in my experience that dilemma is less problematic at the level of uhm staff working 
at sites who are/ Because those staff working at sites are obviously blinded and 
everyone should be blinded to intervention versus control. In fact in my experience in 
practice staff working at sites want the best for the patients enrolled in their care” 
(Z16, REC). 
 
1.7.2 Referral for HIV prevention interventions 
While direct provision was the preferred option for the provision of most prevention 
interventions across sites, in select circumstances participants were referred to other 
healthcare facilities. For the two trials studied here, STI treatment at one site was provided 
through referral to public healthcare services and VMMC at four sites was provided through 
referral to private healthcare facilities. Trial sites also used referral as a strategy for ensuring 
access to STI treatment for participants if an STI remained unresolved after on-site treatment 
and for ensuring access to prevention interventions for non-trial participants.  
 
In the few circumstances where referrals were utilised, sites made significant efforts to 
establish relationships with referral centres. In selecting centres for VMMC referrals, 
interviewees noted that private facilities were more suitable because they were not 
characterised by long queues and poor provider attitudes described as typical of public sector 
services (described under complexities below). In addition, private sector providers were 
reportedly more likely to provide feedback to sites on uptake of services: 
 “That’s a private facility ja which we’ve arranged. It’s part of his normal activity, 
daily activities are circumcision work so he’s quite experienced and obviously a 
specialist and we have an agreement with him that for/ you know if we do have any 
study participants that require male circumcision that we would arrange that with 
him. And he has a process of going through it, he has set up tours to explain to them 
the procedure, and then he makes the appointment for the circumcision, and then he 
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writes us a feedback letter to say that the circumcision was done on this date and 
there was no complications, the person’s coming back for a follow-up on this date. So 
it’s actually something that makes it easier for us because we know we refer our 
participants to somebody that understands the requirements for research as well, so 
we get that bit of paperwork back.” (Z17, site staff, site 5).  
 
REC members described certain requirements that need to be satisfied in cases of referral, 
namely, “…the referral points must be accessible” (Z12, REC); “…where people are going 
to be referred uh we expect the researchers to pay the transport” (C17, REC); and there 
should be an established relationship with the referral centre:  
 “…when a research group or a researcher says…in an information sheet ‘you will be 
referred for treatment’ we want to know where it is and we want a letter from the 
clinic uh involved to say that they’re prepared to accept the patients because the 
Americans in particular will um say in studies you will be referred to an appropriate 
centre, they have no idea where it is, they have no idea whether it’s got the facilities 
and so on. So we’re quite strict about that.” (C17, REC).  
 
 “You know, not just saying, ‘we’re going to refer’, but who are we referring to, and, 
ja, has this already been negotiated” (C6, REC). 
 
Similarly, interviewees across sites commented on the critical factors to consider in the 
referral relationship, namely, accessibility of the referral site; monitoring of referral services 
to ensure quality; and the intricacies of establishing relationships with service providers so as 
to ensure feedback to sites:  
 “So we look at whether the participant can access that clinic we are referring to and 
we write them a letter, send it with the participant to the clinic…” (C8, site staff, site 
3). 
 
 “But you know for situations where you’ve got to outsource that we then would need 
to actually come up with ehm you know proposals as to how we can build in 
monitoring and evaluations of those services so that we ensure that when we‘re 
referring our participants they are going to get good quality you know eh good health 
quality…as a researcher the issue becomes my responsibility to an extent to check 
what kind of services are provided you know and whether those are in line with the 
national department of health eh policies” (Z22, site staff, site 1).  
 
 “… I think there’s an understanding, that it’s a joint health service, in many ways… 
we’ve been very careful not to cultivate the ‘us-and-them’, but really more of, how 
can we do this together… we need info from them, if our participants go to them 
because of an adverse event, we need info back, but then it works in the other 
direction, they need good information from us. …like any relationship, at the 
foundation is communication, and also, mutual respect, you know, so we’ve really 




Where possible, rather than refer, sites have established partnerships with government to 
ensure access to prevention interventions on-site, e.g., condom provision and STI treatment. 
Interviewees across three sites described that in future, they will ensure on-site STI treatment 
by procuring drugs from the DoH, “on the proviso that we supply the stats to them” (C11, site 
staff, site 5) for example:  
 “No we don’t get any STI treatment through Department of Health. We’re busy 
negotiating with them at the moment” (Z17, site staff, site 5). 
 
 “We have now signed the Memorandum of Understanding with the Department of 
Health, and we are going to get supplies as a site so that we can be able to provide 
that...” (Z15, site staff, site 3).  
  
 “…our primary healthcare nurse has managed to work with the government to get the 
treatment, so instead of us referring people to site where, half the time they don’t get 
there, and when they get there, you can never guarantee that the counselling that you 
offer is the same counselling that they offer… we’ve got our interests in these 
participants and these communities, so the way we treat them will totally be different 
from a person that’s just offering the service. So what we do in the trials that I work 
in, is that we offer/ and it has changed like over that/ I think it’s in the past two years 
that we have started to offer it on-site, rather than to refer.” (Z11, site staff, site 2). 
 
However, it was reported that establishing this relationship was not always easy, for example:  
 “…And it took us, how many years? I mean [phase IIB trial] was 2006, to 2008, and 
only now, only last year [2010], we were able to get the drugs from the government to 
give to STI” (Z11, site staff, site 2). 
 
1.7.2.1 Complexities with referral  
 
1.7.2.1.1 Maintaining confidentiality 
Interviewees at some sites expressed concern that maintaining confidentiality of a 
participant’s health status and trial participation was complicated when participants were 
referred. Referral to ‘accessible’ centres also increased the likelihood that the participant 
would be recognisable to staff at the referral centre:  
 “Because most of the participants still don’t to go to the local clinic just because of 
the way it’s seen. It’s either a family member working there and you know they don’t 
want to go there for treatment because then everybody would know.” (Z17, site staff, 
site 5). 
 
Confidentiality concerns decreased the likelihood that participants would fulfil the referral, 
for example:  
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 “Maybe you have diagnosed the HIV status or maybe you’re helping them to follow 
up or for management of some other ailment then it’s important for you to make sure 
that the confidentiality issue remains or they understand that there’s other people who 
are going to help them then they need to know more about their health status or their 
HIV status in that case. So I think confidentiality’s number one issue or problem.” 
(C3, site staff, site 2).  
    
 “…it’s difficult to control or to manage the confidentiality after it leaves you know the 
trial site. I think that one it creates a bit of a/ I think that’s why participants they feel 
sort of reluctant to even be referred.” (C8, site staff, site 3).  
 
An interviewee at one site reported that when participants were reluctant to be referred due to 
confidentiality concerns, they were counselled on the risks and benefits of referral and 
assured that confidentiality would be maintained at referral sites.  
 
1.7.2.1.2 Long waiting queues 
Respondents at all sites reported that a lack of financial and human resources at public 
healthcare facilities created long queues which deterred participants from accessing services 
at these facilities. For example: 
 “…they are a bit reluctant to go or they will tell you about the long list that they are 
going to have…the long queue that they are going to have to wait for and then as a 
result they don’t even [go]…” (Z15, site staff, site 3). 
 
 “And then now they’ve got to go to the local clinic and they queue, and the risk was 
that they end up not going there” (Z11, site staff, site 2).  
 
1.7.2.1.3 Poor provider attitudes 
Interviewees at some sites said that the value-laden and judgmental attitudes of healthcare 
providers in the public healthcare sector was a barrier to participant uptake of referrals:  
 “But normally when they go to local clinic they treat the STI, they are scared to go 
there because they said they found out the nurses they are too cheeky for them. They 
ask them ‘last month you were here with an STI, you came back again so we are not 
going to tolerate this thing.’ So they scared to go there.” (Z4, site staff, site 2). 
 
 “But they tell you that at the clinic they are going to be scolded for that… to go to our 
healthcare facilities…I mean the facilities are there but it’s usually the attitude that 
everybody/ I think healthcare workers they still have a long way to educate each other 
regarding their approach, but you always hear everybody say it’s also because they 
are overworked, they become, they become irritable…” (Z15, site staff, site 3).  
 
 “I think when you go to clinics, mostly here, you find that the people, the staff who is 
working in the clinic is more like older ladies, older guys, so when the participant 
comes or when the patient or the community member comes and picks up a box of 
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condoms, there’s always remarks, you know, they always say something. So with us, 
we try to make them feel at home, so they prefer to come to us.” (Z8, site staff, site 4).  
 
1.7.2.1.4 No feedback from referral centres 
Interviewees at some sites described that the feedback loop between referral centres and trial 
sites was poor and that site staff had to actively engage with the referral clinic to get feedback 
on participants:  
 R: So you don’t get the feedback from that referral clinic?                                                 
C8: No. Ja until you follow it up and want to find out from the participant maybe 
to say “did you receive this” after maybe the participant has gone to the clinic then 
you phone again and find out to say “how did it go, did you receive any help after 
that”. Otherwise they normally don’t send us the feedback. (C8, site staff, site 3). 
 
 “…we always ask…whoever we are referring to, to provide feedback to us and I think 
one challenge has been we normally don’t receive any responses or feedback from the 
referral clinic” (C3, site staff, site 2).  
 
 “…to get information from that healthcare provider is extremely challenging” (C7, 
site staff, site 4). 
 
1.7.3 Comparing access strategies for providing prevention interventions with 
recommendations in ethics guidelines 
Guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) specify that 
researchers and sponsors should ensure access to prevention services for trial participants but 
allow some flexibility by not specifying which HIV prevention interventions should be 
provided on-site and which should be accessed via referrals.  
 
But for a few exceptions, most HIV prevention interventions for trial participants were 
provided on-site. The challenges identified with referral above created barriers to the use of 
referral as an access strategy for the standard of prevention. Given the potential of HIV 
prevention interventions to impact on HIV incidence, on-site provision of services helped site 
staff to maintain better control. Similar challenges with referral have been identified 
elsewhere and it has been noted that simply referring participants to available services was 
inadequate in that often they did not fulfil the referral (Heise et al., 2008; Ngongo, Priddy, et 




In line with guideline requirements, where referral networks were established, sites 
endeavoured to ensure referral uptake by following up with participants or by linking with 
referral centres to ensure feedback to sites.  
 
Some sites reported that they had created partnerships with government where the DoH 
provided the treatment at no cost to sites and the site was able to provide the prevention 
service on-site, thus increasing the ability to monitor quality and uptake of services and 
improve participant retention.  
 
1.8 Comparing monitoring practices for the standard of prevention with 
recommendations in ethics guidelines  
Ethics guidelines recommend that the provision of risk-reduction interventions be monitored 
for quality (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) and uptake 
(UNAIDS/AVAC, 2011), including “the standards of referral services” (UNAIDS/AVAC, 
2011, p. 51). 
 
Mechanisms for monitoring risk-reduction interventions were not addressed in the protocol or 
accompanying documents. However, the risk-reduction worksheet that captured the 
counselling session and condom provision was reviewed by counselling mentors. Further, at 
some sites the provision of risk-reduction counselling was monitored for quality: 
 “…what my role, I’ve got a, I think it’s a checklist where I used to sit down with the 
counsellors to see their chart-notes. To see that ok so much condoms have been 
issued.” (Z2, site staff, site 1).  
 
Many reported practices could reflect monitoring activities such as recording condoms 
dispensed, recording STIs and their resolution, and recording uptake of PEP and VMMC. The 
uptake of individual components of the standard of prevention package is collated in 
participants’ records.  
 
Interviewees at some sites reported that there were no formal mechanisms for monitoring the 
quality of risk-reduction interventions. However, guidelines (MRC, 2003; UNAIDS/WHO, 
2012) do not explain what they mean by monitoring the quality of risk-reduction 
interventions, and except for counselling, it is unclear how the quality of these prevention 




While some interviewees described the importance of monitoring referral networks, no 
formal monitoring mechanisms of referral networks were reported. Ngongo, Priddy, et al. 
(2012, p. 1286) found that in certain contexts, “formal assessment of quality of referral points 
in general is rare”. However, most prevention interventions were provided on-site and referral 
was a limited strategy reserved for the provision of select prevention services, suggesting that 
monitoring of referral centres was not a necessary priority in most settings.  
 
2. Summary  
This chapter addressed the research question of the extent to which actual HIV prevention 
practices in HVTs corresponded with related recommendations in ethics guidelines and to 
identify complexities with implementation. All ethics guidelines require that participants be 
ensured access to a comprehensive package of HIV prevention interventions, described as 
‘state-of-the-art’ (UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) or ‘optimal’ (MRC, 2003). 
The HVTs in the present study satisfied these ethics recommendations by providing risk-
reduction counselling, and access to male and female condoms, STI treatment (cf. MRC, 
2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012), and VMMC and PEP, where indicated 
(cf. UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012).  
 
Several complexities were identified with meeting ethics guideline requirements to provide 
an optimal or state-of-the-art prevention package. Most complexities can be clustered at four 
major thematic levels, namely (1) partnerships/funding; (2) provider-promotion; (3) 
participant acceptability and uptake, and (4) cultural/gender norms (discussed in Chapter 11). 
The next chapter presents stakeholders’ perspectives on selected standard of prevention 








PERSPECTIVES ON STANDARD OF PREVENTION 
RECOMMENDATIONS IN ETHICS GUIDELINES 
 
This chapter presents respondents’ perspectives on selected standard of prevention 
recommendations in ethics guidelines. Respondents were asked about their perspectives on 
the utility of ethics guidelines in addressing ethical complexities. They were also asked to 
comment on specific standard of prevention recommendations in UNAIDS/WHO (2012) 
guidelines, namely, that 1) access to all state-of-the-art HIV risk-reduction methods should be 
ensured for participants; 2) new tools should be added to the package based on consultation 
among all research stakeholders; and 3) trials should not be conducted when agreements have 
not been reached among all research stakeholders on the standard of prevention. These 
particular recommendations were selected because they have been identified as potentially 
divisive (Essack, Slack, et al., 2010; Philpott et al., 2011), and as requiring further in-depth 
exploration (Moorhouse et al., 2014).    
 
1. Awareness of ethics guidelines  
One of the key identified obstacles to the implementation of recommendations in ethics 
guidelines was a lack of accessibility, awareness and understanding of these guidelines, even 
among REC members:  
 “…we are not educating our committee members, you know we’re falling very short 
there. You know, we’re busy educating everybody else, (laughs) but not locally, and 
unless you’re familiar with the UNAIDS guidelines, you don’t know what is expected 
really” (C6, REC).  
 
Some key stakeholders, including communities, reportedly had no mechanisms to access 
ethics guidelines nor were they aware of specific guideline requirements for HVTs:  
 “I think as a community person and also the community representative on staff, I 
don’t think we as the community understand those guidelines… there’s no document 
that is available to the community to say [these] are the guidelines of the prevention 
and all those things” (Z2, site staff, site 1).    
 
Even when guidelines were accessible, without accompanying awareness and understanding 
of what guidelines entail, it is unlikely that ethics recommendations will be consciously 
implemented in trials. Therefore, there is a need for more “…training about ethical standards 
[and] policies” given that at present “there is no time to absorb them and make them a 
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reality thing” (C1, site staff, site 1).  
 
2. The value of ethics guidelines  
One of the key purposes of ethics guidelines is to offer stakeholders sound direction on 
current ethical complexities (Moorhouse et al., 2014). To this end, MRC (2003) guidelines 
were developed to provide information, and some resolution, on key ethical challenges and 
dilemmas. Similarly, UNAIDS/WHO (2012) guidelines purport to capture some of the 
critical ethical elements for consideration during the development of biomedical HIV 
prevention interventions and GPP guidelines (UNAIDS/AVAC, 2011) aim to provide 
systematic guidance on effective stakeholder engagement during HIV prevention trials.  
 
A few respondents reported that they did not consult UNAIDS guidelines at all regarding 
standards of prevention. Rather, they argued that their practices were based on sound clinical 
judgements and the application of ethics principles. Another potential reason for the lack of 
reference to these guidelines may be because they were not formally endorsed nationally or 
by the implementer’s respective institutions (cf. Haire, 2013). 
 
Among those who perceived guidelines as valuable, different aspects of the guidelines were 
reported as having appeal. In line with guidelines’ (MRC, 2003; UNAIDS/WHO, 2012) aims 
to offer comprehensive guidance on critical ethical elements, some respondents stated that 
guidelines provided a valuable benchmark against which to compare actual practices in 
HVTs, for example:  
 “…because that’s what really guides us even in general when looking at the protocol, 
to say is it going to provide the participants what the guidelines say I need to provide 
to participants? I do agree that it’s been very helpful.” (Z15, site staff, site 3).  
 
While acknowledging that guidelines are not mandatory or binding, and therefore not 
enforceable, another respondent stated that guidelines served to regulate research, albeit 
implicitly, in terms of their ratification of ethical standards for research:  
 “I think it’s absolutely necessary that you have the guidelines. It may appear to be a 
nuisance, or it may appear to be of no consequence. But, it is there, for want of a 
better word, [as] a watchdog in place.” (Z10, site staff, site 5).  
 
However, guidelines were perceived as less valuable as stand-alone documents – rather they 
were seen as providing helpful direction relative to other considerations when balancing 
competing ethical obligations. The importance of value-judgments were emphasised in the 
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caveat that the ethicality of guidelines cannot merely be assumed by virtue of being 
guidelines nor can a recommendation be argued as valid just because it is stipulated in 
guidelines: “I don’t think you can simply point to a guideline, and say, it must be true or it 
must be ethical because this guideline says it is” (C5, REC).  
 
3. Perspectives on UNAIDS ethics recommendations  
As indicated in Chapters 3 and 5, standard of prevention recommendations in 
UNAIDS/WHO (2012) guidelines have been the source of intense debate. Among the 
concerns raised are that standard of prevention norms are infeasible and impractical (HPTN, 
2009), and set a very high standard (Essack, Slack, et al., 2010; Macklin, 2009). Some 
respondents concurred that UNAIDS recommendations have “upped the ante in terms of the 
requirements of research…and are making, quite a lot of demands on researchers” (C6, 
REC). The dissimilarity between UNAIDS/WHO (2012) guideline recommendations and the 
arguably more pragmatic HPTN (2009) guidelines was also noted. While recommendations 
in UNAIDS guidelines were considered “unrealistic”, it was argued that, “that doesn’t mean 
to say that one mustn’t again aspire, I suppose that’s what ethics is about. But the HPTN 
ones, I think are a bit more realistic….” (C6, REC).  
 
Respondents were asked to specifically reflect on selected standard of prevention norms in 
UNAIDS/WHO (2012) guidelines, as detailed below.  
 
3.1 Perspectives on the state-of-the-art requirement 
 
3.1.1 Support for state-of-the-art prevention 
Despite the criticisms identified in the literature, there was some support for the provision of 
state-of-the-art HIV risk-reduction interventions for HVT participants:  
 “Yes they must be given the best prevention ever.” (Z1, CAB, site 1)  
  
 “I think it’s quite right [that participants are offered state-of-the-art prevention 
interventions]” (Z19, CAB, site 4).  
 
 “…the participants have to have the best choice offered to them” (Z10, site staff, site 
5).  
 
 “I think that’s entirely appropriate…” (C19, REC).  
 
As indicated from the quotes above, respondents tended to interpret state-of-the-art 
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prevention as the best available prevention strategies.  
 
The state-of-the-art standard was also perceived by a few respondents as easily 
implementable and affordable:  
 “…it’s very easy for a site to do so” (Z19, CAB, site 4).  
 
 “…in the context of South Africa, we’re slightly different from other African 
countries, I think here, that standard of care is affordable” (Z12, REC).  
 
3.1.2 Complexities with state-of-the-art prevention 
 
3.1.2.1 State-of-the-art is an undue inducement 
While CAB respondents largely advocated for the provision of a state-of-the-art standard of 
prevention for participants, one CAB member argued that to do so would be unfair and would 
raise concerns about undue inducement (see Chapter 8).  
 
3.1.2.2 State-of-the-art is vague 
While guidelines establish the substantive standard of state-of-the-art (UNAIDS/WHO, 
2012), defining this standard is a task left to the reader. It is therefore concerning that several 
respondents in this study reported that the state-of-the-art requirement is unclear and too 
vague:  
 “…I think it’s a very vague ethical recommendation … it needs more clarification.” 
(C21, REC). 
 
 “…there’s just a minor problem with that requirement, because half the time it’s 
difficult to define the standard” (Z11, site staff, site 2). 
 
 “…state-of–the-art, um, makes me more uncomfortable than ‘optimal’ treatment 
(laughs). Um, because it seems fuzzier…. Thinking about prevention, what would 
state-of-the-art prevention be?...I find it harder to have a clear opinion or to imagine 
coming up with what state-of-the-art would be, and …to what degree you would 
require it.” (C5, REC). 
  
This vagueness also renders the state-of-the-art recommendation open to multiple 
interpretations, potentially polarised by the interests of different stakeholder groups, for 
example: 
 “…state-of-the-art is in the eye of the beholder and …may vary between scientists and 
stakeholder groups and may vary within stakeholder groups certainly and so I 
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suppose it’s a potential concern that some stakeholders may define a different state-
of-the-art than others.” (Z16, REC).  
 
 “The researchers would say ‘you are crazy. I mean what are you expecting of us?’ 
The community would grab it because it’s good care for them” (C6, REC).  
 
While acknowledging that it is difficult to operationalise vague guidelines, a few respondents 
argued that vagueness may be warranted because it allows some latitude in interpretation, 
suitable to the dynamic nature of the HIV prevention field:  
 “…it’s for us to unpack what that state-of-the-art is” (Z15, site staff, site 3).  
 
 “I think that’s entirely appropriate and I think they are necessarily vague because the 
landscape is changing…but the vagueness also I suppose creates problems about 
what is sufficient and what is state-of-the-art and so it’s a catch 22” (C19, REC).  
 
 “So, you know, I think it’s a very dynamic field and it needs ongoing dialogue, and 
it’s gonna change so frequently that I think we should be careful not to, you know, 
um, spend hours coming up with guidelines which then need to be changed within a 
month, and then we’re reluctant to be flexible and dynamic because we’ve put so 
many hours into them” (Z18, site staff, site 5).  
 
Vagueness was argued to be valuable because it provides welcomed reprieve from guidelines 
which were perceived as too rigid and therefore likely to be ignored:   
 “I don’t think you could remove the flexibility because people then won’t adhere to 
the guidelines, which I think is a problem with Helsinki. It is too rigid in some 
respects so you end up ignoring the guideline because it is ridiculous.” (C6, REC).  
 
However, one respondent did perceive that rather than flexible, the state-of-the-art 
requirement was too rigid:  
 “…the problem with those kind of unanimous blanket statements is there’s always the 
ridiculous outlier scenario… I don’t know what’s coming down the pipe, so I’d rather 
keep my options open.” (Z18, site staff, site 5).  
 
While there was little consensus on exactly what constitutes state-of-the-art, the prevention 
package provided to participants in the phase IIB trial was considered, at the time, “a 
comprehensive state-of-the-art package” (C19, REC).  
 
3.1.2.3 State-of-the-art sets the bar too high  
Another criticism was that the state-of-the-art requirement sets the bar too high and therefore 
is an unrealistic, unreasonable, and “very limiting” standard (Z5, site staff, site 2).  
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 “I don’t think that it’s reasonable to require that the best form of every kind of 
prevention be available to everybody, all the time” (C5, REC).  
 
In this way, the state-of-the-art standard was perceived as not feasibly implementable under 
all circumstances. In resonance, recent research on care and prevention recommendations in 
ethics guidelines (Moorhouse et al., 2014) found that South African stakeholders rated 
standard of prevention norms in UNAIDS/WHO (2012) and GPP (UNAIDS/AVAC, 2011) 
guidelines lower than care norms in terms of familiarity, understanding and implementability. 
REC respondents in particular were more sceptical of trial sites’ abilities to implement these 
prevention norms (Moorhouse et al., 2014).  
 
Despite concerns that state-of-the-art is infeasible and impractical (see also HPTN, 2009), it 
was acknowledged that this high standard has actually been achieved in HVTs:  
 “….To me they are probably too absolute, and they are too high. But having said that, 
again, your sites that are doing these studies and are actually meeting these 
requirements. So, from our perspective where I’m sitting it is less of a problem 
because they are doing it. In less well-resourced sites, it may be possible to not do the 
study at all because it’s almost self-defeating. So, I’m probably, you know, sitting… 
with well-resourced sites. I’m not able to give the best answer, because I think it’s 
happening, I think/ and the researchers are good. Whether it’s possible to enforce, 
without cutting off your own nose, I don’t know.” (C6, REC). 
 
3.1.2.4 State-of-the-art needs localisation 
Many respondents contended that a state-of-the-art package customised to the local setting is 
preferable, for example:  
 “…obviously because one has to consider the context… so the state-of-the-art would 
be whatever the national guidelines are” (C21, REC). 
 
 “I think that it’s true, they should be provided with everything but then you also have 
to look at your, the context of uh you know your settings… You provide it as far as 
possible but if it’s not feasible in your setting, then you can't really do it.” (Z7, site 
staff, site 1).  
 
 “Many of these studies are done in the global world, and what may be appropriate 
for Brazil, may not be appropriate for a site in Gugulethu…the world is not the same 
place, all over the place. Um, and I think we need to be careful that having a blanket 
statement that could actually cause more harm than good” (Z18, site staff, site 5).  
  
  “…what is considered state-of-the-art in in the in the States is obviously different 
from state-of-the-art in Africa…” (C21, REC).  
 
While several respondents argued that the standard of prevention should be benchmarked 
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against the public healthcare sector, there was some uncertainty about whether the prevention 
package offered in the South African public health system would be considered state-of-the-
art and which level of localisation (e.g., national, provincial, metropolis) would be most 
appropriate:  
 “So it just gets into the grey area that I’m never sure about which is what's state-of-
the-art versus what's standard of care… but I don’t know that it needs to be the 
responsibility of the trial to provide a service that’s not in fact a public sector 
service.” (Z16, REC).  
  
 “I think we have to take the local context into consideration but sure there would be a 
tension between state-of-the-art versus sort of a customised state-of-the-art.” (Z13, 
network representative).  
 
 “So, the [state-of-the-art] standard is also situational based, and what is standard in 
KZN may not be standard in Soweto. And, so, the first problem with that clause is, 
what’s the standard?” (Z11, site staff, site 2).  
 
It was argued that the standard of prevention implemented in developed country contexts 
should not be imposed on developing contexts, where it is unlikely to be feasible. Even 
within one context, there may be differences in public health practice. Given potential socio-
cultural and economic idiosyncrasies of each context, a one-size-fits-all approach was 
perceived as encumbering implementation. Instead, a customised prevention package would 
demand that the state-of-the-art standard is dictated by local realities, always implementable, 
and does not impact on the real world significance of the data. However, it was cautioned that 
a customised prevention package runs the risk that the package may be suboptimal in some 
contexts:  
 “…it also does allow for some accommodation to what is feasible locally, provided 
that that’s not just nothing.” (C19, REC). 
 
Another benefit of defining state-of-the-art in relation to the national standard of prevention 
was that it would enable establishing a fixed standard “for a South African setting for 
instance…it would be very simple, just mandate that that standard of care be provided to all 
participants.” (Z16, REC).  
 
It has been argued that the procedural standard (UNAIDS/WHO, 2012) requiring consultation 
and negotiation among all research stakeholders on the standard of prevention, permits such 
customisation (Macklin, 2009). However, this supposition appears discordant with the view 
that the primary intention of the UNAIDS guidelines is to avoid double-standards between 
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high- and middle- or low-income countries, and serve as “a tool in the progressive realisation 
of the right to health” (Haire et al., 2013, p. 3). Rather, a customised standard of prevention 
appears to fit well within the HPTN guidelines, which through their adoption of a social 
justice perspective, aim to minimise double standards between trial participants and their 
local communities.  
 
3.2 Perspectives on the stakeholder consultation requirement 
 
3.2.1 Support for consultation and consensus among research stakeholders  
Several respondents, particularly CAB representatives, supported the idea that new 
prevention interventions should be added to the prevention package based on consultation 
among research stakeholders:  
 “…the involvement of all stakeholders. I think it is essential. It’s not just important 
but it is the core” (Z3, CAB, site 2).  
 
 “It’s something that’s difficult but it’s something that needs to be put into practice. I 
think it’s something that needs to happen” (Z11, site staff, site 2).  
 
 “I think it’s a very good requirement because everybody must agree with the same 
thing” (Z19, CAB, site 4).  
 
 “I think it’s a sound recommendation” (C14, network representative).  
 
A few respondents identified the rationale for, and benefits of, stakeholder consultation. The 
ethical principle of respect for communities was perceived as justifying stakeholder 
consultation on standards of prevention. Such consultation was identified as serving several 
purposes including fostering community ownership of the research and meeting the 
community’s desire to be involved in decisions that affect it. For example:  
 “..it’s very good to involve everyone, it respects the notion, and the principle of 
community engagement” (Z12, REC).  
 
 “…gone are the days when people just used to take and swallow what they are given. 
People want to be involved from the plannery stage…” (Z3, CAB, site 2).  
  
 “…it’s very important because like I said communities are not the way they used to be 
before, you know they know their rights, so you need to explain to them what’s going 
to be conducted in their area, so you need to get their permission also. So I think it’s 
actually very important to engage stakeholders because they are the activist, they are 
the people who are advocating on behalf of the community” (Z8, site staff, site 3).  
 
Community mobilisation and engagement were considered critical for fostering buy-in and 
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community ownership of research whereas a failure to engage communities was argued to be 
detrimental to research: 
 “…[when communities are engaged] we’ll provide that little pondokkie12 as our 
counselling room for the person that’s going/ because now they all are involved and 
they can relate and identify with the thing [research]. Yet if you just come upon them 
and force it down their throats, it’s not going to work” (Z3, CAB, site 2).  
 
Consultation was also argued to promote ethical research in that it serves an oversight or 
“watchdog” function (J1, site staff, site 2). However, among those respondents who 
supported stakeholder engagement, few specified the finer decision-making required by 
ethics guidelines for standards of prevention. Most perceived this ethical recommendation as 
synonymous with broad community engagement, consultation and mobilisation.  
 
3.2.2 Complexities with consultation and consensus among research stakeholders on 
the standard of prevention 
Even when the idea of consultation and consensus was deemed sound and feasible, several 
respondents went on to qualify their support (see below), and most respondents were critical 
of the recommendation for stakeholder consultation on the standard of prevention.  
 
3.2.2.1 Questioning research stakeholders 
Ethics guidelines (UNAIDS/WHO, 2012, p.45) specify that decisions on the addition of new 
tools to the prevention package should be made in consultation with “all research 
stakeholders, including the community”. Since these guidelines do not expand on who is 
considered a research stakeholder, this recommendation was perceived as equivocal. 
Respondents questioned which specific stakeholder groups should be included in standard of 
prevention determinations. While vagueness may be argued to ensure generic applicability 
depending on circumstances (Macklin, 2012), some respondents questioned the lack of 
specificity. For example:   
 “…it says all the research stakeholders, and I think it’s [not] all the research 
stakeholders that play a part. It’s only the people that play part that really must be 
part of that.” (Z11, site staff, site 2).  
 
 “I’m not sure who are regarded as the stakeholders” (Z18, site staff, site 5) 
 
                                                             
12 Pondokkie is a colloquial term for small room/house.  
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 “…it’s an open point of whom are you going to consider as a stakeholder” (C16, site 
staff, site 3).  
 
 “The question is going to be really when you say stakeholders, we have to unpack 
that. We have to unpack it because most of the time who are we really referring to as 
stakeholders?” (Z15, site staff, site 3).  
 
Even when the recommendations of consultation and consensus were endorsed by 
respondents, it was done under the proviso that only relevant stakeholders should be 
consulted, as aptly indicated by the retraction from ‘everyone’ to ‘all the important 
stakeholders’ in the quote below:  
 “…it is crucial to make sure that everyone, eh eh all the important stakeholders 
reach an agreement as to okay this is the package that needs to be provided” (Z22, 
site staff, site 1, emphasis added).  
 
Some respondents attempted to delineate those stakeholders they considered relevant. These 
stakeholders were limited to investigators, sponsors and RECs, with some also considering 
CABs as valuable stakeholders to be included in standard of prevention determinations. 
However, while some argued that such involvement was considered feasible in terms of the 
current CAB model, others contended that the CAB model was inadequate for ensuring 
community representativity in decision-making. There was also some scepticism about 
whether CABs are actually involved in such intricate decision-making such as on standards 
of prevention:  
 “Um off the top of my head I would say that although studies are typically asked to 
provide an indication that the community support and agree with the study I’m not 
sure that the CAB or the community representatives necessarily comment on detail as 
fine as the standard of care that’s gonna be provided” (C19, REC).  
 
Analogously, some CAB respondents in this study reported having made limited inputs on 
standard of prevention decisions in practice and for some, the standard of prevention was not 
highly prioritised (see Chapter 7). A lack of scientific expertise was noted to potentially 
impede CAB review of standards of prevention in protocols. Similarly, it could be argued that 
this paucity of scientific knowledge among CAB members does not bode well for the 
negotiation of technical study design considerations such as feasibility, expected impact, and 
the ability to isolate the efficacy of the biomedical HIV modality being tested - all of which 
are required to be considered during stakeholder negotiations (UNAIDS/WHO, 2012). A 
community liaison officer also questioned the value that CABs would contribute to such 
technical decision-making:  
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 “…let’s take for the scientific working group, they are all doctors, they understand 
what are they talking about. And these people, maybe this community, maybe it’s a 
teacher or it’s somebody who hasn’t any understanding of the science whatsoever.” 
(Z2, site staff, site 1).  
 
A more restricted view of who would constitute a research stakeholder was also held by some 
respondents who cautioned against affording too many stakeholders the opportunity to 
participate in decision-making: 
 “I would hate to give you know um too many voices the opportunity to participate in 
the discussion because it may be a never ending discussion and could change from 
time to time.” (C20, REC).  
 
 “Well I think you know it’s quite a lot of stakeholders involved in the protocols but it 
should be the ones that actually going to have to provide it that definitely need to 
agree on what should be there and all that should be accessible to participants.” 
(Z17, site staff, site 5).  
 
As with state-of-the-art, vague recommendations run the risk of being open to multiple 
interpretations. While the need to maintain flexibility in guidelines is acknowledged, 
implementers would benefit from frameworks that provide more concrete direction. For 
example, Tarantola et al. (2007) provide an exhaustive list of all research stakeholders which 
may be of value when determining who should be involved in standard of prevention 
determinations and GPP guidelines (UNAIDS/AVAC, 2011) also explicate the relevant 
stakeholders in HIV prevention trials.  
 
3.2.2.2 Questioning the consultation process 
While consultation and negotiation are advocated in guidelines (UNAIDS/AVAC, 2011; 
UNAIDS/WHO, 2012), the process for consultation is not specified (Cohen et al., 2014; 
Philpott et al., 2011), and left to the discretion of implementers. Therefore, there is likely to 
be “enormous variation in the way it’s operationalised” (C19, REC).  
 
Respondents defined consultation differently. Some understood consultation to mean one-
way communication or information sharing: “everybody needs to know what’s going to be 
available” (Z17, site staff, site 5) and “everybody has the right to be informed” (Z10, site 
staff, site 5). However, most respondents equated consultation with face-to-face meetings. 
The value of large consultative forums was questioned, particularly with regard to 




 “…I tend to…be sceptical of these kind of, consultation processes… these kind of 
things seem naive to me because it imagines that if we’re all in the room and we start 
from square one then there won’t be any power, there won’t be any ignorance, there 
won’t be any, you know, conflict” (C5, REC). 
 
 “I guess I’m a bit sceptical about meetings generally because… I think there would be 
a problem practically getting people together. I mean government people rarely turn 
up for meetings. There’s quite a high opportunity cost of people’s time, and I guess I 
wouldn’t support that too easily” (C6, REC).  
 
 “There’s a time and a complexity concern obviously…” (Z12, REC) 
 
 “Of course, what you mean by consultation, you know you have to, give people plenty 
of time, you have to help them understand what the other options are, and then, why 
yours are the best. That’s different than just having them show up and giving 
PowerPoint and saying, ‘Do you agree?’” (C6, REC).   
 
The manner in which consultations are conceptualised has obvious implications for the 
implementability of this ethical recommendation. Some respondents deemed protocol 
development and review to serve as an adequate consultative device:  
 R: Uhm do you think that consultation happens in other ways beside perhaps 
meetings or direct discussions in the sense that CABs may get to review the protocol, 
RECs review the protocol. Do you think that this may be considered by sites as in 
some sense, consultation?                                                                                           
Z6: I do and it probably happens at other levels as well but uhm uh yeah I mean I 
don’t think that necessarily the absence of a formal ‘ok today we’re having a meeting 
to discuss standard of care before we start trial X’ uhm the absence of that type of 
meeting means the absence of consideration of the issues on an ongoing basis (Z6, 
site staff, site 2).  
 
 “…at the moment our PI’s are having to consult communities. I guess, you know, the 
criticism is it’s after the fact. You know, you’re presenting them with a protocol. You 
know, you’re not going in and saying let’s develop a protocol, which I think does have 
very practical problems. So if they agree to it, you have/ you can tick that box. The 
same with the MCC, the same with the ethics committee…I would stay that is a 
reasonable standard of consensus…you know, having meetings would be, I think a 
huge investment of time, and not necessarily productive time/ you know if it can be 
done separately. Because already, I think that trying to get through many of these 
processes is quite a task.” (C6, REC) 
 
 “I think that’s one method of consultation, protocol review… that protocol document, 
you know, goes through the protocol development process, and then it’s reviewed by 
local ethical bodies, and national ethical bodies, so, um, that’s another form of 




The requirement for stakeholder consultation was perceived by some as too demanding 
(“quite a task”) and vague (“would it be each country, would it be continental?”; “it’s 
difficult to define the standard”).  
 
3.2.2.3 Questioning consensus 
 Some respondents also critiqued the recommendation that consensus be reached on the 
standard of prevention prior to every trial (UNAIDS/WHO, 2012).  
 
It was noted that consensus is difficult to achieve and an unlikely outcome of consultation on 
the standard of prevention, which is an issue already marred by debate:  
 “… I don’t think you can kind of bring everyone together and hope that they will, 
from the bottom up, produce something that’s, kind of, shared… it would make sense 
to develop a package, and motivate for it, and then, properly get people involved and 
get them to sign off on it” (C5, REC).  
   
 “…there’s a difference between consensus and unanimity. And (.) I think that, it’s 
very good to involve everyone, it respects the notion, and the principle of community 
engagement, but at the end of the day you’ll find/in my opinion there doesn’t need to 
be unanimity on the issue. There just needs to be consensus. So even if some of the 
stakeholders disagree, to anything, whether it’s study design or whether it’s whatever, 
the bottom line is that, as long as most of the stakeholders are in general agreement 
(R: Mm), then, at the end of the day there’s consensus.” (Z12, REC).  
 
 “I think that’s uh being rather fanciful…I think to say that you have to get absolute 
agreement is, would be a major barrier.” (C18, site staff, site 4).  
 
 I’m a little hesitant to say that we have to reach consensus across the board or we 
can’t do this study.” (Z18, site staff, site 5).  
 
Given that stakeholders have varying perspectives and are driven by their own self-interests, 
the recommendation for stakeholder agreement was argued as being “to the detriment of the 
participants and maybe even to doing vaccine trials” (C4, site staff, site 2). As evidenced by 
varying perspectives both within and across stakeholder groups in this study, and the 
perspective that “state-of-the-art is in the eye of the beholder” (Z16, REC), it follows that it 
may be problematic to require agreement on an issue for which there are many opposing 
perspectives.  
 
Still others argued that the requirement for stakeholder agreement in itself is not situated in 
the reality that under certain circumstances, disagreements best serve active decision-making. 
Disagreements may in fact indicate that procedural justice is working (Ashcroft, 2008). 
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Consensus, on the other hand, may be achieved for a variety of reasons including skewed 
power dynamics and passive compliance merely to reach resolution. For example:  
 “Because sometimes we agree to disagree. And there are healthy disagreements, 
which can make the trial…there are those agreements, sometimes we agree, but is it 
because we agree, or is it because sometimes we get too tired to disagree…For me it 
would be healthy, even if we disagree. Because disagreeing, sometimes takes us 
somewhere” (Z11, site staff, site 2).  
 
The recommendation that consensus should be achieved prior to the commencement of every 
trial was also not favourably received, considered infeasible and unlikely to be implemented:  
 “Uhm in the sense that we’re part of an iterative process, it’s a bit unlikely that that’s 
gonna happen. You know it’s not like we’ve landed from Mars and we’re confronting 
a problem that is unique to Mars and we have one intervention and we’re going to see 
if it works in one trial. The whole vaccine development process has been going on for 
20 years. So in the sense that each trial needs to confront this every time a new trial is 
done, uhm I think is unlikely to uhm to really take off in my view” (Z6, site staff, site 
2).  
 
The analogy of an alien landing may indicate the extent to which this recommendation was 
considered incredulous. During the introductory consultation with HVT stakeholders in this 
study, it was reported that since HVTs are ongoing processes, decisions on what to include in 
the prevention package are rarely established through dialogue – and it may not be feasible to 
have consensus debates on the standard of prevention for every trial (Essack, Koen & Slack, 
2009).  
 
One proposal was that instead of endeavouring to achieve consensus on the standard of 
prevention for every trial, it would be more worthwhile to consult stakeholders only when the 
proposed prevention package deviates from the normative standard or accepted practice.  
 
4. Summary  
This chapter addressed the research question of what are the perspectives of HVT 
stakeholders on selected norms in ethics guidelines. These norms in UNAIDS/WHO (2012) 
guidelines have been identified as controversial (Essack, Slack, et al., 2010; Haire et al., 
2013; HPTN, 2009; Philpott et al., 2011), including those specifying that participants should 
get access to ‘state-of-the-art’ prevention interventions; that new tools should be added based 
on consultation among all research stakeholders, including the community; and that trials 
should not be conducted unless agreement is reached among all research stakeholders on the 
standard of prevention. 
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Respondents were asked to share their perspectives on these particular ethical norms. While 
there was modest support for these ethics recommendations, most respondents identified 
several complexities. The ‘state-of-the-art’ recommendation was considered too vague, too 
absolute and as requiring localisation. The consultation requirement was questioned in terms 
of who would constitute relevant stakeholders, the challenges of achieving consensus, and the 
nature and composition of the consultation process.  
 
The procedural recommendation of stakeholder consultation on the standard of prevention, 
opens the state-of-the-art standard to negotiation. Respondents in this study questioned which 
stakeholders should be included in such decisions. By opening the normative standard for 
negotiation, there is also potential to undercut the state-of-the-art norm, and thus lower the 








In the preceding results chapters (Chapters 7-10), specific findings were discussed in relation 
to ethics guidelines and literature. Chapter 7 presented empirical data on the key dimensions 
of standard of prevention decision-making. It explored perspectives on why participants 
should receive access to prevention interventions in HVTs; which stakeholders were involved 
in standard of prevention decision-making and their roles; how decisions were made and at 
which time-points (the decision-making processes); and the related complexities experienced 
by stakeholders. Correspondence with norms in ethics guidelines was evaluated for each of 
these dimensions. Key findings included that there was little consensus on the ethical 
rationale for providing prevention interventions to trial participants. The various justifications 
offered by respondents closely resembled those declared in ethics guidelines and identified in 
the literature. However, respondents in this study identified mitigating community mistrust of 
research as an additional rationale for providing prevention interventions to participants. In 
practice, the protocol development committee emerged as the primary decision-making body 
for the standard of prevention. RECs and CABs did not entirely satisfy their standard of 
prevention review responsibilities outlined in ethics guidelines, focusing more on procedural 
rather than substantive ethical issues. Practices deviated from guidelines with regard to the 
declaration of the standard of prevention in ICFs and protocols. Key identified complexities 
included sponsor funding policy, REC and CAB capacity deficiencies, and the presence of 
power inequalities at various stages of decision-making.  
 
Chapter 8 presented stakeholders’ practices and perspectives on the evolving standard of 
prevention. It explored how stakeholders made the decision to add VMMC to the prevention 
package and their perspectives on the relevant criteria for adding new tools to the standard of 
prevention. Practices and perspectives were compared with norms in ethics guidelines. 
Perceived challenges with the evolving standard of prevention were described, and guidelines 
were examined to identify whether they anticipated these real-world concerns. Findings 
indicated that respondents endorsed ethics guideline recommendations that new tools should 
be scientifically validated although they argued that this broad concept is difficult to 
operationalise; respondents also generally subscribed to the more conservative interpretation 
of guidelines that new tools should be approved by national regulators in the host country 
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before being added to the standard of prevention. In addition, there was some support that 
new prevention methods should be available in the public healthcare sector and that 
determinations on what to provide should consider the phase of the trial/risk level of 
participants. However, in practice, VMMC was added to the package when it was 
scientifically validated but not necessarily endorsed by national bodies for use. The evolving 
standard of prevention was perceived as particularly contentious and respondents raised the 
usual concerns reflecting tensions between 1) science and ethics; 2) ethics and pragmatics of 
cost; and 3) protecting participants versus creating undue inducements and inequities between 
participants and their communities. In addition, they raised concerns that new partially 
effective prevention interventions may undermine existing, efficacious interventions.  
 
In Chapter 9, standard of prevention implementation practices and perspectives were 
examined for trial participants and other morally relevant groups (participants’ partners, 
families and the wider community) vis-à-vis ethics recommendations. Complexities with 
implementing standards of prevention in HVTs were also identified. Despite the complexities 
identified at the level of decision-making, many site practices for standards of prevention 
could reflect ethics guideline recommendations. Trial participants were provided with risk-
reduction counselling and ‘access’ to male and female condoms, STI treatment, as well as 
VMMC and PEP, where indicated. Several complexities were identified with meeting ethics 
guideline requirements to provide an optimal or state-of-the-art prevention package – these 
can be broadly clustered at four major thematic levels, namely, partnerships/funding, 
provider-promotion; participant acceptability and uptake; and cultural/gender norms.  
  
Chapter 10 presented stakeholders’ perspectives on selected standard of prevention norms in 
ethics guidelines, namely, that participants should get access to ‘state-of-the-art’ prevention 
interventions; that new tools should be added based on consultation among all research 
stakeholders, including the community; and that trials should not be conducted unless 
agreement is reached among all research stakeholders on the standard of prevention. While 
there was modest support for these ethical recommendations, most respondents identified 
several complexities. The ‘state-of-the-art’ recommendation was considered too vague, too 
absolute and as requiring localisation. The consultation requirement was also questioned in 
terms of who would constitute relevant stakeholders, the challenges of achieving consensus, 




This discussion chapter attempts to identify and relate the underlying ideas or assumptions 
(latent themes) (Braun & Clarke, 2006) in respondents’ reports of their practices and 
perspectives on the standard of prevention to the literature and normative frameworks. This 
chapter aims to move beyond a descriptive analysis of the results by offering an explanation 
and interpretation of the study’s key findings. It ends by reflecting on the study limitations 
and the role of the researcher in the research process (reflexivity).  
 
Key complexities identified by respondents are clustered thematically into four overarching 
themes, namely: 1) dynamics of standard of prevention decision-making and implementation; 
2) defining the standard of prevention through consultation, consensus and negotiation; 3) 
ensuring access to HIV prevention interventions; and 4) double standards of prevention.  
 
1. The dynamics of standard of prevention determinations and implementation 
 
1.1 The impact of culture  
This study found that cultural taboos impeded CAB discussions on the standard of 
prevention. Many of the communities where HVTs are conducted are permeated by 
established cultural mores and values where sex is considered a taboo subject (Ndinda, 
Uzodike, Chimbwete & Mgeyane, 2011). Such taboos may also be ingrained due to politico-
legal prohibitions during apartheid, where issues of sex and sexuality were highly censored 
and subjected to repressive policing (Posel, 2004). Further, there is increasing recognition of 
the role of culture in HIV prevention (Leclerc-Madlala, Simbayi & Cloete, 2009). 
 
Previous research in a South African rural community revealed that sex is a taboo subject and 
its discussion is obscured by the use of polite language, euphemisms, and gestures (Ndinda et 
al., 2011). Further, discussions related to sex are gendered (Ndinda et al., 2011). While 
counter-intuitive given their involvement in HVTs, some CAB respondents in this study 
reported that their standard of prevention discussions were constrained by cultural taboos. As 
with some CAB respondents in this study, men from particular ethnic groups may “exhibit 
significant levels of anxiety in discussing private sex matters in the presence of women” 
(Ndinda et al., 2011, p. 4). For some CABs, the proscription on discussing sex in a mixed-sex 
group limited discussions about certain HIV prevention components, for example, VMMC. 
Given that the desired outcome of CAB involvement includes input into the design of risk-
reduction strategies (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012), in some 
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contexts, cultural norms may impede the full realisation of ethics recommendations, and 
deserves further detailed exploration.  
 
Reservations about discussing sexual activity between different sexes also influenced the 
uptake of prevention interventions. For example, some male participants were uncomfortable 
disclosing STI symptoms to female clinicians, given gendered taboos about discussing sex 
(cf. Ndinda et al., 2011). While not explicitly reported in this study, it is plausible that socio-
cultural taboos, may impact on risk-reduction counselling as well as other prevention 
interventions that rely on self-report, e.g., access to PEP.  
 
In traditionally male circumcising communities, it was reported that customary practices of 
male circumcision limited uptake of VMMC at certain sites (cf. Mark et al., 2012), and may 
have also impacted on provider-promotion of this particular prevention intervention.  
 
1.2 Gendered prevention practices 
The provision of some prevention interventions, for example, counselling and female 
condoms, presented gendered challenges. Preconceived notions about women’s sexuality and 
indoctrination of gendered norms which prescribe that women should be more conservative 
in their sexual behaviour than men, including that women should have fewer sexual partners 
(cf. Kelly & Bazzini, 2001; Kreager & Staff, 2009) impacted on the willingness of some 
female participants to disclose risky sexual activity during counselling sessions. A counsellor 
at one site noted this gendered dimension to social desirability bias in her observation of a 
female participant’s reluctance to disclose that she had multiple sexual partners: “…it would 
have been better [easier to disclose] if she was a male” (Z4, site staff, site 2). Some work is 
being done to explore less biased methods for eliciting sexual risk behaviour electronically to 
eliminate the role of interpersonal inhibitions (e.g., Bowling, 2005; Dolezal et al., 2012). 
 
Both trials sampled in this study enrolled male and female participants and in South Africa, 
women are at heightened risk for HIV infection (Abdool Karim, Siboko & Baxter, 2010; 
Leclerc-Madlala et al., 2009; Ramjee, 2013). While male condoms offer effective dual 
protection against unintended pregnancies and STIs, including HIV, male condom use may 
be difficult for women to negotiate (Langen, 2007). At the time this research was undertaken, 
the female condom was the only available female-initiated dual barrier method. Research has 
shown that when used correctly and consistently, female condoms are as effective as male 
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condoms (Vijayakumar et al., 2006). Other studies have demonstrated that availability of 
female condoms increased the number of protected sex acts (Barbosa, Kalckmann, Berquo & 
Stein, 2007) and a systematic review of 21 studies across various contexts demonstrated that 
increasing the availability and accessibility of female condoms improved condom use 
(Charania et al., 2011).  
 
There was, however, a gender gap in condom provision in both trials and at all sites in this 
study. In the main, male condoms were consistently available, provided during counselling 
sessions, and at strategic places at the sites, e.g., restrooms. Further, the number of male 
condoms accessed was at the discretion of the participant. In contrast, female condoms were 
not always available, generally provided in counselling sessions and with a predetermined 
limitation on the number of condoms provided. This disparity in access may unwittingly 
validate perceptions that women have (or should have) fewer sexual partners than men (cf. 
Kelly & Bazzini, 2001; Kreager & Staff, 2009).  
 
Shortages in supply of female condoms reported in this study mirror poor availability in the 
public sector. While South Africa’s female condom distribution programme is one of the 
highest in the world, it is still woefully inadequate compared to male condom distribution 
(Beksinska, Smit & Mantell, 2012). In 2010/11, the South African DoH distributed just short 
of 100 male condoms for every female condom (DoH, 2011) and this variance may widen 
prospectively with a target of distributing 1 billion male condoms and 20 million female 
condoms by 2016 (SANAC, 2011). Further, in developing country contexts in general, there 
is a higher probability of an individual accessing ART than a reliable supply of female 
condoms (Oxfam, 2008). Challenges with availability and uptake of female condoms have 
also been reported in other empirical studies (Heise et al., 2008; Ngongo, Priddy, et al., 2012) 
and may relate to expense and availability (Padian et al., 2008; Surratt et al., 1998). Female 
condoms are approximately 18 times more expensive than male condoms (Beksinska et al., 
2012). Some have even argued that erratic availability may have stifled demand (Parker, 
2010). Respondents in this study also perceived the high cost as contributing to poor 
accessibility. However, given that VMMC was promoted and ensured, despite being 
significantly more expensive than female condoms, cost alone does not provide an adequate 
justification for sporadic access. Some have even contested that the provision of VMMC to 
male participants in trials that enrol both men and women may introduce a gender bias in 
terms of benefits accrued to participants (cf. McGrory et al., 2010). Since women in 
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developing countries, and particularly in Southern Africa, are at heightened risk for HIV 
infection (Quinn & Overbaugh, 2005; Ramjee, 2000), increasing access to female condoms 
should be ensured.   
 
Gender and cultural norms and stereotypes may also influence the uptake of prevention 
interventions. Data from this study indicated that female condom uptake across sites was 
predominantly poor, citing reasons related to the product. Concerns that female condoms are 
noisy and too big have been reported elsewhere (Motsi, Banda & Mabvurira, 2012). Another 
explanation for poor uptake may relate to barriers including embarrassment or reticence to 
obtain condoms from sources that require in-person contact (UNFPA, 2002). Accepted 
notions of masculinity and femininity in many cultural settings dictate that women should be 
sexually innocent; this may create reluctance among females to request condoms from 
providers, carry them or suggest their use (Upadhyaya & Gumashta, 2012). Given reports in 
this study that for some female participants, disclosures of risky sexual behaviours is a 
challenge due to gender stereotypes, it is plausible that concerns about being perceived as 
promiscuous by counsellors, may impact on uptake.  
 
Findings show that condom uptake is higher when not mediated by a provider (UNFPA, 
2002; Wells & Alano, 2013) and since female condoms are generally obtained through 
provider contact and not through dispensers (Holt et al., 2013), this may negatively affect 
uptake. Therefore, changes in dispensing practices of female condoms appear to be indicated 
by this study.  
 
Ethics guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) mention 
concerns about gender and cultural dynamics primarily in terms of informed consent 
practices but recommend that counselling be gender and culture sensitive (MRC, 2003; 
UNAIDS/WHO, 2012) and that monitoring activities evaluate the extent to which this is 
achieved (UNAIDS/WHO, 2012). GPP guidelines (UNAIDS/AVAC, 2011) acknowledge 
that there may be socio-cultural taboos around certain trial procedures. However, except for 
counselling, guidelines do not anticipate that the provision of prevention services may present 
gendered complexities nor that cultural and gender dynamics may constrain community input 




Data from this study indicate that consistent with guideline recommendations to enhance 
socio-cultural competency (UNAIDS/AVAC, 2011), trial site staff are fairly knowledgeable 
about the socio-cultural context within which they operate, and how culture and gender 
norms may promote or constrain uptake of particular prevention interventions. However, the 
fact that cultural prescriptions may impede CAB inputs and that some prevention 
interventions may present gendered challenges was not always anticipated by trial 
implementers.  
 
1.3 Power dynamics 
Given that HIV prevention research is often funded by high-income countries and conducted 
in lower- and middle-income countries, the potential for power dynamics to impact on 
research has been widely acknowledged both in the literature (e.g., Emanuel et al., 2004; 
Essack, Koen, et al., 2010; Gahagan et al., 2008; Macklin, 2010; MacQueen, 2011) and ethics 
guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). This is fairly 
predictable, given the differing positions, interests and mandates of various HVT 
stakeholders, including sponsors, investigators, host governments and communities. These 
concerns were borne out in this study, which revealed that real and perceived power 
dynamics were imbued across all phases of research. This data augments the guidelines and 
literature by detailing how power dynamics influenced the standard of prevention in practice.  
 
One of the most common appraisals of power can be found in French and Raven’s (1959) 
typology of five power bases. They contend that A’s power over B is determined by: 1) A’s 
ability to provide benefits to B and the extent to which B believes A controls these rewards 
(reward power); 2) A's ability to punish B if B does not comply with A's wishes (coercive 
power); 3) A's possession of special knowledge or expertise (expert power); 4) A's lawful 
authority to influence B (legitimate power); and 5) the extent to which A appeals to B or B 
identifies with A (referent power). This model is applied to the sections on power dynamics 
below.  
 
1.3.1 Power dynamics at protocol development level 
The protocol development committee was portrayed as the primary decision-making body in 
terms of the standard of prevention. In theory, this committee, with representatives of key 
stakeholders from sponsoring and host countries, is likely to be characterised by power 
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differentials (real or perceived). This was confirmed by data which revealed perceptions that 
power dynamics impact on standard of prevention decision-making.  
 
The negotiating power of stakeholder representatives within the protocol committee was 
perceived as imbalanced in favour of sponsor representatives. GPP guidelines 
(UNAIDS/AVAC, 2011, p. 18) recognise the ubiquitous presence of power dynamics 
between “funders and funding recipients with respect to a range of issues, such as decision-
making processes, priority setting, control of resources, and equitable recognition of input.” 
Frustrations at these pervasive inequalities in power were revealed in some interviews where 
the rhetorical device of ‘othering’ was observed in discussions about the sponsor. The 
sponsor was sometimes depicted as the other – “not on the same boat” (Z5, site staff, site 2) 
as other stakeholders with reference to protecting participants. ‘Othering’ entails identifying 
those deemed as different from oneself or the mainstream and “can reinforce or reproduce 
positions of domination and subordination” (Johnson et al., 2004, p. 253). While the group 
typically referred to as the other is often the subordinate and marginalised group (Johnson et 
al., 2004), in this research sponsors were perceived to straddle both groups, as explained 
more fully below.  
 
Firstly, sponsors were argued to be the dominant group with regard to their command of the 
decision-making power (cf. UNAIDS/AVAC, 2011) and to hold the upper-hand in standard 
of prevention negotiations through the subjection of funding recipients to rigid funding 
policies. Anxiety, albeit from one respondent, that being too demanding may result in sponsor 
‘shopping’ for more amenable trial sites (cf. Schüklenk, 2010; Upton, 2011) illuminates the 
perception of the sponsor as omnipotent – there was a perceived threat that sites were 
compelled to restrict their budgetary requests to comply with sponsor policy or risk being 
deserted in a very competitive funding environment. Concerns that requiring sponsors to 
assume the responsibility of providing prevention services may make sites less attractive to 
some funders, were also raised at an introductory consultation for the present study (Essack et 
al., 2009). These sentiments also hinted at uneasiness that sponsors may ‘prey’ on less 
experienced and vulnerable sites, tipping the negotiations further in the sponsor’s favour. 
This evokes concern about the potential for exploitation inherent when developed countries 
conduct research in developing country contexts (cf. Emanuel et al., 2004; Macklin, 2004). In 
this regard, it is argued that collaborative partnerships between stakeholders in the sponsor 
and host countries may minimise the possibility of exploitation (Emanuel et al., 2004). 
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However, some respondents in this study indicated their frustration with inflexible funding 
policies and questioned whether the protocol development process was truly collaborative.  
 
Secondly, sponsors were also marginalised as ethically ambiguous in that they were 
perceived as protecting their own interests rather than being concerned about the welfare of 
participants (see Chapter 7). It is not surprising that ‘othering’ discourse was evoked in 
interviews since research stakeholders involved in determining the prevention package had 
various competing interests (cf. UNAIDS/AVAC, 2011), which may reinforce power 
imbalances.  
 
Despite concerns of power asymmetry between sponsors and researchers, this data also 
indicated that investigators represented on the protocol committee wielded considerable 
decision-making authority in standard of prevention determinations. For example, while 
sponsor policy dictated that funds could not be used for VMMC and STI treatment, 
investigators “pushed very hard” (Z9, network representative) to ensure that a 
comprehensive prevention package was ensured for trial participants. Therefore, rather than 
victims of a skewed power dynamic where sponsors control the resources and researchers 
compete for these resources (reward power), investigators are also powerful influencers of 
decisions and showed resolve in ensuring a ‘state-of-the-art’ prevention package for 
participants. This is in line with suppositions that PIs “are key decision-makers in the 
research hierarchy” (Haire, 2013, p. 2).  
 
However, there were key differences in the standard of prevention across trial protocols – in 
the phase I trial, a comprehensive prevention package was not written into the protocol; 
neither was such a package offered in some of the other trials referenced by respondents in 
this study. This may suggest that investigator influence worked in tandem with other factors 
to determine the standard of prevention, including the phase of the trial. Alternatively, this 
influence could be investigator-specific – reliant on the personal characteristics and 
convictions (referent power), as well as experience (expert power) and perceived power of 
the investigator. The latter, based on individual characteristics, present an arbitrary criterion, 
unlikely to be possessed by all investigators. Therefore, less experienced or less powerful 
investigators are unlikely to be as vociferous in their demands. In such circumstances, it is 
plausible that a lower standard of prevention could be settled upon during protocol 
development.   
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In terms of community input into the protocol, one of the key challenges with authentically 
and meaningfully engaging communities in protocol development was the presence of an 
“inherent power dynamic” between sponsors/researchers and the lay community. Further, the 
current discourse on community partnership in research does not adequately recognise the 
entrenched power imbalances between communities and trialists (West Slevin et al., 2008). 
Many CAB and community members do not possess the basic tools necessary to engage, 
partner or negotiate constructively in debates on science, protocols (West Slevin et al., 2008) 
or the standard of prevention. Similarly, at a consultation on standards of prevention, 
participants raised concerns about whether the requirement for “‘negotiation’ is realistic 
given the knowledge and power differentials that often characterize the relationships between 
a research enterprise and community advisory structures” (McGrory et al., 2010, pp. 20-21). 
These power inequities create scepticism regarding whether communities can make 
meaningful inputs into standard of prevention decisions (cf. Macklin, 2010). 
 
In recognition of this potential imbalance of power, CAB representatives on the protocol 
committee were reported to have received network-provided support, including capacity 
building on standards of prevention, in order to facilitate their meaningful engagement and 
participation in the protocol development process. This practice is in line with 
recommendations in normative frameworks (MRC, 2003; Tarantola et al., 2007; 
UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) to develop the capacity of communities to 
make decisions. Community engagement should aim to minimise power differentials and 
create mechanisms for addressing deep-rooted power differentials (West Slevin et al., 2008).  
 
In terms of within-stakeholder power differentials, it was reported that the manner in which 
CAB representatives were selected for protocol committees perpetuated perceptions of 
marginalisation among some CAB members at other sites. Similarly, investigators at some 
sites perceived a more limited role for themselves in making substantive inputs into the 
standard of prevention; rather, this role was advanced to the national PI or protocol chair. 
Challenges with ensuring meaningful community engagement reported in this study reflect 
pragmatic and logistical constraints, and the need for improved research literacy, rather than 
disagreement with ethical norms for community engagement.  
 
Relationships of power inform the quality of community engagement (Upton, 2011). The 
ideals of community engagement embodied in ethics guidelines (MRC, 2003; 
237 
 
UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) reflect high expectations when compared to 
on the ground experiences (Upton, 2011). Therefore, while the protocol team ticks the boxes 
for collaborative decision-making, given the nominal representativity of key stakeholder 
groups, this data questions: 1) whether inherent power dynamics between and within 
stakeholder groups compromise the consultative and inclusive nature of such decisions and 2) 
given observed power differentials, whether negotiation of the standard of prevention is the 
most suitable mechanism for decision-making.  
 
1.3.2 Power dynamics at protocol review level  
Ethics guidelines recommend that community representatives participate in the review of the 
trial protocol (UNAIDS/WHO, 2012) and make inputs into the informed consent process 
(MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). Across sites, CAB 
representatives were involved in the review of relevant study materials, including ICFs and 
protocol summaries, and at some sites, CAB representatives were able to review the protocol 
in its entirety. Data from this study revealed the perception by some, that CAB review of 
study materials and/or protocols was a tokenistic exercise in community engagement. 
Simultaneous review of protocols by REC members and CABs was considered by some as 
disingenuous and limiting the power of CABs to make substantive inputs into protocols. This 
perception was challenged by the assertion that there have been instances where CAB input 
has resulted in changes to the protocol, even post-REC approval.  
 
CAB members expressed frustration that they had limited authority and no legal power 
(‘legitimate power’) to demand changes to protocols. The SA National Health Act (2003) 
makes the ethical review of research a statutory requirement, with RECs considered the 
primary protectors of human research participants (Dhai, 2005). The National Health Act 
(2003) recognises two roles for RECs, namely, 1) reviewing research and ensuring that it is 
relevant; and 2) granting approval for research when it meets ethical standards. Unlike this 
power bestowed to RECs by law (NHA, 2003), it has been contended that there are no legal 
requirements for community oversight of research in South Africa (Reddy et al., 2010).  
 
While guidelines emphasise that the desired relationship between stakeholders is that of equal 
partners (UNAIDS/AVAC, 2011), perceptions of power imbalances are likely to strain the 
ability to operate as equals (cf. Cargo & Mercer, 2008). Inequalities in power can be 
accentuated in circumstances where there is an imbalance in literacy, education and economic 
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resources (UNAIDS/AVAC, 2011) or legal authority. In order to achieve meaningful 
participation, such structural power imbalances between stakeholders should be recognised 
and strategies implemented to overcome them (UNAIDS/WHO, 2012). Key strategies could 
include stakeholder outreach, engagement and education (UNAIDS/AVAC, 2011; 
UNAIDS/WHO, 2012), including developing stakeholder knowledge and understanding of 
the research process and fostering research literacy (McGrory et al., 2010; UNAIDS/AVAC, 
2011). Meaningful stakeholder engagement is essential for building research literacy. 
Reciprocally, improved research competency is likely to facilitate the active and meaningful 
engagement of stakeholders in the research process (UNAIDS/AVAC, 2011). In South 
Africa, findings regarding HIV-related knowledge have been mixed (van Loggerenberg et al., 
2012), with relatively low knowledge of certain HIV risk-reduction measures reported in 
some studies (Shisana et al., 2009) and a recent regression in public knowledge of HIV and 
HIV prevention (Shisana et al., 2014). Therefore, to ensure effective decision-making, CABs 
need ethics and research literacy training so that they are able to critically evaluate study 
protocols and actively engage with the research.  
 
Some commentators have suggested another mechanism to address concerns about unequal 
legitimate power and truly enable the CAB’s responsibility to protect participants and 
community members. It is argued that CABs “must have real power and binding decision 
making authority, equal to that of a researcher or Research Ethics Committee” (Reddy et al., 
2010, p. 7). The argument that CABs have no legal authority is debatable however, since the 
National Health Act affords legal weight to national ethics guidelines, including MRC 
(2003). These guidelines (MRC, 2003) recommend community inputs into all phases of the 
research. The gap between guidelines and practices is however perpetuated by the absence of 
guidance for RECs on how to enforce principles of community engagement in research, 
including the implementation of GPP guidelines (UNAIDS/AVAC, 2011). Further, data from 
this study indicate that CAB knowledge of both substantive and implementation issues on the 
standard of prevention, was inadequate. Challenges in grappling with substantive issues 
identified in this study may reflect that in the past CABs were involved primarily in the 
procedural aspects of research, where rather than determining benefits, their role was to 
communicate risks and benefits to participants and the wider community (Cox, Rouff, 
Svendsen, Markowitz, & Abrams, 1998; Morin et al., 2008; Strauss et al., 2001). Further, 
Slack (2014) identified the concern that “unreasonable” requests may be solicited during 
consultation processes with CABs. While attractive from a collaborative and participatory 
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perspective, before considering ratifying the legitimate power (French & Raven, 1959) of 
CABs, significant efforts must be made to enable CABs to make empowered and valid 
decisions.  
 
In this study, CABs’ perception of their power or powerlessness was also related to their 
specific roles. For some, changing the name of the CAB was perceived to fundamentally 
encroach on their role. The rhetorical power of changing the name from ‘community advisory 
board’ to ‘community research support group’ perpetuated perceptions that the advisory 
power of CABs was meaningless since “the power of advising had been taken away” (C1, 
site staff, site 1). This frustration suggests that CAB members place immense value in their 
“advisory” role to sites and communities. Through their Masikhulisane training (Galloway, 
2005), CABs reported that one of their key roles was advocating for trial participants. 
However, given ethics guidelines’ (UNAIDS/WHO, 2012) emphasis on maintaining 
participants’ confidentiality, at most sites CABs were denied direct access to participants. 
Where such relationships between CABs and participants were encouraged, CABs perceived 
access to participants as a “powerful strategy” in fulfilling their role as advocates (Slack, 
2014).  
 
The need for improved capacity of CABs and RECs to critically review protocols in terms of 
the substantive issues was noted by respondents. A lack of capacity in CABs and RECs to 
review critical issues like the standard of prevention tips the balance of power in favour of 
science rather than the welfare of participants. Concerns that poor research literacy may 
impede the ability of some CABs to actively engage in research, including the review of 
study protocols have been raised elsewhere (Koen et al., 2013; West Slevin et al., 2008). 
However, lack of scientific understanding does not automatically preclude active community 
participation in such decisions. While poor scientific language and understanding may be an 
impediment, there are many examples of where communities have found innovative ways of 
communicating and explaining complex scientific concepts (Ndebele, Wassenaar, Munalula 
& Masire, 2012; Upton, 2011). For example, the concept of a vector is explained as 
analogous to a spoon used to get sugar from a bowl into a cup of tea (Upton, 2011). Such 
clear explanations dissolve divisions in terms of cultural understandings and educational 
levels, especially where deficits in science education continue to be problematic for most 
South Africans (Upton, 2011). UNAIDS/WHO (2012, p. 22) recommends “capacity-building 
programmes in the science and ethics of biomedical HIV prevention research by relevant 
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scientific institutions and local and international organisations” as well as “early involvement 
of communities in the design and implementation of HIV prevention product development 
plans and protocols”. 
 
REC review of the standard of prevention in protocols and ICFs was limited to ascertaining 
the presence of such a package, rather than addressing the more substantive issues. Similarly 
to reports in this study, a previous survey of South African RECs also indicated that 
consideration of substantive ethical issues – like standards of prevention and care – are 
impeded by procedural and bureaucratic demands (Moodley & Myer, 2007). Findings of 
variable research ethics capacity on RECs and the need to build health research ethics 
capacity on these committees (expert power) is supported by previous research. Milford, et al. 
(2006, p. 5) found the majority (73%) of REC members who had previously reviewed HVT 
protocols “agreed that there was a lack of general and sufficient ongoing training for 
members in health research ethics.” In response to this need, there have been several 
initiatives to build health research capacity in Africa (Ndebele et al., 2014), including: 
funding from the WHO-UNAIDS African AIDS Vaccine Programme (AAVP); the 
African Malaria Network Trust (AMANET); the National Institutes of Health’s (NIH) 
Fogarty International Center’s South African Research Ethics Training Initiative 
(SARETI); the International Research Ethics Network for Southern Africa (IRENSA); 
the West African Bioethics Initiative (WAB); the Wellcome Trust; the European 
Union (EU); the Global Bioethics Forum; the World Health Organization (WHO), and 
the EU European Developing Countries Clinical Trials Partnership (EDCTP) which 
partially funds, for example, a high-level online capacity building programme known 
as TRREE (IJsselmuiden, Marais, Wassenaar & Mokgatla-Moipolai, 2012, p. 3).  
 
1.3.3 Power dynamics at protocol implementation level 
The power to influence standard of prevention decisions was also observed at 
implementation. This study found that provider beliefs about a prevention intervention may 
temper if, how and when it is provided to participants. For example, respondents identified 
concerns about mechanical promotion of condoms, anxieties about promoting VMMC in 
certain cultural contexts, and concerns about the efficacy of PEP – all of which point to the 
critical role of provider attitudes in uptake of services (Bharat & Mahendra, 2007; Hoffman, 
Mantell, Exner & Stein, 2004). In this way, providers have some influence over the 
prevention package offered to trial participants and/or participant uptake of prevention 
interventions. According to French and Raven’s (1959) typology, this influence can be 
classified as expert power, since research staff may be perceived as possessing special 
knowledge or expertise. Further, power inequalities are inherent in patient-provider 
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relationships (UNAIDS/AVAC, 2011) and this may transcend to research. Authority usually 
resides with people in particular positions (“legitimate power”) or with special expertise 
(“expert power”) (Cheng, 2009). Deference to authority and/or expertise is still a feature of 
much South African culture given its history of colonisation. Previous research on 
stakeholders’ perspectives on the ethics of HVTs in South Africa identified this concern: 
“…and coming from this disenfranchised type of history. . . most participants are still under 
that belief that the investigator knows it all…” (Essack, Koen, et al., 2010, p. 14). The 
underlying belief in the omniscience of medical researchers (Newman et al., 2011), may hold 
significant power in framing participant choices. It has been observed that average people 
submit to the demands of authority with very little conscious deliberation and that even mere 
symbols of authority (e.g., titles, uniform, insignia, epaulettes) may be enough to elicit 
compliance (Cheng, 2009).  
 
That the role for providers in determining standard of prevention options for participants may 
increase as the standard of prevention evolves, was identified by a PI at one site. As the menu 
of prevention tools expands, providers may increasingly be tasked with helping participants 
determine the best combination of services for their individual risk profiles. Enabling 
participant preferences in terms of which prevention options to take up is in line with the 
ethical principle of respect for autonomy. Respect for autonomy obligates researchers to 
recognise trial participants as individuals who have the right to make their own decisions, 
even when such decisions are based on values or worldviews that do not accord with those of 
the provider (Entwistle, Carter, Cribb & McCaffery, 2010). Respect for autonomy also entails 
that researchers create conditions necessary for participants to exert their autonomous choice. 
It would extend to ensuring access to prevention options and ensuring comprehensive 
counselling on all prevention options in enabling participants to make their own decisions 
about which prevention interventions, if any, are most appropriate for them. Therefore, 
adequately informed, skilled and motivated providers are central to participant uptake of 
services.  
 
2. Defining the standard of prevention through consultation, consensus, and 
negotiation 
Ethics guidelines do not prescribe a process for decision-making (Haire, 2013; Philpott, 
2011) but different mechanisms for standard of prevention determinations are recommended, 
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including, agreement/consensus (UNAIDS/WHO, 2012), consultation (MRC, 2003; 
UNAIDS/WHO, 2012) and negotiation (UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012).  
 
These data indicated support, especially among CAB respondents, for consultation on the 
standard of prevention – grounded in the ethical principle of respect for communities (cf. 
Weijer, 1999). However, this ethical recommendation was questioned by some respondents in 
this study as potentially opening up consultation to too many stakeholders. This concern may 
derive from the redefining of ‘community’ as all research stakeholders (cf. UNAIDS/AVAC, 
2011), which has been argued as failing to “clarify who exactly researchers should engage 
with, at what time-points, and to what ethical end” (Koen et al., 2013, p.147). Findings from 
a parallel quantitative study indicated that respondents did not overwhelmingly support the 
stakeholder consultation recommendation (Moorhouse et al., 2014).  
 
In resonance with perceptions of respondents in this study, being over-inclusive in selecting 
stakeholders for consultation has been suggested to impede good stakeholder engagement 
(Koen et al., 2013; McGrory et al., 2010). Further, requiring all stakeholders to contribute to 
all levels of the research process without considering their expertise or their priorities is 
incompatible with the principle of respect for communities (Koen et al., 2013). 
Commentators have argued that while communities should be involved in decisions that 
affect them, decisions which require high-level scientific or technical expertise may be 
exempt (Koen et al., 2013). Meaningful engagement, as opposed to tokenistic engagement, 
would require that relevant stakeholders be involved in decision-making “about trial aspects 
for which they have expertise” (Koen et al., 2013, p. 147). Similarly McGrory et al. (2010) 
contend that while it may not be substantively or logistically feasible to consult all research 
stakeholders on all issues, it may be more appropriate and practically achievable to identify 
which specific stakeholders can best address different aspects of a trial (McGrory et al., 
2010). The procedural recommendation requiring negotiation among research stakeholders 
that considers trial feasibility may not lend itself to inputs from those without requisite 
scientific and statistical expertise. Given that technical value judgements are warranted for 
feasibility determinations, this ethical recommendation has been criticised as favouring the 
research enterprise since feasibility determinations “can only be made by the research elite” 




Secondly, these data identified challenges with how best to operationalise the ethical 
requirement for stakeholder consultation. Respondents were particularly averse to large 
consultative meetings, such as those suggested by the good governance model (Tarantola et 
al., 2007). In practice, consultation formats varied and included formal and informal 
dialogue. The involvement of various stakeholder representatives in the development and 
review of protocols was also regarded as an adequate consultative device. Therefore, while 
the ethical requirement of stakeholder consultation on standards of prevention was supported, 
guidelines need more specification in terms of which particular stakeholders to consult on 
which aspects of the standard of prevention, what format such consultations should take (e.g., 
meetings, protocol reviews) as well as the frequency and time-points of consultations (cf. 
Koen et al., 2013; Moorhouse et al., 2014). Consideration should be given to refining the 
good governance model to reflect these concerns.  
 
Findings from this study indicate that trial implementers and other key stakeholders 
questioned ethics guideline requirements that trials should not be conducted without the 
agreement of all research stakeholders on the standard of prevention (UNAIDS/WHO, 2012). 
This recommendation does not consider that consensus may be difficult to achieve and 
evaluate (Essack, Slack, et al., 2010). There is obvious value in consulting relevant research 
stakeholders on how best to operationalise standard of prevention decisions, “however 
substantive ethical decisions are not best achieved by consensus” (Stobie & Slack, 2010, p. 
151). Some commentators have called for a procedural approach focussed on structured 
negotiating processes for making decisions on the evolving standard of prevention (Hankins 
et al., 2009) and it is anticipated that large consultative meetings will help clarify obligations 
to participants (Tarantola et al., 2007). Still, given the lack of consensus on what constitutes 
appropriate standards of prevention at a substantive level, “this approach only reassigns the 
difficult struggle with norms and standards to consultative meetings” (Stobie & Slack, 2010, 
p. 151). Decision-making that is procedurally fair may not necessarily result in the morally 
right outcome (Ashcroft, 2008). Therefore, soliciting the perspectives of affected parties may 
be morally relevant but not morally definitive (Essack, Slack, et al., 2010; Grady et al., 2008; 
Slack & Stobie, 2010). Unless consultations are informed by substantive and normative 
principles and guided by formal structures for consensus decision-making, conflict and 
contention are likely; such consultations run the risk of limiting the input of less powerful, 
less vocal, and less intractable group members (Johnson-Masotti, Pinkerton, Holtgrave, 
Valdiserri & Willingham, 2000; Philpott et al., 2011). 
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Negotiation is another mechanism for decision-making (Cheng, 2009) and “is a process of 
two (or more) parties combining their conflicting points of view into a single decision” 
(Zartman, 1977, p. 622, emphasis added). Since power pervades all facets of negotiation 
(Cheng, 2009), it is unclear whether negotiation best serves the process of decision-making 
on the standard of prevention as “the very idea of negotiation intuitively conjures images of 
power contests and tough bargaining” (Cheng, 2009, Power section, para. 1). By definition 
then, negotiation is most likely to result in a compromise position rather than the substantive 
standard established in ethics guidelines. Asymmetries in power are likely to influence 
standard of prevention negotiations and determine the final outcome (Cheng, 2009). One of 
the criticisms of proceduralism in ethics is that processes of consensus and negotiation are 
favoured over establishing substantive norms (London & Zollman, 2010) and such processes 
may not best serve values of fairness (Schüklenk, 2010).  
 
This was not just a hypothetical concern of some respondents, but has been evinced by this 
data which showed the pervasive influence of power during protocol development, review 
and implementation, as well as research showing that more powerful countries (e.g., the US) 
dominate exchanges with less powerful counterparts (Cheng, 2009). Previous research has 
also demonstrated that strict sponsor policies have influenced care and prevention services 
offered to participants (Heise et al., 2008; Philpott et al., 2010), including regarding protocol 
omissions on the care to be provided to participants (Slack, 2014).  
 
“Current ethical guidance in HIV prevention trials places disproportionate emphasis on 
negotiation, which given the substantial inequities between the negotiating parties is likely to 
result in outcomes that suit the interests of research enterprise over the interests of the 
research participant” (Haire, 2013, p. 266). To date, most CABs at sites have not been tasked 
with the responsibility of ‘negotiating’ evolving standards of prevention in trials (McGrory et 
al., 2010). This study found that practices for protocol development and review reflect efforts 
to engage community representatives to make inputs into the design of standards of 
prevention (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). However, like with 
HIV care and treatment (Slack, 2014), the recommendation for negotiation on standards of 
prevention was not realised in practice. It has been argued elsewhere (Haire et al., 2013) that 
structural inequalities between research and community representatives and between high- 
and low/middle-income countries constrain the ability to ‘negotiate’ the standard of 
prevention. As evidenced by inequalities in power, research literacy and scientific expertise, 
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realising the ‘ideals’ of negotiation will require significant improvements in the capacity of 
stakeholders to engage at this level (West Slevin et al., 2008), including a shared 
understanding of the scientific, ethical and political implications of such decisions (McGrory 
et al., 2010). These data support calls for the development, piloting and evaluation of 
frameworks to operationalise ethical requirements for consultation, consensus and negotiation 
(McGrory et al., 2010; Philpott et al., 2011).  
 
In an assessment of GPP guidelines at research centres in eastern and southern Africa, 
respondents placed lower relevance at baseline on stakeholder engagement in protocol 
development and standards of prevention (Ngongo, Hannah, et al., 2012). A quantitative 
assessment of key stakeholders’ perspectives on ethical guidelines also found that 
respondents did not overwhelmingly support the recommendation for stakeholder 
consultation for adding new tools to the prevention package (Moorhouse et al., 2014). Low 
scores were also awarded on dimensions of perceived protection for the recommendations of 
stakeholder consultation and negotiation; and overall the most poorly ranked 
recommendation was that stakeholders should negotiate adding new methods to the risk-
reduction package (Moorhouse et al., 2014). This suggests that these recommendations are 
perceived as challenging for respondents and difficult to implement and understand. 
 
3. Ensuring access to HIV prevention interventions: Sourcing funding and 
establishing partnerships 
Ethics guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) require that 
trial participants are ensured ‘access’ to HIV risk-reduction interventions. Ensuring access to 
prevention interventions through a combination of on-site provision and referral has been 
reported in other empirical studies (Haire, 2013; Heise et al., 2008; MacQueen et al., 2008; 
Ngongo, Priddy, et al., 2012). This study found that South African HVT implementers favour 
the more onerous direct provision of prevention interventions over referral. The reasons for 
this preference included better monitoring of uptake, efficiency in service delivery, and 
improved participant retention. However, the ability to offer all prevention interventions on-
site was inhibited by funding constraints.  
 
3.1 Funding standard of prevention interventions in HVTs  
Guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) obligate sponsors 
and researchers to ensure access (directly or via referrals) to prevention interventions, but 
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exactly who should assume the cost burden has been subject to debate. There has been some 
agreement that ensuring access to prevention interventions is a shared responsibility among 
sponsors, researchers and host governments (Macklin, 2008; Tarantola et al., 2007; 
UNAIDS/WHO, 2012) and that novel partnerships for ensuring access to prevention 
interventions should be developed and explored (Tarantola et al., 2007).  
 
HIV prevention trials are expensive to conduct (MacQueen, 2011). For example, HVTN 505 
was estimated to cost between US$75-80 million (RTWG, 2013), a substantial amount in a 
finite and potentially dwindling pool of resources. Availability of research funding may 
become increasingly difficult given imminent budget cuts due to potential sequestration of 
funds from those federal agencies supporting HIV vaccine research (RTWG, 2013). 
Financing and resources for HIV prevention trials are obtained from several donors, each 
with their own interests, missions, mandates and policies – all of which impact on both the 
design and conduct of trials (Philpott et al., 2010). The US remains the largest investor in 
HIV prevention research and development, with US government agencies accounting for 
74% of the total HIV vaccine research and development funding – 66% of which was 
contributed by the NIH (RTWG, 2013). In 2012, the NIH funded more than two-thirds of the 
ongoing HVTs (RTWG, 2013).  
 
Notwithstanding this laudable investment in HIV vaccine research, one of the challenges of 
conducting research in developing country contexts is that the research process and funding 
are controlled by the sponsor (usually from a developed country context) and these “funds 
come with specific instructions on how the money should be used to the satisfaction of the 
donor” (Gwandure & Mayekiso, 2012, p. 174). Complexities regarding funding appeared to 
permeate both the design and implementation of the prevention package, and had 
implications for current and evolving standards of prevention. The standard of prevention 
was influenced by funding in two primary ways: it was constrained in terms of sponsor policy 
on what constituted allowable costs in research and it depended on whether research 
networks and investigators acquired funding from alternative sources or partnered with 
service providers to ensure access.  
 
Donor funding comes with strict ‘terms and conditions’ (Senanayake & Hamm, 2004). For 
example, donors like the NIH have policies that prevent the use of donor funds for non-
research related care (Heise et al., 2008; Philpott et al., 2010). In its grants policy statement 
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(2013), the NIH specifies that as a federal grantor agency, it is responsible to Congress and 
US taxpayers in executing its mission to facilitate research both cost-effectively and in 
compliance with applicable rules and regulations. Policymakers have interpreted the NIH’s 
authorising legislation as barring the use of taxpayer dollars for the procurement of drugs or 
the provision of non-research related care (Philpott et al., 2010). Similarly, respondents in 
this study, including research network representatives and investigators, interpreted the 
sponsor policy as prohibiting the purchase of drugs for the treatment of STIs or for PEP, and 
the provision of VMMC. Concerns that funding restrictions may limit which prevention 
methods can be ensured through donor funds are anticipated by some guidelines 
(UNAIDS/AVAC, 2011). On the contrary, Haire (2013) argues that NIH policy does not 
restrict the provision of standard of prevention interventions, including STI-based HIV 
prevention services and condoms. These diverse interpretations affirm the need for sponsors 
to develop clear and understandable funding policies (Heise et al., 2008).  
 
Respondents perceived sponsor policy as rigid, non-negotiable and a ‘cop-out’ – by 
definition, a ‘cop-out’ entails avoiding doing something that one ought to do (Oxford 
Dictionaries, 2014) or failing to fulfil a commitment or responsibility (American Heritage 
Dictionary of the English Language, 2009). Respondents argued that sponsor policy and 
related funding restrictions made it possible for sponsors to renege on their ethical obligations 
to ensure access to HIV risk-reduction interventions for trial participants. In this way, 
sponsors were sometimes portrayed as flouting their ethical responsibilities to advance their 
own interests to carry out research efficiently and effectively, given their primary mission to 
conduct research as opposed to providing health benefits to research participants (cf. 
Macklin, 2004). Further, because sponsors controlled the funding, some respondents 
considered them to command supreme decision-making authority to the extent that standard 
of prevention determinations were perceived as “obscured at the top, with ill-defined or 
inconsistent donor policies that restrict what is considered ‘possible’” (Heise et al., 2008, p. 
75).  
 
The potential for sponsors’ policies to impact on standards of care and prevention have been 
reported in other empirical studies. Findings from the HPTN’s partnering for care study 
indicated that researchers “were keenly aware that the funding they received for research had 
strict rules governing how it could be used” (MacQueen et al., 2008, p. 11). The standard of 
care mapping study conducted by the GCM found that donor policies that restricted how 
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research funds may be used, limited the level of care provided to participants (Heise et al., 
2008; Philpott et al., 2010). In contrast, Haire (2013) found that most investigators reported 
that sponsor policies positively influenced the provision of prevention services. Still, some 
respondents did indicate frustration with funding policies, for example, “...[w]e informed 
community leaders of what we could offer, but there was not much we could negotiate! It is 
often assumed that the researchers make the decisions as to what to offer, but in many cases, 
our hands are tied” (Haire, 2013, p. 102). The metaphor ‘our hands are tied’ echoes the 
frustration of respondents in the present study, that there was little that could be done to 
remedy limitations imposed by sponsor funding policy. Similarly, sponsors may argue that 
their ‘hands are tied’ by the authorising legal framework and accompanying rules and 
regulations. Constraints imposed on funding by US federal regulations have also been 
critiqued because they preclude compensation for research-related injury (Cleaton-Jones & 
Wassenaar, 2010; Mamotte et al., 2013). However, the recent U.S. Presidential Commission 
for the Study of Bioethics Report (2011) recommended changes to policy and that 
participants are morally entitled to compensation for research-related injury. Despite the 
constraints imposed by sponsor funding policy, trial sites did actually provide access to a 
range of HIV prevention interventions.  
 
3.2 Partnering for prevention 
Guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) require that 
counselling should be provided to participants and that access to prevention interventions 
should be ensured. This distinction in obligations (actually provide versus ensure access) may 
explain why counselling was the only prevention intervention described in the phase I 
protocol and in the ICFs for both trials. While donor funding supported the provision of risk-
reduction counselling (by paying salaries of counsellors), other components of the prevention 
package were ensured through various strategies. More specifically, male and female 
condoms were procured from the DoH, at no cost to sites. For STI treatment, sites had to 
engage the DoH to dispense STI treatment on-site, or themselves raise funds; alternatively 
they made referrals to the public healthcare sector. Further, the research network raised funds 
to pay for VMMC in the phase IIB trial only. Various strategies were used to ensure on-site 
access to PEP, including, through a “site kitty” (Slack, 2014), and/or procured from the DoH 
or other sources like PEPFAR, or provided through the study budget. Alternatively, 
participants were referred to the public healthcare sector where PEP could be accessed in 
cases of sexual assault only.  
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Restrictions on sponsor funds for care provision not necessary for scientific validity or 
participant safety (Philpott et al., 2010) have led researchers to partner creatively with other 
stakeholders in ensuring access to key prevention services. Site practices for ensuring access 
to prevention interventions indicated that the burden of providing prevention interventions is 
shared among sponsors, researchers, government service providers, and in some instances 
private donors, as recommended in guidelines (cf. UNAIDS/WHO, 2012) and by key 
commentators (Macklin, 2008; Tarantola et al., 2007). Further, sourcing alternative funds and 
partnering with service providers to ensure access to prevention interventions resonates 
squarely with guideline recommendations (UNAIDS/AVAC, 2011).  
 
Given this complex funding environment, site practices indicated the critical role of 
collaborative partnerships in ensuring access to standards of prevention. The South African 
DoH (and by inference the government) emerged as a key partner in ensuring access to 
prevention services, serving as both a procurement source and a service provider. A key 
characteristic of the success of these partnerships was that they were mutually beneficial – in 
exchange for free condoms and STI treatment, sites provided the DoH with statistics that 
contributed towards provincial and national performance targets. These data have indicated 
that host country governments through provincial and local healthcare systems have taken 
responsibility in delivering prevention interventions to participants. Such partnerships ensure 
that national authorities are fully engaged in the decision-making process and that 
interventions are sustainable post-trial (Tarantola et al., 2007). Still, engaging this partner was 
associated with some tensions, for example, limited accessibility of female condoms or 
constraints on STI treatment at public sector facilities, as predicted by some authors 
(Chatterjee et al., 2006). Further, the range of prevention interventions that could be ensured 
through this partnership were confined to their national availability (cf. UNAIDS/AVAC, 
2011). At the time that the two trials were initiated, the standard of prevention in South 
Africa included HCT, male and female condoms, and syndromic management of STIs. 
VMMC was not yet rolled out as an HIV prevention intervention (de Bruyn, 2009) and PEP 
was (and still is) limited to occupational injuries and for rape survivors (SANAC, 2011) who 
have reported the sexual assault to the police.  
 
Reported practices related to adding VMMC to the prevention package indicated that funding 
complexities were also relevant as the standard of prevention evolved. Since sponsor funding 
was perceived to prohibit the provision of VMMC in HVTs, funding was sourced by the 
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research network from the product developer for the phase IIB trial. Network representatives 
confirmed that as the standard of prevention evolves, it remains unlikely that prevention 
interventions like PrEP or microbicides will be supported via donor funds, and that it will 
become increasingly important to develop strategic partnerships in order to source alternate 
funds (cf. Tarantola et al., 2007). The present data reaffirm recommendations for donors to 
“develop and implement funding policies that are clear and understandable, that are 
objectively and scientifically based, and that enable and encourage researchers to ratchet up 
the local standards of care in a manner that is sustainable even after a study ends” (Heise et 
al., 2008, p. 72). Similarly, the International Research Panel of the Presidential Commission 
for the Study of Bioethical Issues (2011) recommended that existing regulations need to be 
reviewed and refined given that clear, sound and harmonised rules promote efficiency and 
quality.  
 
Commentators, including some respondents in this study, have suggested that cost is an 
inadequate justification for not ensuring access to new scientifically validated or approved 
prevention interventions (e.g., Cowan & Macklin, 2014; Haire, 2013). However, data from 
this study indicated that in practice the standard of prevention ensured in HVTs depended on 
a host of factors including the study budget, donor policies, site availability of funds and the 
standard of prevention available in the host country. Therefore, cost is a relevant additional 
criterion to consider when making decisions to add a new prevention intervention to the 
prevention package (Jay et al., n.d.; McGrory et al., 2010; Tarantola et al., 2007).  
 
Researchers may increasingly call on their partnerships with government in ensuring access 
to prevention interventions given that the available prevention interventions offered in the 
public sector may evolve in the future. The current NSP (SANAC, 2011) specifically calls for 
the consideration of new modalities for HIV prevention, including PrEP, microbicides and 
PEP for all risky sexual exposures; however, it notes that further work is still required on the 
feasibility of implementing these strategies. The NSP states that policy decisions on the 
introduction of PrEP and microbicides will depend on scientific evidence of efficacy, 
guidance from international bodies and the registration of such interventions with the MCC 
for use (SANAC, 2011). Such policy-level deliberations consider scientific evidence from 
clinical trials, including factors such as cost-effectiveness, feasibility, scalability, and 
competing healthcare needs (Dawson, 2012).  
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In addition to the cost of ensuring access to interventions, as the standard of prevention 
evolves the need to increase the number of trial participants to meet study endpoints, will also 
amplify costs – all in a context of increasing research costs and diminishing budgets (Haire et 
al., 2012; RTWG, 2013). Together, these data indicate that diversifying funding sources, 
solidifying existing partnerships, and establishing new collaborations will be essential as the 
standard of prevention evolves and as South Africa seeks to expand trial site capacity to 
conduct large-scale efficacy trials towards the development of a licenced vaccine (Esparza, 
2013).  
 
4. Double standards of prevention 
Raging debates about ethical double standards in research emerged in 1997 over the PMTCT 
trials conducted in developing country contexts and evaluating experimental regimens against 
placebo-controls rather than the established effective intervention (ACTG076) that had 
become standard practice in the US (Angell, 1997; Lurie & Wolf 1997). Some contested that 
the use of placebo in these trials constituted a double standard in research ethics between 
developed and developing countries (Angell, 1997; Lurie & Wolf, 1997). However, others 
argued that the ACTG076 regimen was not affordable or feasible in developing country 
contexts; rather, the research question was whether the experimental intervention was better 
than the status quo of nothing (Varmus & Satcher, 1997). This controversy positioned those 
who argued for a universal standard against those who argued for a context-specific 
interpretation. These trials, deemed unethical by critics, demonstrated that a single dose of 
neviripine could effectively and sustainably reduce mother-to-child transmission of HIV, 
which had a profound impact on perinatal HIV treatment in developing countries, including 
South Africa (Coetzee et al., 2005; Colvin et al., 2007).  
 
The choice between ‘best-known’ and ‘best available’ standards of care as the comparator 
arm of clinical trials remains a fundamental ethical dilemma for trials in resource-constrained 
contexts (Dawson et al., 2014). Data from the present study revealed that concerns about so-
called double standards exist beyond the pre-occupation with ensuring parity between 
developed and developing countries. The theme of double standards captures this concern as 
well as variability in decision-making about current versus evolving standards of prevention 
and the potential for differences in standards of prevention both within and across trial sites 




4.1 Local versus international ‘state-of-the-art’ 
Contentions abound about whether the standard of prevention should be benchmarked against 
the best available in the world, the local standard of prevention, or somewhere in between. 
Some guidelines (UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) have argued that a ‘state-
of-the-art’ prevention package be ensured for participants. However, disagreement remains, 
even at the level of ethics guidelines (HPTN, 2009; UNAIDS/AVAC, 2011; UNAIDS/WHO, 
2012), about whether standard of prevention packages should be benchmarked on 
international or national standards. While the recommendation that state-of-the-art prevention 
interventions be provided to participants has generally been interpreted as benchmarked on 
universal best practice (Haire, 2013; Macklin, 2009b), guidelines also assert that clinical 
trials should be integrated with national prevention plans (UNAIDS/WHO, 2012) and that 
negotiations and discussions consider current standards of prevention and services available 
nationally and locally (UNAIDS/AVAC, 2011). These ambiguities open guidelines to 
multiple interpretations, which may create real differences in the standard of prevention for 
trial participants.  
 
Earlier versions of UNAIDS guidelines referred to ‘proven’ and ‘validated’ methods; these 
terms were contentious, and their replacement with ‘state-of-the-art’ was assumed to 
strengthen the guidance point (Macklin, 2012). However, data from this study indicated that 
rather than being unambiguous, the state-of-the-art standard is ‘in the eye of the beholder’, 
that is, a matter of personal opinion. The term ‘state-of-the-art’ was argued to be vague and 
enabling multiple interpretations as evinced by the lack of consensus even among 
respondents on what was considered state-of-the-art. Concerns that ‘state-of-the-art’ is too 
vague have been reported elsewhere (Haire, 2013; McGrory et al., 2010; Philpott et al., 
2011). The diversity of opinion on what constitutes ‘state-of-the-art’ contradicts the 
supposition that there is increasing consensus that a state-of-the-art prevention package 
should be provided to participants (Macklin, 2008). While it was acknowledged that 
vagueness permits flexibility given the evolving nature of standards of prevention as well as 
changing circumstances (cf. Macklin, 2012), vagueness may also enable the perpetuation of 
double standards. A parallel quantitative study (Moorhouse et al., 2014) found low scores on 
dimensions of implementability and understanding of prevention recommendations which 
may reflect that respondents struggle to interpret and operationalise key but broad concepts 




Respondents in this study, especially REC representatives, strongly endorsed that standards 
of prevention be benchmarked against national rather than international policy. This 
perspective closely resembles the position of HPTN (2009) guidelines which advocate for a 
prevention package that can be feasibly implemented into local health systems. Similar 
perspectives were articulated in terms of ancillary care (Slack, 2014). Some of the arguments 
in favour of this position included minimising concerns about undue inducement, reducing 
disparities between trial participants and their communities, and ensuring sustainability of 
interventions post-trial. This reasoning closely resembles arguments in HPTN guidelines 
(2009) critiquing the ‘state-of-the-art’ standard. HPTN guidelines (2009) were founded on 
social justice principles, which entail avoiding exploitation, treating people equally and 
making efforts to minimise health disparities. The challenge for researchers conducting 
research in developing contexts is “to improve health without taking unfair advantage of, or 
increasing, existing social inequalities” (HPTN, 2009, p. 10). Social justice demands that the 
standard of prevention not be radically superior to the current local standard of prevention as 
this would create inequities between trial participants and host communities (HPTN, 2009). 
While South African ethics guidelines (MRC, 2003) emphasise social justice among ethical 
principles, it also states that participants should receive services that they would not 
otherwise obtain.  
 
Universalists argue that the researcher’s primary obligation is to protect participants and that 
this would require importing standards of care and prevention from the developed world 
(Haire, 2013). Advocates of a universal standard contend that failure to provide state-of-the-
art interventions is unjust and would constitute ethical double standards (Heise & Wood, 
2005). Adopting the best international standard would also reduce the likelihood of 
inconsistencies among different sites in multicountry trials that may occur if standards of 
prevention are negotiated locally and based on local realities (Heise & Wood, 2005). 
However, the ideal of a universal fixed standard is not without challenges. Context is an 
important consideration because it impacts on determinations of feasibility and 
appropriateness of the intervention (Heise & Wood, 2005), as well as whether standards in 
guidelines can be applied in the actual research setting that presents unique political, social, 
economic, cultural and regulatory constraints and challenges (HPTN, 2009). For example, in 
practice, funding complexities and multiple other factors, constrain the implementation of the 
best available standard for all HVTs. Further, the ‘state-of-the-art’ is ever evolving (cf. Heise 
& Wood, 2005).  
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Relativists, in contrast, contend that community interests are best served by taking into 
account local realities; as such, the background standard of prevention should reflect the local 
baseline currently available in the community, even if that is nothing (Haire, 2013). 
Respondents in the present study adopted a middle-ground position, maintaining that ‘perfect 
should not be the enemy of good’. It was argued that the standard of prevention implemented 
in developed country contexts should not be imposed on developing contexts, where it is 
unlikely to be feasible. At a minimum, the standard of prevention in HVTs should be 
benchmarked on national standards, provided that this baseline is not wholly inadequate (cf. 
Heise & Woods, 2005). The present author supports the perspective that the standard of 
prevention be benchmarked against national rather than international standards, with the 
addendum that where scientifically validated prevention interventions are not nationally 
approved, sponsors, trial implementers, community representatives and research ethics 
committees should advocate for their approval. This is especially important given the 
potential for protracted approval in some contexts. The present researcher also endorses the 
provision of a higher standard of prevention than that locally available when it is feasible to 
do so, but contends that this would be morally praiseworthy rather than obligatory. In other 
words, researchers should make efforts to improve the standard of prevention but ensure that 
research remains relevant to the health context in which it is conducted (cf. Dawson et al., 
2014). This position most closely concurs with Shapiro and Benatars’ view that the standard 
of care: 
should be based on principles that promote fairer distribution of burdens and benefits, 
both short and long term for participants and communities. First, research should be 
undertaken in the best interests of trial participants by involving them in decisions 
around research design and implementation. Second, the dignity of participants should 
be respected, wherever they are in the world. Third, consideration should be given to 
the broader community benefit that could be achieved by raising the standard of 
healthcare through partnerships created by the research endeavour. That the ideal of 
first world healthcare cannot be achieved immediately in developing countries should 
not be a deterrent to efforts to raise existing levels of care. By setting high ideals and 
working towards them, the standard of care could be progressively ratcheted upwards 
(Shapiro & Benatar 2005, p. 44).  
 
The ambiguity regarding whether the standard should be ‘best-known’ or ‘best available’, 
was evinced in practice with the addition of VMMC. In some trials, participants were offered 
VMMC based on evidence of efficacy while others waited for national guidelines on VMMC 




4.2 Within-country differences in standards of prevention  
This study found differences in the prevention interventions offered to participants enrolled 
on different protocols at the same site and across different sites. In terms of VMMC, securing 
funding for one trial (phase IIB) but not others created within-site differences between 
participants enrolled on different protocols. Given that participants can only be referred to the 
public healthcare system in cases of sexual assault (cf. DoH, 2008), ensuring funding for PEP 
for all risky sexual exposures for selected trials was a cause of frustration, particularly for 
newer sites that did not enjoy the benefits of a “site-kitty” (Slack, 2014) to self-fund PEP. 
Therefore, where trials and sites use different approaches for prevention interventions (e.g., 
VMMC and PEP), this may create differences between participants enrolled in different 
protocols at the same site or between participants at different sites. These complexities may 
raise concerns about fairness if participants within the same country receive different benefits 
but endure the same level of risk.  
 
Findings of variability in standards of prevention are not new. Empirical data have shown 
that the standard of prevention implemented in trials is variable (Heise et al., 2008; Ngongo, 
Priddy, et al., 2012) and anything but standard (McGrory et al., 2010). For example, Ngongo, 
Priddy, et al. (2012) found that prevention interventions such as female condoms, VMMC 
and PEP were not provided consistently across ten IAVI research centres. However, data 
from the present study identify that differences stemmed from a range of factors including 
whether alternate funds were secured, whether the site was able to self-fund services or 
whether they referred participants to the public healthcare system. 
 
Ethics guidelines assert that protocols may vary in “modes of delivery” for prevention 
interventions (UNAIDS/WHO, 2012, p. 45), that negotiations should occur on a trial-by-trial 
basis (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) and that when funding 
restrictions limit which interventions can be provided, researchers should find alternative 
funding or establish partnerships to ensure access (UNAIDS/AVAC, 2011). This suggests 
that guidelines allow for some flexibility of approach to the implementation of standards of 
prevention. Some respondents valued the ability to make decisions on a site-by-site basis, 
although the unintended consequence of such decision-making may be inequitable outcomes 
for trial participants. Some commentators have endeavoured to develop a “standard 
approach” to prevention services (Ngongo, Priddy, et al., 2012, p. 1278) while others have 
argued that standardised approaches may be constraining if mandated (Slack, 2014).  
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Current ethics guidelines provide little direction on within-country differences on standards 
of prevention. However, an earlier version of GPP guidelines (UNAIDS/AVAC, 2007, p. 29) 
recommended that trial sponsors should ensure that core elements of the prevention package 
are consistent across trials and networks. This resonates with the views of some respondents 
in this study as well as some Ugandan consultation participants who “argued for developing a 
core, evidence-based prevention package that is feasible to deliver” (McGrory et al., 2010, p. 
20). In practice, this would entail mandating a standard of prevention package but allowing 
flexibility in the operationalisation thereof (e.g., on-site provision versus referral). This would 
minimise within and between site differences and ensure ‘reasonably commensurate 
outcomes’ for participants (cf. Slack, 2014). However, at present “no clear, specific 
international or national guidelines for the type of prevention package that must be provided 
in HIV prevention trials” exists (McGrory et al., 2010, p. 20).  
 
4.3 Ambiguities regarding regulatory approval 
The recommendation that the prevention modality should be approved by the regulator in the 
host country before it is added to the prevention package (UNAIDS/AVAC, 2011) was 
espoused by respondents in this study. However, the companion guidelines (UNAIDS/WHO, 
2012) do not specify whether approval of the national regulatory authority is required, or 
whether any regulatory or normative body approval would be sufficient (Haire, 2013). This 
opens guidelines to multiple interpretations, as aptly demonstrated by the range of 
perspectives on regulatory approval. On the one hand, it has been strongly argued that once a 
prevention intervention is approved by a regulatory authority in any country, it “would need 
to be added into various other prevention studies as part of the ‘standard prevention 
package’” (Haire et al., 2012, p. 27). On the other hand, it is noted that the framing of the 
guidance point on the standard of prevention “arguably provides a source of moral authority 
for delaying the introduction of a ‘state-of-the-art’ intervention until such time as it is listed 
in national guidelines” (Haire, 2013, pp. 168-169). In view of the inconsistencies in 
guidelines and the potential for multiple interpretations, respondents in this study appeared to 
favour the stricter interpretation of guidelines by endorsing national regulatory approval. 
There is little consensus on this issue (Philpott et al., 2011). For example, in developing key 
criteria to guide standard of prevention decision-making, meeting participants at the Ugandan 
consultation agreed that once a new method has been recommended for use by relevant 
international or national agencies, it should be provided in trials; departures from this 
recommendation should be ethically and scientifically justified in the study protocol (Philpott 
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et al., 2011, emphasis added). Still, a number of participants emphasised that they expect new 
tools to be nationally approved and available before they are added to the prevention package 
(Philpott et al., 2011, emphasis added). Furthermore, it was noted that considerations of 
feasibility in terms of local availability and accessibility, manufacturing and importation 
restrictions are also relevant (Philpott et al., 2011). However, the endorsement of national 
regulatory approval has been criticised as unnecessarily and unethically delaying the 
introduction of new and effective HIV prevention interventions (Haire et al., 2012).  
In terms of the evolving standard of prevention, these dichotomous interpretations have 
bearing on the inclusion of PrEP in the standard of prevention in developing country 
contexts. PrEP is now considered scientifically validated and, barring exceptional 
circumstances, should be included in the standard of prevention of future HIV prevention 
trials (Cowan & Macklin, 2014; Haire, 2014). PrEP could also be argued to meet the clinical 
validation threshold specified in the three-step framework (Jay et al., n.d.). While PrEP has 
been approved by the US FDA (FDA, 2012), to date it has not been approved in any of the 
eight countries in which these trials were conducted, including South Africa (Bekker et al., 
2012; Haire, 2013; Hankins & Dybul, 2013). Therefore, based on the endorsement of national 
regulatory approval by most respondents in this study, it is likely that they would argue that 
PrEP cannot be mandated as standard of prevention in South African HVTs, although they 
are likely to endorse that participants are educated about the benefits of PrEP and where it 
can be accessed.  
 
The three-step framework however, argues that clinical validation is not contingent on 
regulatory approval and that in resource-constrained contexts, if the prevention intervention is 
considered an appropriate, realistic practice but has not been instituted in the local healthcare 
system due only to cost, the validation threshold is satisfied (Jay et al., n.d.). The exception 
relates to those prevention interventions that would severely constrain local healthcare system 
capacity, and are perceived as unsustainable and an inappropriate use of clinical resources. 
Such interventions are not considered clinically validated (Jay et al., n.d.).  
 
Failure to include PrEP in the standard of prevention however, may pose complexities in 
multicountry trials both in terms of the interpretability of findings and ethical double 
standards between resourced and resource-constrained contexts (Haire et al., 2013; Haire, 
2014). Further, given that some South African practitioners are already prescribing PrEP in 
the private sector (Rebe & McIntyre, 2014), HVT stakeholders would need to consider 
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seriously the impact on scientific outcomes if some participants opted to access PrEP 
privately. The HVTN 505 study conducted a survey among participants and found only a 
small percentage indicating intent to use PrEP, which appeared greatest if PrEP was provided 
in the trial or covered through medical insurance (Fuchs et al., 2013). After consultation with 
community stakeholders, the HVTN 505 team decided to offer education about PrEP to 
participants, include active behavioural and biologic monitoring of PrEP use, and collaborate 
with trial sites to ensure referrals to community providers. One suggestion has been that 
future trials include PrEP as an active comparator, which may help relieve the tension 
between finding new effective products while protecting trial participants (Haire, 2014). 
Finally, denying trial participants access to a prevention intervention simply because it has 
not been registered in the country where they live, has been argued to be ethically 
problematic (Cowan & Macklin, 2014). Despite the criteria endorsed by respondents in the 
present study, if mechanisms to ensure access to PrEP in HVTs are established (despite 
complex funding constraints), it is possible that RECs may indeed approve such prevention 
packages as occurred with VMMC and PEP. 
  
These divergent perspectives raise important questions about the role of national regulatory 
authorities, and who should be the vanguard of decision-making for standards of prevention? 
Is it researchers, RECs and regulatory authorities in sponsor countries? If community 
participation principles are meaningfully implemented, would it not be their counterparts in 
host countries? It seems unlikely that researchers in the US would add a tool to the prevention 
package if it was approved by the South African MCC or a regulatory authority in another 
developing country, but not by the FDA? Of course, delays in regulatory approval will 
unduly prolong the provision of effective services to those who need it most (cf. Haire, 2013). 
But is the solution to flout national authorities all together or directly address such concerns 
with the regulatory authority, with an emphasis on expediency? Since PrEP can be considered 
scientifically validated and has been approved by the US FDA (Cowan & Macklin, 2014; 
Haire, 2013), “it is seductively easy to conclude that PrEP should be added to standard of 
prevention immediately” (Haire, 2013, p. 175). If this approach is mandated, the role of 
national regulatory authorities, important stakeholders in HVTs, and who have a valid role in 
determining which prevention interventions are prioritised in their countries, would be 
undercut (Haire, 2013). National regulators constitute a significant public good, whose 
primary objective is to protect the public from harm (Chilengi, 2009). Nevertheless, it is 
possible that PrEP products (e.g., Truvada) currently licenced for treatment may not need to 
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be approved by regulators for off-label use as prevention – nevirapine, for example, is 
routinely provided in PMTCT programmes, although it has not been approved by regulatory 
authorities for this purpose (Kim et al., 2010). Such interventions are funded because of 
“broad support and guidance from national and global normative bodies, such as WHO” 
(Kim et al., 2010, p. 4).  
 
4.4 Perspectives versus practices  
The availability of prevention interventions in the public healthcare sector was endorsed by 
several respondents as another criterion for consideration when determining the prevention 
package for HVTs. Such a locally customised package would circumvent the challenges 
identified with access to a state-of-the-art package (cf. HPTN, 2009) and guarantee 
sustainability of interventions post-trial. However, this is a lower requirement than was 
accepted and advocated for HIV treatment. South African guidelines (MRC, 2003, p. 33) 
described that “some consensus existed that trial participants should receive better treatment 
and care than would be available to them in the current public healthcare system in South 
Africa.” This may suggest ‘double standards’ in perspectives on standards of prevention and 
HIV treatment.  
 
Despite the strong advocacy for a national benchmark and public sector availability by REC 
respondents in this study, actual practices reflect differences between perspectives and 
practices. For the phase IIB trial, RECs across South Africa approved the inclusion of 
VMMC and PEP for all risky sexual exposures as standard of prevention despite these 
services not routinely being offered in the public sector, and in advance of national guidelines 
on VMMC. Therefore, “it is possible, where scientific validity is unequivocal, for trial 
protocols to adopt interventions as standard of prevention ahead of national guidelines” 
(Haire et al., 2013, p.6). Further, this approach coheres with reciprocal justice rationales 
expressed by some respondents that participants are deserving of special protection through 
the provision of services not routinely available, because they endure greater risks than 
community members through their participation. Indeed, in many countries the standard of 
prevention implemented in trials deviates from both national policy and services 
implemented in healthcare settings (McGrory et al., 2010). However, it is unclear how such 
packages are ensured given the funding restrictions reported in this study and elsewhere (cf. 




In terms of the decision-making criteria of national regulatory approval and public sector 
availability endorsed by many respondents in this study, this present researcher argues that 
since regulatory authorities are a protective mechanism (Dawson, 2012; Chilengi, 2009), the 
endorsement of national regulatory approval is reasonable. However, the requirement that 
prevention interventions should be available in the public sector – which is grossly variable 
according to provincial and urban/rural location – services the interests of science more than 
the welfare of trial participants. Varying local standards of prevention complicate what is 
provided to participants in multi-centre trials. If the local standard is used, it may create 
differences between participants enrolled in the same trial at different trial sites. 
Respondent’s distinction between theoretical access (national policy) and actual access 
(public sector availability) is similar to Haire and Jorden’s (2013) assertions that there is 
often a gulf between written standards of healthcare and the actual reality experienced in 
healthcare centres, where these standards are not always realised. Therefore, the suggestion 
that rollout in the public healthcare sector should precede the provision of an intervention to 
participants in trials, may unduly delay the inclusion of effective interventions in the standard 
of prevention. Therefore, implementing written standards of prevention (national policy) may 
result in ‘ratcheting up’ the standard of prevention in the host community (Jay et al., n.d.; 
Haire & Jordens, 2013).  
 
4.5 Current versus evolving standards of prevention 
This data resonates with concerns already flagged in the literature (Essack, Slack, et al., 2010; 
Padian et al., 2008) that the standard of evidence for new prevention interventions surpasses 
what is expected for tools in the current prevention package. Respondents in this study 
strongly endorsed the ethics guideline recommendation that new tools should be scientifically 
validated (MRC, 2003; UNAIDS/AVAC, 2011, UNAIDS/WHO, 2012). However, they 
voiced concern about the vagueness and resultant difficulty of operationalising this 
requirement (cf. McGrory et al., 2010). Given claims that guidelines are vague, it is 
unsurprising that prevention interventions are subjected to variable standards of evidence. 
Few tools in the current standard of prevention have demonstrated conclusive evidence of 
effectiveness – more often, the evidence is incomplete or conflicting (Padian et al., 2011). 
While RCTs are considered the gold standard for establishing the efficacy of interventions, 
prevention interventions including PEP and STI treatment have not been proved effective in 
reducing HIV risk in RCTs (Padian et al., 2008). Some respondents conceded that rather than 
because of their scientific validity, these tools were provided because it was morally 
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praiseworthy. Practice data also indicated that uncertainty about the scientific validity of an 
intervention may contribute to poor provider-promotion of such interventions – at one site it 
was reported that PEP was provided inconsistently because of provider reservations about 
efficacy. The potential for provider beliefs to impact on standards of prevention has been 
previously identified (McGrory et al., 2010).  
 
5. Study limitations and reflexivity 
This study adopted a qualitative approach, which allowed for a rich and detailed account of 
standard of prevention practices, perspectives and complexities. This depth and detail was 
enabled by the relatively small sample size, and the focus on only two HVTs at South African 
HVT sites. The data represents a time-limited assessment of practices at five HVT sites and 
two trials under the umbrella of one research network. The sample was non-random and 
limited by small sample sizes of CABs (n=6), RECs (n=8) and site staff at one site (nsite3=3). 
Therefore, the perspectives of these stakeholder groups may not be representative of the full 
range of possible viewpoints within these stakeholder groups. While efforts were made to 
sample representatives from sponsor organisations, these interviews did not materialise due to 
non-response from this stakeholder group to invitations to participate in the study. For these 
reasons, the representational generalisability (Lewis & Ritchie, 2013) of study findings is 
limited. Nevertheless, these findings raise a number of critical issues regarding standard of 
prevention decision-making and implementation in HVTs and the implementation of related 
norms in ethics guidelines. The themes identified in this research were mostly congruent with 
previous (albeit limited) empirical research on standards of prevention in other contexts, 
suggesting that some issues may be experienced in contexts outside South Africa, and in 
other HIV prevention trials more broadly. Therefore, this research can be argued to be 
inferentially generalisable (Lewis & Ritchie, 2013). Further, while many of the issues raised 
could be argued to be context-specific, the fact that South Africa is considered the epicentre 
of the epidemic suggests that concerns identified in this study could arguably reflect global 
concerns, and that recommendations may be relevant to other international contexts 
(Rohleder et al., 2009).  
 
Despite utilising a semi-structured interview guide, the use of a flexible qualitative approach 
reduced the ability to comprehensively compare data across sites. The various roles, expertise 
and experience of individual respondents in relation to HVTs also contributed to the range of 
responses to interview questions. For example, in response to the question ‘could you tell me 
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about how condoms are provided to participants’, one respondent may have included details 
on condom negotiation skills while another may have not. Since there was no specific 
question on condom demonstrations and negotiation, it cannot be assumed that if respondents 
did not raise this, it was not practiced at the site. Similarly, just because a complexity was not 
identified by a respondent, it does not necessarily mean that it was not experienced at a site. 
Although qualitative in nature, some of the data in this study may lend itself to quantitative 
analysis, which may facilitate systematic comparisons of practices across sites and 
stakeholder groups.  
 
Given the additional ethics review cost and logistical requirements necessary to access trial 
participants and referral site representatives, these stakeholders were not sampled, even 
though they were likely to provide an additional perspective on the research questions. Direct 
observations of HIV prevention services at sites or referral centres were also not undertaken. 
However, this study’s sample and methodology were designed to facilitate critical reflection 
about prevention services rather than to audit ‘end-users’. It was hoped that CAB members, 
as a proxy for the community, would provide some indication of the experiences of 
participants. Future explorations on standards of prevention should include the perspectives 
trial participants, where feasible, and sponsor organisations and government representatives 
(including referral service providers), who were identified as key partners in ensuring access 
to standard of prevention interventions.  
 
Reflexivity entails critical reflection of the research process and the researcher’s own role in 
shaping the collection and analysis of data (Mays & Pope, 2000). In qualitative inquiry, the 
researcher is considered the primary instrument of data collection and analysis (Merriam, 
2002). As such, the possibility of the researcher’s influence on respondents’ reports of their 
practices and perspectives was carefully considered.  
 
While the present researcher did not approach the data analysis with preconceived 
conclusions, particular positions on standards of prevention were preferred; these were 
developed through previous conceptual research on the topic. Firstly, the researcher agrees 
with the position that keeping trial participants HIV-uninfected is an ethical imperative in 
clinical trials of HIV preventive interventions. We have argued elsewhere that certain 
guideline recommendations set a very high standard and that there are complexities with key 
HVT-specific guidelines (cf. Essack, Slack, et al., 2010). While some commentators argue 
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that protecting the welfare of participants should always surpass scientific considerations, 
these tasks are not always ethically distinct. Rather, it could be argued that when/if adding 
new tools to the prevention package invalidates trials, then the ethical obligation to provide 
all state-of-the-art methods is weakened because participants will be exposed to risks and 
inconvenience for no social benefit and valuable resources will be wasted (cf. Essack, Slack, 
et al., 2010). The researcher is somewhat sceptical of the feasibility of arguments that the 
standard of prevention should be the best available in the world but wary of those who 
contend that it should be on par with local healthcare practice, even if that is nothing. Some 
of the findings in this study conflict with this researcher’s personal perspectives, for example, 
respondents’ endorsement that the standard of prevention be determined by public healthcare 
availability of interventions. The researcher contends that the standard of prevention should 
be aligned with written national policy rather than be contingent on public healthcare sector 
rollout. This will help ensure ‘reasonably commensurate outcomes’ (cf. Slack, 2014) for 
participants across various South African sites rather than being subject to the variable access 
characteristic of the local healthcare sector or the undue delays between research evidence 
and public sector rollout (e.g., PMTCT, VMMC). Further, the researcher argues that the 
provision of a higher standard of prevention than that nationally available (e.g., PEP for all 
risky sexual exposures) is morally praiseworthy but cannot be considered mandatory. While 
the researcher had spent little time exploring the decision-making aspect of standards of 
prevention, she had participated in three meetings/workshops on the topic, one of which 
attempted to develop criteria for making decisions on the evolving standard of prevention (cf. 
McGrory et al., 2010; Philpott et al., 2011).  
 
As far as possible, the researcher tried not to discuss her personal views with respondents 
before or during interviews. During interviews, she endeavoured to remain impartial and non-
judgemental, although at times exercising empathy through affirmations of respondents’ 
reports, e.g., “mhm”. While intended to signify that she was listening to the respondent, such 
responses may also have been interpreted by respondents as agreement with their 
perspectives.  
 
At the time this research was conducted, the researcher was employed at an HVT ethics 
group (HIV AIDS Vaccines Ethics group [HAVEG] http://www.saavi.org.za/haveg/ 
index.htm), which conducts research to inform the ethical conduct of HVTs. In this position, 
the researcher conducted social science research on ethical issues in HIV prevention research. 
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While the researcher had limited previous direct contact with site staff and other stakeholders, 
HAVEG was well known among HVT stakeholders, and had close working relationships 
with sites. Therefore, the researcher’s affiliation with HAVEG may have introduced some 
respondent bias, especially since this research explored practices and perspectives on a 
controversial ethical issue (cf. Macklin, 2008). In some interviews, respondents’ awareness of 
the researcher’s affiliation was apparent. For example, one respondent noted that the 
researcher was more likely to be knowledgeable about specific ethics terminology and theory 
while another commented positively on HAVEG’s previous work. It is possible that some 
respondents softened responses regarding their perspectives on ethics guidelines, given that a 
few respondents conflated HAVEG with guideline developers. Further, this study relied on 
self-report of HIV prevention decision-making and implementation practices. Self-report, as 
confirmed by data in the present study, is prone to social desirability bias (Chillag et al., 
2006; van de Mortel, 2008). To reduce the potential for social desirability, the study was 
introduced to sites at a sensitising consultation, where it was emphasised that the study was 
being conducted in the spirit of critical reflection rather than as an audit. The key aims of this 
consultation were to: 1) affirm care and prevention responsibilities as a concern shared by 
many research collaborators including trial sites; 2) hear from site staff and CABs about their 
prior work, current activities and core priorities around care and prevention in trials; and 3) 
raise awareness about the proposed study, to identify trial site and CAB concerns about the 
study, to obtain inputs on the aims, design and outputs of the study and to amend the study, 
where possible (Essack, Koen & Slack, 2009). Further, data triangulation (interviews and 
document review), may have circumvented some of this potential bias in respondent reports 
of practices.  
 
Findings of this study that cultural norms may restrict the discussion of sex-related issues in 
the presence of women, raised the possibility that such norms may have played out in 
interviews. As a female researcher, some male CAB respondents may not have fully 
disclosed their perspectives and practices on certain HIV prevention issues. Despite the 
potential for these biases, respondents appeared generally unguarded in presenting their 
practices and perspectives.  
 
As explicated in the methodology chapter (Chapter 6), a critical thematic approach to data 
analysis was adopted, enabling a descriptive, critical and interpretive analysis of the data. 
This approach to the analysis and interpretation of results cannot be considered definitive, 
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given that different approaches are likely to yield different interpretations of the data. 
Specifically, due to limited philosophical expertise, the researcher was unable to undertake a 
moral philosophical analysis of standards of prevention, which might have provided a useful 
adjunct to this social science analysis or served as a useful lens through which to interpret the 
data. Readers are referred to Haire (2013) for a detailed normative analysis related to 




This chapter discussed four overarching themes identified in respondents’ reports of their 
practices and perspectives on standards of prevention. It aimed to provide a deeper 
interpretation of data through contextualising findings within the larger body of literature and 
in relation to relevant normative frameworks.  
 
In terms of theme 1, ‘dynamics of standard of prevention decision-making and 
implementation’, findings suggested that gender and cultural norms impacted on standard of 
prevention decision-making and implementation. Cultural taboos about discussing sex in 
certain groups impeded some CAB input into the design of prevention interventions. It also 
impacted on self-report practices, and ultimately on participant uptake of prevention 
interventions. The gender gap between access to male and female condoms at sites and in the 
public sector may have several potential negative consequences for uptake of this important 
female-initiated intervention. Power dynamics were observed in all phases of HVTs, from 
protocol development to implementation. These inequalities evoked ‘othering’ discourse, 
which in turn complicated the ethical ideals of collaboration on standards of prevention.   
 
Theme 2, ‘defining the standard of prevention through consultation, consensus, and 
negotiation’ identified the perils of these decision-making mechanisms recommended in 
guidelines, including that inherent power dynamics between and within stakeholder groups 
may compromise the consultative and intended inclusive nature of standard of prevention 
decision-making. Given observed power differentials, this study also questioned the 





Theme 3, ensuring access to HIV prevention interventions: sourcing funding and establishing 
partnerships, captured findings which suggested that funding complexities pervaded both the 
design and implementation of the prevention package, and had implications for current and 
evolving standards of prevention. Given complexities with funding, South African sites 
developed strategic partnerships with government stakeholders (DoH) and other partners to 
ensure access to prevention interventions. 
 
Theme 4, ‘double standards of prevention’, discussed findings that double standards existed 
beyond the pre-occupation with ensuring parity between developed and developing countries. 
Concerns included variability in decision-making about current versus evolving standards of 
prevention; requiring national regulatory approval before adding a new method to the 
prevention package; deviations between stakeholder practices and perspectives; and the 
potential for differences in standards of prevention both within and across trial sites in the 





CONCLUSIONS AND RECOMMENDATIONS 
 
As new prevention tools are proven effective, the standard of prevention in HIV prevention 
trials is becoming an increasingly complex and divisive ethical issue (Macklin, 2008; 
Moorhouse et al., 2014). Ethics guidelines (MRC, 2003; UNAIDS/AVAC, 2011; 
UNAIDS/WHO, 2012) make a range of recommendations about the standard of prevention, 
including that participants should be provided with access to all ‘state-of-the-art’ prevention 
interventions; that details of risk-reduction interventions should be included in protocols and 
consent forms; and that standard of prevention decisions should be made in consultation with 
relevant stakeholders. These recommendations have been described as setting a very high 
substantive and procedural standard (Essack, Slack, et al., 2010; HPTN, 2009; Macklin, 
2009), and as impractical and infeasible, particularly in resource-constrained contexts 
(Macklin, 2010).  
 
This study responded to calls by commentators to document standard of prevention practices 
at sites (Essack, Slack, et al., 2010), and assess the extent to which actual practices (what is 
happening) corresponded with ethics guidance (what ought to be happening according to 
norms) (Macklin, 2010). While recent research (Haire & Jordens, 2013; Heise et al., 2008; 
Ngongo, Priddy, et al., 2012) has explored the standard of prevention in HIV prevention 
trials, there has been no detailed exploration of standard of prevention practices in South 
African HVTs, nor efforts to comprehensively compare practices with recommendations in 
ethics guidelines. The current study aimed to address this gap.  
 
By documenting decision-making and implementation practices in South African HVTs, this 
study hopefully contributes to existing empirical data on standards of prevention in HIV 
prevention trials. By evaluating the congruence or difference between stakeholder practices 
and related ethical standards in guidelines, this data responds to debates about the 
implementability of these ethical standards (cf. HPTN, 2009; Macklin, 2009; 2010; 
Moorhouse et al., 2014). By exploring complexities in actual standard of prevention practices 
and examining resonance with ethics guidelines, this research identifies areas where site 
practices and ethics guidelines could be strengthened. In this way, this study was careful to 
interrogate practices and norms equally, operating under the assumption that practice can 
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inform ethical theory just as ethical theory can inform practice (Frith, 2008). Empirical 
accounts of ethical issues not only help to identify novel ethical complexities but also help to 
develop moral norms and theories that are responsive to issues identified on the ground 
(Caplan, 1982). By seeking stakeholder perspectives on key standard of prevention ethics 
recommendations, this study may help distinguish between functional norms (those extolled 
and implemented in practice) and non-functional norms (those extolled but ‘ignored’) (Reese 
& Fremouw, 1964). Further, it may also indicate which norms in guidelines are not extolled 
but implemented, or not extolled and not implemented. Finally, data on standard of 
prevention decision-making and implementation complexities are also likely to be of value to 
trial implementers planning and conducting future HIV prevention trials.  
 
This chapter presents an overview of the main study findings, conclusions and 
recommendations. 
 
1. Key study findings 
 
1.1 Actual practices versus ethics norms  
This study aimed to explore the correspondence between standard of prevention decision-
making (Chapter 7) and implementation (Chapter 9) practices with related recommendations 
in ethics guidelines. 
 
1.1.1 Standard of prevention decision-making 
Decisions about which prevention components to include in the standard of prevention 
package were made primarily by the protocol committee during protocol development. These 
decisions were “vetted” by RECs and CABs during the review process. Therefore, key 
research stakeholders (sponsors, research networks, investigators, RECs and community 
representatives) were engaged in standard of prevention determinations, as recommended by 
ethics guidelines (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012 ). Community 
engagement practices at sites resonated with ethics recommendations to involve community 
representatives in protocol development and review, and to build their capacity to make 
decisions. Challenges in ensuring meaningful community engagement reported in this study 
reflected pragmatic and logistical constraints, and the need for improved research literacy, 
rather than disagreement with norms requiring community engagement. However, given the 
reported complexities with involving representatives of all sites (investigators and CABs) on 
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protocol development committees, in practice, engaging all research stakeholders on all 
standard of prevention decisions appeared to be impractical in this context.  
 
There was a difference in the standard of prevention outlined in the phase I and phase IIB 
protocols, indicating that protocol writers may have accorded different obligations to early- 
and late-phase trial participants, based on their perception of participants’ risk of HIV 
infection. Ethics guidelines do not specify whether the obligation to provide prevention 
services differs according to the phase of the trial or vulnerability of participants.  
 
In practice, agreement between stakeholders on the prevention package was not sought prior 
to commencement of the HVTs, nor was a process of formal negotiation utilised to determine 
components of the prevention package. Therefore, reported practices did not cohere with 
recommendations for consensus (UNAIDS/WHO, 2012) and negotiation (UNAIDS/AVAC, 
2011; UNAIDS/WHO, 2012) on the standard of prevention package.  
 
The range of perspectives on the substantive standard indicate that there is little consensus on 
standards of prevention, including regarding fundamental concepts like ‘state-of-the-art’ and 
‘scientific validity’. This data corroborates criticisms of consensus identified in the literature 
(Essack, Slack, et al., 2010; London & Zollman, 2010; Schüklenk, 2010; Slack & Stobie, 
2010) and concludes that given the vagueness of guidelines and the absence of clear 
operational frameworks, recommendations to agree on the standard of prevention, prior to the 
implementation of each trial (UNAIDS/WHO, 2012) are not currently feasible in this context. 
While this study did not evaluate the pragmatic value and implementability of currently 
available frameworks for decision-making (e.g., Jay et al., n.d.; McGrory et al., 2010; 
Philpott et al., 2011; Tarantola et al., 2007), this study has provided empirical data identifying 
the critical need for such frameworks to be piloted, evaluated, and if necessary refined. 
 
1.1.2 Standard of prevention implementation 
The HVTs in the present study provided participants with risk-reduction counselling and 
access to male and female condoms and STI treatment (MRC, 2003; UNAIDS/AVAC, 2011; 
UNAIDS/WHO, 2012) as well as VMMC and PEP, where indicated (UNAIDS/AVAC, 2011; 
UNAIDS/WHO, 2012), in accordance with ethics guideline recommendations. However, 
inconsistent access to female condoms at most sites suggests that the obligation to ensure 
access to female condoms was not wholly fulfilled. In some instances, site practices exceeded 
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recommendations in guidelines, for example, by paying for VMMC at private facilities and 
by providing assisted referrals to participants’ partners. Site services also sometimes 
exceeded preventive options available in the local community, for example, by ensuring 
access to PEP for all sexual exposures, and to VMMC at a time of limited public sector 
access. This indicates that, in the setting in which these data were collected, ethics 
recommendations to ensure access to state-of-the-art services were achievable, and in some 
cases exceeded. However, this finding may not hold as the state-of-the-art evolves since it 
may become increasingly difficult – scientifically and logistically – to ensure access to state-
of-the-art interventions.  
 
This study found that in practice, the burden of ensuring access to prevention interventions is 
shared among sponsors, research networks, researchers, host governments, and in some 
instances private donors, in congruence with guideline (UNAIDS/WHO, 2012) 
recommendations. The availability of funding and establishment of strategic partnerships 
affected standard of prevention determinations and were critical factors in ensuring access to 
prevention interventions. However, the bulk of the responsibility to ensure access to 
prevention interventions was assumed by research networks, researchers and the host 
government, with sponsors making a nominal contribution due to funding policy restrictions. 
Ultimately, the package of prevention implemented in HVTs was dependent on several 
factors, including donor funding policy, securing alternate funds, the prevention interventions 
available locally, the partnerships established, and available site resources.  
 
This study found that South African HVT implementers favoured the more onerous direct 
provision of prevention interventions over referral (‘access’). However, whether prevention 
interventions were provided on-site or via referral was contingent on the available funding 
and the nature of established partnerships – as a procurement source or a service provider.  
 
This study found that in practice, sites provided substantially more to participants than was 
specified in consent documents for both trials and in the phase I trial protocol. REC and CAB 
practices for the review of protocols were largely consistent with ethics guideline 
recommendations (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012), except for 
the requirement that RECs approve plans for monitoring risk-reduction interventions – such 
plans were not included in study protocols or ethics applications. Therefore, ethics 
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recommendations for protocol drafting and review, and ethical oversight of standards of 
prevention were only partially achieved.  
 
1.2 Responsiveness of ethics guidelines to standard of prevention complexities  
Ethics guidelines anticipate some of the core thematic complexities raised by stakeholders. 
As predicted by guidelines (UNAIDS/AVAC, 2011), in practice, sponsor funding restrictions 
had implications for the provision of prevention services. However, respondents raised 
critical concerns that a lack of clear sponsor funding policies may enable sponsors to renege 
on their ethical obligations to help keep trial participants HIV-uninfected. 
 
Guidelines anticipate the potential for power inequalities in research and provide several 
remedial strategies (MRC, 2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). This study 
provides empirical evidence of how such concerns play out in practice. Power pervaded all 
stages of HVT decision-making from protocol development, where sponsors were perceived 
as commanding decision-making authority, to protocol implementation, where deference to 
the perceived authority and expertise of providers may have mediated participant uptake of 
services. While guidelines recognise the potential for power imbalances, they recommend 
negotiation and consensus as mechanisms for standard of prevention decision-making. 
However, the premise of negotiation rests on the assumption that the negotiating parties are, 
for the most part, equal partners (cf. UNAIDS/AVAC, 2011). Given the power inequalities 
reported in this study, and that power pervades all facets of negotiation (Cheng, 2009), this 
study questions whether negotiation is the most appropriate mechanism for standard of 
prevention decision-making.  
 
The assessment of correspondence between practices and guidelines also identified which 
empirically-identified concerns were not anticipated by guidelines. 
 
This study identified the novel perspective that cultural prescriptions may limit community 
inputs into the design and review of standards of prevention. Findings also indicated the 
potential for gendered prevention practices. For example, in practice there was a gender gap 
in the provision of condoms, with female condoms only intermittently available and 
subjected to restrictive dispensing practices. Guidelines do not anticipate that socio-cultural 
taboos may hinder community inputs into standard of prevention determinations nor that the 
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promotion and uptake of prevention interventions may be influenced by cultural and gender 
norms.  
 
The potential for so-called double standards (Macklin, 2004; 2009; Haire et al., 2013) exists 
beyond predominant concerns about ensuring equitable outcomes for participants in 
developed and developing country contexts. Stakeholder perspectives highlighted the lack of 
normative clarity on key concepts like ‘state-of-the-art’, ‘scientific validity’ and ‘approval by 
relevant bodies’. Ill-defined and broadly worded guidelines (Haire, 2013; Moorhouse et al., 
2014) create normative ambiguities and may inadvertently perpetuate differences in the 
implementation of standards of prevention. HVT stakeholders might therefore experience 
uncertainty about whether the ‘state-of-the-art’ should be benchmarked against international 
or national standards (Dawson et al., 2014) and whether regulatory approval is required of 
national or any authorities (Haire, 2013).  
 
Given the multiple factors found to impact on standard of prevention decision-making and 
implementation, within-country differences in standards of prevention between trial 
participants are possible, and were reported in this study. While the flexibility to determine 
standards of prevention on a site-by-site basis was valued by some stakeholders and 
supported by guidelines, such practices may also create site-level differences.  
 
Standards of prevention may differ between trials at one trial site, and within trials across 
different sites, raising concerns about fairness if participants are exposed to the same level of 
risk but receive different benefits. The potential for such differences in prevention outcomes 
for participants within one country is not anticipated in guidelines.  
 
Empirical data from this study have illuminated the internal conflict in guidelines between 
substantive norms requiring access to state-of-the-art prevention interventions, and 
procedural norms recommending negotiation of the prevention package. Guidelines provide 
little direction on how to resolve tensions which result when procedural outcomes conflict 
with substantive norms, except that implementation practices should not compromise 
fundamental substantive ethical standards (MRC, 2003). In practice, stakeholders 
endeavoured to meet substantive norms to provide counselling and access to state-of-the-art 
prevention interventions in HVTs trials. However, they have largely failed to implement 
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procedural recommendations for consensus and negotiation in determining the prevention 
package.  
 
1.3 The evolving standard of prevention and perspectives on norms in ethics 
guidance 
Finally, this study explored stakeholder practices and perspectives on the evolving standard 
of prevention (Chapter 8) and perspectives on selected standard of prevention 
recommendations in ethics guidelines (Chapter 10).  
 
The addition of VMMC to the prevention package identified differences between stakeholder 
practices and perspectives. VMMC was added to the prevention package based on scientific 
validation determined by evidence from three clinical trials and prior to its endorsement by 
national bodies or the development of national guidelines for use (cf. Haire & Jordens, 2013). 
Stakeholder perspectives however, reflect endorsement of scientific validity (MRC, 2003; 
UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) and approval by national regulatory 
authorities (UNAIDS/AVAC, 2011). Further, these findings indicated some endorsement of 
additional criteria of availability in the public healthcare sector and the phase of the trial, 
which are not explicit requirements of guidelines (MRC, 2003; UNAIDS/AVAC, 2011; 
UNAIDS/WHO, 2012). Stakeholders in this study did not spontaneously endorse stakeholder 
consultation as a mechanism for the enhancement of the standard of prevention. While 
stakeholder perspectives are not morally definitive, the data suggest challenges with 
implementing consultation recommendations in practice, including regarding which 
stakeholders should be consulted and when, and what format consultations should take 
(Moorhouse et al., 2014). Guidelines do not prescribe appropriate consultation formats; 
however, some respondents considered the process of developing and reviewing the protocol 
as a legitimate consultative mechanism. Since protocols are developed by the protocol 
committee (with representation, albeit nominal, from all stakeholder groups) and reviewed by 
national regulatory authorities, RECs and CABs, the present researcher agrees that protocol 
development and review may serve as one mechanism of stakeholder consultation.  
 
The addition of VMMC demonstrated that adding new prevention tools that are not available 
in the public sector presented challenges when donor funding policy also precluded their 
provision. This study found that establishing partnerships with private donors was an 
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effective strategy in ensuring access to interventions not yet incorporated in national policy or 
not rolled out in the public sector.  
 
2. Recommendations 
This empirical study on standards of prevention in South African HVTs, considered norms, 
perspectives and practices on standards of prevention. Specific recommendations for norms, 
practices and future research are detailed in Appendix 9. The following section considers 
recommendations in relation to major study findings.  
 
2.1 Recommendations for future research  
This study identified the tension experienced by some CAB respondents (and potentially host 
communities) when socio-cultural taboos about discussing sex (cf. Ndinda et al., 2011) 
intersect with ethics guideline recommendations for input into standards of prevention. 
Further, findings suggested the potential for gender/cultural norms and stereotypes to impact 
on the design, accessibility, promotion and uptake of prevention interventions. More detailed 
research that clarifies the extent to which gender norms and cultural prescriptions influence 
the realisation of recommendations in ethics guidelines should be undertaken. Innovative 
strategies for facilitating CAB inputs into standards of prevention without compromising 
cultural ideologies should be developed and tested.  
 
Further, as new tools (e.g., PrEP) are added to the prevention package, trials will become 
increasingly expensive to conduct (Haire et al., 2013). Even though the cost of providing 
prevention interventions may not be borne by sponsors themselves, the willingness of 
sponsors to accommodate increasing costs as a result of longer and larger trials necessitated 
by enhanced standards of prevention, needs urgent exploration.  
 
Given the paucity of evidence supporting consultative decision-making processes for 
standards of prevention, and indications of the difficulty implementing these 
recommendations in practice, future research should pilot and evaluate existing frameworks 
that propose procedural decision-making processes (e.g., Tarantola et al., 2007) that take into 
account some of the challenges with consultation reported in this study. Further, stakeholder 
perspectives on the value of frameworks (e.g., Jay et al., n.d.) that attempt to offer operational 
guidance on when to add new methods to the prevention package, should be explored. The 
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pragmatic value of such frameworks for trial implementers could also be determined through 
piloting exercises.   
 
As new prevention tools emerge, a critical gap in knowledge remains regarding the threshold 
at which adding new methods will invalidate trials. Protecting the welfare of participants 
necessitates the provision of all prevention methods (Haire, 2013; Macklin, 2010; 
UNAIDS/WHO, 2012; UNAIDS/AVAC, 2011). However, if the feasibility of obtaining 
meaningful results from the trial is adversely impacted by the addition of new HIV 
prevention methods, then the ethical obligation to provide all state-of-the-art methods is 
weakened because participants will be exposed to risks and inconvenience for no social 
benefit and valuable resources will be wasted (Emanuel et al., 2004; Essack, Slack, et al., 
2010). Therefore, defining the threshold at which adding new tools invalidates trials, remains 
an important ethical undertaking (Essack, Slack, et al., 2010). 
 
2.2 Recommendations for ethics guidelines  
This study aimed to make recommendations for ethics guidance.  
 
Complexities associated with power dynamics identified in this study suggest that ethical 
recommendations to ‘negotiate’ standards of prevention may be compromised by power 
inequities. Guidelines should therefore carefully consider alternative mechanisms for 
standard of prevention decision-making, which are constructive and engender collaboration 
rather than opposition (‘us’ versus ‘them’). To minimise the potential for procedural 
outcomes to conflict with substantive norms, consideration should be given to implementing 
procedural recommendations only in those circumstances where the proposed prevention 
package deviates from the substantive standard or accepted practice. Further, rather than 
establishing a ceiling (all state-of-the-art) and allowing that it be lowered through negotiation 
under prescribed conditions, consideration could be given to establishing a minimum core 
standard of prevention, and ratcheting it up. In this way, procedural outcomes would not 
conflict with the substantive norms.  
 
Findings about perceived complexities regarding provider-promotion and participant uptake 
suggests that guideline recommendations to ‘monitor’ the quality of prevention interventions 




One of the key criticisms (Koen et al., 2013; Moorhouse et al., 2014; Philpott et al., 2011) of 
guideline recommendations on standards of prevention was that fundamental concepts (e.g., 
‘state-of-the-art’, ‘scientific validity’, ‘consultation’ ‘approval by relevant bodies’ and 
‘research stakeholders’) were considered too vague, creating complexities with interpreting 
and operationalising these recommendations in practice. In the absence of clarity, 
stakeholders in this study favoured a ‘state-of-the-art’ interpreted as the best available in the 
country and endorsed national regulatory approval as a criterion for the addition of new 
prevention tools. Further, findings from this study that RECs applied variable standards in 
reviewing protocols overlap with concerns about the variability of REC decisions in multi-
site clinical trials (Shah, Whittle, Wilfond, Gensler, & Wendler, 2004). This suggests that 
RECs need clearer substantive and procedural guidance on how to review standards of 
prevention. These findings echo recommendations from a parallel quantitative study that 
guideline developers should consider clarifying vague concepts (Moorhouse et al., 2014) or 
develop a clearer guidance point (both in terms of substantive and procedural norms). 
Alternatively, if guideline developers opt to maintain broadly phrased recommendations, 
resources and operational frameworks should be developed as an adjunct to guidelines 
(Moorhouse et al., 2014).  
 
While recommendations to aspire to state-of-the-art prevention services were intended to 
minimise so-called double standards between developed and developing countries (Haire et 
al., 2013), the present empirical data indicate the potential for different standards between 
participants enrolled in different protocols and/or at different sites. Further, findings showed 
that between-site differences may be enabled by certain guideline assertions, e.g., that 
protocols may vary in “modes of delivery” for prevention interventions (UNAIDS/WHO, 
2012, p. 45) and that standard of prevention negotiations occur on a trial-by-trial basis (MRC, 
2003; UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012). This suggests that ethics guidelines 
will need to address the issue of different standards between trials implemented within the 
same site or between sites within the same country. For example, guideline developers could 
refer to the first version of GPP guidance (UNAIDS/AVAC, 2007) which recommended that 
trial sponsors should ensure that core elements of the prevention package are consistent 
across trials and networks. 
 
While guidelines are generally silent on whether the obligation to provide prevention services 
may or should differ according to the phase of the trial or risk-level of participants, these data 
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indicated that protocol-writers, and some stakeholders in this study, assigned different 
standard of prevention obligations for early-phase versus late-phase trial participants. Given 
that risk may be related to the study product (Gray et al., 2010; Halpern et al., 2008; van 
Damme et al., 2002) and not only the risk behaviour of participants, guidelines should 
consider clarifying whether obligations to participants differ based on trial phases/risk-levels.  
 
Practice data also identified that sites endeavoured to provide prevention interventions to 
persons not enrolled in trials. However, guidance is unclear on the standard of prevention for 
those not enrolled in trials (Tarantola et al., 2007). Future revisions should be clearer on 
what, if anything, should be ensured for those not enrolled in trials. 
 
2.3 Recommendations for stakeholder practices 
This study aimed to make recommendations for improved stakeholder practices.  
 
Data in this study suggested a perception that standard of prevention decision-making occurs 
in a top-down manner, given that protocol development is a fairly centralised activity and that 
CAB and REC review occur concurrently, raising concerns about tokenistic CAB 
engagement. This confirms previous reports (Hannah et al., 2012; Ngongo, Hannah, et al., 
2012), that there are gaps between GPP guidelines (UNAIDS/AVAC, 2011) and actual 
practices of stakeholder engagement in protocols and standards of prevention. Given 
concerns about how CAB representatives were selected for protocol development 
committees, it is recommended that the research network, trial sites and CAB representatives 
should explore alternative mechanisms to enable stakeholder inputs on standards of 
prevention. One possibility may be to encourage a CAB representative at each site to serve on 
RECs reviewing HIV prevention trial protocols. As statutory bodies for the ethical oversight 
of research, RECs may also be well placed to request that sites document efforts (and 
challenges) in meeting requirements in GPP guidelines (UNAIDS/AVAC, 2011). 
 
Reported complexities with the implementation of prevention interventions may be relevant 
as new prevention methods, e.g., PrEP and microbicides, become accepted as part of the 
standard of prevention. Data in this study reflecting challenges in funding certain prevention 
interventions suggest that sponsor restrictions on how funding can be utilised need to be 
revisited (Philpott et al., 2010) in a way that satisfies ethical responsibilities to ensure access 
to prevention interventions. It is recommended that sponsors clarify their funding policies and 
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develop a more formal policy on standards of prevention, in collaboration with HVT 
stakeholders. Given the potential for reduced funding in future trials and the cost implications 
of enhanced prevention packages, trial implementers should make efforts to diversify funding 
sources and carefully consider the partnerships that need to be established to enable access to 
upcoming prevention tools, for example, to procure products for on-site dispensing, or to 
establish innovative referral relationships.  
 
As new prevention interventions become standard of prevention, the role of partnerships to 
ensure access to prevention interventions becomes increasingly important given the potential 
for sponsor funding restrictions. The DoH emerged as a key partner in ensuring access to 
many prevention services. However, engaging this partner was associated with some 
tensions, for example, poor accessibility of female condoms. Data in this study describing 
tensions related to engaging key partners suggest that new sites should engage critical 
stakeholders in an early, sustained and strategic manner. It also suggests the usefulness of 
ongoing evaluation of the quality of key partnerships. Sites should also capitalise on targets 
set in the NSP to increase access to female condoms to 20 million by 2016 (SANAC, 2011). 
Nevertheless, given that the gap in distribution between male and female condoms appears to 
be widening prospectively (500 million male condoms and 9 million female condoms to be 
distributed in 2012 versus 1 billion and 20 million respectively to be distributed by 2016) 
(SANAC, 2011), investigators should lobby HIV prevention activist groups in advocating for 
improved access to female condoms. If HVT stakeholders, including the South African 
government, are to meet their obligations to protect the vulnerable, increasing access to 
female condoms must be ensured. Further, sites should be cautious about the consequences of 
relying on partnerships to ensure access to prevention interventions that may subject them to 
gender, cultural or political barriers set by the state.  
 
Given this study’s findings that site staff promotion of some prevention interventions may be 
adversely impacted by the cultural context and perceptions of the efficacy of the intervention, 
sites should consider implementing formal mechanisms to assess provider-promotion of 
prevention services and to train staff to ensure consistent promotion. Strategies should be 
developed to identify, interrogate and respect objections to uptake from certain sub-groups 




Findings also indicated that consent forms contained fewer disclosures about prevention 
options than were actually provided to participants. While the information sheet and consent 
form is only part of the informed consent process (Flory & Emanuel, 2004), given that 
participants may use the consent form for reference purposes (Ramjee et al., 2010), it is 
recommended that they contain more information on the standard of prevention. 
Alternatively, an additional fact sheet on standards of prevention could be provided to 
participants. This may also help counter potential variability in provider-promotion of 
services. More detailed disclosures in consent forms should, where possible, preserve site 
flexibility in implementing prevention services. Given their important role in the ethical 
oversight of research, it is imperative that RECs and CABs review the ‘actual’ versus the 
‘written’ standard of prevention for all trials. These findings support the recommendation by 
Heise et al. (2008, p. 67) that all trials “should explicitly define standards of care that will be 
provided at each trial site; the broad elements of care can be described in the protocol, while 
specific elements can be written into site standard operating procedures.” 
 
2.4 Recommendations for capacity building  
This study found gaps in socio-cultural, research (cf. UNAIDS/AVAC, 2011) and ethics 
competencies. While site staff were fairly knowledgeable about the socio-cultural context in 
which they conducted trials, they did not anticipate that cultural prescriptions may impede 
CAB inputs into the design of prevention interventions or that female condoms would present 
gendered challenges. This underscores the pivotal importance of “understanding the norms, 
practices and beliefs of relevant local cultures” to inform “the development of appropriate 
trial designs and procedures” (UNAIDS/AVAC, 2011, pp. 22-23).  
 
Further, findings from this study indicated that CAB knowledge of both substantive and 
implementation issues on the standard of prevention was inadequate. While many of the CAB 
respondents could detail their concerns regarding issues of HIV care and treatment, the 
standard of prevention was not consistently noted as a concern by CAB respondents nor was 
it described as a critical element of the review process. Further, a lack of research literacy and 
understanding of science appeared to have impeded protocol review. To ensure effective 
decision-making, CABs need ethics and research literacy training so that they are able to 
critically evaluate study protocols and actively engage with the research. This underlines the 
importance of continuously engaging in intensive efforts to build research competency, which 
“enables and empowers stakeholders to provide meaningful input into the research process 
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and enhances understanding of the concepts, purposes, practices, limitations, and results of 
biomedical HIV prevention trials” (UNAIDS/AVAC, 2011, p. 23). More use could be made 
of specific funding opportunities (e.g., Wellcome Trust’s ‘Public Engagement with Health 
Research’13, the European and Developing Countries Clinical Trial Partnership (EDCTP)14, 
and European Union (EU), ‘Science and Society’15) to fund the building of such capacity, 
unless additional HVT sponsors are earmarked for such engagement.  
 
Variability in the review of HVT protocols by RECs suggested variable research ethics 
capacity (among other issues), which limited the ability of RECs to interrogate major 
substantive issues, such as standards of prevention. In line with NHREC guidelines that REC 
members receive initial and ongoing research ethics training (Cleaton-Jones & Wassenaar, 
2010), RECs could benefit from intensive ethics training including on mechanisms to 
enhance their interrogation of substantive ethical issues. The lack of accessibility, awareness 
and understanding of HVT-specific ethics guidelines also emphasises the need to build ethics 
competency among all HVT stakeholders as a matter of priority.  
 
3. Conclusion 
This thesis aimed to explore standards of prevention in South African HVTs in order to 
provide insight into actual practices at sites in relation to standard of prevention norms in 
guidelines. It highlighted areas where practices were congruent with (and exceeded) guideline 
recommendations, where they deviated from guidance, and whether guidance provides useful 
direction to stakeholders in addressing on the ground complexities.  
 
South African HVT stakeholders are endeavouring to meet their obligations to protect trial 
participants and help them remain HIV-uninfected. Despite concerns that ethics guidelines set 
the bar high (Essack, Slack, et al., 2010; HPTN, 2009; Macklin, 2009) and may be infeasible, 
especially in resource-constrained contexts (Macklin, 2010), this study found that in the 
main, there was a commendably high degree of correspondence between actual practices at 
South African HVT sites and related recommendations in ethics guidelines. However, points 
of deviation between guidelines and practices have elucidated that we need improved 
guidance, strengthened practices and better oversight capacity if we are to fully ensure the 
                                                             
13 http://www.wellcome.ac.uk/Funding/Public-engagement/index.htm 
14 http://www.edctp.org/calls-and-grants/  
15 http://ec.europa.eu/research/science-society/index.cfm?fuseaction=public.topic&id=1241  
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well-being of trial participants. It is hoped that these empirical findings will usefully inform 
and enhance normative debate on standards of prevention and also contribute practical 
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Appendix 1: Standard of prevention norms in HVT-specific ethics guidelines 
 
Term  Abbreviation 
Care Cx 
Prevention Prevention 
Risk-reduction counselling RRC 
Risk-reduction interventions RRIs 
Treatment Rx 
Standard of prevention SoP 
Trial participant TP 
 
Dimension MRC (2003) HIV Preventive vaccine 
research. Book 5 
UNAIDS (2007). Ethical 
considerations 
UNAIDS-AVAC (2011) Good 
Participatory Practice (GPP) 
My notes:  









families & the 
community  
The research protocol should 
specify referral processes for those 
persons excluded from the trial, 
where relevant (GP4, Research 
protocols & study populations, p. 
9). 
 
Participants should be informed 
how to obtain (STI) Rx for their 
partners (GP 14, HIV RRIs, p. 29) 
 
Sponsors & investigators should 
build capacity of trial linked 
healthcare centres to deliver 
services to the host community, & 
ensure that there is a contribution 
of lasting benefit to host 
communities (bolded GP 16, Rx & 
Cx, p. 31) 
 
Ways should be explored with local 
authorities to provide trial 
volunteers & participants with 
information about HIV Px & Rx 
services available in the community 
(GP 13, SoP, p. 46). 
 
Clinical trials should be integrated 
into national Px, Rx, & Cx plans so 
that services provided through 
clinical trials or arrangements 
brokered for TPs serve to improve 
the health conditions of both the 
TPs & the community from which 
they are drawn, & (to) support & to 
strengthen a country’s 
comprehensive response to the 
epidemic (GP 14, Cx & Rx, p. 49-50). 
 
There should be an ongoing 
Research teams & relevant 
stakeholders discuss & negotiate 
the comprehensive HIV prevention 
package, taking account of the 
following: 
• The HIV prevention services 
that will be available to 
partners of trial participants. 
(Standard of HIV prevention, p. 51) 
In addressing what should be 
provided to screen-outs, 
components not specified. Perhaps 
the lack of guidance on Px services 
for screen-outs is that most 
volunteers may not meet enrolment 
criteria because they are already 
infected à HIV Px not required & 
positive Px is dealt with under Cx & 
Rx.  
 
GPP has the clearest statement on 
services for partners. 
 
Only MRC (2003) specifies the 
mechanism for accessing services 







Dimension MRC (2003) HIV Preventive vaccine 
research. Book 5 
UNAIDS (2007). Ethical 
considerations 
UNAIDS-AVAC (2011) Good 
Participatory Practice (GPP) 
My notes:  
Across guideline analysis 
iterative consultative process to 
facilitate local or national decision-
making about the appropriate level 
of support, Cx, & Rx provided to 
potential & enrolled participants 
(GP 12, Benefits, p. 43) 
 




General support & services not 
specific to Px: 
Statement on referral for screen 
outs. Implies that screen-outs get 
the standard available in the local 
healthcare system. Also a 
statement that capacity should be 
built to deliver services to host 
communities.  
 
Px-specific: Does state that TPs be 
informed about where partners can 
be treated for STIs, but no detail on 
whether this Rx will be offered at 
the site or through the local 
healthcare system.  
Screen-outs & partners 
 
Covers all levels of the ‘who’ 
specified in the good governance 
model. 
General statement in Cx section 
that support should be provided to 
potential participants. 
 
Px-specific: trial volunteers should 
be provided with info on the HIV px 
services available in the community; 
the health conditions of the 
community should be improved. 
How? By integrating clinical trials 
into national prevention plans.  
 
Revisions should include a clearer 
statement on what components of 
prevention should be provided to 
those who screen out, if anything  
 
 
Screen-outs & the host community 
 
 Only covers three levels of the 
‘who’ specified in the good 
governance model, i.e. TPs (see 
below), screen-outs & host 
community. Does not “other 
persons linked to trial participants 
but not considered for enrolment, 
There should be discussion & 
negotiation about the prevention 
services that will be available to 
partners of TPss. Nothing on screen 
outs or the wider community.  
The good governance model 
requires that stakeholders consider 
‘who’ should get services: trial 
participants, screen-outs, 





Dimension MRC (2003) HIV Preventive vaccine 
research. Book 5 
UNAIDS (2007). Ethical 
considerations 
UNAIDS-AVAC (2011) Good 
Participatory Practice (GPP) 
My notes:  
Across guideline analysis 










The most appropriate RRC & access 
to preventive methods should be 
provided to all TPs (GP 14, RRIs, p. 
28: bolded GP). 
 
Investigators are morally compelled 
to provide optimal risk-reduction 
measures to TPs (GP 14, RRIs, p. 
28). 
 
Every effort must be made to 
provide participants with optimal 
RRC & interventions to prevent HIV 




Researchers, research staff, & trial 
sponsors should ensure that 
appropriate counselling & access to 
all state-of-the-art HIV risk-
reduction methods are provided to 
participants through-out the trial 
(GP 13, SoP, p. 45, bolded GP).  
 
Protocols for HIV Px research 
obligate researchers to provide the 
full range of information & services 
for risk-reduction... If researchers 
can’t guarantee this standard, it is 
unethical to conduct the trial (GP 
13, SoP, p. 45). 
 
All TPs should receive HIV RRC, as 
well as access & entitlement to 
proven Px methods, & to post-
exposure prophylaxis in the event 
of a known likely exposure (GP 13, 
SoP, p. 46) 
 
Some of the activities related to the 
conduct of HIV biomedical HIV Px 
trials which may benefit those who 
participate may actually be rights. 
At a minimum, participants 
should:…receive comprehensive 
information regarding HIV 
transmission 
The term “standard of HIV 
prevention” refers to the package 
of comprehensive counselling & 
state-of-the-art HIV risk-reduction 
methods provided or made 
available to participants in 
biomedical HIV prevention trials 
(Standard of HIV px, p. 48). 
There is fairly good consistency in 
the 3 guidelines in terms of the 
substantive standard – TPs should 
receive optimal/ state-of the art 
risk-reduction methods. However, 
EC seems to set the highest 
substantive standard. If this 
standard can’t be achieved then it is 
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& how it can be prevented; receive 
access to HIV testing & Px methods, 
including male & female condoms, 
sterile injecting equipment, & 
sexual & reproductive healthcare 
services…(GP 12, Benefits, p. 44) 




Advocates an OPTIMAL package but 
does not state that “all” preventive 
methods should be provided.  
 
 
The meaning of the term 
“appropriate” is not clear. 
 
Requires that investigators provide 











Advocates a STATE OF THE ART 
package & specifies that “all” state 
of the art HIV risk-reduction 
measures are provided. 
 
The meaning of the term 
“appropriate” is not clear. 
 
Requires that researchers & 
sponsors ensure that preventive 
methods are actually provided to all 
TPs à very high standard (Macklin, 
2009). 
 
Requirement to provide all state of 
the art methods has been criticised 
as setting too high a standard (cf. 
HPTN, 2009). 
 
Advocates for STATE OF THE ART 
HIV risk-reduction methods.  
 
No substantive statement. 
 
Requires that HIV px methods are 
provided OR made available 
Optimal or state of the art 
 
EC & MRC state that access should 
be provided  
GPP states that Px methods are 
provided OR made available 
 
Only EC requires that ALL state of 
the art methods should be 
provided.   
Little clarity on what exactly is 
state-of-the-art. 
According to Tarantola et al. (2007) 
standards in ethical guidelines 
provide little practical guidance. 
They do not specify the type, level & 
duration of prevention. However, 
good governance as an outcome 
aims to ensure compliance with 
international & national scientific & 
ethical standards which would 
mean that all prevention services 
should be provided to trial 
participants & consulting on what 
to provide would be illogical. 
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• methods to decrease risk of 
HIV infection 
• comprehensive RRC   
Preventive methods should include 
(but not ltd to):  
• Basic principles of risk-free & 
safer sexual practices 
• Education concerning general 
health & identification & Px of 
STIs;  
• Appropriate access to barrier 
methods, such as condoms & 
info about where barrier 
methods are locally available  
• Rx of STIs & info about how 
partners can be treated 
• Counselling around the 
potential benefits & risks of 







• proven Px methods & PEP;  
• Counselling 
• Appropriate access to male/ 
female condoms;  
• Rx for other STIs. 
• Provision for family planning, 
pregnancy, childbirth services 
• Sterile injecting equipment & 
medical substitution therapy;  
 
Counselling should include: 
• Basic principles of safer sexual 
practice & safer injecting 
practices 
• Education concerning general 
health & Rx of STIs 
• The potential benefits & risks 
of PEP & how it can be 
accessed. 
• Reproductive health, 
contraception pregnancy Cx 
etc. 
• Strategies to reduce domestic 
violence 
 
Protocols for HIV Px research 
obligate researchers to provide the 
full range of information & 
services for risk-reduction, 
although they vary in defining the 
package of services & modes of 
delivery (GP 13, SoP, p. 45).  
 
are discussed, & their 
appropriateness for the trial design 
& population assessed, including: 
• Risk assessment & risk-
reduction counselling— 
including partner & couple 
counselling. 
• Male & female condoms—with 
appropriate instructions & 
demonstrations. 
• Testing for & treatment of 
sexually transmitted infections. 
• Sterile injecting equipment & 
drug substitution treatment. 
• Medical male circumcision. 
• Post-exposure prophylaxis. 
•  Other novel HIV risk-reduction 
strategies as they become 
available. 
consistent. However, only EC & GPP 
require provision of PEP & medical 
substitution therapy. Only EC 
requires provision of reproductive 
healthcare services However, when 
reading the substantive standard it 









Dimension MRC (2003) HIV Preventive vaccine 
research. Book 5 
UNAIDS (2007). Ethical 
considerations 
UNAIDS-AVAC (2011) Good 
Participatory Practice (GPP) 
My notes:  
Across guideline analysis 
Researchers should guarantee that 
all communities engaged in 
biomedical HIV Px trials have state 
of the art reproductive healthcare 
services. 
 
In GP 16: IC, p. 54: 
Each prospective participant must 
be informed... that they will receive 
counselling concerning how to 
reduce their risk of HIV exposure & 
access to risk-reduction means (in 
particular, male & female condoms, 
clean injecting equipment, & where 
relevant, male circumcision)... 
 




Outdated given changes in the Px 
field but does specify that services 
may be included that are not on the 
list: “no ltd to”. 
  
Does not require provision of PEP 
even though it states that 
investigators are morally compelled 
to provide optimal risk-reduction 
methods.  
 
Deals mainly with HIV px (“diseases 
specifically targeted by the vaccine 
being studies”) & not px for 
“diseases diagnosed as part of the 
study design” nor “other diseases 
unrelated to the purpose of the 
trial” (Tarantola et al., 2007 
Very comprehensive in terms of 
components although no specific 
mention made of male 
circumcision.  
 
Confusing statement that protocols 
obligate researchers to provide full 
range of information & services BUT 
vary in defining the package of 
services. If all services, then surely 
package already defined.  
 
Identifying components related to 
reproductive healthcare & 
pregnancy Cx seems at odds under 
SoP à these are more Cx 
components.  
 
Very comprehensive.  
 
 
Deals exclusively with HIV px 
(“diseases specifically targeted by 
the vaccine being studies”) & not px 
for “diseases diagnosed as part of 
the study design” nor “other 
diseases unrelated to the purpose 
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Focus on HIV px & some mention of 
“diseases/ (procedures) diagnosed 











Counselling should be: i). 
Conducted in accordance with 
recognised national counselling 
guidelines; ii). Appropriate to 
participants’ culture, language, 
gender & age; & iii). Based on 
reliable information about the 
prevailing social & behavioural 
characteristics of the research 
population (GP 14, RRIs, p. 29). 
-Counsellors should get training, 
supervision & support (GP 14, RRIs, 
p. 29). 
 
The most suitable parties to be risk-
reduction counsellors should be 
considered (GP 14, RRIs, p. 28). 
In order to provide a contribution 
of lasting benefit to the 
participating community, 
consideration could be given to 
developing the capacity of 
community members to provide 
counselling. To prevent any real or 
perceived conflict of interest, 
consideration could be given to 
utilizing counsellors from an 
independent organisation (GP 14, 
Counselling: The technique/ 
frequency/ message content of 
counselling sessions should be 
agreed upon by the community-
government-investigator-sponsor 
partnership: based on reliable 
information about soc-behavioural 
characteristics (GP 13, SoP, p. 47). 
 
Consideration should be given to 
providing counselling through an 
agency independent of the 
investigators. If so, standard must 
be high. This must be evaluated. 
Pros & cons must be debated by 




Risk assessment & risk-reduction 
counselling— including partner & 
couple counselling. 
 
Trial sponsors, network leadership, 
& local research teams provide 
opportunities & time for local 
stakeholders, in 
particular community stakeholders, 
to contribute to trial design issues 
& procedures such as products to 
be tested, trial objectives, 
recruitment strategies, informed 
consent 
materials & procedures, 
reimbursement policies, 
counselling approaches, follow-up 
procedures, & post-trial access to 
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RRIs, p. 28). 
 
Every effort must be made to 
ensure that counsellors involved in 
consent & risk-reduction 
procedures understand the 
potentially harmful consequences 
of participants’ mistaken belief that 
they may be protected from HIV 
infection (GP 14, RRIs, p. 28) & (GP 
9: Potential harms; p. 17) 
 




Cf. DoH (2010) HIV counselling & 
testing guidelines.  
 
Requires agreement amongst the 
community-government-
investigator-sponsor partnership on 
the technique/ frequency/ message 
content of counselling sessions. 
Identified stakeholders do not map 
with those identified by Tarantola 
et al (2007) although Tarantola 
does not specify that all 
stakeholders must be involved in all 
decision-making.  
 
It is unclear whether agreement will 
require mere endorsement of the 
counselling or negotiated 
discussions on what the counselling 
should entail.  
 
Only recommendation is the 
suggestion that RRC involve 
partners and couples counselling 
and that local and community 
stakeholders should make inputs 
into counselling approaches during 
protocol development.  
 
4. 
Why should Px 
methods be 
provided?  
Reducing the risk of HIV infection 
among participants is an essential 
ethical component of HIV 
preventive vaccine trials. This is 
The principle of beneficence 
justifies this approach. This 
obligation pertains not only to the 
preventive method being studied, 
Helping trial participants reduce 
their risk of acquiring HIV is a key 
ethical obligation of research teams 
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especially critical given that phase 
III efficacy trials rest on some 
exposure to HIV infection. In order 
to manage the perceived conflict of 
interest between risk-reduction & 
scientific goals of the research, & to 
promote the welfare of 
participating individuals, 
investigators are morally compelled 
to provide optimal risk-reduction 
measures to participants. This is 
clearly captured in Book 1, 3.1.3 x, 
which states that research 
objectives are subordinate to the 
principle that human beings should 
be treated with respect (GP 14, 





but also to reducing the risk that 
any TP will acquire HIV infection 
during a biomedical HIV Px trial (GP 
13, SoP, p. 45). 
 
Some have contended that to 
promise antiretroviral Rx to HIV Px 
TPs who become infected would 
constitute an undue inducement to 
participate in the trial. That 
supposition is most unlikely, since 
biomedical HIV Px trials enrol 
healthy people, not individuals who 
are already sick & need Rx. If 
anything, the possibility of being 
protected from acquiring HIV by the 
preventive method itself could 
conceivably be considered an undue 
inducement; however, if that were 
the case, clinical trials of preventive 
methods could never be ethically 
carried out. Concerns that any form 
of Cx & Rx promised to participants 
in research on biomedical HIV 
preventive interventions could be 
an undue inducement are 
unwarranted. 
 
Some may argue that provision of 
state-of-the-art Px, Cx, & Rx 
services for participants introduces 
local inequalities & is therefore 
unjust when non-participants do 
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However, all scale-up programmes 
involve temporary inequalities in 
the community until universal 
access can be attained. Achieving a 
perfect system of equal justice is a 
long-term process (GP 12, Benefits, 
p. 44) 




No clear rationale – but seems to 
use compensation for harm 
argument. 
 
Identify the rationale for providing 
state of the art Px services as based 
on beneficence.  
 
Tarantola et al. (2007) argue that 
beneficence & justice both obligate 
researchers to provide RRIs to 
participants but” these obligations 
are poorly defined in practical 
terms, inconsistently understood or 
inadequately applied.” 
 
Rationale not based on ethical 
principles but general statement 
that it is an ethical obligation.  
The good governance model states 
that beneficence & social justice 
obligate researchers & sponsors to 
provide services but that these 















It is recommended that before the 
start of a trial, a process of 
consultation between community 
representatives, investigators, host 
government & sponsors be used to 
design an effective risk-reduction 
strategy & its parameters (GP 14, 
RRIs, p. 28).  
 
Community participation could 
incl., but not be ltd to, input into 
appropriate RRIs (GP 5, CP, p.10). 
 
Community participation should 
enhance the scientific quality or 
Px trials should not be conducted 
when agreements have not been 
reached among all research 
stakeholders on SoP (Context, p. 
13). 
 
Researchers should engage 
appropriate stakeholders in 
tailoring the design, 
implementation, & oversight of 
RRIs... (GP 13, SoP, p. 46). 
 
Participation of the community in 
the planning & implementation of a 
biomedical HIV Px product 
Determining the components of the 
HIV prevention package is a joint 
effort between research teams & 
relevant stakeholders. Trial 
sponsors & implementers must 
work with relevant stakeholders in 
establishing the type, scope, & 
process by which participants are 
provided with, or referred to, 
services to access the full HIV 
prevention package. How trial sites 
help participants prevent HIV 
acquisition is often at the forefront 
of community stakeholder 
concerns. Therefore, successful 
All guidelines have a role for 
stakeholder consultation in making 
decisions about “what” to provide 
to participants. 
 
MRC, EC & GPP also identify a role 
for stakeholders in determining 
“how” RRIs should be implemented 
in the trial.  
 
Consultation re implementation is 
ethically justified. However, 
consultation may inadvertently 
serve to lower the substantive 
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ethical soundness of the proposed 
research (GP 5, CP, p.10). 
 
The method & process for 
monitoring RRIs should be designed 
& agreed upon by the partnership 
of community, host, government, 
investigator & sponsors (GP 15, 




development strategy can provide 
at least these favourable 
consequences: *insight into the 
design of RRIs (GP 2: CP, p. 20) 
 
The technique, frequency, & 
message content of counselling 
sessions should be agreed upon by 
the community-government-
investigator-sponsor partnership, 
& should be based upon reliable 
information about the prevailing 
social & behavioural characteristics 
of the study population (GP 13, 
SoP, p. 47). 
 
Before a trial commences, 
researchers, trial sponsors, 
countries, & communities should 
agree on a plan for monitoring the 
initial & continuing adequacy of 
the informed consent process & 
RRIs, including counselling & access 
to proven HIV risk-reduction 
methods (GP 17, Monitoring of IC & 
interventions, p. 56). 
 
It is imperative that appropriate 
financial arrangements are in place 
to implement agreements made 
between partners at the time that a 
study is initiated. These 
agreements should cover the 
period of the trial but also address 
negotiation with stakeholders 
about the prevention package to 
be provided to trial participants is 
likely to have a significant influence 
on community stakeholder 
perceptions of a trial (Standard of 
HIV prevention, p. 49) 
 
Research teams & relevant 
stakeholders negotiate the HIV 
prevention package during the 
protocol development phase of the 
trial (Standard of HIV prevention, p. 
49). 
 
Research teams & relevant 
stakeholders discuss & negotiate 
the comprehensive HIV prevention 
package & consult local HIV 
prevention service providers when 
appropriate. All scientifically 
validated methods are discussed, & 
their appropriateness for the trial 
design & population assessed 
(Standard of HIV prevention, p. 50). 
 
Research teams & relevant 
stakeholders discuss & negotiate 
the comprehensive HIV prevention 
package, taking account of the 
following: 
a. The HIV prevention package 
required as a minimum for the trial 
protocol. 
determine ‘what’ should be 
provided to participants.  
 
These guidelines only specify the 
outcome of consultation. They do 
not specify the process for 
consultation, the ethical goals of 
consultation nor any procedures for 
resolving disagreements. Assumes 
that all stakeholders will agree, 
even though identified stakeholders 
come from vastly different positions 
in research.  
 
The purpose of consultation varies 
from agreement, partnership, 
getting inputs, achieving consensus 
on various aspects of the SoP.  
 
Only a few stakeholders are 
identified for involvement in 
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what will be provided to study 
participants once the study is 
completed (Context, p. 12). 
 
Members of the community who 
may contribute to the development 
of a safe & effective HIV Px product 
include....those who provide 
healthcare & other services to 
people living with & affected by HIV 
(GP 2, CP, p. 19). 
 
 
b. Current HIV prevention 
standards & services available 
nationally & locally. 
c. Current national laws on HIV 
prevention strategies & services, as 
well as national ethical guidance on 
research. 
d. The trial’s funding source, any 
implications this may have for the 
prevention package, & how these 
will be 
addressed to ensure participants 
are offered a comprehensive 
package. 
e. The HIV prevention services & 
options that will be offered through 
referral mechanisms. 
f. The HIV prevention services that 
will be available to partners of trial 
participants. 
g. The impact that any services 
offered by the trial, as well as those 
to which participants will be 
referred by the trial, could have on 
local services. 
(Standard of HIV prevention, p. 51) 
 
Research teams & relevant 
stakeholders discuss how the HIV 
prevention package will be 
implemented & monitored, 
including uptake & standards of 
referral services (Standard of HIV 
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ID’s a role for stakeholder 
consultation in decision-making 
before & during the research 
process to design & make inputs 
into ‘appropriate’ RRIs & also for 
monitoring RRIs. Therefore 
consultation required for ‘what’ 
(designing RRIs) & ‘how’ 
(monitoring RRIs.  
 
Tarantola et al. (2007) provide a 
comprehensive list of research 
stakeholders. Not all these 
stakeholders identified for decision-
making in MRC (2003). While 
Tarantola specifies the process for 
making decisions, no ethical 
rationale for consultation is 
identified nor is there mechanisms 
for resolving disagreements.  
 
While there is concern that 
consultation may lower the 
standard that the package be 
optimal, there is a proviso that 
community participation should 
enhance the scientific & ethical 
conduct of the trial. Therefore the 
purpose of asking stakeholders 
what to provide may help to ratchet 
up the standard of prevention. 
 
ID’s a huge role for stakeholder 
consultation ito the ‘what’ 
(designing RRIs) & ‘how’ 
(implementing & monitoring RRIs.  
 
Tarantola et al. (2007) requires 
consultation on the type, level & 
duration of px services. In 
deliberations several criteria are 
considered including how will 
uptake of services & 
implementation be monitored 
(prospective criteria). Given that an 
aim of the model is to comply with 
ethical guidelines it is not clear why 
stakeholders should deliberate on 
what to provide as there is a set 
standard in ethical guidelines.  
ID’s a large role for stakeholder 
consultation, discussion and 
negotiation on ‘what’ (establishing 
the type, scope, & process by which 
participants are provided with, or 
referred to, services to access the 
full HIV prevention package) & 
‘how’ (direct provision or referral; 
implementation and monitoring).  
 
Tarantola et al. (2007) requires 
consultation on the type, level & 
duration of px services. In 
considerations several criteria are 
considered including how will 
uptake of services & 
implementation be monitored 
(prospective criteria) 
 
These guidelines map closely with 
the model ito consultation to define 
the type, scope & duration of 
prevention available to TPs & host 
communities. 
 
Only guidelines that require 
consideration of the 
appropriateness for the trial 
design & population (Standard of 





It is recommended that before the 
start of a trial, a process of 
The appropriateness of plans to 
monitor RRIs should be determined 
NIL UNAIDS EC omits “SoP” as an item 
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consultation between community 
representatives, investigators, host 
government & sponsors be used to 
design an effective risk-reduction 
strategy & its parameters. The local 
research ethics committee should 
approve the risk-reduction 
strategy (GP 14, RRIs, p. 28). 
 
The research protocol should 
outline the benefits that 
participants in HIV preventive 
vaccine trials should experience as 
a result of their participation… At a 
minimum participants should 
…receive comprehensive 
information regarding HIV 
transmission & how it can be 
prevented, & access to appropriate 
HIV Px methods, including barrier 
methods…Expected benefits should 
be described in the research 
protocol presented to research 
ethics committees (GP 10: Benefits, 
p. 19-20). 
 
Plans to monitor consent, & RRIs, 
should be submitted for approval to 
local research ethics committees 
(GP 15, Monitoring informed 
consent & RRIs, p.30). 
 
 
by the scientific & ethical review 
committees that are responsible 
for providing prior & continuing 
review of the trial (GP 17, 
Monitoring of IC & interventions, p. 
57). 
 
Only anticipated benefits of study-
related procedures required for the 
safe & scientific conduct of the trial 
should be considered in the risk-
benefit analysis, that is, only 
healthcare benefits derived directly 
from the study design. Extraneous 
benefits, such as payment or 
ancillary services, such as HIV RRIs 
or reproductive healthcare services, 
should not be considered in the 
risk-benefit analysis (GP 12, 
Benefits, p. 43). 
 
Consideration should be given to 
expansion of the responsibilities of 
the clinical trial monitor to include 
adherence to … counselling 
standards…The appropriateness of 
such plans should be determined 
by the scientific & ethical review 
committees that are responsible 
for providing prior & continuing 
review of the trial (GP 17, 
Monitoring IC & intervention, p. 
57). 
review! Only monitoring plans need 
to be reviewed by REC.  
 
“The ethical review of such 
protocols normally addresses 
the issue of what prevention 
package will continue to be 
promoted or will be undertaken in 
order to comply with both ethical 
standards & the imperative to 
determine the efficacy & safety of a 
product against the background of 
established, ongoing or planned 
prevention modalities” (Tarantola 
et al., 2007, p. 4865). 
 
Tarantola et al. (2007) also identify 
RECs as key research stakeholders 
to be involved in consultations re 
the SoP.  
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strategy & plans for monitoring the 
RRIs. 
 
Consistent with Tarantola et al. 
(2007) which states that RECs will 
review the px package. RECs also 
identified as a stakeholder to be 
included in consultations.  
monitoring plans.  
 
Revisions should specify a role for 
RECs in reviewing & approving 
prevention services.  
 
Not consistent with Tarantola et al 
(2007) which states that RECs will 
review the px package. RECs also 
identified as a stakeholder to be 




are made on 
what to include 






Risk minimization measures 
include…Provision of supportive 
counselling for the duration of the 
trial, & appropriate referral after 
the trial is completed (GP 9, 
Potential harms, p. 18) 
 
Capacity of trial-linked healthcare 
service centres in the host 
community should be 
strengthened. That is, the ‘local 
standard of Cx’ in the host 
community should be improved so 
that it is provided with a 
contribution of lasting benefit (GP 
16, Cx & Rx, p. 33) 
 
Trial sponsors, countries, & 
researchers should ensure that 
trials take place only in 
communities where participants 
will have access to, & can be 
referred to, ongoing psycho-social 
services, including counselling, 
social support groups, & legal 
support (GP 11: Potential harms, p. 
40). 
 
It is imperative that appropriate 
financial arrangements are in place 
to implement agreements made 
between partners at the time that a 
study is initiated. These agreements 
should cover the period of the trial 
but also address what will be 
provided to study participants once 
the study is completed (Context, p. 
12). 
 
NIL Tarantola et al. Also have 
sustainability requirements that 
must be considered in decision-
making (prospective criteria): 
Sustainability beyond project 
lifespan: What is the likely 
sustainability of approaches beyond 
the end of the 
research project in technical, 
operational & financial 
terms? Who will deliver the 
services? Who will deliver 
care & treatment? How? What 
additional skills & 
systems would be required? 
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counselling services should be 
available post-trial. 
 
participants can access 













NIL NIL Deviations from expected standard 
HIV prevention packages at a trial 
site or among trial sites in multisite 
studies may be caused by national 
legal restrictions (Standard of HIV 
prevention, p. 49). 
 
When funding-body restrictions 
limit which prevention methods can 
be paid for by trial funds, research 
teams have the responsibility to 
find other ways to provide these 
methods, such as through 
alternative funding streams or 
linkages with NGOs or CBOs 
(Standard of HIV prevention, p. 49).  
 
Research teams & relevant 
stakeholders discuss & negotiate 
the comprehensive HIV prevention 
package, taking account of the 
following: 
• Current HIV prevention 
standards & services available 
nationally & locally. 
• Current national laws on HIV 
prevention strategies & 
services, as well as national 
ethical guidance on research. 
•  The trial’s funding source, any 
Government & sponsors are 
considered key research 
stakeholders to be involved in 
consultations re the SoP.  
 
Further ito nornmative criteria, 
Tarantola et al require that 
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implications this may have for 
the prevention package, & how 
these will be addressed to 
ensure participants are offered 
a comprehensive package. 
• The impact that any services 
offered by the trial, as well as 
those to which participants will 
be referred by the trial, could 
have on local services.  
(Standard of HIV prevention, p. 51) 
 
Trial sponsors ensure sufficient 
funding & research teams create a 
budget & allocate funds & staff 
time to ensure provision of the 
comprehensive HIV prevention 
package (Standard of HIV 
prevention, p. 51) 
. 




No consideration of how sponsor, 
government policies may factor into 
decision-making on the SoP, except 
that counselling should be 
conducted according to national 
guidelines. There may be countries 
where a prevention tool is 
unavailable & not approved by 
regulatory authorities à this is not 
accounted for in these guidelines.  
 
No consideration of how sponsor, 
government policies may factor into 
decision-making on the SoP. There 
may be countries where a 
prevention tool is unavailable & not 
approved by regulatory authorities 




Sponsor, government & other 
policies may place restrictions wrt 
SoP. Stakeholder discussion should 
consider several factors including 






As new methods of Px are 
discovered & validated, these must 
be added to the preventive 
New HIV risk-reduction methods 
should be added... as they are 
scientifically validated or as they 
Research teams may need to 
review the HIV prevention package 
regularly, taking into consideration 
Given that Tarantola et al (2007) 
has not yet been applied to SoP, it 
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should be made 
on adding new 







methods offered to TPs (GP 14, 
RRIs, p. 29, also in bolded GP). 
are approved by relevant 
authorities (GP 13, SoP, p. 45, 
bolded GP).  
 
Mechanisms for negotiation among 
all research stakeholders, incl. the 
community, about the standards 
for enhancement of the risk-
reduction package need to be set in 
the study protocol. Negotiations 
should take into consideration 
feasibility, expected impact, & the 
ability to isolate the efficacy of the 
biomedical HIV modality being 
tested (GP 13, SoP, p. 47). 
 
A decision to introduce the new 
method in a trial that is already 
underway has to be made 
collectively as it may have 
implications for resource 
requirements, sample sizes, & 
potential futility of continuing the 
trial (Context: p. 12). 
new HIV counselling models & risk-
reduction methods that are 
scientifically validated &, when 
appropriate, approved by national 
bodies for use (Standard of HIV 
prevention, p. 49) 
consider for evolving standards of 
prevention. However, issues of 
scientific criteria & regulatory 
approval are covered ito normative 
& evaluative criteria.  
 
Jay et al three-step framework may 
be helpful in terms of clarifying 
scientific validity and ambiguities 
regarding regulatory approval. 




Scientific validation only – no role 
for stakeholder consultation. 
 
No direction on how &/or when 
new methods are scientifically 
validated – may be defined 
different by different regulatory 
authorities (McGrory et al., 2010) 
 
The term “offered” rather than 
Must be scientifically validated or 
approved by relevant authorities. 
But what does this mean when 
normative & regulatory bodies may 
define these differently (cf McGrory 
et al., 2010). Also need to consider 
feasibility, expected impact, & the 
ability to isolate the efficacy of the 
biomedical HIV modality being 
tested. 
Must be scientifically approved, or 
when appropriate, approved by 
national regulatory authorities. But 
what does this mean when 
normative & regulatory bodies may 
define these differently (cf McGrory 
et al., 2010).  
 
These considerations only consider 
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“provided” is used here.   
These considerations only consider 
scientific design of the study. Would 
cultural or religious objections be 
considered? However resources also 
mentioned in the Context section.  
 
Tarantola specifies scientific 
considerations as part of 1 of 4 
criteria of importance in decision-
making.  
 
cultural or religious objections be 
considered? However resources also 
mentioned in the Context section.  
 
Tarantola specifies scientific 
considerations as part of 1 of 4 













NIL New methods should be added 
based on consultation among all 
research stakeholders (GP 13, SoP, 
p. 45, bolded GP). 
 
Mechanisms for negotiation among 
all research stakeholders, incl. the 
community, about the standards 
for enhancement of the risk-
reduction package need to be set in 
the study protocol (GP 13, SoP, p. 
47). 
 
The discovery of additional safe & 
effective biomedical HIV preventive 
interventions will necessitate 
discussions among all research 
stakeholders involved in planned or 
active trials of other biomedical HIV 
Px tools. A decision to introduce 
the new method in a trial that is 
already underway has to be made 
NIL EC suggests that consultation will 
play a role and EC holds up a 
scientific standard too. 
 
There is no guidance on how the 
substantive + procedural standards 
must work together. What if 
consultation serves to lower the 
standard? In fact Macklin (2009) 
suggests that the procedural 
standard is a solution to the state of 
the art requirement in the bolded 
GP.  
 
Adding new methods to the current 
package will require consultation 
for the purposes of negotiation, 
discussion & partnership. In adding 
new methods, stakeholders are not 
merely required to agree with the 
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collectively as it may have 
implications for resource 
requirements, sample sizes, & 
potential futility of continuing the 
trial. The possibility that such a 
decision could be required should 
be anticipated during initial 
discussions among the research 
stakeholders (Context: p. 12) 
 




No role for stakeholder consultation 
when making decisions to add new 
methods. However, stakeholders 
may have important inputs to make 
re feasibility, regulatory & scientific 
approvals. 
 
Large role for stakeholder 
consultation ito adding new 
methods to the package. Again, 
who constitutes all research 
stakeholders not defined nor is a 
process for consultation specified. 
These guidelines also do not spell 
out why stakeholders should be 
consulted à is it respect for 
communities? 
 
Only identifies scientific criteria for 
not including a method in the 
standard of prevention. However 
stakeholders may object to the 
provision of a prevention method 
like male circumcision on other 
grounds such as religious or cultural 
objections. If circumcision not 
provided, then consultation would 
have lowered the substantive 
standard that the package be state 
of the art. If circumcision provided 
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consultation is tokenistic & does not 
appropriately satisfy the principle of 




What should be 
in the protocol? 
The protocol must describe 
potential risks, & steps that will be 
taken to reduce these risks to 
minimum…Risk minimization 
measures that should be taken 
include: …ensuring that 
participants are provided with 
optimal RRIs(GP 9: Potential harms, 
p. 18) 
 
The research protocol should 
outline the benefits that 
participants in HIV preventive 
vaccine trials should experience as 
a result of their participation… At a 
minimum participants should 
…receive comprehensive 
information regarding HIV 
transmission & how it can be 
prevented, & access to appropriate 
HIV Px methods, including barrier 
methods…Expected benefits should 
be described in the research 
protocol presented to research 
ethics committees, & in the 
informed consent process (GP 10: 
Benefits, p. 19-20). 
The research protocol should 
specify referral processes for those 
persons excluded from the trial, 
Mechanisms for negotiation among 
all research stakeholders, including 
the community, about the 
standards for enhancement of the 
risk-reduction package during the 
trial as new biomedical HIV Px 
modalities are scientifically 
validated or are approved by 
national authorities need to be set 
in the study protocol (GP 13, SoP, 
p. 47). 
 
Protocols for HIV Px research 
obligate researchers to provide the 
full range of information & services 
for risk-reduction, although they 
vary in defining the package of 
services & modes of delivery. If the 
study aims to test a product by 
comparing its additive effects to 
those of routinely practiced Px, in 
all cases this Px standard should be 
defined in the study protocol as 
well as in informed consent 
documents (GP 13, SoP, p. 45) 
 
The research protocol should 
provide an accurate statement of 
the anticipated benefit of the 
procedures & interventions 
NIL According to Tarantola et al. (2007, 
p. 4865) ”in every prevention trial 
testing a prevention technology 
(e.g. a vaccine candidate), the 
standard of prevention offered 
to trial participants & members of 
their community is normally set, 
considering that the very purpose of 
such trials is to test a technology (in 
this case a vaccine candidate) 
against the background of other 
ongoing or planned prevention 
activities” & that “standards of 
prevention form an integral part of 
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where relevant (GP4, research 
protocols & study populations, p. 
8). 
 
required for the scientific conduct 
of the trial. The protocol should 
outline any services, products, & 
other ancillary interventions 
provided in the course of the 
research that are likely to be 
beneficial to persons participating 
in the trials (GP 12: p.43). 
 
Research protocols should specify, 
as fully as reasonably possible, the 
nature, magnitude, & probability of 
all potential harms resulting from 
participation in a biomedical HIV Px 
trial, as well as the modalities by 
which to minimise the harms & 
mitigate or remedy them. (GP 11: p. 
40) 
 




Research protocol should outline 
benefits & risk minimization 
measures –> RRIs fall in both. It 
should also specify referral 
processes for those excluded from 
the trial.  
 
Consistent with Tarantola et al. 
(2007) which states that the SoP 
should be defined in the protocol.  
 
The research protocol should 
outline: *benefits & risk 
minimization measures –> both 
which include RR services; 
*mechanisms for negotiation 
among all research SHs for adding 
new tools; *the SoP 
 
Consistent with Tarantola et al. 
(2007) which states that the SoP 
should be defined in the protocol.  
 
No statement on what should be in 
the protocol. Only requirement is to 
allow local and community 
stakeholders to make inputs into 
the protocol, including with regard 
to counselling approaches.  
 
8. 
What should be 
in the informed 
Participants must be informed of & 
should understand the risks & risk 
minimisation measures that will be 
If the study aims to test a product 
by comparing its additive effects to 
those of routinely practiced Px, in 
NIL 
 
Informed consent is a process by 
Fairly consistent requirements 
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consent form/ 
process?  
taken, & these measures should be 
included in the informed consent 
form (GP 9: Potential harms, p.18) 
 
The research protocol should 
outline the benefits that 
participants in HIV preventive 
vaccine trials should experience as 
a result of their participation… At a 
minimum participants should 
…receive comprehensive 
information regarding HIV 
transmission & how it can be 
prevented, & access to appropriate 
HIV Px methods, including barrier 
methods…Expected benefits should 
be described in... the informed 
consent process (GP 10: Benefits, p. 
19-20). 
 
Each prospective participant must 
be counselled, using appropriate 
language & techniques, to 
understand ...that they will receive 
counselling & access to the means 
of risk-reduction... (GP 12: 
Informed consent, p. 22). 
 
all cases this Px standard should be 
defined in the study protocol as 
well as in informed consent 
documents (p. 45). 
 
Each prospective participant must 
be informed... that they will receive 
counselling concerning how to 
reduce their risk of HIV exposure & 
access to risk-reduction means (in 
particular, male & female condoms, 
clean injecting equipment, & where 
relevant, male circumcision)...(GP 
16, Informed consent, p. 54). 
 
which a competent individual is 
provided with enough info about a 
trial to make an independent 
decision whether or not to 
participate in the trial. In this 
process, research staff members 
educate the prospective participant 
about the trial, including about the 
potential risks & benefits, trial 
procedures, & what is expected of 
the participant. When an individual 
provides consent, this is 
documented on the informed 
consent form. Informed consent is 
an ongoing process. Participants 
may decide to drop out of the trial 
at any point, even after providing 
consent to enrol in the trial 
(Informed consent, p. 45) 
 
To improve relevant stakeholder 
understanding of the prevention 
package offered & the clinical trial 
process, research 
teams can describe the trial as 
comparing the study product plus 
the HIV prevention package, with 
the placebo (or comparator arm) 
plus the HIV prevention package 
(Standard of HIV prevention, p. 49). 
Info on Px services does not need to 
be in the IC form per se but must be 
included in the IC process. 




RRIs should be outlined in the IC 
form (GP 9) & IC process (GP 10). 
Each TP must be counselled that 
they will receive RRC & access to 
SoP must be defined in IC 
documents & each TP must be 
informed that they will receive RRC 
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Counselling should be...Based on 
reliable information about the 
prevailing social & behavioural 
characteristics of the research 
population (GP 14, RRIs, p. 29). 
 
Those who plan & conduct HIV 
vaccine research should have a 
good understanding of the social, 
political, health & cultural context 
of a specific community or 
population where the research will 
occur (p. 9).  
 
 
Trial sponsors & researchers should 
collaborate with governments in 
low- & middle-income countries to 
explore, develop, & strengthen 
national & local capacity to deliver 
the highest possible level of HIV 
Px, Cx, & Rx services (GP 14, Cx & 




Research teams determine which 
stakeholders already provide HIV 
prevention services, what types of 
services they provide, & their 
capacity to provide adequate 
services. This will enable research 
teams to provide optimal referrals 
& make linkages when necessary 
(Standard of HIV px, p. 50).  
EC & GPP require some form of 
research/ assessment in host 
communities.  
 
Tarantola et al. (2007) require 
consideration of both factual 
criteria (background evidence 
relevant to decision making such as 
what prevention services are 
available in the local community & 
are there existing referral networks) 
& prospective criteria (projection of 
resources, mechanisms, resource 
needs & impact for each optional 
approach, e.g., who/how will 
uptake of services & 
implementation be monitored). 
Both require some research or 
assessment components.  




Does not speak directly about Px, 
apart from counselling, & does not 
identify the need for research in 
order to ensure that Px services are 
accessed during the trial. However, 
formative research is NB to ID the 
level of services available in the 
community in order to establish 
effective referral networks as well 
as areas where capacity needs to be 
built.  
No assessment of the services 
available in the community/ local 
healthcare system but does 
mention the need to explore 
national & local capacity to deliver 
Px services.   
Requires an assessment of current 
providers of HIV prevention services 
and their capacity.   
There is differential emphasis on 




In order to provide a contribution 
of lasting benefit to the 
participating community, 
Local capacity may need to be 
developed to provide RRC in a 
culturally suitable & sustainable 
Research teams & relevant 
stakeholders discuss & negotiate a 
stakeholder education plan to 
All three ethical guidelines consider 
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consideration could be given to 
developing the capacity of 
community members to provide 
counselling (GP 14, RRIs, p. 28). 
 
All risk-reduction counsellors 
should be provided with 
appropriate training, supervision & 
support, including ethical 
responsibilities, lines of 
accountability &, if necessary, 
anticipated personal & professional 
conflicts (GP 14, RRIs, p. 28). 
 
Sponsors & investigators should 
build capacity of trial linked 
healthcare centres to deliver 
services to the host community, & 
ensure that there is a contribution 
of lasting benefit to host 
communities (GP 16, Cx & Rx, p. 31) 
 
Capacity of trial-linked healthcare 
service centres in the host 
community should be 
strengthened. That is, the ‘local 
standard of Cx’ in the host 
community should be improved so 
that it is provided with a 
contribution of lasting benefit (GP 
16, Cx & Rx, p. 33) 
 
fashion, guided by the best 
scientific data (GP 13, SoP, p. 47). 
 
Researchers should guarantee that 
all communities engaged in 
biomedical HIV Px trials have state 
of the art reproductive healthcare 
services (GP 13, SoP, p. 45). 
 
Trial sponsors & researchers should 
collaborate with governments in 
low- & middle-income countries to 
explore, develop, & strengthen 
national & local capacity to deliver 
the highest possible level of HIV Px, 
Cx, & Rx services through strategic 
investment & development of trial-
related resources (GP 14, Cx & Rx, 
p. 49). 
 
Clinical trials should be integrated 
into national Px, Rx, & Cx plans so 
that services provided through 
clinical trials or arrangements 
brokered for TPs serve to improve 
the health conditions of both the 
TPs & the community from which 
they are drawn, & (to) support & to 
strengthen a country’s 
comprehensive response to the 
epidemic (GP 14, Cx & Rx, p. 49-50). 
 
cover the life-cycle of the trial. The 
plan defines the following: 
a. The range of different 
stakeholders that could benefit 
from specific education about HIV, 
HIV prevention options, & general 
research literacy (GPP for 
stakeholder education planning, p. 
38). 
“An overall agreement 
is emerging however among those 
involved in the conduct of vaccine & 
clinical trials that it is important to 
do as much as is feasible to improve 
medical care to participants in trials 
as well as to improve care in 
general in resource-poor settings 
where trials are conducted” 
(Tarantola et al., 2007, p. 4863) 
 
Tarantola et al (2007) also require 
that the capacity of communities to 
make decisions is developed.  
My notes:  
Within 
Capacity building efforts focused 
mostly on RRC. A general statement 
Capacity building to deliver Px 
services to TPs & to improve health 
In terms of the standard of 






Dimension MRC (2003) HIV Preventive vaccine 
research. Book 5 
UNAIDS (2007). Ethical 
considerations 
UNAIDS-AVAC (2011) Good 
Participatory Practice (GPP) 
My notes:  
Across guideline analysis 
guidelines 
analysis 
in the section on care & treatment 
on improving capacity of trial-linked 
healthcare service centres in the 
community to benefit the host 
community.  
conditions for community  
 













Ways should be explored with local 
authorities to provide trial 
volunteers & participants with 
information about HIV Px & Rx 
services available in the community 
(GP 13, SoP, p. 46). 
 
Trial sponsors & researchers should 
collaborate with governments in 
low- & middle-income countries to 
explore, develop, & strengthen 
national & local capacity to deliver 
the highest possible level of HIV Px, 
Cx, & Rx services through strategic 
investment & development of trial-
related resources. In most 
situations, no one stakeholder 
should bear the entire burden of 
providing resources for such 
services & the central responsibility 
for delivery should lie with local 
health systems (GP 14, Cx & Rx, p. 
49) 
 
Site selection for moving forward 
into empirical efficacy trials of 
biomedical HIV Px technologies is a 
major challenge. Part of this 
challenge is the need to integrate 
Research teams determine which 
stakeholders already provide HIV 
prevention services, what types of 
services they provide, & their 
capacity to provide adequate 
services. This will enable research 
teams to provide optimal referrals 
& make linkages when necessary 
(Standard of HIV prevention, p. 50). 
 
Research teams & relevant 
stakeholders discuss & negotiate 
the comprehensive HIV prevention 
package & 
consult local HIV prevention 
service providers when appropriate 
(Standard of HIV prevention, p. 50). 
 
Only EC identifies integrating with 
the local healthcare system as a 
mechanism of ensuring access to 
services. 
 
Ito criteria to consider in 
deliberations, Tarantola at el (2007) 
require the establishment new 
collaborative partnerships to 
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biomedical HIV Px tool 
development with other HIV Px 
modalities, all of which need to be 
integrated with HIV Rx & Cx as 
provided by the local healthcare 
system. It is imperative that 
appropriate financial arrangements 
are in place to implement 
agreements made between 
partners at the time a study is 
initiated. These agreements should 
cover the period of the trial but 
also address what will be provided 
to study participants once the study 
is completed (Context, p. 12). 
 
Site selection for moving forward 
into empirical efficacy trials of 
biomedical HIV Px technologies is a 
major challenge. Part of this 
challenge is the need to integrate 
biomedical HIV Px tool 
development with other HIV Px 
modalities, all of which need to be 
integrated with HIV Rx & Cx as 
provided by the local healthcare 
system (Context, p. 12). 
 
Clinical trials should be integrated 
into national Px, Rx, & Cx plans so 
that services provided through 
clinical trials or arrangements 
brokered for TPs serve to improve 
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TPs & the community from which 
they are drawn, & support & to 
strengthen a country’s 
comprehensive response to the 






No partnership mechanisms for 
ensuring access to prevention 
methods identified. 
Mechanisms to ensure provision of 
Px services have been identified – 
these are located in different GPs 
across the guidelines – mechanisms 
should rather be clustered together 
under the SOP GP.  
 
There should be collaboration with 
governments to explore, develop, & 
strengthen national & local 
capacity to deliver the highest 
possible level of HIV 
Px 
 
Suggests that the responsibility to 
ensure access to services is a shared 
one with primary lying with the 
local health systems. There is much 
emphasis on working with local 
authorities & government & 
integration with the healthcare 
system & national Px plans.  
 
Partnerships/linkages with HIV 
prevention service providers should 







It is recommended that the 
following components of risk-
reduction be monitored: i) Quality 
of protocols for counselling, STI 
management, & referral (GP 15, 
Referral mechanisms should be 
established & follow-up 
mechanisms instituted to ensure 
quality case management services 
(GP 13, SoP, p. 46). 
Trial sponsors & implementers 
must work with relevant 
stakeholders in 
establishing the type, scope, & 
process by which participants 
Tarantola et al criteria involve 
thinking about how each prevention 
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like referral  
Monitoring informed consent & 
RRIs, p. 31). 
 
Risk minimization measures 
include…Provision of supportive 
counselling for the duration of the 
trial, & appropriate referral after 
the trial is completed (GP 9, 
Potential harms, p. 18) 
 
The research protocol should 
specify referral processes for those 
persons excluded from the trial, 
where relevant (GP4, Research 
protocols & study populations, p. 9) 
 
 
Trial sponsors, countries, & 
researchers should ensure that 
trials take place only in 
communities where participants 
will have access to, & can be 
referred to, ongoing psycho-social 
services, including counselling, 
social support groups, & legal 
support (GP 11: Potential harms, p. 
40). 
 
are provided with, or referred to, 
services to access the full HIV 
prevention package (Standard of 
HIV prevention, p. 49)  
 
Research teams determine which 
stakeholders already provide HIV 
prevention services, what types of 
services they provide, & their 
capacity to provide adequate 
services. This will enable research 
teams to provide optimal referrals 
& make linkages when necessary 
(Standard of HIV prevention, p. 50). 
 
Research teams & relevant 
stakeholders discuss & negotiate 
the comprehensive HIV prevention 
package & 
consult local HIV prevention 
service providers when appropriate 
(Standard of HIV prevention, p. 50). 
 
Research teams & relevant 
stakeholders discuss & negotiate 
the comprehensive HIV prevention 
package, taking account of the 
following: 
• The HIV prevention services & 
options that will be offered 
through referral mechanisms. 
 (Standard of HIV prevention, p. 51) 
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stakeholders discuss how the HIV 
prevention package will be 
implemented & monitored, 
including uptake & standards of 
referral services (Standard of HIV 
prevention, p. 51). 
My notes:  
Within 
guidelines 
There is a statement that referrals 
for risk-reduction services should be 
monitored as well as a general 
statement on referral – not linked 
with ensuring access to Px services 
& a statement on referral to 
counselling services post-trail. 
Mention is made to trial-linked 
healthcare centres in the GP on care 
& treatment (see capacity building 
above).  
 
There is a statement that referral 
mechanisms should be established 
& monitored.  
Explicit statements the HIV 
prevention options may be provided 
via referrals and that standards of 












Strategies to offset vulnerability 
include capacity building for, & the 
early involvement of, participating 
communities (see Point 5), the 
development of advocacy 
processes & meaningful & ongoing 
informed consent procedures (see 
Points 12 & 13). 
 
Factors of particular reference to 
HIV vaccine research (see Point 13) 
include: Legal marginalisation of 
groups from which participants 
might be drawn, such as 
...intravenous drug users...& 
limited availability & sustainability 
Trial sponsors, researchers & 
advocates should continue efforts 
to resolve conflicts about legal 
constraints on public health 
practice such as abortion or 
interventions for IDUs (GP 13, SoP, 
p. 46). 
NIL Only EC specifically identifies a role 
for advocacy in ensuring access to 
Px services, particularly those 
considered illegal in some contexts, 
e.g., provision of clean needles.  
 
MRC & GPP provide no guidance on 
what to do in contexts where Px 
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of healthcare & Rx options (GP 7, 
vulnerability, p. 15) 
 




MRC does not directly address 
advocacy as a mechanism in 
ensuring Px services. The closure of 
PrEP trial provides NB evidence of 
the role of advocacy in trials as well 
as the consequences of failure to 
provide an OPTIMAL package 
regardless of legality 
 
However in the GP on vulnerability 
it mentions that advocates could 
play a role in addressing the needs 
of legally marginalised communities 
like IDUs.  
 
EC identifies that when there are 
legal constraints in providing 
components of the package, efforts 
should be made to resolve such 
conflicts. It does not address the 
role of advocacy in improving the 




What should be 
monitored? 
A plan for... evaluating the quality 
of RRIs, should be agreed upon 
before the trial commences & be 
implemented throughout the trial 
(bolded GP: 15, Monitoring 
informed consent & RRIs, p. 30). 
 
RRIs should be evaluated to ensure 
that quality interventions are 
provided to participants throughout 
the trial (GP 15, Monitoring 
informed consent & RRIs, p. 30) 
 
It is recommended that the 
following components of risk-
reduction be monitored: i) Quality 
Before a trial commences, 
researchers, trial sponsors, 
countries, & communities should 
agree on a plan for monitoring the 
initial & continuing adequacy of 
the informed consent process & 
RRIs, including counselling & access 
to proven HIV risk-reduction 
methods (GP 17, Monitoring IC & 
interventions, p. 56, bolded GP). 
 
The provision of HIV RRC should be 
monitored to ensure quality & to 
minimise the potential conflict of 
interest between risk-reduction 
goals & the biomedical Px trial’s 
Research teams & relevant 
stakeholders discuss how the HIV 
prevention package will be 
implemented & monitored, 
including uptake & standards of 
referral services (Standard of HIV 
prevention, p. 51). 
Ito monitoring Tarantola et al 
(2007) specify that monitoring & 
accountability are important 
considerations in decision-making, 
that is, who should make sure that 
the proposed standard is actually 
being implemented? How will the 
approaches be monitored? What 
should be the transparency & 





Dimension MRC (2003) HIV Preventive vaccine 
research. Book 5 
UNAIDS (2007). Ethical 
considerations 
UNAIDS-AVAC (2011) Good 
Participatory Practice (GPP) 
My notes:  
Across guideline analysis 
of protocols for counselling, STI 
management, & referral; ii) 
Cultural, linguistic, gender & age 
appropriateness of the counselling 
for target groups; iii) Counsellor 
skills & the degree to which 
counsellor training corresponds 
with policy developed by the 
National Minimum Standards 
Committee for the Accreditation & 
Training of HIV/AIDS counsellors; iv) 
Procedures by which risk-reduction 
counsellors are selected, trained & 
supervised; v). Availability of 
adequate supplies of barrier 
methods & risk-reduction 
materials; & vi) RRIs should also be 
evaluated by participant 
satisfaction, & with regard to their 
efficacy in reducing high-risk 
behaviour (GP 15, Monitoring 
informed consent & RRIs, p. 31). 
 
To reduce a real or perceived 
conflict of interest, evaluation of 
risk-reduction measures could be 
done by, or in collaboration with, 
an independent agency. (GP 15, 
Monitoring informed consent & 
RRIs, p. 31).  
 
Consider appointing an 
independent monitor, or 
expanding the trial monitor’s 
scientific goals (GP 13, SoP, p. 47).  
 
National & international research 
oversight groups should evaluate 
the pros & cons of independent 
organisations implementing RRIs in 
biomedical HIV Px trials; where 
such efforts are warranted & 
feasible, they should be undertaken 
& rigorously evaluated (GP 13, SoP, 
p. 47). 
 
Monitoring should include quality 
assurance of gender- & culture-
sensitive counselling services, 
appropriate procedures for 
adolescents, & evaluation of the 
impact of the trial on the 
vulnerabilities of the communities 
involved in the study (GP 17:, p. 56) 
 
Consideration should be given to 
expansion of the responsibilities of 
the clinical trial monitor to include 
adherence to the recruitment & 
informed consent processes & to 
counselling standards (GP 17, Cx & 
Rx, p. 57). 
 
Ways should be explored with local 
authorities to provide trial 
volunteers & participants with 
information about HIV Px & Rx 





Dimension MRC (2003) HIV Preventive vaccine 
research. Book 5 
UNAIDS (2007). Ethical 
considerations 
UNAIDS-AVAC (2011) Good 
Participatory Practice (GPP) 
My notes:  
Across guideline analysis 
responsibilities, to evaluate risk-
reduction measures (GP 15, 
Monitoring informed consent & 
RRIs, p. 31). 
 
community. Referral mechanisms 
should be established & follow-up 
mechanisms instituted to ensure 
quality case management services 
(GP 13, SoP, p. 46). 
 




RRIs should be monitored for 
quality as well as monitoring of 
referral. Most of the emphasis is on 




RRIs should be monitored, 
particularly the provision of RRC, as 
well as referral mechanisms. 
 
Uptake of Px services should be 
monitored as well as adequacy of 
referral networks but no mention of 
monitoring RRIs for quality. 
Tarantola et al provides a process 
for documenting all decisions about 
the standard of prevention. This is 
an important requirement given the 





What should be 
documented? 
NIL NIL Research teams maintain clear 
written records of discussions & 
agreements. This includes 
recommendations, actions taken by 
the research team, & any 
unresolved issues that require 
follow-up (Standard of HIV 
prevention, p. 51). 
 




NIL. NB considering emphasis on SH 
consultation in decision-making. 
However, assumption that any 
monitoring will require 
documentation as well.  
 
NIL. NB considering emphasis on SH 
consultation in decision-making. 
All discussion and agreements 
should be documented..  
A key outcome of the GGM is to 
document terms of agreement & 
responsibilities prior to the trial 
(Tarantola et al., 2007) 
 
 































Appendix 4: Information sheet and informed consent form 
 
Information Sheet: 
Care and prevention in HIV vaccine trials in South Africa:  




Hello. We are from the HIV/AIDS Vaccines Ethics Group (HAVEG), based at the University 
of KwaZulu-Natal. HAVEG does ethical-legal research in HIV vaccine trials. 
 
We are inviting you to participate in a study. 
 
This study will explore care and prevention in HIV vaccine trials.  
 
Who funds our study? 
This study is funded by the Wellcome Trust, a UK-based charity that funds health research.  
 
What is the purpose of our study? 
Our study will look at how researchers help HIV vaccine trial participants to avoid HIV, get 
care for HIV if they do get infected, or get care for other health problems. It will look at how 
these important decisions are made. In other words, we are exploring care and prevention 
practices at HIV vaccine sites in South Africa – delivery of services to participants and 
decision-making to provide services.  
 
We are interested in the challenges and successes experienced by researchers, as well as the 
concerns and views of other stakeholders on this issue (e.g. members of Community 
Advisory Boards (CAB), ethics bodies and sponsor teams). 
 
We are also interested in the views of stakeholders about ethical standards in recent 
guidelines on HIV vaccine trials.  
 
We want to see whether what happens in practice matches what ethical guidelines say should 
happen. If there is not a good match, we want to understand why: for example, are ethical 
guidelines too difficult to implement? We also want to see if ethical guidelines help 
stakeholders with the actual concerns and worries they have. If guidelines don’t address 
people’s real concerns, how can they be improved?  
 
Based on the findings, we will make recommendations to strengthen care and prevention 
practices (including the sharing of best practices), and to make ethical guidelines clearer or 
stronger.  
 
What inputs have sites and community representatives had into our study? 
In July 2009, we met with site staff and CABs from all HIV vaccine trial sites to tell them our 
broad aims and get their views and concerns. We clarified that the research was part of a 
collaborative effort towards a shared goal of strong care and prevention at South African 








What procedures will this study involve?  
We will conduct general interviews with some site-staff (e.g. PIs, medical officers) and some 
other stakeholders (e.g. CAB members, review body members, sponsors). The interviews will 
explore their views about the important issues in care and prevention in HIV vaccine trials, 
and challenges and successes. For selected site staff, we will also conduct a detailed specific 
interview about what is actually provided to participants at their sites and how.  
 
We will also ask site staff and members of CABs and RECs to answer a questionnaire that 
explores their views of ethical guidelines for HIV vaccine trials. 
 
Later on we may ask some stakeholders to be involved in focus groups. 
 
As background to gathering data from people, we will also be looking at various documents. 
We will look at ethical guidelines to understand what is expected of researchers. Where we 
get permission, we will also look at documents like HIV vaccine trial protocols, standard 
operating procedures and training materials. We will also try to understand each site better by 
looking at information on their websites or public documents. 
 
Why have you been chosen? 
You have been identified as someone we would like to talk to because of your work at HIV 
vaccine sites or your involvement in a community organisation, review body or sponsor team. 
 
Do you have to take part? 
No. You can refuse to take part. Even if you agree, you can change your mind at any time. 
You can also refuse to take part in certain procedures or answer certain questions. You can 
also choose to make your answers hypothetical and not about the actual group or institution 
you represent. 
 
What are the risks of taking part in this study? 
If you are taking part in an interview, you may feel worried to talk about care and 
prevention practices that are not working well in the group or institution that you are 
a part of. You may worry that talking about these will have negative consequences 
for you or your organisation. Remember that you can choose not to take part, or not 
to answer certain questions. You can also make your answers general and not about 
your actual organisation. 
 
We will make every effort to make your responses anonymous. We will not report any names 
of people when writing reports. We will group together information about sites into a national 
‘picture” before any public release. This information will be shared with stakeholders at a 
national consultation before public dissemination. 
 
We are not tasked to monitor practices. However, if you inform us of something that appears 
to be a serious breach of practice that poses a direct risk to the health and welfare of an actual 
HIV vaccine trial participant, then it seems wrong for us to do nothing. So in this event, we 
will discuss the issue in a confidential research meeting. We may ask you for more details. A 
decision may be made to contact the site Principal Investigator for clarification and remedial 
action if necessary. In this event you will be informed and every effort will be made to 
maintain your confidentiality and resolve the issue in a collegial and respectful manner. Sites 
may have to contact their research ethics committee and/or other institutional bodies as per 





If you are taking part in the questionnaire, you may worry that we are testing how much you 
know about ethical standards. This is not the case: rather, we hope to identify those areas 
where ethical standards may have to be clarified, disseminated better, or even changed. 
 
What are the benefits of this study? 
There are no direct benefits to participants. It is possible that taking part in the study makes 
you think about the issues in a new and more helpful way, however there is no guarantee that 
this will happen. 
 
In the long run, we hope this research will identify (at a national level) practice areas that 
need strengthening as well as best practices. We also hope that recommendations for 
improved guidelines will make for clearer direction on this issue.  
 
A site-level report identifying issues, challenges and successes at each site will be offered to 
participating sites to maximize benefits to them.  
 
What will happen to the data and how will confidentiality be maintained? 
In general, only research staff at HAVEG will have access to the data from this study. 
 
If you take part in interviews, your name and other identifying details will not be stored 
together with any data. We hope to record your interview using a digital recorder. This 
recording is only for our own records, so that we can get an accurate record of what is said. 
We will transcribe parts of the recording.. You may refuse to be recorded if you wish.  
 
Because there are a small number of target groups, it is possible that interviewees will be 
identifiable through, for example, rich text quotes. Every effort will be made to make 
interviewees as anonymous as possible.  
 
If you take part in the questionnaire, your name and other identifying details will not be 
stored together with any data. 
 
If you take part in focus groups held later on, you will be asked not to disclose things that are 
discussed in the group. We can’t guarantee that every focus group participant will honour this 
agreement, so we will ask all focus group participants to be careful about disclosing 
information. Focus groups may be recorded if participants agree. 
The tape recordings, transcripts and questionnaire data will be stored safely, that is, in a 
locked cabinet, and electronic records will be password protected.  
 
All the data will be kept for 5 years then destroyed.  
 
What will happen to the results? 
Results will be written into: 
Ø A national report for discussion at a national consultation and eventual public 
dissemination 
Ø Academic publications in open access journals 
Ø Conference presentations 
Ø Two doctoral dissertations, if post-graduate approval is received.   
 
No participants in our study will be named in any written document and efforts will be made 





identification of specific sites. Sites will not be named in written reports. Site data will be 
aggregated to form a national picture. However, due to the fact that there are only limited 
HIV vaccine trial sites in South Africa, it is conceivable that some sites may be identified.  
 
A national-level report will be developed and discussed at a national consultation. An 
individual report tailored to each site will be offered to each site, but not for public release. 
 
What do you need to do? 
If you agree to participate in this study, we will need you to sign the informed consent form 
below and return it to us. We will ask you to discuss any questions you may have about the 
study with us.  
 
If you are a member of a trial site, CAB, review body or sponsor team taking part in a general 
interview about concerns and challenges, we will need about 1 to 2 hours of time. This may 
be in person or over the phone. 
 
If you are member of a trial site taking part in a specific interview about care and prevention 
practices we will need about 1 to 2 hours of time. This may be in person or over the 
telephone. 
 
If you are a member of a trial site, CAB or REC taking part in a questionnaire about ethical 
standards, we will need about 30 minutes. This may be in person, over the telephone or over 
email. 
 
At a later stage you may be asked to participate in a follow up focus group.   
 
Remember, even if you agree to take part in some procedures you can refuse to participate in 
others.  
  
NOTE: You may not be invited to take part in all of these procedures, because some are 
reserved for particular stakeholder groups.  
 
Will participants in this study be paid?  
Site staff and members of CABs, review bodies and sponsor teams taking part in a general 
semi-structured interview will be offered R50.00 as payment to compensate them for their 
time, inconvenience and expenses.  
 
Site staff taking part in specific interviews about care or prevention practices will be offered 
R50.00 respectively. 
 
Site staff, CAB members or REC members who take part in a questionnaire about ethical 
standards will be offered R35.00. 
 
If we hold focus groups later on, participants will be offered R50.00.  
 
NOTE: You may not be asked to take part in all of these instruments, because some of the 
instruments are reserved for particular stakeholder groups.  
 
Was this research ethically approved? 





Ø BREC at University of KwaZulu-Natal  BE 241/09 
Ø Wits HREC (Medical)    M091140 
Ø MEDUNSA      MREC/P/13/2010: CR 
Ø University of Cape Town HREC   REF 476/2009 
Ø Walter Sisulu      089/009 
 
Who can I contact if I have questions? 
For questions related to the study, please contact the PI who is Graham Lindegger at 033 260 
6166 or lindegger@ukzn.ac.za. You may also contact the co-PI who is Catherine Slack on 
033 2606166 or slackca@ukzn.ac.za 
 
For questions about ethical issues in the study, you may contact the BREC ethics committee 
through Ms A Marimuthu on 031 260 4769, fax 031 260 4609 or email brec@ukzn.ac.za 
 
For Cape Town based participants: For questions about ethical issues in the study, you may 









Consent to take part 
 
I, __________________________________________________________ (full names of 
participant) confirm that I understand this consent form and the nature of the study and agree 
to take part in: 
 
 Insert X 
The general interview on care / prevention 
 
 
The specific interview on care / prevention (Site staff only) 
 
X 
The questionnaire on ethical guidelines related to care and prevention 
 
 




I understand that I can withdraw from the study/ components of the study at any time. 
 
SIGNATURE OF PARTICIPANT                          DATE 
 
__________________________   ______________________________ 
 
Tape recording consent 
 
I, __________________________________________________________ (full names of 
participant) consent to the tape-recording of the interview or focus group.  
 
 
SIGNATURE OF PARTICIPANT                           DATE 
 
 






Appendix 5: Semi-structured interview guide for the prevention-specific interview 
 
NOTE: These were the kinds of questions asked. However, the guide was adapted and refined 
as data collection proceeded and for each stakeholder group, where relevant. 
 
Interviewer to explore current prevention service, e.g. 
Ø What prevention services do participants receive?  
o Risk-reduction counselling 
o Male and female condoms 
o STI diagnosis and treatment 
o Male circumcision 
o PEP 
o Other? E.g. Clean needles 
 
Interviewer to explore EACH of the tools identified by interviewee (above), e.g.  
Ø Who receives these services (e.g. TPs only, screen-outs, partners, the 
community)? 
Ø How are prevention services provided (direct provision or referral)?   
Ø To what extent is referral assisted or formalised?  
 
Interviewer to explore decision-making practices and perspectives, e.g. 
Ø How is it decided which methods to provide or not? 
Ø Which stakeholders groups are involved in decision making? Can you describe 
the nature of their involvement? 
Ø Have there ever been disagreements among stakeholders on what to include in 
the risk-reduction package? If so, how have these been resolved? 
Ø Have you found ethical guidelines helpful in making decisions about what 
prevention services to provide to participants? 
Ø Ethical guidelines require that participants should be provided with state of the 
art, optimal or proven HIV prevention methods. What do you think about these 
requirements? 
Ø How are decisions made on who pays for prevention services to be provided to 
participants 
Prompts to explore: proven efficacy; acceptability, resources; sponsor policy, ethical 
guidelines, community input, ethics input, characteristics of population; sustainability 
 
Interviewer to explore issues of adding new prevention methods, e.g. 
Ø What is the process for adding new methods to the risk-reduction package? 
Ø Reflecting on the issue of circumcision, can you describe key considerations in 
adding new methods? 
Ø Anticipating the results of PrEP and microbicides, can you describe key issues in 
adding new methods?  
Ø What are your thoughts on new ethical guideline requirements that new 
prevention methods should be added based on consultation among all research 
stakeholders when they are approved or scientifically validated? Is this feasible? 
 
Interviewer to consider asking more general questions, e.g. 
Ø Are services monitored for (i) uptake and (ii) quality? 






Ø Is feedback given to stakeholders on the prevention services that participants 
get? 
Ø You mentioned X was critical, can you tell me more about that? 
Ø Have there ever been disagreements among stakeholders on what to include in 
the risk-reduction package? If so, how have these been resolved? 







Appendix 6: Semi-structured interview guide for the general interview on care and 
prevention 
 
NOTE: These were the kinds of questions asked. However, the guide was adapted and refined 
as data collection proceeded and for each stakeholder group, where relevant. 
 
A Interviewer to ask general questions on interviewee role in trials, e.g.  
Ø What has your role been in HIV vaccine trials generally? 
Ø What is your role/involvement in relation to care and prevention in trials?  
B Interviewer to explore general issues, e,g. 
Ø From your perspective what are the key issues in care and prevention in HVTs?  
Ø What challenges do you face about this issue, and how have you addressed them? 
Ø In your view, what has worked well/badly? 
C Interviewer to explore issues around decision-making, e.g.  
Ø When reflecting on how decisions get made to provide services, what comes to mind?  
Ø How are decisions made about what services to provide? 
Ø To what extent have (or should) key stakeholders been involved? 
Ø Can you describe successes or challenges?  
D Interviewer to explore factors influencing practices, e.g. 
Ø Can you describe access to care and prevention services in the general community? 
E Interviewer to explore ethical guidance, e.g.  
Ø In general, what are your overall impressions of the ethical guidance on this issue? 
Ø What are some of the big issues we should understand about the ethical guidance? 
Ø How well do you think guidelines help you with your dilemmas about this issue? 
Ø What do you think some of the challenges are in implementing ethical guidance? 
Ø Do you think that guidelines are helpful for making decisions around practice on the 
ground? 
Ø Why do you think participants should be provided with care and/or prevention 
services? 
F Interviewer to explore interviewee-prioritized issues & themes, e.g. 






Appendix 7: Transcript conventions 
 
• An identifier was allocated to each respondent to ensure anonymity (e.g., Z16, REC), to 
indicate that this was the 16th interview conducted by the researcher, with an REC 
member). 
• Each speaker was clearly identified throughout the transcript (R=researcher; 
V=volunteer).  
• Some details of the conversation other than words were included, for example laughter 
and sighs.  
 
Specific conventions are detailed below:  
 
(interruption)  interruptions of the interviews were recorded  
 
(.)   a period in parenthesis indicates a short pause  
 
(pause)  Indicates a long pause 
 
____ Underlining indicates particular emphasis or stress on a particular 
word 
 
(unclear)  indicates inaudible bits of speech 
 
((words)) words in double parentheses indicate that the transcriber is guessing 
at what is being said, because speech is unclear – transcriber is not 
certain that this is exactly what is being said. 
 
/ A sudden change in the direction of talk was indicated by a forward 
slash, e.g. Standards of prevention are/at this site we provided 





Appendix 8: Coding framework 
 
A. DECISON MAKING PRACTICES AND PERSPECTIVES ON THE STANDARD OF PREVENTION 
 
1. Stakeholders involved in decision-making 
1.1. Protocol writing team  
1.1.1. Sponsor representatives 
1.1.2. Network representatives 
1.1.3. Local investigators/site staff 
1.1.4. Local CAB 
1.2. Local trial sites 
1.3. REC involvement 
1.4. MCC  
1.5. SA government/DOH involvement 
1.6. Trial participants 
 
2. Protocol writing practices  
 
3. Relevant criteria for designing the standard of prevention package 
3.1. Affordability (cost of the intervention) 
3.2. Availability of funding  
3.3. Available in host country (local standard of prevention)  
3.4. Clear information (clear counselling messages) 
3.5. Effects of combining prevention modalities 
3.6. Ethics requirements 
3.7. Impact on trial feasibility 
3.8. Investigator requests/demands  
3.9. Level of evidence  
3.10. Participant requests 
3.11. Phase of the trial/Risk-level of participants 
3.12. Preventing undue inducement  
3.13. Regulatory approval 
3.14. Required statistical power 
3.15. Responding to site-specific/protocol specific/case specific demands 
3.16. Scientific validity 
3.17. Sponsor policy 
3.18. Sustainability post-trial 
3.19. To retain participants 
3.20. Type of population 
 
4. Rationale for providing (not providing) a standard of prevention  
4.1. A fair thing to do 
4.2. An ethical obligation 
4.3. Beneficence 
4.4. Duty of rescue 
4.5. Morally praiseworthy  
4.6. Non-maleficence 
4.7. Prevention is better than treatment 





4.9. Satisfying ethical guidelines and requirements 
4.10. The right thing to do 
4.11. To counteract behavioural disinhibition 
4.12. To facilitate informed decision-making 
4.13. To help participants remain negative 
4.14. To reduce misperceptions that trials increase HIV 
 
5. Decision-making process  
5.1. Consulting CABs 
5.2. Consulting ethics groups 
5.3. Consulting investigators 
5.4. Face-to-face meetings (protocol-writing practices)  
5.5. Informal dialogue 
5.6. Protocol-by-protocol  
5.7. Scientific discussions  
5.8. Site-by-site 
5.9. Small groups to resolve specific issues 
5.10. Standardised package 
5.11. Through protocol review  
5.11.1. Protocol as a mechanism of consensus 
 
6. Stakeholder decision-making roles and practices  
6.1. Protocol writing team  
6.1.1. Developing (drafting) protocol 
6.1.2. Discussing standard of prevention 
6.2. Sponsor representatives 
6.2.1. Sponsor as dictator 
6.2.2. Sponsor dominates numbers 
6.2.3. Sponsor as meeting leader 
6.2.4. Funding 
6.3. Network representatives 
6.3.1. Finding funding  
6.3.2. Overseeing trial implementation 
6.4. Local investigators/site staff 
6.4.1. Investigator as driver of decision-making 
6.4.2. Investigator as advocate 
6.4.3. Site staff decide on what to offer participants on individual need 
basis 
6.5. Local CAB 
6.5.1. CAB input (or lack thereof) in making decisions  
6.5.2. Rationale  
6.5.3. Benefits  
6.5.4. Challenges 
6.6. Local sites 
6.6.1. Site-level decisions on what to provide 
6.7. REC involvement 
6.7.1. Approving deviations from the protocol 
6.7.2. Approving the standard of prevention 
6.7.3. No input/advocacy on standards of prevention 
6.7.4. Protecting participants 





6.7.5.1. Community representation on REC 
6.7.6. REC requirements for the standard of prevention (including 
implementation) 
6.7.7. Reviewing the protocol  
6.8. MCC  
6.8.1. Reviewing the protocol 
6.9. SA government/DOH involvement 
6.9.1. Referral centre 
6.9.2. Procurement source  
6.10. Participants 
6.10.1. Decide which services to take up 
6.11. Stakeholder relationships 
 
7. The evolving standard of prevention (adding new tools) 
7.1. Participants substitute new interventions for old ones 
 
8. Decision-making challenges 
8.1. Balancing prevention package against undue inducement worries 
8.2. Community understanding of scientific concepts 
8.3. Finding funding  
8.4. Tension between science and ethics 
8.5. Threats to trial feasibility/scientific validity 
8.6. Variation across sites/protocols 
8.7. Working around sponsor policy 
 
B. SERVICE DELIVERY PRACTICES AND PERSPECTIVES (Reducing risk of HIV infection) 
 
1. The standard package of HIV prevention  
1.1. Access strategies 
1.1.1. On-site provision 
1.1.1.1. Benefits 
1.1.1.1.1. Efficient delivery of services 
1.1.1.1.2. Improved control 
1.1.1.1.3. Improved monitoring  
1.1.1.1.4. Improved retention 
1.1.1.1.5. One-stop shop for participants 
1.1.1.2. Challenges 
1.1.1.2.1. Participant dependency 
1.1.1.2.2. Researcher’s dilemma 
1.1.2. Referral 
1.1.2.1. Assisted referrals 
1.1.2.2. Benefits 
1.1.2.3. Challenges 
1.1.2.3.1. Long waiting periods to access services 
1.1.2.3.2. Provider attitudes 
1.1.2.3.3. Provider knowledge 
1.1.2.3.4. Quality of care in the public healthcare 
sector 
1.1.2.3.5. Variable access to prevention services 
1.1.2.3.6. Concerns about confidentiality 





1.1.2.5. Follow up 
1.1.2.6. Private healthcare services 
1.1.2.7. Public healthcare services 
1.2. Documenting the standard of prevention 
1.2.1. Keeping records 
1.2.2. SOPs and other site documents 
1.2.3. The informed consent form 
1.2.4. The protocol 
1.3. For non-trial participants 
1.4. General education on HIV prevention 
1.5. Monitoring the standard of prevention 
1.5.1. Adverse event reporting 
1.5.2. For quality 
1.5.3. For uptake 
1.5.4. What is monitored  
1.5.5. Who monitors 
1.6. Education on HIV prevention 
 
1.7. Counselling  
1.7.1. HIV Counselling and Testing 
1.7.2. Risk-reduction counselling 
1.7.2.1. Rationale  
1.7.2.2. Implementation 
1.7.2.2.1. Risk-assessment 
1.7.2.2.2. Risk-reduction plans 
1.7.2.2.3. Checklist/worksheet 
1.7.2.2.4. Guidelines 
1.7.2.3. Couples counselling  
1.7.2.4. Counsellor training 
1.7.2.5. Challenges 
1.7.2.5.1. Participant behaviour change 
1.7.2.5.2. Participant social desirability 





1.8.2.1. Condom negotiation skills 
1.8.2.2. Condom demonstrations 
1.8.3. Non-trial participants 




1.8.4.1. Condom acceptability/uptake 
1.8.4.2. Access to condoms 
1.8.4.3. Staff chart-noting of condom provision (Participants 
pressured to use condoms) 
1.8.5. Procurement of condoms 






1.9. STI Treatment 
1.9.1. Rationale 
1.9.2. Source of funding 
1.9.3. Implementation 
1.9.3.1. Syndromic management 
1.9.3.2. Diagnostic tests 
1.9.3.3. Guidelines 
1.9.3.4. On-site provision 
1.9.3.5. Referral 
1.9.3.6. Following up participants 
1.9.3.7. Counselling on STIs 
1.9.4. Source of funding 
1.9.5. Procuring medication 
1.9.6. Non-trial participants 




1.9.7.1. Funding of STI treatment 
1.9.7.2. Syndromic management 
1.9.7.3. Complexities with referral 
1.9.7.4. Adherence to treatment 
1.9.7.5. No evidence for efficacy 
 
1.10. Post-exposure prophylaxis (PEP) 
1.10.1. Rationale 
1.10.2. Implementation  
1.10.2.1. Guidelines/SOPs 
1.10.2.2. Counselling on PEP 
1.10.2.3. Uptake of PEP 
1.10.3. Source of funding 
1.10.4. Procuring medication 
1.10.5. Non-trial participants 




1.10.6.1. Restrictions on PEP administration 
1.10.6.2. Accessibility of PEP 
1.10.6.3. Impact on trial feasibility 
1.10.6.4. Implementation complexities 
1.10.6.5. Participant misuse of PEP 
1.10.6.6. Provider attitudes to PEP 
1.10.6.7. No evidence for efficacy 
 











1.11.2.3. Counselling on VMMC 
1.11.2.4. Uptake of VMMC 
1.11.3. Source of funding 
1.11.4. Non-trial participants 
1.11.4.1. Volunteers at screening 
1.11.4.2. Partners  
1.11.4.3. Community 
1.11.5. Complexities 
1.11.5.1. Availability of VMMC in the public healthcare sector  
1.11.5.2. CAB concerns about VMMC 
1.11.5.3. Traditional versus medical circumcision 
1.11.5.4. Cultural taboos around discussing VMMC 
1.11.5.5. Variable uptake across sites 
1.11.5.6. VMMC as an inducement to participate 
 
2. Access strategies  
2.1. On-site provision 
2.1.1. Benefits 
2.1.1.1. Improved control 
2.1.1.2. Improved monitoring 
2.1.1.3. One-stop shop for participants 
2.1.2. Challenges 
2.1.2.1. Researcher’s dilemma 
2.1.2.2. Participants dependent on site for services  
2.2. Referral  
2.2.1. Public healthcare services 
2.2.2. Private healthcare services 
2.2.3. Benefits 
2.2.4. Challenges with referral 
2.2.4.1. Quality of care in the public healthcare system 
2.2.4.2. Variable access to prevention services across sites 
2.2.5. Establishing relationships with services providers 
2.2.6. Follow-up 
2.2.7. Capacity building  
2.3. Post-trial access 
 
3. Justifying the standard of prevention 
3.1. An ethical obligation  
3.2. Non-maleficence (reducing risk) 
3.3. Reciprocal justice 
3.4. To facilitate informed decision-making 
3.5. The right thing to do 
 
4. Monitoring the standard of prevention 
4.1. For uptake 
4.2. For quality 
4.3. What is monitored? 
4.4. Who monitors? 
 





5.1. The protocol 
5.2. Informed consent forms/process 
5.3. Keeping records 
 
6. PERSPECTIVES ON STATE OF THE ART STANDARD OF PREVENTION  
6.1. Unpacking state of the art 
6.2. Support for a state of the art prevention package 
6.3. Objections to a state of the art prevention package 
6.3.1. Undue inducement 
6.3.2. Behavioural disinhibition 
6.3.3. Inequities between participants and community 
 
7. Challenges regarding implementing state of the art standard of prevention 
7.1. Difficult to explain partial efficacy 
7.2. Participants substitute old with the new interventions   
7.3. Behaviour change is complex 
7.4. CAB access to participants  
7.5. De-motivated counsellors 
7.6. Funding  
7.7. Donor restrictions 
7.8. Government policies 
 
C. PERSPECTIVES ON ETHICAL GUIDELINES 
 
1. Perspectives on stakeholder consultation  
a. (Qualified) support for stakeholder consultations 
b. Objections to stakeholder consultations  
c. Recommendations for stakeholder consultation  
d. Rationale for stakeholder consultation  
2. Perspectives on state of the art standard 
a. Local state of the art 
b. Support for state of the art prevention 
c. Objections to state of the art prevention 
d. Unpacking state of the art 
3. Accessibility of guidelines  
4. Adherence to ethical guidelines 
5. Awareness (unawareness) of ethical guidelines  
6. Context-specific application (interpretation) of guidelines 
7. Tension between state of the art and stakeholder consultation requirements 





Appendix 9: Recommendations related to norms, perspectives and practices 
 
Recommendations related to norms (ethics guidelines) 
South African ethics guidelines (MRC, 2003) should be updated to reflect recent evolutions in HIV prevention. 
Future revisions of MRC (2003) guidelines should consider providing some direction on strategic partnerships in ensuring access to prevention 
interventions.  
International guidelines (UNAIDS/AVAC, 2011; UNAIDS/WHO, 2012) should consider clarifying vague concepts and/or developing 
frameworks to facilitate the operationalisation of vague concepts. 
Empirical data from this study have illuminated the internal conflict in guidelines between substantive norms requiring access to ‘state-of-the-art’ 
prevention interventions, and procedural norms recommending consultation and negotiation of the prevention package. Guidelines should offer 
clearer direction about how to resolve conflicts between substantive recommendations and stakeholder inputs. 
Careful consideration should be given to recommended decision-making process of negotiation and agreement given findings of the 
pervasiveness of power inequities between HVT stakeholders. Guidelines should therefore carefully consider alternative mechanisms for standard 
of prevention decision-making, which are constructive and engender collaboration rather than opposition.  
Guidance should clarify standard of prevention obligations to non-trial participants. 
Guidance should clarify whether the standard of prevention differs based on participants’ vulnerability/phase of the trial. 
Guidance should provide direction on some of the complexities with standards of prevention faced by trial implementers such as the potential for 
different standards of prevention within countries (between different trials and sites), provider-promotion, participant uptake and the influence of 






Recommendations related perspectives and practices (by stakeholder group) 
Sponsors should clarify their funding policy in a way that clearly indicates which prevention services are permitted, and which is cognisant of 
ethical requirements to ensure access to standard of prevention interventions. 
HVT trial implementers and community representative structures should explore alternative mechanisms to ensure stakeholder inputs on 
standards of prevention.  
HVT implementers should establish creative partnerships and diversify funding sources. 
As trial site capacity expands, new sites should engage the DoH as a potential procurement source and referral centre. 
Sites should endeavour to evaluate and monitor the quality of prevention interventions, including provider-promotion of services. 
Sites should consider strategies to improve access to female condoms, including lobbying HIV prevention activist groups in advocating for 
improved accessibility of female condoms. 
Given the potential for dispensing practices to impact on condom uptake, sites should consider ensuring access to female condoms outside 
counselling sessions.  
Protocols and consent forms should contain more information on the standard of prevention. Alternatively an additional fact sheet on the standard 
of prevention could be provided to participants. 
The capacity of CABs to review protocols in terms of standards of prevention, and the scientific implications for study design, should be actively 
built. 
Consideration should be given to including a CAB representative at each site on local RECs that review HIV prevention trial protocols. 
RECs should consider revising ethics application forms to require detailed information on the standard of prevention that will be provided to 
participants, and efforts (if any), to monitor the provision of these service. 
RECs should request that sites document efforts (and challenges) in implementing GPP guideline requirements. 
RECs could benefit from intensive ethics training including on mechanisms to enhance their interrogation of substantive issues, such as the 






Recommendations for future research 
Given findings that socio-cultural norms may constrain CAB inputs on the standard of prevention, and impact on provider-promotion and 
participant uptake of prevention interventions, more detailed research should be undertaken that clarifies the extent to which gender norms and 
cultural prescriptions influence the realisation of recommendations in ethics guidelines.  
Future research should pilot and evaluate existing frameworks that propose procedural decision-making processes (e.g., Tarantola et al., 2007) 
that take into account some of the challenges with consultation reported in this study. 
The perspectives of stakeholders should be canvassed regarding the value of frameworks (e.g., Jay et al., n.d.) that attempt to offer operational 
guidance on when to add new methods to the prevention package. 
There is a critical gap in knowledge with regard to the threshold at which adding new prevention methods will invalidate trials. 
 
 
 
 
 
 
